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HIV-1 has caused a marked shift in the epidemiology of meningitis in sub-Saharan Africa and 
Mycobacterium tuberculosis is now a leading cause of meningitis in adults. Diagnosis of tuberculous 
meningitis (TBM) is notoriously difficult, compounded by an atypical cerebrospinal (CSF) picture in HIV 
co-infection. The WHO-recommended standard quadruple TB therapy may not be the optimal 
regimen in TBM as rifampicin does not readily penetrate into the CSF at the current dose. Better 
diagnostics and treatments are needed to tackle the disconcertingly high TBM mortality of at least 
50% in people living with HIV (PLHIV). The goals of this PhD thesis were to first identify improved 
approaches to the diagnosis of TBM; and second, to investigate the safety and pharmacokinetics of a 
novel approach to treatment with high-dose rifampicin through a phase II open-label randomised 
controlled trial in predominantly HIV-positive adults.    
To begin, using retrospective data from two Ugandan referral hospitals, I showed that the 
introduction of the Cepheid Xpert MTB/Rif assay had markedly increased the microbiological 
confirmation of TBM. However, around half of TBM cases were treated on the basis of clinical 
suspicion alone, despite negative CSF TB tests. So, better diagnostics were still needed. I went on to 
examine the novel Xpert Ultra assay in a prospective diagnostic accuracy study, and found it to be the 
best CSF test for TBM, with a sensitivity of 77% and a negative predictive value of 93% for probable/
definite TBM, significantly better than Xpert MTB/Rif. A high CSF lactate and low CSF glucose were 
good discriminators of definite TBM. Given that CSF collection can be delayed or contraindicated, a 
non-CSF dependent test would be valuable, so i explored the potential of urine TB testing. Urine TB-
lipoarabinomannan (Alere LAM) and/or urine Xpert Ultra were positive in 50% of probable/definite 
TBM cases, suggesting extra-meningeal disseminated TB disease is highly prevalent in adults with 
HIV/TBM. In this exploratory study urine Xpert Ultra had prognostic value in definite TBM.  
The phase II randomised clinical trial demonstrated that with WHO-recommended TB treatment 
(containing rifampicin 10 mg/kg/day), CSF rifampicin was undetectable (<0.25 mg/L) in around half of 
participants, and only 11% achieved a CSF rifampicin concentration above the minimal inhibitory 
concentration (MIC) of the predominant M. tuberculosis strain in Uganda. Intravenous rifampicin 20 
mg/kg/day yielded a ~6-fold increase in serum and CSF exposures; and oral rifampicin 35 mg/kg/day 
yielded an ~8-fold increase in serum and CSF exposures compared to standard of care. All 
participants in the investigational arms had detectable CSF rifampicin, and almost all had CSF levels 
above the rifampicin MIC. Importantly, there was no excess toxicity in the high-dose rifampicin arms. 
Overall, the most common adverse event was elevated alanine transaminase, attributed to
ii 
 drug-induced liver injury, which occurred in 7 (12%) of participants overall, 4 of which were in the 
control arm. 
Together, this research has shown that, in Uganda, TBM is a usually a manifestation of disseminated 
TB disease resultant upon advanced HIV-related immune suppression, and carries a high case-fatality. 
Xpert Ultra is a step forward but cannot be used as a ‘rule-out’ test. A diagnostic test that combines 
pathogen-detection with a host biomarker may be the most sensitive approach for TBM. The WHO-
recommended TB therapy for TBM is sub-optimal and high-dose rifampicin is a promising and safe 
intervention that needs to be further investigated in a phase III trial.  
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Preface 
I present this thesis as a research paper style thesis. The ten chapters comprise a total of seven 
research papers that have been submitted or published in peer-reviewed journals and are indicated in 
the table of contents. Cover sheets are provided with each paper that detail publication details and 
co-author contributions. Forewords to each chapter aim to connect the story between the different 
chapters. The thesis also comprises an introduction, a discussion, a conclusion and an appendix 
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Thesis Outline 
Improving diagnosis and treatment of tuberculous meningitis 
BACKGROUND 
Chapter 1 is a general introduction to the epidemiology, clinical features, and outcomes of Tuberculosis (TB) 
and tuberculous meningitis (TBM) with respect to HIV co-infection. Thereafter there is a more detailed 
introduction to 1) diagnosis of TBM; 2) treatment of TBM. The scientific rationale for the research conducted 
during the PhD is explained.  
Chapter 2 is an overview of PhD aim, objectives, setting and methods. A number of methodologies are used to 
test the pre-specified hypotheses including a retrospective data analysis, two prospective observational 
cohort studies, and a randomized clinical trial. The protocol paper for the clinical trial is featured in the 
Appendix 5.  
PART I – DIAGNOSTIC RESEARCH 
Chapter 3 is a review paper that describes the recent landscape of TBM pathogenesis and diagnostic research. 
Research Paper: Cresswell FV, Davis A, Sharma K et al. Recent updates in pathogenesis and diagnostics of 
tuberculous meningitis. Wellcome Open Research; 2019.  
Chapter 4 is a retrospective cohort study that describes the landscape regarding TBM diagnosis and hospital 
outomes in the PhD study setting. Research paper: Cresswell FV, Bangdiwala AS, Bahr NC et al. “Diagnosis and 
outcomes from tuberculous meningitis in the Xpert MTB/Rif era: findings from a 6.5-year HIV-positive cohort in 
Uganda”. Wellcome Open Res.2018;3:64. 
Chapter 5 Is a prospective diagnostic accuracy study of Xpert MTB/Rif Ultra on cerebrospinal fluid carried out 
in patients presenting to two Ugandan referral hospitals with suspected TBM. Research paper: Cresswell FV, 
Tugume L, Bahr NC et al. Xpert MTB/Rif Ultra for the diagnosis of HIV-associated Tuberculous meningitis: a 
prospective validation. Lancet Infectious Diseases. 2020;20(3):308-317.   
Chapter 6 I investigate the potential of urine diagnostics including Xpert MTB/Rif Ultra and Alere TB-LAM 
lateral flow assay in TBM diagnosis and prognostication.  Research paper: Cresswell FV, Ellis J, Kagimu E et al. 
Utility of urine diagnostics with TB-lipoarabinomannan and Xpert MTB/Rif Ultra in Ugandan adults with HIV-
associated meningitis. Open Forum Infectious Diseases. 2020;7(4):ofaa100.  
xvi 
PART II – TREATMENT RESEARCH 
Chapter 7 is a review article covering the of rationale and evidence relating to intensifying the treatment of 
TBM. This explains why I decided that high-dose rifampicin was the right option to study in Uganda.  Research 
paper: Cresswell FV, te Brake L, Ruslami R, Dooley K, Aarnoutse R, van Crevel R. Intensified Treatment of 
tuberculous meningitis. Expert Review in Clin Pharm.2019;12(3):267-288.  
Chapter 8 is the largest piece of PhD research conducted, a phase II randomised clinical trial of high-dose 
intravenous and oral rifampicin with the aim of characterising the safety and pharmacokinetics of rifampicin in 
blood and cerebrospinal fluid of adults with TBM. The clinical trial protocol has been published as a paper and 
is featured in the appendix. The trial results paper presents the safety and pharmacokinetic data by trial arm. 
Research paper: submitted to Lancet Infectious Diseases.  
PUBLIC ENGAGEMENT 
Chapter 9 describes the series of public engagement activities relating to the PhD, including two community 
events, radio and TV pieces, and several events at HIV clinics or hospitals near the trial sites. The aims and 
outcomes of the public engagement activities are described in an open letter.  Research paper: Cresswell FV, 
Ssebambulidde K, Martyn E et al. Public engagement activities in Uganda on advanced HIV disease, lumbar 
punctures and meningitis. Open letter published on African Academy of Sciences Open Research 2020, 3:33.  
DISCUSSION AND CONCLUSION 
Chapter 10: The discussion provides a summary of the scientific findings of the research conducted, 
limitations of the research, the implications of the findings and plans for future research.  
APPENDIX 
The appendix features the following items: 
1. Systematic review and meta-analysis of TB meningitis outcomes.
2. The uniform TB meningitis clinical case definition.
3. The pilot study of TB-lipoarabinomannan on cerebrospinal fluid conducted during the PhD.
4. The literature search strategy for the review papers.
5. The phase II randomised controlled clinical trial (Rift study) protocol manuscript.





1 Chapter One: Introduction 
1.1 Summary 
1.2 General introduction to HIV-associated Tuberculosis & TB meningitis 
1.2.1  Epidemiology of HIV-associated Tuberculosis 
Tuberculosis (TB), an infection caused by Mycobacterium tuberculosis complex, has been a foe since ancient 
times, with Egyptian mummies providing archeological evidence of spinal TB disease. In the 19th century, TB 
incidence peaked at 1000 per 100,000 (1%) population per year in the USA, and the only available treatments 
were open-air treatment in sanatoria or thoracic surgery.1 Thankfully, with the decline of poverty in the 20th 
This section begins by briefly reviewing the epidemiology, immunological and clinical features of 
Tuberculosis (TB) in relation to HIV infection and touches on why M. tuberculosis has a greater 
predilection for extrapulmonary sites, including the central nervous system, in people with advanced 
HIV-related immunosuppression. An overview on TB meningitis (TBM) epidemiology, pathogenesis, 
clinical features and outcomes in relation to HIV co-infection follows. Thereafter, a more focussed 
introduction into the diagnostics and treatment of TBM is provided.  
Part 1: Diagnostics for TBM: Traditional microbiology techniques such as smear microscopy and culture 
have a number of shortfalls. Nucleic acid amplification tests including Xpert MTB/Rif Ultra and next 
generation sequencing technologies are introduced and remaining research questions around Xpert 
Ultra are presented. Existing urine and CSF biomarkers have poor to moderate diagnostic performance 
but future candidates are more promising. Evidence and research gaps relating to urine biomarkers in 
TBM are described.   
Part 2: Treatment of TBM: Current TB treatment regimens are long, toxic and not universally effective. 
Repurposed or redeveloped (dose-optimised) drugs such as high-dose rifampicin may help to improve 
the efficacy and shorten the duration of TB therapy. Rifampicin is rapidly bactericidal and is the key 
sterilizing drug but inter-individual variability in exposure is large and low rifampicin exposure can lead 
to treatment failure and drug resistance. This is particularly relevant to TBM as only ~5% of plasma 
rifampicin penetrates across the blood-cerebrospinal fluid (CSF) barrier and rifampicin is undetectable in 
the CSF of the majority of TBM patients at the current dose (10 mg/kg). High-dose rifampicin is a 
promising approach for TBM treatment, and generation of safety and pharmacokinetic-
pharmacodynamic data from HIV-positive adults in Africa is a priority.  
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century and the evolution of antituberculous chemotherapy between 1944 and 1980s, outcomes improved 
and transmission declined markedly, such that in 1989 the US Department of Health and Human Services 
planned to eradicate TB from the USA by 2010.2,3 
Alas the progress was short-lived, in part due to a false sense of security that TB was a disease of the past and 
a resultant decline in funding for TB research and treatment,4 but largely due to the unfolding HIV epidemic in 
sub-Saharan Africa in the 1980s. In 2019, M. tuberculosis remained the single leading infectious cause of 
death and one of the top ten overall causes of death worldwide, resulting in 1.4 million deaths amongst the 
estimated 10 million people (range 8.9 to 11.0 million) who fell ill with the disease.5 Illustrated in Figure 1.1 is 
the sharp increase in TB incidence during the 1990s in HIV-endemic parts of Africa. HIV emerged as the 
primary risk factor for the development of TB disease, with the dual infections able to potentiate one 
another’s pathology, a twin epidemic was born. The rapid resurgence of TB as a public health threat led to the 
World Health Organisation (WHO) declaring TB a global emergency in 1993.6 It is estimated that a third of the 
world’s population in latently infected with M. tuberculosis.7  
Figure 1.1 TB incidence rates in WHO regions between 1990 and 2008.8  
TB disease risk is increased at all levels of HIV-related immunosuppression, but the risk increases as CD4 T-cell 
count declines, and is up to 30-fold greater in those with CD4 T-cell count <100 cells/µl, when compared to 
their HIV-negative counterparts.9,10,11 The annual risk of active TB disease in people living with HIV (PLHIV) is 
~10% per year, and can be as high as 30% per year with advanced HIV disease.10,11 Unfortunately, even when 
HIV antiretroviral therapy (ART) has been successfully initiated and CD4 T-cell count has normalized, the TB-
risk remains elevated (up to 5-fold) compared to HIV-negative adults,12 suggesting there is a persistent deficit 
in the host immune response to M. tuberculosis. The proportion of incident TB which relates to reactivation of 
latent disease or de novo infection in PLHIV is likely to vary depending on regional TB prevalence; evidence 
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from South African gold miners suggests that reactivation of latent disease is the main cause of TB in early HIV 
infection, but with more advanced HIV immune suppression active TB more commonly reflects rapid 
progression of disease following recent (re)infection.13,14  
Despite the rapid scale up of ART and a decline in peak annual HIV incidence, 38 million [95% confidence 
interval (CI) 31.6-44.5 million] people were living with HIV in 2019, two-thirds of which are in the WHO Africa 
region, equating to 1 in every 25 adults aged 15-49 years (3.7%).15 Worldwide in 2019, 815,000 [95% CI 
729,000-906,000] new TB infections occurred in PLHIV, 
73% of which were in the WHO Africa region, resulting 
in 208,000 deaths from TB in PLHIV.5  TB remains the 
leading cause of mortality in PLHIV, but thankfully there 
is a gradual decline in TB mortality in both HIV-positive 
and negative persons (Figure 1.2), though perhaps not 
marked enough to meet the WHO End TB strategy goals 
of reducing deaths from TB by 90% by 2030, compared 
with 2015.16 
Figure 1.2. Global trends in estimated number of deaths caused by HIV and TB, 2000-2018. The shaded area = uncertainty intervals.17  
1.2.2 Immunological and clinical features of HIV-associated TB 
Protective immune responses to TB are incredibly complex and involve both the innate and adaptive immune 
system and granuloma formation at the site of primary infection in the lungs. As well as depleting CD4+ T-cell 
numbers, HIV infection impairs CD4+ T-cell function, with potential mechanisms including impaired activation 
of macrophages and recruitment of monocytes, and reduced capacity to secrete chemokines and cytokines.18 
HIV also impairs neutrophil function, the importance of which has more recently been discovered, through 
impaired phagocytosis and killing capacity.19,20 
Granuloma formation, comprising a multicelluar ecosystem of activated macrophages, T-cells, B-cells, 
neutrophils, fibroblasts, and dentritic cells, works to contain M. tuberculosis and prevent dissemination to 
extra-pulmonary sites.11 However, as a result of impaired cell-mediated immunity in HIV co-infection 
granuloma formation fails, and whilst the host is spared the cavitating lung disease which relates to 
granuloma formation, the bacilli more commonly enter the lymphatic system or are haematogenously 
disseminated to multiple organs including the brain. In the context of HIV-associated CD4+ T-cell depletion 
and dysfunction M. tuberculosis bacteraemia can be detected in 10-40% of febrile TB patients, which results 
in the seeding of meninges (and other bodily organs) with bacilli.21,22  
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The classical spectrum of clinical outcomes of exposure to aerosolized M. tuberculosis is illustrated in Figure 
1.3a, the red lines signify the more common outcomes in people with advanced HIV-related immune 
dysfunction and resultant failure to control bacillary replication. More recently it has been recognized that the 
two-state paradigm - latent TB infection (LTBI) and active TB disease - is too simplistic, in fact it there is an 
undulating disease course from the latent state to the active disease state which passes through the ‘minimal’ 
disease and ‘sub-clinical’ disease states, illustrated in Figure 1.3b. During the minimal disease state the 
individual remains asymptomatic but there is evidence of metabolic activity at the site of infection and 
incipient disease through evolving radiological changes (on X-ray, computerized tomography (CT), or positron 
emission tomography (PET) scan).23,24 During sub-clinical disease M. tuberculosis can be cultured from the 
sputum despite the absence of any symptoms of TB disease, potentially contributing to community 
transmission.25 The optimal way to diagnose and treat these intermediary disease states remains to be 
determined. It is also known that people can self-clear LTBI infection (i.e. without antimicrobial therapy) but 
this relies on a robust host response and is unlikely to be achievable with advanced HIV-related immune 
suppression, indeed it is more likely to be the case that individuals with immune suppression progress more 
rapidly towards the active disease state.     
 
Figure 1.3a and b. Spectrum of outcomes following exposure to M. tuberculosis. Adapted from H. Esmail11 
1.3a. Solid lines show common outcomes/routes of progression. Dashed lines show infrequent routes of progression. Red lines signify 
that the outcome or route of progression is more common in those with impaired cell-mediated immunity (e.g. advanced HIV). Blue 
lines signify that the outcome/route of progression is more common in immunocompetent hosts.  
1.3b. Latent TB infection progresses to the active TB disease state over a period of months or even years through states called minimal 
and sub-clinical TB. TST = tuberculin skin test, IGRA = interferon gamma release assay, H = isoniazid, P = rifapentine, Sm = smear 
microscopy 
The clinical presentation of HIV-associated TB differs depending on the extent of host immune suppression. A 
study in Uganda found that at higher CD4 T-cell counts (>300-400 cells/µl) apical pulmonary cavitatory disease 
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and sputum smear positivity is similar to HIV-negative counterparts. However, as CD4 T-cell count declines 
lymphadenopathy, pleural effusions, miliary disease pattern, and lower lung field disease become more 
common.26,27  
Post-mortem studies have established that TB disease at the time of death is a commonplace in hospitalized 
PLHIV in sub-Saharan Africa. In a 2015 meta-analysis, TB was found in 43% (95% CI 38-48%) of HIV-positive 
cadavers, it was disseminated in 88% of cases, and due to the atypical presentation of TB in advanced HIV 
disease it was often unsuspected at the time of death.28 The lungs commonly show a miliary pattern as well as 
consolidation, and spleen, liver, bone marrow were also frequently affected organs.29 Given that 
haematogenous dissemination (miliary TB) deposits bacilli throughout the body, it is unsurprising that a 
significant proportion of cadavers with disseminated TB have central nervous system (CNS) involvement; a 
Kenyan autopsy study found that 26% of cadavers with disseminated TB had evidence of meningeal 
involvement.30   
1.2.3 Tuberculous meningitis epidemiology 
Dr James Hakim, a Zimbabwean Physician, described the marked change in the pattern of meningitis seen in 
Harare Central Hospital in the 1990s; total patient admissions increased from 53,000 to 73,000 per annum 
and rates of meningitis rose from 78 to 523 cases per 100,000 admissions per year between 1985 and 1995. 
He goes on to describe how in 1985 bacterial meningitis was the most common cause of meningitis (92.5%) 
but by 1995 this had fallen to 25.5% with TBM accounting for 28.3% of cases (up from 2.5% in 1985).31 This 
shift in meningitis aetiology has occurred in many HIV endemic high TB prevalence countries, and M. 
tuberculosis is now the second leading cause of meningitis in adults in South Africa and Uganda (after 
cryptococcal meningitis).32,33,34  
Accurate national epidemiological data about tuberculous meningitis (TBM) incidence in many TB endemic 
countries is lacking, due to both challenges in making a diagnosis and weak reporting systems. Robust national 
level TBM data is available from only a few countries and is summarised in Table 1.1.  












USA 35 2016 9272 1882 84 0.9 National 
CHINA 36 2008-2017 19279 6433 440 2.3 Hospital 
CANADA 37 1970-2001 82764 - 824 1.0 National 
UK 38 2019 4651 2759 98 2.1 National 
GERMANY 39 2002-2009 46,349 - 422 0.9 National 
Table 1.1 Reported TB meningitis data in relation to TB and extra-pulmonary TB.  
Based on the above data, and a global TB incidence of 10 million cases in 2019,5 a conservative estimate of 
~1% of all TB cases being TBM would give a global burden of ~100,000 cases/year.40 However, the true burden 
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is likely to be somewhat greater than 100,000 cases/year as disseminated extra-pulmonary manifestations of 
TB are more common in settings of high HIV and TB prevalence, from which data are not available. Some 
experts estimate that in sub-Saharan African countries TBM could represent up to 5% of all TB cases.41 
Modelling studies are required to obtain a more accurate estimate of true global burden of TBM.  
1.2.4 Pathogenesis of HIV-associated TB meningitis 
As early as 1992, it was reported that extra-pulmonary TB, in particular TBM, occurred with greater frequency 
in people with TB who were HIV co-infected.42 The contemporaneous nature of disseminated TB, miliary TB 
and TBM observed in the post-HIV era differs from the pathological model of Arnold and Rich, whose autopsy 
work in the USA in 1946 lead to the proposition that TBM begins from the rupture of a single long-standing 
granuloma (a Rich focus) on the meninges or cortex.43 Whilst the Arnold and Rich model may still hold true for 
immune competent hosts, more recent post-mortem studies in Africa suggest that meningeal involvement is 
part of a more broadly generalised picture in HIV/TB.29 A similar phenomenon is also observed in childhood 
TBM, in whom miliary TB and TBM develop most often within 3 months of primary infection, when fresh 
anatomic changes are still found in the primary lung focus.44,45 
Following bacillary invasion of the subarachnoid space, host 
immune responses give rise to a granulomatous 
inflammation predominantly affecting the basal meninges. 
The inflammatory exudate can obstruct the normal flow of 
CSF, resulting in hydrocephalus, raised intracranial 
pressure, cerebral hypoxia and infarction. Even in the 
absence of hydrocephalus, vasculitis of small and medium 
size blood vessels is common resulting in stroke in up to 
60% of TBM patients.46 The spectrum of brain pathology is 
illustrated in Figure 1.4. 
Figure 1.4. Pathological features of TB meningitis. Clockwise from top left: basal meningeal exudate; cerebral middle cerebral artery 
territory infarct; enlarged ventricles as a result of hydrocephalus; tuberculous brain abscess.  
Research is underway to fully characterize the immune response in different populations with the hope of 
identifying a host-directed therapy capable of regulating the aberrant response and improving outcomes. CSF 
cytokine profiling from Vietnamese HIV-positive adults with TBM suggest that the immune response is 
dysregulated and ineffective (rather than attenuated) in advanced HIV-associated TBM and highlights a role 
for neutrophils in the pathogenesis.47 Further detail relating to the pathogenesis of TBM are given in the 
















1.2.4.1 Immune reconstitution inflammatory syndrome  
Antiretroviral therapy is essential in combatting TB and HIV co-infection, but can be complicated by immune 
reconstitution inflammatory syndrome (TB-IRIS). ART results in a rapid restoration of TB-specific immune 
response which can be associated with a systemic inflammatory picture or worsening of CNS symptoms in 
TBM. Depending on the TB treatment status at ART initiation, this immune-mediated worsening of TB 
pathology can take the form of paradoxical TB-IRIS, ART-associated TB or unmasking TB-IRIS, see Figure 1.5. 
IRIS has been reported in 8%-40% of people with HIV/TB following ART initiation.48 Predictors of IRIS include a 
baseline CD4+ T-cell count <50 cells/μL, rapid restoration of CD4+ T-cell counts, rapid decline in on-ART HIV 
viral load, and severity of TB disease.48,11 A consensus IRIS case definition has been created to support 
diagnosis and standardise classification, though it requires failure of TB therapy (e.g. resistance or poor 
adherence), drug reactions and opportunistic infections to be excluded, all challenging in LMIC settings.49  
Figure 1.5. Chronological illustration of 
paradoxical immune reconstitution 
inflammatory syndrome (IRIS), 
antiretroviral therapy (ART)-associated 
tuberculosis (TB) and unmasking TB-
IRIS. 49  
1.2.5 Clinical features of HIV-associated TB meningitis 
After an initial non-specific prodrome, the meningitic symptoms of headache, neck stiffness and vomiting 
develop. As the intracranial pathology progresses altered mental status and focal neurological deficits 
including cranial nerve palsies and hemiplegia ensue. This progresses to certain death without treatment. 
Most of the evidence suggests that HIV co-infection does not significantly influence the age of clinical 
presentation of TBM in adults, the interval from symptoms to clinical presentation, or the neurological 
findings at clinical presentation.50 However, abnormal clinical findings outside the CNS occur more frequently 
in HIV-positive patients, including low body mass index, other features of HIV disease and TB involvement of 
other organs, including pulmonary, nodal, spinal, pleural and abdominal disease.42,51,52 In Vietnam, Thwaites et 
al. found an independent association between multidrug resistant (MDR) TBM and HIV co-infection, which 
occurred in 13% of HIV-positive and 4% of HIV-negative patients.53  
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1.2.6 Clinical outcomes from HIV-associated TB meningitis  
Survival from TBM varies drastically in the literature by geographical region and HIV status, the reasons for 
which are unclear. Meta-analysis of data from 748 HIV-positive and 951 HIV-negative Vietnamese adults with 
TBM found HIV co-infection to be a strong independent predictor of 9-month mortality [hazard ratio (HR)=3.94; 
95% CI 2.79–5.56].54 Amongst PLHIV, other baseline characteristics which were associated with 9-month 
mortality were lower weight, higher Medical Research Council (MRC) severity grade, lower plasma sodium, 
lower CD4 T-cell count and lower CSF lymphocyte count, as shown in Table 1.2.55  
HIV-negative HIV-positive 
Variable HR (p-value) Variable HR (p-value) 
Age [per +10 years] 1.24 (<0.001) Low weight [per +10kgs] 0.73 (<0.001) 
Previous TB treatment 1.57 (0.015) MRC grade II/III 4.08 (<0.001) 
MRC grade II/III 3.05 (<0.001) Plasma sodium [115vs125 mmol/l] 1.63 (<0.001) 
Focal neurological signs 1.65 (0.007) CD4 count* 0.9 (0.002) 
No dexamethasone 1.97 (<0.001) CSF lymphocytes* 0.93 (0.004) 
CSF lymphocyte count 0.86 (<0.001)   
HR=hazard ratio, * = HR per 2-fold increase 
MRC grade I = Glasgow coma scale (GCS) 15 and no focal neurology 
MRC grade II = GCS 15 with focal neurology or GCS 11 to 14 without focal neurology 
MRC grade III = GCS<10 with or without focal neurology  
Table 1.2. Final Cox regression models for 9-month mortality in Vietnamese TBM cohort54 
However, it is not clear whether these findings are generalizable to other geographical regions. The extent of 
the heterogeneity in clinical outcomes in other populations remained to be described, which prompted myself 
and colleagues to perform a systematic review and meta-analysis on global TBM outcomes. This has recently 
been published in Open Forum Infectious Disease and is included in Appendix 1. We reviewed 2,197 articles, 
selected 39 eligible studies including data for 5752 adults with TBM from 18 countries.  
Our data demonstrated a 3-
fold higher pooled-mortality in 
PLHIV, overall mortality was 
57% (95% CI 48-67%), versus 
16% (10-24%) in HIV-negative 
adults. HIV status explained a 
significant amount of the 
heterogeneity in mortality 
between studies (P <0.01), 
Figure 1.6.56   
Figure 1.6. Forest plot depicting TB meningitis mortality by HIV status. Reproduced with permission from Stadelman, OFID, 2020.56   
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We also described global disparities in TBM outcomes by geographic region; mortality varied widely within 
and between regions with studies from sub-Saharan Africa having a range of 23-80% and Asian studies 
ranging from 2-67%. Pooled mortality by country, and the relative paucity of studies from Africa, South and 
Central America is illustrated in Figure 1.7.  
Figure 1.7. TB meningitis pooled mortality by country. For countries with only a single study the mortality shown relates to the single 
study. Reproduced from Stadelman, OFID, 2020.56   
Additionally, temporal change in pooled mortality was reviewed in 5-year intervals between 1995 and 2018. 
Reported TBM outcomes have not improved over two decades, the possible reasons for which are manifold, 
but the observation highlights that we still have a long way to go in optimising the diagnosis, treatment and 
outcomes from this illness.  
Further studies in PLHIV are required to identify the unique determinants of the 3-fold increased mortality. 
Possible explanations include: 
1. Diagnostic delay may be greater in HIV – the CSF picture can be atypical.57
2. Altered pharmacokinetics of TB drugs - adults with advanced HIV frequently suffer with diarrhoea,
HIV-associated enteropathy and wasting, which have been associated with malabsorption and
reduced bioavailability of antituberculous therapy.58
3. Concomitant HIV-related illnesses may contribute to the poor outcomes observed. One report
suggests that AIDS-related illnesses accounted for up to 50% of the mortality in children with TBM
who are not on ART.59 There is no good data co-infections/morbidities from adults.
4. Different immune response in HIV – host response could be attenuated, aberrant or excessive within
the CNS or more systemically.60
5. TB immune reconstitution inflammatory syndrome may also play a role in TBM morbidity and
mortality in HIV.61,62
6. Misclassification of non-TB brain infection as TBM and resultant lack of response to TB therapy and
poor outcome
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As well as death, long-term disability is a major challenge in TBM, exacerbated by the lack of rehabilitation 
services in low- and middle-income countries (LMIC). In our systematic review, long-term disability was 
reported in around a third of TBM survivors (32% [95% CI 22-43%] by Barthel Index and 26% [18-35%] by 
modified Rankin scale).56  
1.3 Part I introduction: Diagnostics for TB meningitis 
Here, I focus more specifically on the diagnostics of TBM. Given my work seeks to improve diagnostics of HIV-
related TBM I give more weight to modalities that are likely to be relevant and scalable to high TB and HIV 
prevalence settings. The research paper on Recent Developments in Tuberculous Meningitis Pathogenesis and 
Diagnostics in chapter 3 covers general diagnostic insights from the last 5 years in more detail so this 
introduction provides further background information and probes more deeply into diagnostic considerations 
in HIV-associated meningitis in particular.  
Making a TBM diagnosis is a challenge. There are a number of reasons for this; first, a diagnosis of TBM can 
only be confirmed by collecting a CSF sample via a lumbar puncture, an invasive procedure that carries risks of 
infection, bleeding and nerve damage if not done correctly. The procedure requires a spinal needle and an 
appropriately trained healthcare worker, neither of which are universally available in hospital settings in LMIC 
settings. In addition, the patient or their family may refuse to have the procedure due to misconceptions 
about lumbar punctures killing people, when actually it because they are generally only performed when a 
patient is very sick and therefore at high risk of dying from the underlying disease. The myths and resistance 
around lumbar punctures prompted me to undertake some public engagement activities which are detailed in 
chapter 9. Further, lumbar puncture is contraindicated in people with space occupying lesions in the brain 
which can be common in CNS TB infection due to tuberculomas or tuberculous abscesses. The second 
challenge is that the CSF sample should be processed quickly before cells decay outside the body and it 
requires a degree of laboratory expertise to get an accurate CSF microscopy result. Even with the best 
laboratory expertise and equipment the currently available diagnostics are only moderately sensitive and thus 
can yield a negative result when the patient actually has the disease. Thirdly, deciding whether or not to 
initiate TBM treatment is often a highly emotive decision; not initiating treatment in someone who has the 
disease will result in certain death, yet initiating treatment in someone who does not have TBM, condemns 
the individual to 12 months of antituberculous therapy from which pill burden, toxicity and drug-drug 
interactions are a real problem. Even in research settings such as clinical trials a microbiologically-confirmed 
diagnosis is only made in around half the participants.63  
An additional challenge is encountered in HIV endemic settings - distinguishing TBM from other a host of 
other subacute meningoencephalitides seen in advanced HIV disease.64 Mimics of TBM include cryptococcal 
meningitis, cytomegalovirus encephalitis, cerebral toxoplasmosis, primary CNS lymphoma, and bacterial 
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meningitis. Thankfully point of care cryptococcal antigen testing (CrAg LFA, IMMY, Norman, OK, USA) can now 
assist the diagnosis of cryptococcal meningitis at the beside (provided testing kits are available), or CSF can be 
sent to the laboratory for India Ink staining.64  Distinguishing viral meningitides from TBM is possible if viral 
polymerase chain reaction (PCR) assays are available in the hospital laboratory, something currently not 
available in government facilities in Uganda.  
However, due to the lack of a widely available, rapid, accurate diagnostic test for TBM and the challenges in 
excluding other conditions in the differential diagnosis in LMIC settings a sensitive and specific clinical 
algorithm would be a useful tool in supporting clinicians in making the difficult decision about treatment 
initiation. 
1.3.1 Clinical models 
Nine clinical models have been created in an attempt to distinguish adult TBM from other causes of 
meningitis including cryptococcal meningitis and bacterial meningitis.65,66,67,68,69 The Thwaites et al. algorithm 
(which includes age, duration of symptoms, blood white cell count, CSF white count and neutrophilia), 
demonstrated high sensitivity and moderate specificity (91.7% and 79.7% respectively) when evaluated 
prospectively in Vietnamese HIV-negative patients.70 However, sensitivity and specificity declined to 78% and 
43% respectively when it was used in a Malawian population with high HIV prevalence.71 No published models 
can effectively differentiate TBM from a host of other neurological pathologies found in HIV-positive adults.66  
There is therefore interest is using modern data science techniques to derive a multivariable clinical 
prediction model from large individual patient datasets from different geographical settings.72 This model 
could be accessible via a mobile phone application, giving clinicians a percentage likelihood of their patient 
actually having TBM based on a variety of available clinical or laboratory parameters.  
1.3.2 Uniform clinical case definition 
In 2010 a group of experts in the field defined the uniform TBM clinical case definition, which defines cases as 
‘definite’, ‘probable’, ‘possible’ or ‘not TBM’ based on the number of points derived from criteria including 
clinical, CSF, brain imaging and evidence of TB elsewhere in the body (see Figure 1.8 and proforma in 
Appendix 2 for further details).73 It is important to note that this case definition was not designed as a 
diagnostic aid, it is a standardised tool intended for use when classifying enrolees in research studies on novel 
diagnostic assays or therapeutics in the absence of a perfect gold standard. This case definition was derived 
by expert consensus rather than being data-driven and may therefore perform better in some contexts than 
others.  
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Figure 1.8. Consensus uniform case definition for tuberculous meningitis research 
The potential to score points in this tool is affected by the ability to comprehensively investigate patients with 
brain, chest and abdominal imaging as well as microbiological sampling from outside the CNS; in LMIC settings 
the ability to score a high number of points may therefore be compromised.  
1.3.3 CSF microscopy 
TBM classically causes a marked CSF lymphocyte pleocytosis, high protein and low glucose (white cells >5 
cells/µl, protein >45g/l, glucose <2.2mmol), however this “typical” pattern occurs in under two-thirds of HIV-
positive TBM patients making the diagnosis more challenging.74 In our retrospective cohort of TBM patients in 
Kampala (chapter 4), a third (25/76) of patients with TBM microbiologically-confirmed (by Xpert MTB/Rif or 
culture) had an acellular CSF (<5 cells/µl) and 4% (3/76) also had normal CSF protein and glucose.57 This 
finding is consistent with other HIV-positive cohorts (at least outside of Asia) and highlights the additional 
challenge faced in diagnosing HIV-associated TBM.51,52,65,75  
CSF Ziehl-Neelsen (ZN) staining for the presence of acid-fast bacilli (AFB) is probably the most widely available 
diagnostic test worldwide. However, the low bacillary burden renders CSF smear microscopy a poor test in 
most settings, even with the presence of an expert microscopist who can dedicate the requisite length of time 
to reading each slide. Centrifugation of large volume CSF followed by examination for >30 minutes by an 
expert microscopist in a Vietnamese research facility yielded a positive result in 58% of TBM cases.76 However, 
this is not achievable in most busy public hospital laboratories. In Uganda, sensitivity of ZN stain is at best 22% 
in the Makerere University Microbiology Laboratory.77,78 A modified ZN stain with cytospin, which includes 
centrifugation and an additional Triton-X processing step, is intended to enhance intracellular staining of 
mycobacteria in CSF and make detection by the microscopist easier. Modified ZN stain was recently tested in 
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Xpert MTB/Rif and culture in a 618-participant study (194, 31.4% of whom were HIV-positive) with the 
uniform case definition of definite/probable/possible TBM as the reference standard. Sensitivity of 
conventional ZN and modified ZN were 33.9% and 34.5% respectively (P=1.0 for the difference between 
tests), sensitivity of culture and Xpert were 31.8% and 25.1% respectively. When using culture as a reference, 
sensitivities of conventional ZN, modified ZN, and Xpert were 66.4%, 67.5%, and 72.3%, respectively. In 
summary, the more complex procedure did not improve performance.79 Use of an ESAT-6 intracellular 
immunocytochemical stain has also been studied in a small number of patients in China with performance 
similar to the modified ZN with cytospin.80,79 Auramine stain with fluorescence microscopy or light emitting 
diode-based fluorescent microscopes can improve bacillary detection further, though there is a lack of good 
data on this in TBM.  
1.3.4 CSF TB Culture 
The major downfall of culture is that turn-around time (around 7 to 30 days) is too slow to guide clinical 
care.77 Although liquid culture with a mycobacterial growth indicator tube (MGIT) theoretically has a limit of 
detection of ~10 colony forming units (CFU)/ml it can only detect viable bacilli and thus is of limited use in 
those on antituberculous therapy, following delays in sample processing or where bacilli have been damaged 
by host inflammatory response. The sensitivity of liquid culture ranges between 43% (10/23) to71% (94/132) 
when measured against definite/probable TBM alongside AFB smear microscopy +/- Xpert +/- Ultra.77,76,81,82 
Lastly, culture techniques are not widely available in many of the highest burden settings or are limited to 
retreatment cases where there is a concern for drug resistance. Nonetheless, in the absence of a better test 
for TBM, culture techniques continue to have a place in the diagnostic repertoire and have the added 
advantage of being able to provide information on the number of days to positivity (which gives an indication 
about bacillary load) and phenotypic drug susceptibility can be performed on the isolate.  
1.3.5 Molecular tests / nucleic acid amplification tests 
Nucleic acid amplification tests (NAAT), including polymerase chain reaction, were developed in the 1980s and tests for TB have been available since the 1990s. Comm r ial assays (e.g. Roche, Amplicor M. 
tuberculosis) are costly (£25-50 per test) and require experienced laboratory technologists, as well as costly 
equipment and reagents, precluding their use in many settings.83 Line-probe assays such as Genotype 
MTBDRplus (Hain LifescienceGbmH, Nehren, Germany) are widely used to genotype culture isolates and 
rapidly determine whether rifampicin or isoniazid-resistance is present, but they can also be done directly on 
the CSF specimen.84 Currently, many laboratories in higher income settings with the requisite expertise use 
their own ‘in-house’ TB PCR assay, which uses more cost-effective equipment and reagents available from 
diverse suppliers (~£15 per test) and can involve primers for the IS6110, 16S rDNA or any other region of the 
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genome which uniquely identifies M. tuberculosis complex.85 A systematic review and meta-analysis including 
14 studies on commercial NAATs reported a pooled sensitivity of 56% (95% CI 46-66%) and specificity of 98% 
(95% CI 97-99%).85 The summary accuracy could not be determined for the 35 ‘in-house’ tests as the results 
were too heterogeneous.85 The loop-mediated isothermal amplification (LAMP) assay is a low cost, low tech 
option but does not have any advantages over the Xpert MTB/Rif system.86,87 
1.3.5.1 Xpert MTB/Rif 
The Xpert MTB/Rif (Xpert) assay, Figure 1.9, a cartridge-based system, was developed by researchers from 
Rutgers New Jersey Medical School and the biotech company Cepheid to overcome the need for laboratory 
expertise, sample processing which can generate aerosols, and reagents which are prone to stocking out. 
Xpert uses a hemi-nested PCR to amplify the rifampicin resistance-determining region of the rpoB gene and 
has a run-time of about 2 hours.88 Five rpoB molecular beacons detect both the presence of M. tuberculosis 
and mutations responsible for approximately 95% of rifampicin resistance. Owing to its ease of operation and 
large-scale applicability outside conventional laboratories, the WHO recommended the use and rapid scale up 
of Xpert in 2010. An unprecedented uptake followed, with over 2300 GeneXpert instruments and 6 million 
cartridges procured in the public sector in 104 countries by March 2014. In 2013, the WHO expert group 
made a policy update which widened the recommended use of Xpert to cover paediatric TB, extra-pulmonary 
TB, TBM, HIV-associated TB and as an initial test (before smear microscopy) for pulmonary TB.89,90 
In analytical studies, Xpert has a limit of detection (LOD) of 
113 CFU/ml (95% CI 91.9-158.2).88,91 Using pooled data 
from 13 studies Xpert in CSF showed a sensitivity of 80.5% 
against culture and 62.8% against a clinical reference 
standard. Xpert had a consistently high specificity of 
~99%.92 In HIV-positive adults in Uganda, a sensitivity of 
72% against a culture-based reference standard has been 
reported when a good volume of CSF (>6mls) is 
centrifuged prior to analysis.77  
Figure 1.9. Illustration of Xpert MTB/Rif assay and procedure.93  
Despite Xpert representing a huge step forward in TB diagnostics in LMIC settings, the developers of Xpert 
recognised its limitations in terms of sensitivity on smear-negative and extra-pulmonary samples and in the 
diagnosis of rifampicin resistance (which frequently gave ‘indeterminate’ results) and continued to refine the 
assay. The next generation assay, Xpert MTB/Rif Ultra (Xpert Ultra), intended to improve on these issues was 
endorsed by the WHO in 2017.  
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1.3.5.2 Xpert MTB/Rif Ultra 
The Xpert MTB/Rif Ultra assay has a number of technical optimisations: i) two additional probes targeting two 
multicopy genes (IS6110, IS1081) ii) a re-engineered cartridge that doubles the amount of sample that can be 
tested iii) optimised thermal cycling, iv) a semiquantitative ‘trace’ category corresponding to the lowest 
bacillary burden.91,94  In analytical studies Xpert Ultra has an LOD of 16 CFU/ml, an 7-fold improvement on 
Xpert (Figure 1.10).91 The sensitivity of Xpert Ultra persists at sub-LOD concentrations, with 48% of the 
samples tested being positive by Ultra at 2.5 CFU/ml.91 
Figure 1.10. Xpert and Xpert Ultra limit of detection for M. tuberculosis H37Rv. The limit of detection of tuberculosis detection is 
shown for Xpert (A) versus Ultra (B). The limit of detection for generating a rifampicin susceptibility rather than an indeterminate 
result is shown for Xpert (C) versus Ultra (D).91  
The first diagnostic accuracy study comparing Xpert Ultra to Xpert MTB/Rif in pulmonary TB used culture as a 
reference standard and found a 5% higher sensitivity overall, with highest sensitivity increases of +17% among 
smear-negative and +12% among HIV-positive patients. However, these gains came at the expense of 
specificity, which was 2.7% lower, with specificity-decreases highest in patients with a history of TB who had 
completed treatment in the last 2 years (-5.4%, 95% CI -9.1 to -3.1).94,95 Of the 43 participants who were 
positive by Xpert Ultra whilst negative by culture, next generation sequencing of amplicons from 12/14 
cartridges confirmed the presence M. tuberculosis DNA suggesting that these are not false-positive DNA 
results per se, though whether the presence of DNA signified presence of active TB disease was uncertain.95 
The authors believe Ultra-positive culture-negative results represent the presence of M. tuberculosis DNA 
fragments or intact bacilli (living or dead) which are not culture-viable or below the LOD on culture.95 It has 
since become clear that people who have been successfully treated for pulmonary TB can remain positive on 
Xpert Ultra (usually trace category) for years after completion of therapy. This complicates the interpretation 
of results in people with a history of TB and has led to difficult decisions by clinicians and stakeholders about 
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the trade-off between increased sensitivity and earlier treatment of paucibacillary individuals but over 
treatment of people with a prior history of TB. A microsimulation modelling approach has estimated that 7 
unnecessary treatments are generated per TB death averted when switching from Xpert MTB/Rif to Xpert 
Ultra in a South African setting, excluding the benefits of reduced transmission.96   
Despite these challenges, in 2017 the WHO endorsed transitioning to Xpert Ultra in all settings. The Xpert 
Ultra assay can be run on the same machine, simply requiring a software update, and has a slightly shorter 
run time of 84 minutes. It has proven highly specific when tested on 30 different isolates of nontuberculous 
mycobacteria (NTM) and 18 bacteria to assess potential cross-reactivity.91  
At the time of planning my PhD research, there had only been a single study of Xpert Ultra on CSF, conducted 
by our research team in Uganda, in which I contributed by supporting the processing of stored samples with 
the Xpert Ultra cartridges and manuscript write up. We evaluated Ultra on cryopreserved CSF from 129 
predominantly HIV-positive individuals with suspected meningitis at Mbarara Regional Referral Hospital from 
February 2015 to November 2016.81 This study used MGIT culture, Xpert MTB/Rif and Xpert Ultra in the 
diagnostic panel and TB was microbiologically-confirmed in 22/129 (17.1%) of CSF samples, of which 21 were 
positive by Xpert Ultra, 10 were positive by Xpert MTB/Rif and 10 by MGIT culture (Figure 1.11).  
Figure 1.11. Venn diagram illustrating overlap of positive CSF tests for M. tuberculosis in the 2018 Xpert Ultra study using 
cryopreserved CSF81 
In the absence of a suitable gold standard we used a composite 
reference standard (any positive CSF test for M. tuberculosis, i.e. definite 
TBM with inclusion of the Ultra result) for evaluating the performance of 
Ultra. Compared to a composite reference standard, sensitivity of Xpert 
Ultra was 95% (21/22, 95% CI, 77-99%), significantly greater than either 
Xpert MTB/Rif or MGIT culture (both 45% sensitive, 10/22, P<0.0034).97 
Against a clinical reference standard of ‘probable/definite’ TBM73 we 
found that Xpert Ultra had a lower sensitivity of 70% (95%CI 47 to 87; 16 
of 23 cases) suggesting that up to 1 in 3 of TBM cases remain negative by all tests. Alternatively, it may be the 
case that the category of ‘probable’ TBM is non-specific and people with non-TB related brain pathology (for 
example tumours or viral encephalitides) are being incorrectly included in the probable category.  
Following this first study on Xpert Ultra in TBM using cryopreserved samples some questions remained in my 
mind which warranted further investigation in a prospective study, namely: 
1. What is the performance of Xpert Ultra on fresh CSF samples?
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3. If the sensitivity of Xpert Ultra is 70% for definite/probable TBM, is it possible to identify missed TBM
cases by CSF culture, post-mortem examination in deceased patients without an antemortem
diagnosis, and metagenomic next generation sequencing.
4. Are patients with alternative non-TB infection or pathologies misclassified as possible/probable TBM?
This prompted the prospective Xpert Ultra diagnostic accuracy study which features in chapter 5. 
1.3.5.3 Next-generation sequencing technologies 
The existing paradigm for diagnosing a neurological infection relies on a clinician formulating a differential 
diagnosis and sending CSF for a battery of tests. However, given that CSF volume is usually limited it can be 
impossible to perform all the tests of interest, and further the clinician may not have considered the actual 
pathogen responsible, especially true for rare pathogens or atypical presentations. As such, even with the 
diagnostics available in a higher-income setting hospital laboratory only about 50% of meningoencephalitis 
cases have a cause identified. Failure to obtain a timely diagnosis contributes to poor outcomes and high 
healthcare burden.98   
Unbiased metagenomic next generation sequencing (mNGS) approaches do not require a priori selection of a 
pathogen and allow for the identification of a multitude of potential pathogens (spanning bacterial, viral, 
fungal, parasitic) to be identified by a single assay (Figure 1.12). The technique has proven useful in identifying 
pathogens missed by conventional microbiology techniques in recent study of 204 meningoencephalitis cases 
in the USA.98 Sequencing platforms are increasingly available in LMIC settings, a bioinformatic pipeline is 
available through a cloud-based system mitigating the need for large servers in-country, and the cost is 
coming down rapidly.   
There is a single published small Chinese study on CSF mNGS in comparison with ZN stain, PCR and culture in 
23 patients who were treated for TBM of which 12 were definite cases. Amongst definite cases mNGS had a 
sensitivity of 66.7% (8/12). Further, mNGS detected M. tuberculosis complex DNA in 10 of the 11 samples who 
were clinically treated for TBM without a positive ZN stain, Xpert or culture.99 Unfortunately the uniform case 
definition was not used to classify cases and no detail is given about the abundance of reads to M. 
tuberculosis. 
For pathogens of interest which are usually present at very low abundance (e.g. M. tuberculosis), enrichment 
techniques can be used to increase the abundance of DNA prior sequencing to increase the likelihood of 
detection, a so called ‘biased’ approach. Given that TBM is a paucibacillary condition, enrichment techniques 
may be particularly useful. A Chinese paper has investigated a clustered regularly interspaced short 
palindromic repeat (CRISPR)-associated proteins (Cas) enrichment technique prior to conventional PCR, 
alongside Xpert and culture on 26 CSF samples from individuals treated for TBM. CRISPR-MTB had a sensitivity 
of 73%, higher than Xpert (54%) and culture (23%), against a reference of clinically treated TB (uniform case 











Figure 1.12. Metagenomic next-generation sequencing in the diagnosis of meningoencephalitis. Adapted from Ramachandran Nature 
Reviews Neurology 2020.101 
Next generation sequencing (Figure 1.12) for TBM is a relatively data free zone, for now at least. During the 
course of my PhD, we formed a collaboration with Dr Wilson and Dr Ramachandran, Neurologists at the 
University of California San Francisco (UCSF), supported by a US National Institute of Health R01 award 
(Principal Investigator Dr M Wilson, UCSF). Samples of CSF from adults with a suspected brain infection in 
Uganda were shipped to the UCSF Chan Zuckerberg Biohub for DNA and RNA sequencing. Firstly, Dr Wilson 
was keen to explore whether mNGS could be coupled with a CRISPR-Cas9 enrichment technology tool that 
enriches pathogen sequences of interest to improve detection of TBM. Secondly, given that 90-98% of mNGS 
sequencing data is derived from the host (rather than pathogen), host transcriptomic profiling (HTP) may 
identify pathogen-specific signatures which could be used for diagnostic purposes. Dr Wilson’s team 
combined CSF mNGS and HTP to identify cases of TBM missed by Xpert Ultra and to identify other potential 
pathogens misclassified as TBM. This work, if successful, holds promise of better meningoencephalitis 
diagnosis in future, but thought needs to be given to how this technology can be used in real-time to guide 
patient care and how it can be applied to LMIC settings.  
1.3.6 CSF Biomarkers 
In light of the fact that TBM is a paucibacillary disease with marked inflammation, one could hypothesise that 
using an immunology-based diagnostic test would be a better approach than hunting for scarce bacilli. A 
biomarker is defined as ‘an objective characteristic that indicates a normal or pathogenic process’ and can 
originate from the host or the pathogen of interest.102 There is considerable research interest in developing 
biomarker based tests for TB but progress has been relatively limited thus far. A recent systematic review of 
potential TB biomarkers or biosignatures by Foundation for Innovative New Diagnostics (FIND) identified 44 
    
For patients with meningoencephalitis, 
metagenomic next generation 
sequencing (mNGS) of cerebrospinal fluid 
(CSF) or brain tissue is an 
unbiased tool to identify viral, bacterial, 
fungal or parasitic infections. DNA and RNA 
in a sample can degrade if the 
sample is not quickly frozen. CSF and 
brain tissue samples need to be handled 
in a sterile manner to avoid microbial 
contamination. Organisms 
such as Treponema pallidum, whose DNA 
is hard to detect by PCR in CSF, will be 
similarly difficult to detect by mNGS. 
RNA and DNA are extracted 
and randomly amplified (after 
reverse transcription of the RNA) to 
generate cDNA molecules for 
sequencing. A Clinical Laboratory 
Improvement Amendments 
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contamination. Enough sequences 
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sensitivity for detecting non- 
human sequences against the 
human background. 
The millions of sequences that 
are generated for each patient 
sample are analysed with a 
standardized and clinically validated 
bioinformatics pipeline. Sequences 
mapping to the human genome, 
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of CSF mNGS data, are removed. 
After additional quality filtering, non- 
human sequences are searched 
against large genetic databases to 
determine the best organism 
matches. 
A report is provided to the clinician 
listing RNA or DNA viruses, parasites, 
fungi or 
bacteria that were detected above the 
reporting threshold. Organisms known 
to be 





‘front-runners’ of which 37 (84%) were of host origin and included antibodies, cytokines, chemokines and RNA 
signatures.102  The ideal TBM biomarker would ideally be instrument free so it could be performed at the 
point of care (or require minimal instrumentation) and would utilise readily accessible samples such as blood, 
urine, saliva or breath, so that lumbar puncture could be avoided. Though, even finding a biomarker that 
could be performed at the point-of-care (POC) on CSF would be a big step forward. 
1.3.6.1 CSF host biomarkers 
So far, a number of host biomarkers have been studied on CSF including adenosine deaminase (ADA, an 
enzyme produced by lymphocytes), IFN-g levels, interferon gamma release assays (IGRAs) and antibodies 
(anti-M37Ra, anti-M37Rv, anti-antigen-5).103 Whilst they can boast a moderate sensitivity, all are limited by 
high laboratory infrastructure requirements and cost. Further, heterogeneous study design and lack of 
reference to the uniform case definition makes cross-study comparisons challenging. Where HIV co-infection 
has been studied, more false-positives arise (giving reduced specificity). A number of meta-analyses have 
been published which summarise some of the biomarkers studied to date (Table 1.3).  
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ADA = adenosine deaminase, IGRA = interferon gamma release assays, IFN-g = interferon gamma 
Table 1.3. Summary of studies and meta-analyses on host CSF biomarkers 
No single host biomarker appears to be the perfect candidate in isolation so a combination of biomarkers, or a 
biomarker ‘signature’ may perform better. This may be particularly true if the signature combines both host 
and pathogen biomarkers.  
1.3.6.2 CSF pathogen biomarkers -TB-lipoarabinomannan 
Pathogen-based biomarkers tend to be more specific than host-biomarkers which can be elevated in the 
setting of other infectious or non-infectious conditions. The composition of volatile organic compounds 
(VOCs) in breath can be affected by the presence of M. tuberculosis in the lungs and are being studied for the 
diagnosis of pulmonary TB, but VOCs may have limited mileage in TBM as the infection can be 
compartmentalised to the CNS. Of all the TB antigens, lipoarabinomannan (LAM) is the marker with the 
largest evidence base and potential. LAM, a 17.3 kDa lipopolysaccharide mycobacterial cell wall component, 
has been studied on a number of bodily fluids – sputum, pleural fluid, CSF, and urine.  
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In earlier studies, LAM was detected using an enzyme-linked immunosorbent assay (TB ELISA, Clearview, 
Inverness Medical Innovations, USA). A pilot study in South Africa using cryopreserved CSF samples with 
culture as a reference standard found sensitivity of CSF LAM ELISA to be quite promising (64%) though 
specificity was only 69% (using a cut-point of 0.22).111 Since then a true POC LAM lateral flow assay (LFA) has 
been developed (Alere Determine TB-LAM Ag assay, Abbot, Chicago, IL, USA), which is easy to use, well priced 
(~£3 per test) and provides semi-quantitative results (negative, positive in the range 1+ to 4+). Minimal 
training is required and the results are read by comparing the visible band on the test strip with the 
manufacturer’s reference card after exactly 25 minutes has elapsed, see Figure 1.13.  
a) b) 
Figure 1.13. a) Alere Determine TB-LAM assay package insert demonstrating the steps involved to generate a result and ease of use, b) 
a photo of three Alere LAM results illustrating the real-life appearance of the negative and positive (+3 and +5) results. Photo kindly 
provided by Dr A Gupta-Wright.     
There was initial excitement around the performance of Alere Determine TB-LAM LFA (Alere LAM) on CSF 
after an autopsy study in Uganda which tested 91 cryopreserved CSF samples collected from the fourth 
ventricle with Alere LAM and reported a sensitivity of 75% and specificity of 87% against definite 
(microbiologically or histopathologically-confirmed) TBM.112 Whether such an impressive sensitivity was 
possible because the study design (autopsy) pre-selected patients with the highest bacillary burden, or 
whether ventricular CSF has a particularly high antigen load, or whether detectable TB antigen load increases 
after the host is deceased is unclear, but unfortunately studies of Alere LAM on lumbar CSF from living 
patients have been less encouraging. In 2016, the meningitis clinical research team in Uganda tested lumbar 
CSF samples collected from 67 patients with suspected meningitis at the bedside with Alere LAM, of which 12 
had definite TBM (Xpert or culture confirmed) and 2 had probable TBM. None of the 67 tests performed 
yielded a positive result and the study was abandoned.113 However, the majority of patients in this small study 
fell into the possible or not TBM group (many actually had cryptococcal meningitis) so there was a low pre-
test probability of disease and further larger studies were warranted. In a diagnostic accuracy study 
conducted between 2014–2017, which included 550 Zambian patients with suspected meningitis and used 
culture-confirmed TBM as a reference standard, CSF LAM had a sensitivity of 21.9% (23/105) and a specificity 
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of 94.2% respectively.114 The culture-based reference standard is not ideal for TBM studies and the 
investigators did not use the uniform case definition so understanding the performance of Alere LAM in 
probable and possible TBM cases was not possible.  
With the transition from Xpert MTB/Rif to Xpert Ultra as the WHO-recommended initial test for TBM, we 
revisited CSF Alere LAM in Uganda in a nested study in hospitalised patients with suspected TBM undergoing 
lumbar puncture (Appendix 3). The poor sensitivity (33% for definite TBM and 24% for definite/probable TBM) 
may relate to the high LAM antigen load required to yield a positive Alere LAM result. 
The novel Fujifilm SILVAMP TB LAM (FujiLAM; Fujifilm, Tokyo, Japan) POC assay, which similar to Alere LAM 
detects the presence of LAM, but combines a pair of high affinity monoclonal antibodies directed towards 
largely M. tuberculosis-specific LAM epitopes and a silver-amplification step that increases the visibility of test 
and control lines.115 FujiLAM offers on average 30% improved sensitivity for detecting TB (independent of 
whether it is pulmonary TB or extrapulmonary TB) compared to Alere LAM across subgroups stratified by CD4 
strata, while maintaining high specificity.115 A single recent study has evaluated FujiLAM on 19 CSF samples 
and found it to have a sensitivity of 47% (compared to 16% for Alere TB-LAM) against microbiologically 
confirmed TBM.116   
However, obtaining CSF via a lumbar puncture is not always possible in LMIC government hospital settings for 
the reasons outlined in section 1.3. Even in the most well-resourced hospitals lumbar punctures can often be 
delayed whilst brain imaging is awaited. So, a non-CSF biomarker that can support diagnosis of TBM or aid 
with prognostication would be very useful. In the next section I describe urine TB diagnostics of TB with a 
particular focus on TBM.     
1.3.7 Urine diagnostics for HIV-associated TB 
Early morning urines for TB culture are still used to diagnose TB of the genitourinary tract, albeit with a long 
diagnostic lead-time. Urine is easy to collect, even in the sickest patients, has low risk of generating infectious 
aerosols, and has relatively few contaminants. This has driven research into urine TB antigens which may be 
of diagnostic or prognostic value, of which the urinary LAM and Xpert MTB/Rif are the most promising to 
date.  
1.3.7.1 Urine TB-Lipoarabinomannan in HIV-associated TB 
I touched on the background of CSF LAM with regards to CSF biomarkers (section 1.3.6.2) but the volume of 
research on urinary LAM is far greater. Despite LAM being studied as early as 1990s, it only gained traction 
more recently when it became clear that its poor sensitivity of around 30% for the detection of TB (culture- or 
Xpert-confirmed) in immunocompetent hosts increases to a moderate sensitivity of 56% (95% CI 41-70%) in 
the most immunocompromised hosts (CD4 <100 cells/µl), see Figure 1.14.117,118,119   
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Figure 1.14. Sensitivity of urine Alere TB-LAM and urine Xpert in urine samples from HIV-positive patients with culture-confirmed 
pulmonary TB by CD4+ T cell strata. Reproduced from Lawn 2012.120   
This was a welcome observation, as those with the most 
advanced HIV have a high early mortality121 and traditional 
microbiological techniques (e.g. smear microscopy) perform 
most poorly in this population. As CD4+ T-cell count declines 
M. tuberculosis becomes haematogenously disseminated and
frequently affects distant organs including the genitourinary
tract with renal micro-abscesses noted in 50-69% of HIV-
positive cadavers.122 LAM antigenaemia may give rise to free
circulating LAM being filtered into the urine (especially
plausible if there is HIV-related nephropathy / proteinuria and the glycolipid molecule has not been 
excessively immune complexed) or M. tuberculosis bacilli can directly infect the renal tract and be secreted 
into the urine.118 The WHO recommend Alere LAM to screen for active TB in PLHIV who are hospitalised with 
signs or symptoms of TB and have a CD4+ T-cell count <100 cells/µl, or who are seriously ill regardless of 
CD4+ count.123 Persons with TBM fall into this ‘seriously ill’ category but unfortunately the implementation of 
the WHO recommendations has been slow and Alere LAM is not universally available.  
The potential of the Alere LAM test as a screening tool to reduce deaths from TB was recently evaluated in an 
RCT in hospitalised PLHIV in Malawi and South Africa (the STAMP trial). In the intervention arm urine was 
tested with Alere LAM assay and Xpert MTB/Rif. Other TB diagnostics and treatment were as per normal 
standard of care. There was a trend towards reduced 56-day mortality overall (adjusted risk difference [aRD], 
-2.8%, 95% CI -5.8 to 0.3%;0=0.074) and a reduced 56-day mortality in pre-specified sub-groups of interest:
CD4+ count < 100 cells/μL (aRD –7.1%, 95% CI –13.7 to –0.4; p=0.036), severe anaemia (–9.0%, –16.6 to –1.3;
p=0.021), and patients with clinically suspected TB (–5.7%, –10.9 to –0.5; p=0.033).124 Further, Alere LAM was
shown to have value as a prognostic tool for 2 month mortality as part of a 6-point risk score in two cohorts of
hospitalised PLHIV in sub-Saharan Africa.122 Meta-analysis of 10 studies has confirmed that urine LAM
positivity is associated with a 2.5-fold increased risk of death, even after adjustment for degree of immune
suppression.125,126
With this new evidence in mind, in 2019 the WHO made a policy update and expanded its recommendations 
for the use of Alere LAM to include outpatient settings where an HIV-positive adult or child has signs or 
symptoms of TB or has a CD4+ T-cell count <100 cells/μL.127 
The novel FujiLAM assay has been compared to the Alere LAM on urine samples in HIV-positive South African 
hospital inpatients. Using a microbiological reference standard, the estimated sensitivity of FujiLAM was 
70·4% compared with 42·3% for Alere LAM (difference +28·1%) and the estimated specificity of FujiLAM was 
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90·8% and 95·0% for Alere LAM (difference –4·2%).115 FujiLAM appears promising as a urine diagnostic and is 
undergoing wider evaluation before it can be considered by WHO and other stakeholders as a routine 
diagnostic option (and will require scale up in manufacturing).  
1.3.7.2   Urine TB-Lipoarabinomannan in TB meningitis 
Given that HIV-associated TBM may occur as part of a more broadly disseminated TB picture one could 
hypothesize that urine TB-LAM would be a good diagnostic biomarker with reasonable sensitivity. Urine 
FujiLAM has not yet been studied in TBM patients and there is only a single study on Alere LAM. A Zambian 
study, including 550 suspected TBM patients, of which 86.2% (474) were HIV-positive compared urine Alere 
LAM to culture-confirmed TBM. Urine LAM had a rather disappointing sensitivity of 24.1% (numerator, 
denominator and 95% CI were not reported). Specificity of urine LAM was quoted as 76.1%, 51 patients had 
positive urine LAM whilst CSF culture was negative. Given that CSF culture is only moderately sensitivity it is 
an imperfect reference standard to use and it is plausible that the 51 positive urine LAM results were 
misclassified as false positive giving rise to the low sensitivity and specificity. The low specificity is particularly 
dubious given a robust South African diagnostic accuracy study of urine LAM, in which the reference standard 
included multiple cultures and NAATs from several extra-pulmonary sites, which found the specificity of urine 
LAM to be extremely high (~99%).128 Further, meta-analysis of 12 studies (using culture or NAAT from any 
bodily site as a reference standard) reported that pooled specificity was 92% (95% CI 80-97%).117 To 
summarize, the Zambian study had sub-optimal methodology and results were not clearly reported in the 
paper, so the true value of urine Alere LAM assay as a diagnostic or prognostic aid in HIV/TBM remains to be 
established and was therefore explored within my PhD research.  
1.3.7.3 Urine Xpert or Ultra in the diagnosis of HIV-associated TB 
Although the WHO has endorsed Xpert for non-respiratory samples, its use on urine has not been 
recommended due to insufficient data. The most thorough study to date by Lawn et al, screened 427 hospital 
admissions in South Africa, and multiple samples were collected for culture and Xpert (including urine, 
sputum, blood, other samples as clinically indicated). The investigators found that sensitivity of urine Xpert 
was 42.4% using unconcentrated urine, but this increased to 59.0% when urine was centrifuged and the cell 
pellet tested with Xpert. As with urine TB-LAM, the yield from urine Xpert was greater among those with CD4+ 
T-cell count <100 cells/µl (77% versus 50% in those with CD4+ T-cell count >100 cells/µl, p=0.001).129
A handful of studies have compared urine LAM and urine Ultra head-to-head. Urine LAM has had a higher 
diagnostic yield in the majority of studies including the STAMP trial.124 It may be that the limit of detection of 
the Xpert assay (131 CFU/ml) is greater than the antigen load required to generate a 1+ positive LAM result. 
Or that they are detecting discrete entities (an antigen versus DNA) which are present in different amounts 
depending on the disease stage/phenotype (Xpert is designed to detect the presence of bacilli, not cell free 
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DNA, and TB-LAM is a circulating antigen). No studies yet have directly compared LAM and Xpert Ultra, but 
given that Ultra has a 7-fold lower limit of detection (16 CFU/ml) than Xpert it may prove to be superior to 
LAM and warrants investigation.  
1.3.7.4 Urine Xpert or Ultra in the diagnosis of HIV-associated TB meningitis 
To our knowledge there is only a single case report of urine Xpert Ultra being used in the diagnosis of TBM. A 
56-year old Ugandan HIV+ diabetic lady presented with a 3-week history of confusion, neck pain and general 
body weakness. CSF examination revealed a lymphocyte pleocytosis (220 cells/µl) but no organisms were 
seen on Gram’s stain, CSF protein was 48 mg/dL, cryptococcal antigen was negative, CSF Xpert Ultra and 
bacterial culture were negative. Urine TB diagnostics were performed – Alere TB LAM was negative but urine 
Ultra was positive (semi-quantitative category: very low). In the absence of an alternative explanation, TBM 
treatment was commenced with good resolution of symptoms at 6 weeks of follow up. CSF mycobacterial 
growth indicator tube culture was reported as negative 6 weeks later.130 Whilst this was simply a case report, 
it supported the idea of Xpert Ultra being further explored in the diagnosis of TBM, and I therefore included 
an exploratory study of urine TB diagnostics in meningitis patients in my PhD research.  
In summary, we know relatively little about TBM in Uganda and we currently lack a highly sensitive POC 
diagnostic test and prognostic marker. A multitude of research questions exist relating to diagnostics. Table 
1.5 outlines some of the most pressing questions for consideration.   
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Table 1.5. Priority research questions on TBM in Uganda, existing evidence and potential approaches to 
addressing the outlined questions. 




How many children / adults 
develop TBM each year in 
Uganda? 
Nil from Uganda. 
EPTB cases reported 
to WHO 
1. Improve data collection through national
TB registers so that site of disease is
captured
2. Create a national TB meningitis registry 
3. Modelling studies 
What is the annual mortality due 
to TBM in Uganda? 
Nil from Uganda 1. Modelling studies 
What are the in-hospital and 
longer-term outcomes from TBM 
in Uganda? 
Nil from Uganda 
1. Retrospective review of available data
through the meningitis research team
2. Prospective study to evaluate functional
outcomes and survival
Understanding risk 
factors for developing 
TB meningitis 
Who is at risk of developing TBM 
disease in Uganda? 
Nil from Uganda 
1. Cross sectional or case-control study to
ascertain risk factors for disease
Understanding risk 
factors for poor 
outcome 
Which baseline characteristics are 
associated with risk of dying? 
1. Cox model to identify baseline and
dynamic risk factors for death
Can a urine biomarker be used as 
prognostic tools in TBM? 
Alere LAM 2.5-fold126 
Xpert 2.0-fold 
increased risk of 
death from 
disseminated TB 
1. Cohort study with baseline urine Alere
LAM and urine Ultra testing with in-
hospital or longer-term mortality data
collection
Can a point of care CSF biomarker 
be used as a prognostic tool? 
Lactate may have a 
role in prognosis 
(India)131(Vietnam)132 
1. Explore relationship between Xpert cycle
threshold and mortality in a cohort study
or with available data 
2. Model baseline CSF lactate & glucose
with outcomes
Improving diagnosis 
of TB meningitis 
Can TBM be differentiated from 
other causes of meningitis with 
urine diagnostics? 
Nil 
1. Cross sectional study in all meningitis
presentations including urine Alere LAM
and urine Ultra and CSF diagnostic panel
Will CSF Xpert Ultra improve 
diagnosis of TBM in real-time 
compared to Xpert MTB/Rif? 
Uganda, frozen CSF 
sensitivity Ultra > 
Xpert 81 
1. Prospective cohort study using Ultra
alongside existing CSF diagnostic panel
Can a CSF biomarker support a 
diagnosis of TBM? 
Lactate has a role in 
TBM diagnosis 
(India)131 
1. Cross-sectional study with CSF TB-LAM in
combination with other diagnostics
Do suspected probable and 
possible TBM patients (negative 
by CSF Ultra & culture) actually 
have TBM? If not, what do they 
have? 
1. Unbiased mNGS to look for presence of 
other pathogens
2. Biased mNGS with enrichment for M.tb
3. Host transcriptomic profiling 
4. Comprehensive meningoencephalitis
diagnostic evaluation for infectious and
non-infectious causes 
Can pathogen and host DNA/RNA 
sequencing data be combined 
into a diagnostic strategy with 
machine learning? 
1. Generate large dataset with detailed
clinical, pathogen and host information
and optimise a disease classifier with
machine learning techniques
Is CSF metagenomic next 
generation sequencing diagnosis 
feasible in Uganda?  
Nil from Uganda 
1. Pilot study using local sequencing and
bio-informatic capabilities 
Text shown in bold denotes those that I addressed during this PhD period. mNGS = metagenomic next generation sequencing, LAM = 
lipoarabinomannan, M.tb = mycobacterium tuberculosis, EPTB = extrapulmonary TB 
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1.4 Part II: Treatment of Tuberculous Meningitis 
1.4.1 Rifampicin 
In 1957, in a soil sample from the French Riviera, a new bacterium was discovered (Streptomyces 
mediteranei) which produced a novel class of molecule with antibiotic activity which was named rifamycin 
(after the scientist’s favourite French crime story ‘Rififi’). A stable semi-synthetic compound with high efficacy 
and good tolerability was produced in 1965, called ‘rifampicin’ and was USA Federal Drug Authority approved 
in 1971. Rifampicin binds to the rpoB portion of the bacterial polymerase, thereby preventing formation of 
new proteins.133 Rifampicin exhibits bactericidal activity (killing actively growing organisms) and sterilizing 
activity (killing the persisting bacilli that are responsible for relapse).133,134 Only around 15% of the circulating 
drug that is unbound to plasma proteins (‘free’ rifampicin) is therapeutically active and able to readily cross 
barriers such as the intact blood-brain barrier.  
Rifampicin is a clinical pharmacologist’s nemesis – a promiscuous inducer of the expression of a broad array of 
enzymes and drug-transporting molecules through its activation of a master transcriptional regulator, the 
pregnane X receptor.135 Rifampicin is the most powerful known inducer of the hepatic cytochrome P450 
system, and through upregulation of the CYP3A4 isoenzyme it increases the metabolism of many drugs and 
thereby lowers their levels and clinical effect, requiring careful dose adjustments to be made. It also induces 
its own metabolism through clearance autoinduction, so levels reduce by about 30-50% over the first month 
of therapy.136 Common side effects include gastrointestinal upset, hypersensitivity reactions (including fever 
and rash) and hepatotoxicity, and it turns bodily fluids alarmingly orange. As well as treating a number of 
other infections such as Legionnaire’s disease and leprosy, rifampicin is the cornerstone of TB therapy.  
1.4.2 Current TB therapy – did we miss a trick with rifampicin dosing? 
The WHO recommended treatment for TB involves a two-month intensive phase of rifampicin (R, 8-12mg/kg), 
isoniazid (H, 4-6mg/kg), pyrazinamide (Z, 20-30mg/kg) and ethambutol (E, 15-20mg/kg) followed by a 
minimum of a 4-month continuation phase of rifampicin and isoniazid, depending on national guidelines and 
modifications for drug-susceptibility results where available.137 This ‘short-course’ TB therapy was defined in 
clinical trials in pulmonary TB in East Africa and India in the 1980s; rifampicin 600 mg when added to 
streptomycin, isoniazid and ethambutol, allowed shortening of therapy to 9-12 months. Shortly after, 
substitution of streptomycin with pyrazinamide allowed 6-8 months of therapy for pulmonary TB.138,139 A 
number of small trials in the 1970 and 80s examined rifampicin doses of up to 1200mg (20 mg/kg) with 
different dosing intervals (weekly, twice/thrice weekly, and daily). Intermittent dosing of rifampicin 20 mg/kg 
was met with a high incidence of flu-like syndrome but despite daily dosing being well-tolerated it didn’t 
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become part of mainstream therapy.140 This was also in part because rifampicin was a prohibitively expensive 
drug in the 1970s, so with large-scale TB programming in mind, the 600 mg dose did the job of shortening 
pulmonary TB therapy and became entrenched in TB treatment regimens in the decades to follow. The 
optimal rifampicin dose was not defined through the modern paradigm of pre-clinical in vitro studies, animal 
or in-human pharmacokinetic-pharmacodynamic dose-optimisation studies, or in silico modelling.  
With the current rifampicin 10 mg/kg/day dose interindividual variability in exposure is large and the margin 
for error is minimal.133 Low rifampicin exposure has been associated with drug resistance, treatment failure 
and delayed bacillary clearance from sputum.141 Owing to the lack of forgiveness with the 10 mg/kg rifampicin 
dose evolution of rifampicin drug resistant tuberculosis has arisen and poses a significant public health 
threat. In South Africa around 15% of hospitalised adults with HIV/TB have multidrug resistant tuberculosis 
(MDR-TB).142   
1.4.3 Challenges with the current first-line TB regimen and finding better options 
The current WHO recommended TB regimen comes with multiple challenges; these have been contributory 
factors to the difficultly in curbing the TB epidemic: 
1. Duration of therapy leads to poor adherence143,144
2. Pill burden leads to poor adherence143,144
3. Inter-individual variability in PK exposure to TB drugs145
4. Sub-optimal response (failure and relapse in ~10%) in those with low exposures or poor
adherence146,138
5. Emergence of resistance in those with low exposures or poor adherence143,147
6. Toxicity including hepatotoxicity, peripheral neuropathy, optic neuritis145
7. Drug-drug interactions relating to rifampicin135
Identification of a novel regimen which addresses these challenges could potentially improve TB outcomes, 
reduce transmission and the emergence of resistance. Unfortunately, M. tuberculosis drug discovery and 
development is an extremely lengthy and expensive process – M. tuberculosis needs to be handled in a 
category 3 biosafety laboratory, is slow growing, and has a dormant (persistent) state where it becomes 
undetectable by conventional tests, clinical trials are long and not necessarily economically attractive 
investments to pharmaceutical companies. As such, progress has been slow with no new first-line TB drugs 
coming to the market since rifampicin in the 1970s, see Figure 1.15. Newer agents such as bedaquiline and 
delamanid are reserved for the treatment of MDR-TB, and have recently allowed MDR-TB regimens to 
become shorter, less toxic and free of the painful daily injections required by aminoglycosides antibiotics.148 
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Figure 1.15. TB drug development timeline. TB drug group classification according to WHO guidelines is displayed in roman numerals. 
Group I drugs are first-line agents and considered the most potent and best tolerated. Group II drugs contain injectable agents 
previously used against multidrug-resistant TB (MDR-TB). Group III includes fluoroquinolones, such as higher generation members 
levofloxacin and moxifloxacin. Group IV drugs are mostly oral bacteriostatic second-line agents. Group V drugs are agents not 
recommended by the WHO for routine use in MDR-TB treatment because of limited data available. Not all TB drugs are depicted. 
Reproduced with permission from Dr L te Brake.149  
Therefore, to bridge the gap until new first-line TB drugs are available, there is an urgent need to repurpose 
drugs that are already licensed or redevelop drugs that are already used by optimising the dose used in the 
standard treatment regimen to maximize bactericidal and sterilizing activities. Rifampicin is one of the drugs 
in need of redevelopment. With hindsight, the historical pharmacokinetic, toxicity, and cost arguments that 
formed the basis of the currently used dose (10 mg/kg) were short-sighted, leaving a lot of room for drug-
dosing improvements. 
1.4.4 Current antimicrobial therapy for TB meningitis 
The short course adult pulmonary TB treatment model defined in the pre-HIV era was extrapolated to all 
forms of extrapulmonary TB disease, including TBM, without disease-specific evidence. The WHO-
recommended treatment for TBM largely follows the same model as treatment of pulmonary tuberculosis 
(described in section 1.4.2) simply with a prolonged continuation phase, depending on national guidelines and 
modifications for drug-susceptibility results where available.137 The WHO 2010 guideline does suggest 
switching ethambutol for streptomycin, due to concerns about ethambutol not penetrating the CNS.137 
However, CNS penetration of streptomycin is only moderate and injections are poorly tolerated and difficult 
to implement, especially in the absence of any strong evidence to support this suggestion. So many countries 
simply treat TB meningitis with 2RHZE/7RH. The extended continuation phase of 7-10 months used in TBM is 
also not evidenced based,150 rather recommended by expert opinion due to concerns relating to drug 
penetration into the CNS. The concerns about drug penetration into the CNS are indeed valid, achieving a 
drug concentration at the site of disease (the meninges and CSF) for an adequate length of time is essential to 
sterilize the site. As I describe below, the penetration of rifampicin and ethambutol into the CNS are poor at 
the currently used doses making the 2RHZE/7RH therapy for TBM questionable. Whilst adoption of the short 
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course pulmonary TB ‘one-size-fits-all‘ model for the treatment of CNS TB makes a lot of sense in terms of 
simplifying national TB programming, it fails to consider PK-PD principals and there is a significant amount of 
research now going towards trying to find a more effective TBM regimen. 
1.4.5 Penetration of TB drugs into the central nervous system 
Importantly, in contrast to antibiotics used to treat pulmonary TB, antimicrobials for CNS TB must cross the 
blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB), and remain in the brain or CSF at the 
site of infection at sufficient concentrations for a sufficient period of time to kill the TB bacilli. CSF is a unique 
compartment, often referred to as a ‘sanctuary site’ as pathogens can exist and replicate in CSF protected 
from antimicrobial drugs that cannot access the compartment. The composition of CSF is carefully regulated 
by the BBB and BCSFB, see Figure 1.16. The relationship between plasma and CSF concentrations is 
continuously dynamic and dependent on a number of factors: 
1. Lipid solubility – lipophilic drugs cross the BBB and BCSFB by transmembrane diffusion more readily.
2. Molecular weight – low molecular weight drugs cross BBB and BCSFB by transmembrane diffusion
more readily
3. Protein binding – highly protein bound drugs are unable to cross the tight junctions between the
epithelial cells of the choroid plexus to enter the CSF. This is particularly relevant in the case of
rifampicin, which is ~85% protein bound; only the unbound or ‘free’ rifampicin is biologically active. In
the absence of meningeal inflammation only the ‘free’ rifampicin crosses the BCSFB. In theory, when
meninges are inflamed in meningitis the tight junctions between cells of the choroid plexus are
disrupted allowing plasma proteins and protein-bound drugs (like rifampicin) to penetrate the CSF
more readily, however it is not clear to what extent or for what duration this applies in TBM, and
particularly HIV-associated TBM where the CSF can be acellular.151
4. Drug transporters - Organic anion-transporting polypeptide (OATP) can inwardly direct certain drugs.
Conversely, transporters, like BCRP and P-glycoprotein (P-gp) in endothelial cells, actively pump
potentially neurotoxic substances out of the brain and into the blood or CSF, thereby protecting the
CNS. This also applies to rifampicin which is actively pumped out by P-gp.149
Rifampicin is arguably the most critical drug in the treatment of TBM, as evidenced by the universally poor 
outcomes of people with rifampicin-resistant disease.53 However, rifampicin has poor CSF penetration, due to 
the reasons outlined above, with reported CSF concentrations often reaching <20% of those in plasma.152 CSF 
rifampicin concentrations were undetectable (below the limit of quantification of 0.26 mg/L) in two-thirds of 
TBM patients in Indonesia and seldom exceeded the minimum inhibitory concentration (MIC) for M. 
tuberculosis.153,154 Thankfully isoniazid and pyrazinamide have excellent CSF penetration,154 though the high 
prevalence of isoniazid resistance in some regions (27% in Vietnam,155 5% in Uganda,156 9% in South Africa157) 
further compromises TBM treatment and pyrazinamide is discontinued at the end of the intensive phase of 
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therapy (week 8). The CSF penetration of all the first-line, second-line, and novel antituberculous drugs is 
outlined in the Chapter 7 review paper - Intensified Antibiotic Treatment for Tuberculous Meningitis (Table 2).   
 
Figure 1.16. Schematic overview of the relation between the 
blood-brain barrier (BBB), made up by brain endothelial cells, 
and the blood-CSF barrier (BCSFB), made up by choroid 
plexus epithelial cells. The ependymal lining of the cerebral 
ventricles forms the barrier between brain (and its interstitial 
fluid, ISF) and CSF. According to this simplified paradigm, 
there is free exchange of drug between the brain ISF and CSF. 
CSF drug concentrations approximate the free drug 
concentration in plasma that is able to penetrate the BBB, 
BCSFB, or both. Displayed efflux transporters may actively 
disturb this equilibrium, by actively transporting drugs into 
the blood or CSF. Reproduced with permission by Dr L te 
Brake.140  
 
It would seemingly make sense to treat TBM with a cocktail of drugs which is able to access the site of disease 
at bactericidal concentration for an adequate duration. The options for achieving this are explored in detail in 
the chapter 7 review paper and summarised below.  
1.4.6 Can we optimise the antimicrobial treatment of TBM?  
There are different strategies that have been considered, are under investigation, or may be relevant in future 
to optimise TBM treatment as listed below:  
1. Prolonging TB treatment – This is unlikely to help; in a meta-analysis, the risk of relapse was extremely 
low (~0.8%), and virtually identical in patients who received <6 months versus >6 months of 
therapy.150 
2. Modification of drug delivery – For example by liposome or nanoparticle-mediated permeation, 
however, this is not at the stage of clinical studies yet. 
3. Inhibition of efflux pumps in the BBB/BCSFB - P-glycoprotein inhibitors might also increase 
antituberculous drug exposure in the CNS, though such approaches are not at the stage of clinical 
studies yet.  
4. Additional drugs – Adding drugs which are effective against M. tuberculosis and penetrate readily into 
the brain and CSF to the standard quadruple TB therapy is an approach receiving considerable 
interest, the in-human clinical trials of which are summarized below and in the chapter 7 review 
paper. Adjunctive oral levofloxacin is the only drug to have been tested in a phase III trial with no 
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reduction in mortality among Vietnamese adults with suspected TBM (except those with isoniazid 
monoresistance).158,159  
5. Increase drug exposures in the CNS by increasing drug doses - a promising strategy is to increase the 
doses of poorly CNS penetrating drugs, where toxicity profiles allow, such that levels in the brain and 
CSF exceed the minimum inhibitory concentration of M. tuberculosis for an effective time period 
daily. This is particularly pertinent to rifampicin, which has been shown to be safe at considerably 
higher doses (up to 4-fold increase above the standard 10 mg/kg) in studies in pulmonary TB, albeit in 
a HIV-negative population.160 Paediatricians in Cape Town have for many years been using an 
intensified regimen of 20 mg/kg rifampicin and 40 mg/kg pyrazinamide, with isoniazid and 
ethionamide (in place of ethambutol) and report good outcomes with few adverse events.161 
Likewise, in the Netherlands, an intensified regimen of oral rifampicin 30 mg/kg (or 15 mg/kg 
intravenously) along with standard dose isoniazid, pyrazinamide and moxifloxacin (in place of 
ethambutol) is used, albeit on the basis of expert opinion rather than high quality clinical trial data.140 
6. Changing the route of drug administration – using intravenous instead of oral administration 
increases the bioavailability of drugs that are poorly (or variably) absorbed from the gut. This may be 
particularly relevant in critical illnesses, such as TBM, where patients are often receiving drugs though 
a nasogastric tube, have paralytic ileus, enteropathy, vomiting or diarrhoea. Such factors could 
explain the lower plasma rifampicin concentrations observed in patients with TBM compared to those 
with pulmonary TB taking the same dose from the same setting in Indonesia.153,162 Currently, few TB 
drugs are available parenterally, namely rifampicin, isoniazid, quinolones, linezolid and 
aminoglycosides. Intrathecal streptomycin was trialed in a small number of patients the 1940s,163 but 
adverse reactions (including death) were frequent so the study was not continued and this has not 
been explored further since as it is a highly risky strategy, especially in LMIC settings.  
7. Personalised therapy based on host pharmacogenomics – isoniazid is metabolised by the genetically 
polymorphic N-acetyltransferase 2 (NAT2) and rapid acetylators have lower isoniazid exposures in 
both plasma and CSF. Isoniazid exposure was strongly related to survival in the recent PK-PD analysis 
of the landmark Vietnam intensified treatment trial.164,158 Rapid acetylators may therefore benefit 
from increased isoniazid doses, something which has been piloted in pulmonary TB but not yet in 
TBM, though a study is planned in China (NCT03787940).165 Rifampicin metabolism is also believed to 
be under a degree of genomic regulation, though pharmacogenomic data from Africa is relatively 
sparse. The SLC01B1, AADAC and CES-1 gene loci (amongst others) have been studied in African 
adults, with conflicting results in different countries, possibly relating to the magnitude of genetic 
diversity across the African continent or the different study methodologies deployed.166,167 The 
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SLC01B1 genotype has been investigated in Uganda in patients with pulmonary TB but was not found 
to influence rifampicin PK.168  
8. Personalising therapy based on specific disease categories – designing specific regimens for patients 
with tuberculomas, spinal TB, HIV coinfection or drug mono-resistance may result in better outcomes 
than the current ‘one-size-fits-all’ approach.  
Of all of these options, and based on accumulating evidence that high-dose rifampicin is safe and more 
efficacious in pulmonary TB, it makes sense to optimise the dose of rifampicin in the treatment of TBM. 
Rifampicin is now a cheap drug with numerous generic options, it is already available in many TB endemic 
countries so could be implemented quickly. But is high-dose rifampicin safe in HIV-associated TB? 
1.4.7 Defining the optimal rifampicin dose – pharmacokinetics-pharmacodynamics 
Pharmacokinetics (PK) is the study of how the human body processes the drug of interest, in relation to the 
absorption, distribution, metabolism and excretion of the drug. Pharmacokinetic studies allow for the 
generation of a PK curve (see Figure 1.17) from which pharmacokinetic parameters can be calculated 
including key parameters such as the following:  
1. Cmax  - the peak concentration of the drug after administration, also known as peak exposure. 
Rifampicin is subject to huge (6 to 10-fold) interindividual variability in peak concentration, the 
reasons for which are multifactorial and not fully elucidated.  
2. Tmax - the time to reach Cmax. This depends on the route of administration and volume and rate of 
distribution of the drug into different compartments (e.g. plasma, tissue, brain etc) 
3. T1/2 – the elimination half-life. This is the time it takes for the concentration to reduce by 50% 
4. AUC0-24hr - the area under the time concentration curve from 0 to 24-hours after drug administration. 
This is often referred to as ‘total exposure’ and depends on the peak concentration and the rate of 
clearance  
5. F - bioavailability - the fraction of the administered drug that reaches the systemic circulation 
6. Cl - clearance - the volume of plasma cleared of the drug per unit time 
7. Vd – volume of distribution – the apparent volume in which the drug is distributed 
8. AUC/MIC - the area of the time concentration curve which is spent above the minimal inhibitory 
concentration (MIC) for the M. tuberculosis isolate. The MIC is the drug concentration which arrests 
visible growth of bacteria in vitro after overnight incubation under unrestricted growth conditions 
with static drug exposure.169 
Pharmacodynamics is the study of how the drug affects the organism or the body, be it a therapeutic or 
toxic effect, and the relationship between the dose, the drug concentration/exposure, and the response 






Fig 1.17a. Example of a PK curve and the key PK parameters 
for a drug that is dosed orally. The blue shaded area on the 
left illustrates the total exposure (AUC) from a single dose 
from administration til elimination. The right-hand blue 
shaded area illustrates the AUC0-24hr if the drug is 
administered once daily.  
Fig 1.17b. Example of a concentration-response 
curve. The response variable used in studies of 
pulmonary TB is ‘time to sputum culture 
conversion’ and in TBM studies has been 
‘survival’.   
The simplest bacteriological pharmacodynamic measure of activity is the minimal inhibitory concentration 
(MIC), the drug concentration which arrests visible growth of bacteria in vitro after overnight incubation 
under unrestricted growth conditions with static drug exposure.169 A clinical dose can be derived by 
comparing drug exposures in preclinical pharmacokinetic models or in-human PK studies with the MICs of 
clinical mycobacterial isolates. However, this simplistic approach fails to understand the relationship between 
dose, exposure, and clinical response. In vitro pharmacodynamic models (e.g. hollow-fibre models) and animal 
models of infection have also been used to create a more dynamic environment in which to examine the 
activity of an antibiotic. These models provide a better understanding of how changes in antibiotic exposure 
over time may influence activity, yet they remain limited in their ability to accurately reflect the human 
infection and host environment.170 While in-human pharmacodynamic studies are challenging to conduct, 
their influence on our understanding of antimicrobial activity in vivo is invaluable for evaluating the dose-
exposure-response relationship and understanding how co-variates (e.g. sex, body weight, comorbid 
conditions) affect that relationship.170 Modern in silico modelling approaches are also extremely useful in 
defining the dose-exposure-response relationship. In silico modelling can be used either at a pre-clinical stage 
or in combining in-human data from multiple studies to be able to analyse the dose-exposure-response 
relationship with greater power or in different populations.   
In the 1970/80s, at the time of defining short-course TB therapy, far less attention was paid to establishing 
the relationship between dose, exposure and pharmacodynamic responses. Furthermore, there was little 
interest for differences among disease-type subsets, such as TBM. No PD targets had been defined. For 
therapeutic drug monitoring purposes in the 1990s a target rifampicin concentration of 8-22 mcg/ml at the 
site of disease was suggested, though this was largely based on expert opinion of observed pharmacokinetic 
data from the pre-HIV era and not on pharmacodynamic effect on bacilli.171 Since then, mouse models 
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suggest that the index which best predicts microbial kill is the total exposure (AUC0-24) over the M. tuberculosis 
MIC (AUC0-24/MIC). Measuring individual level M. tuberculosis MICs is a laborious, complex and costly process 
so a regional or national MIC can be used where available.  
1.4.7.1 What is the optimal rifampicin dose from animal models? 
A number of murine studies have shown that mice can tolerate rifampicin up to a daily dose of 160 mg/kg 
(current in-human dose is 10 mg/kg/day). A series of experiments from St Georges Hospital, London which 
used escalating doses of rifampicin in a Cornell mouse model found that high-dose rifampicin at 30, 40 and 
50mg/kg accelerated the rate of bacterial clearance and killed ‘persistent’ organisms in the lungs and spleen 
so that treatment duration could be shortened without relapse.134,172 With the 30 to 50mg/kg dose there was 
true sterility – negative for CFU count and no resuscitatable bacteria - after 8 weeks of treatment. The 10 
mg/kg dose (and even the 20 mg/kg dose) was unable to eliminate the dormant bacilli leading to disease 
relapse.134  
Mouse models must be extrapolated to humans with caution; mice do not form necrotic caseating 
granulomas in the same way that humans do, the extent of protein binding (and therefore free rifampicin) can 
be different, treatment is usually initiated about two weeks after infection in mouse models whereas it can be 
many months in humans, comorbid conditions such as diabetes and HIV coinfection cannot be studied to 
name but a few of the differences between mice and men. Despite these considerations, compelling animal 
evidence points towards the fact that rifampicin doses of above 30 mg/kg are likely to be the most beneficial 
in humans.134,172  
1.4.7.2 What is the optimal rifampicin dose from clinical studies in pulmonary TB? 
In a small (n=14) proof of concept study in 2007, South African patients with smear positive pulmonary TB 
received rifampicin 20 mg/kg (in isolation before other TB drugs were commenced) and early bactericidal 
activity (EBA) was assessed at day 2 and 5. Compared to historical controls, the 2-day EBA with 1200 mg was 
double that with standard dose rifampicin (600 mg).173 Larger studies with pharmacokinetic evaluation, and 
robust microbiological and clinical endpoints for PK-PD analysis were called for and have been led by the 
PanACEA (Pan African Consortium for Evaluation of Antituberculous Antibiotics) consortium, and the InterTB 
group at St Georges, London.  
The use of serial sputum colony counting as a surrogate efficacy endpoint, and the use of innovative clinical 
trial designs including factorial and multi-arm multistage studies (MAMS), allows the efficacy of drugs to be 
explored efficiently in the PanACEA series of studies. In 2015, a rifampicin dose escalation (20, 25, 30, 35 
mg/kg) study by Boeree et al. (HIGHRIF1) aimed to find the highest tolerated dose in patients with culture-
confirmed pulmonary TB. In all patients, rifampicin was given alone for the first week, with isoniazid, 
pyrazinamide, and ethambutol added in standard doses for the second 7 days of treatment. Dose-limiting 
 36 
toxicity was not found even at the higher dose (35 mg/kg) and there was a more rapid fall in bacterial load 
(CFU count) over 14 days with the higher doses of rifampicin.160 The results of the 40 mg/kg and 50 mg/kg 
arms have just been published in pre-print though only one participant was HIV-positive so it is not clear 
whether the results can be generalized to PLHIV. Whilst 50 mg/kg/day had very impressive early EBA all 
participants experienced tolerability-related AEs (grade <3, largely gastrointestinal, jaundice, pruritis) during 
monotherapy and 11/17 withdrew or stopped the study medication. The 40 mg/kg/day dose was better 
tolerated and only one participant discontinued treatment. The authors concluded that rifampicin 40mg/kg is 
the maximum tolerated dose which should be explored in phase IIB/C treatment shortening trials.174 A 
multisite treatment shortening study of rifampicin 35 mg/kg in pulmonary TB is almost fully recruited 
(RIFASHORT) and results are eagerly awaited. 
In 2016, the RIFATOX study conducted in Uganda, Bolivia and Nepal found that rifampicin 20 mg/kg/day was 
safe but PLHIV were excluded due to concerns about drug interactions with ART.175 Safety of rifampicin 
1200mg (20 mg/kg) administered over a longer period of 2 months was also established in a Peruvian study176 
including n=5 PLHIV and a second PanACEA study (HIGHRIF2) which included n=15 PLHIV. The HIGHRIF2 study 
did not detect an improvement in bacteriological response, and concluded that yet higher rifampicin doses 
may be required to maximize efficacy.177 This was tested in the larger MAMs study which combined rifampicin 
10, 20 or 35mg/kg with other drugs (including isoniazid, pyrazinamide, ethambutol, moxifloxacin, and a new 
compound SQ109) for 12 weeks. The primary endpoint (time to culture conversion in liquid media within 12 
weeks) was faster in the 35 mg/kg rifampicin group than in the control group (median 48 days vs 62 days, 
adjusted HR 1·78; 95% CI, 1·22–2·58, p=0·003), but not in other experimental arms. Clinical outcome 
(recurrence of disease) was similar between groups though numbers were small (11 in total, with one in the R 
35 mg/kg arm).178  
Taken together evidence from pulmonary TB suggests that doses of 35-40 mg/kg are safe (at least in HIV-
negative adults) and have greater early bactericidal activity, but long-term clinical benefits remain to be 
confirmed.  
1.4.7.3 What is the optimal rifampicin dose from TB meningitis studies?  
1.4.7.3.1 The Indonesian trio of TBM trials 
The first study on high-dose rifampicin in TBM was a phase II open-label randomized controlled trial in 
Indonesia (2013), in which Ruslami et al. investigated the safety and PK of intravenous rifampicin (600 mg) as 
well as oral moxifloxacin (400 mg or 800 mg daily), in adults with suspected TBM.153 Although not powered to 
detect a mortality benefit, improved survival was observed in patients receiving intravenous rifampicin (~13 
mg/kg/day, n=29) compared to the oral standard dose (~10 mg/kg/day, n=31) during the initial 2-weeks of TB 
treatment. Participants who received intravenous rifampicin had a more rapid resolution of coma (4 vs 5 days) 
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and markedly reduced mortality at 6-months (34% versus 65%; adjusted HR=0.42; 95% CI, 0.20-0.87, 
P=0.0193), see Figure 1.18.  
Intravenous administration was associated with a 3-
fold increase in plasma AUC0-6 (total exposure up to 6 
hours post dose), Cmax and a 3-fold increase in CSF 
Chighest from 0.21 to 0.60 mg/L. Due to the small sample 
size in this trial it could be argued that the observed 
effect was due to chance (type 1 error). However, 
further pharmacodynamic analysis of this trial 
demonstrated that there was evidence of a rifampicin 
concentration-effect relationship.179 
Figure 1.18. Kaplan-Meier survival estimate according to rifampicin treatment arm in Ruslami et al 2013 Indonesian intensification trial 
This promising result prompted the investigators to seek a safe and effective oral rifampicin dose which might 
have a similar impact on survival. In the Indonesian group’s second open-label phase II randomised trial 
(Yunivita et al. 2016), they compared the safety and PK of intravenous rifampicin 600 mg/day with oral 
rifampicin 750 mg (~17 mg/kg/day) and 900 mg (~20 mg/kg/day) in 30 patients with suspected TBM (in 
combination with standard doses of H, Z, E). In the first days of treatment, the geometric mean plasma AUC0–
24 values following rifampicin 750 mg orally, 900 mg orally and 600 mg intravenously were 131, 165, and 146 
h×mg/L respectively. Exposures to rifampicin varied substantially between individuals and decreased by 30-
50% at the end of week 2 due to autoinduction. A microbiological confirmation of TBM was only made in 13% 
(4/30) patients and survival was not described as this was primarily a PK study. Transient grade 3 alanine 
transaminase (ALT) increases occurred in a quarter of patients (8/30 patients) and one grade 4 ALT increase 
occurred, though not related to rifampicin exposure.180  
Having established the safety of 20 mg/kg/day orally the Indonesian investigators (Dian et al., 2018) 
conducted their third phase II trial, this time double-blinded and placebo-controlled, examining 900 mg (~20 
mg/kg/day) and 1350 mg (~30 mg/kg/day) of oral rifampicin (in combination with standard doses of H, Z, E) 
versus standard of care TB treatment amongst 60 patients with suspected TBM. The total exposure (AUC0-24hr) 
in the standard of care arm was 54 h×mg/L, this increased by 3-fold to 171 and 5-fold to 294 h×mg. /L in the 20 
mg/kg and 30 mg/kg respectively with no increase in adverse events. In CSF, concentrations were 0.28, 0.59 
and 0.74 mg/L in the standard of care, 20 mg/kg and 30 mg/kg arms respectively (p<0.001). In this study an 
impressive 71% of participants had microbiologically-confirmed TBM. There was a trend toward lower 6-
month mortality in the 30 mg/kg/day arm compared to standard of care in participants with ‘definite’ TBM 
(7% vs 36%, p=0.07).181  
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1.4.7.3.2 The Vietnam trial 
Conversely, in the landmark Vietnamese double-blinded, randomised placebo-controlled trial,155 Heemskerk 
et al. randomized 817 adults with suspected TB meningitis to receive either A) an intensified regimen 
containing i) increased oral dose of rifampicin at 15 mg/kg/day and ii) additional oral levofloxacin 20 
mg/kg/day (plus standard of care doses of H, Z and E); or B) standard of care TB treatment during the first 2 
months of therapy. During 9-months of follow-up, 113 (27.7%) patients in the intensified-treatment group 
and 114 (27.9%) patients in the standard-treatment group died (HR 0.94; 95% CI, 0.73 to 1.22; P=0.66). There 
was no evidence of a differential effect of intensified treatment in the overall population, although there was 
a marked survival benefit for patients with isoniazid-resistant infections (HR 0.34; 95% CI 0.15 to 0.76; 
P=0.01).159,63 The results of the PK-PD sub-study within this trial have recently been published. There was an 
approximate doubling of plasma and CSF rifampicin exposures: day 14 plasma AUC0-24 increased from 48.2 
h·mg/L (range 18.2-93.8) to 82.5 h·mg/L (range 8.7-161.0) and CSF AUC0-24  from 3.5 h·mg/L (range 1.2-9.6) to 
6.0 h·mg/L (range 0.7-15.1) in the intensified arm compared to the control arm. However, there was no 
observed association between rifampicin exposure and survival within the range of exposures observed.164 
There was also no relationship between levofloxacin exposure and survival.164 The increase in rifampicin dose 
to 15 mg/kg may have been too modest to elicit a microbiological and clinical impact, bearing in mind that the 
PanACEA MAMs study only found higher early bactericidal activity at a rifampicin dose of 35 mg/kg.178 The 
rifampicin total exposure achieved in the Vietnam study was substantially lower (geometric mean AUC0-24 of 
82.5 h·mg/L) than the most recent Indonesian trial (Dian et al.) where there was a trend towards improved 
outcomes with 30 mg/kg/day (AUC0-24 294 h×mg. /L).181 Total exposure cannot be compared with the 2013 
Ruslami et al. study of IV rifampicin as, due to the timing of sample collection, the investigators were only able 
to calculate the area under the time concentration curve up to 6-hours post dose rather than AUC0-24. The 
hypothesis that the rifampicin exposure in the Vietnam trial was too low to elicit a pharmacodynamic effect is 
supported by the results of a recent meta-analysis of the Indonesian data.  
1.4.7.3.3 Model-based meta-analysis 
Given the modest sample size in each of the three Indonesian trials the individual datasets provided limited 
scope for understanding dose-exposure-response relationships. However, pooling data from the three trials 
and performing a combined analysis with advanced modelling methodologies provided greater statistical 
power to be able to characterize the relationship between individual exposures and mortality, and exposure 
and toxicity. The analysis included data from 1150 PK measurements (including 170 from CSF) and survival 
data included 148 individuals of whom 58 died and 15 dropped out. Nonlinear mixed effects modelling was 
utilised to describe the PK data. The final model featured two disposition compartments, saturable clearance 
and autoinduction. Oral bioavailability was estimated at 78%, clearance decreased with increasing 
concentration, intrinsic clearance was 48%. Only a tiny proportion of rifampicin penetrated into CSF (5.5%; 
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95% CI, 4.5 to 6.4%), and CSF concentration was directly related to plasma concentration and distribution to 
CSF did not saturate within the studied range of rifampicin exposures. Higher levels of protein in the CSF were 
linked to higher CSF rifampicin concentrations (with each 10-fold change in protein concentration there was a 
63% increase in CSF penetration). The model was used to generate individual exposure metrics (AUC0-24 and 
Cmax) to evaluate in the survival model. In the parametric time to event survival model the three main factors 
affecting survival to 6 months were age, baseline Glasgow coma score, and plasma rifampicin AUC0-24. Out of 
the individual PK metrics, plasma AUC0-24 was a better predictor of survival than plasma Cmax or CSF AUC0-24. 
The predicted survival over time per rifampicin dose group included in the three trials is shown in Figure 1.19, 
illustrating that an increase from 450 mg to 1350 mg could be expected to increase survival from 50% to 70% 
in the same population.152  
Figure 1.19: Model-predicted proportion survival over time representative for typical patients (age 30 yrs, baseline GCS = 13) per 
plasma AUC0-24 at day 2.152  
The plasma AUC0-24 at day 2 corresponding to a 50% and a 65% decrease in the hazard was estimated to be 
171 h×mg/L. and 300 h×mg/L respectively. A rifampicin dose of 1800 mg (30 mg/kg in a 60kg individual, or ~35 
mg/kg in a 50kg individual) is likely to attain the desired exposure (300 h×mg/L) in the vast majority of TBM 
patients. The investigators did not find a relationship between rifampicin exposure and adverse events, 
suggesting drug toxicity may be idiosyncratic rather than exposure-related. In summary, a model-based meta-
analysis of data from three Indonesian phase II trials supports the notion that higher dose rifampicin improves 
survival from TBM.  
HIV status did not affect the hazard though there were only a total of 18 HIV-positive people in the whole 
dataset and all participants were Indonesian, so it is unclear whether these findings can be generalised to 
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30–40 mg/kg dose suggested by the model. There are a number of trials planned to do exactly this, 
summarised in the chapter 7 review paper ‘Intensified Antibiotic Treatment for Tuberculous Meningitis’ (Table 
3), including the Rift study conducted during my PhD, the findings of which are presented in chapter 8.  
1.5 Impact of HIV-infection on pharmacokinetics and safety of TB drugs 
Several factors are known to cause interindividual variability in the PK of TB drugs including body weight, sex, 
pharmacogenomics, and comorbid conditions such as diabetes mellitus and possibly HIV infection. 182 For this 
reason it would be remiss to extrapolate safety and PK-PD data from HIV-negative Indonesians to an HIV-
positive African population. In addition, adverse drug reactions during TB treatment are 2- to 4-fold183,135 in 
PLHIV, including drug induced liver injury.184 This highlights the importance of examining the safety and PK-PD 
of a drug within the population where it will be used.  
1.5.1 Does HIV status influence the PK of TB drugs? 
HIV status may have an impact on the PK of TB drugs, though this has been a point of deliberation. Several 
studies have conflicting results and disentangling other confounding factors has not been straightforward. 
Early studies from the 1980s and 90s reported that PLHIV achieve lower plasma concentrations of the orally 
administered first-line antituberculous drugs than their HIV-negative counterparts, though this was largely in 
people with advanced AIDS in the pre-ART era.185,186,187 Though even in a stable outpatient population, 
subtherapeutic range peak rifampicin concentrations (Cmax <8 mg/L) were reported in the majority of patients 
in the Ugandan Infectious Diseases Institute HIV/TB clinic cohort, with a median plasma Cmax of 7.1 mg/L.145  
To explore the impact of HIV status on PK, a systematic review was conducted by the University of Cape Town 
Pharmacometrics group, over half (11/20) of studies included showed a statistically significant difference in 
plasma AUC for a first-line drug by HIV status. The ratio of 
AUC between HIV-positive and HIV-negative participants 
was generally <1.0, as shown in Figure 1.20. In the studies 
that did not find lower drug exposures among PLHIV, the 
majority had higher CD4+ T cell count and were receiving 
ART, suggesting that stage of HIV infection may also 
influence PK. It is possible that successful ART mitigates the 
effect of HIV infection on TB drug PK parameters.  
Figure 1.20. Ratio between the AUC of HIV-positive and HIV-negative TB patients.  
The figure illustrates the 11 studies that identified a difference in AUC between HIV-positive and HIV negative participants. In all but 
one study (Taylor) where a difference was identified, the AUCs were lower in the HIV-positive than HIV-negative (ratio <1) participants. 
Dashed lines represent the 0.8 – 1.25 range, studies with a ratio outside this range were considered to have a clinically relevant 
reduction in AUC. RIF = rifampicin, PZA = pyrazinamide, EMB = ethambutol.182  
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Comparison between individual small studies is limited by sample size, differing sampling strategies and 
analytical methodologies. Therefore, a meta-analysis has been undertaken by the University of Liverpool 
group to definitively answer this question in relation to rifampicin. The meta-analysis included rifampicin PK 
data for 931 individuals, and concluded that HIV status affects the total exposure to rifampicin in the early 
days of treatment (AUC 37.2 h×mg/L in HIV-positive versus 56.7 h×mg/L in HIV-negative, p=0.003) but not once 
steady state has been achieved.171 The lower plasma rifampicin exposure in HIV-positive individuals in the 
initial days of therapy may be particularly relevant in TBM, which carries a high early mortality. Possible 
explanations are HIV enteropathy, diarrhoea, and low bodyweight due to HIV wasting (the latter leading to 
under-dosing using current weight-based algorithms).58,185,186,188 
Additionally, with regards to CSF PK, PLHIV commonly have less marked meningeal inflammation in TBM, as 
measured by lower CSF white blood cell count or protein.52,57,189,190 When the meninges are inflamed the tight 
junctions between cells of the choroid plexus are disrupted allowing plasma proteins and protein-bound drugs 
(like rifampicin) to penetrate the CSF more readily.151 The Indonesian meta-analysis found a correlation 
between CSF protein and CSF rifampicin concentration.152 One could therefore hypothesise that reduced 
meningeal inflammation in HIV-associated TB meningitis may result in lower CSF levels of rifampicin. If this 
hypothesis is valid, then intensified therapies that penetrate effectively into the CNS, regardless of degree of 
meningeal inflammation, may be particularly important in HIV/TBM.  
1.5.2 Does HIV status have an impact on the safety of TB therapy? 
Possible reasons for the increased risk of adverse drug reactions in PLHIV include 1) overlapping toxicities of 
antitubercular and antiretroviral drugs (including skin rashes, gastrointestinal intolerance, hepatotoxicity, 
central nervous system symptoms and peripheral neuropathy); 2) polypharmacy exacerbated by concomitant 
prophylactic antibiotic medications such as fluconazole and trimethoprim-sulfamethoxazole; 3) high rates of 
concomitant viral hepatitis giving rise to liver toxicity; 4) pre-existing HIV-related liver disease giving rise to 
liver toxicity; 5) immune dysregulation in advanced HIV disease; 6) immune reconstitution inflammatory 
syndrome which can be difficult to disentangle from drug toxicity.  
With regards to hepatotoxicity in particular, there is good evidence that being HIV-positive increases the risk 
of developing drug-induced liver injury (DILI) (OR 4.40, 95% CI 1.06 to 18.3) even after adjustment for age, sex 
and baseline liver function tests.184 Though most studies examining drug reactions are retrospective and do 
not allow accurate attribution of the risks conferred by HIV infection itself, by ART, by other concomitant 
medications, or by IRIS.135  
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1.5.2.1 Immune reconstitution inflammatory syndrome and the timing of ART  
As discussed in section 1.2.4.1 TB IRIS is caused by ART-induced restoration of TB-specific immune responses, 
resulting in either the deterioration of a treated infection (paradoxical IRIS) or a new presentation of a 
previously subclinical infection (ART-associated TB or unmasking IRIS). Neurological TB-IRIS, the most severe 
form of IRIS, presents with worsening of headache, onset/exacerbation of focal neurology or seizures. 
Neurological TB-IRIS can be life-threatening and carries a mortality of up to 30%.61  
The decision on when to start ART is a balance of the competing risks of HIV disease progression versus severe 
IRIS, overlapping drug toxicities and pill burden. This quandary has been investigated in a number of large 
randomized controlled trials in suspected TB.191,192,193 There has also been one trial specifically In TBM 
patients.194 The balance of evidence from these studies has given rise to the current recommendations which 
differ between TBM and other forms of TB:   
o CD4 T-cell count <50 – begin ART within the first 2 weeks of TB treatment.195 Early initiation of ART 
increases AIDS-free survival (e.g. reduces risk of death from other opportunistic infections / 
illnesses).192  
o CD4 T-cell count >50 – TB treatment should begin first, followed by ART within the first 8 weeks of 
treatment.195 ART initiation within 8 weeks of TB treatment is associated with a reduction in overall 
mortality, compared with ART initiated after 8 weeks of TB treatment or after TB treatment is 
completed.195 In SAPIT study, deferral of ART to the first 4 weeks of the continuation phase of TB 
therapy in those with higher CD4+ T-cell counts reduced the risk of IRIS and other adverse events 
without increasing the risk of AIDS or death.192 
o TBM – Caution is needed in TBM as immediate ART is associated with more severe adverse events.195 
TBM is unlike other forms of TB in that the infection surrounds a crucial structure (the brain) with a 
very limited ability to expand within the skull should excess inflammation occur. Therefore, ART is 
usually deferred until the intensive phase of TB treatment has been completed regardless of CD4 
count. This is based on the results of a double-blind placebo-controlled RCT of immediate (within 7 
days of TB treatment initiation) or delayed (after week 8 of TB treatment) ART in 253 HIV-positive 
Vietnamese adults with suspected TBM. Immediate ART did not did not improve survival from HIV-
associated TBM and was associated with more grade 4 adverse events (102 in the immediate ART 
group vs 87 in the deferred ART group; P=0.04). Interestingly there was no reported increase in 
neurological events in the immediate ART group which one would have anticipated due to CNS IRIS. It 
is possible that the adjunctive corticosteroids in all participants may have suppressed CNS IRIS. The 
difference between arms was partly driven by the most common laboratory AE - hepatitis 
(transaminases >5x ULN) which occurred in 25% of the immediate ART group and 17% of the deferred 
ART group, but difference did not reach statistical significance.194 The study did not formally 
adjudicate suspected IRIS events. In cryptococcal meningitis early ART was proven to increase early 
mortality due to IRIS,196 so clinicians who managed TBM are cautious about early ART unless there is a 
strong clinical indication. 
43 
1.5.3 Does high dose rifampicin interact with antiretroviral therapy? 
As mentioned in section 1.4.1, rifampicin induces a plethora of metabolic processes inducing expression of 
enzymes and drug transporters (e.g. CYP3A4, CYP2B6, UGT1A1, and P-gp) involved in the metabolism and 
transport of many HIV drugs. Expert opinion suggests that maximal enzyme induction occurs with standard 
dose rifampicin but a dose-related effect has not been excluded.141 Considering that high-dose rifampicin may 
be increasingly considered as a way of improving TB outcomes, establishing the safety and extent of drug-
drug interactions with ART, and their impact on HIV virological control, is key. There is no clinically significant 
interaction between rifampicin and tenofovir or lamivudine, which are the most widely used nucleotide-
reverse transcriptase inhibitor (NRTI) backbone used. Though interactions with the third ART agent cannot be 
avoided.  
The recent RIFAVIRENZ trial, conducted in Uganda, is the only study to have examined the impact of high dose 
rifampicin (20 mg/kg/day) with efavirenz (EFV), dosed at either 600 mg or 800 mg, versus standard dose 
rifampicin (10 mg/kg/day) with EFV 600mg. Despite a slight decrease in EFV AUC0–24 with rifampicin 20mg/kg, 
the geometric mean ratios remained within a preset allowable interval (0.70 to 1.43). The proportion of 
patients with subtherapeutic EFV concentrations in the high-dose rifampicin arms was no greater then with 
the standard dose rifampicin. Strangely, despite everyone switching to standard dose rifampicin at week 8 
and the HIV virological response being equal at week 12, there was a lower proportion with virological 
suppression after 24-weeks among the high-dose rifampicin group with acquisition of the K103N resistance 
mutation in four participants. The possibility of adherence-related failure has been suggested. Adverse events 
were evenly distributed across treatment arms and the proportion of patients with grade >3 increase of 
transaminase (<10%) was comparable to standard dose rifampicin in other studies.197 The upcoming SAEFRIF 
study in Uganda plans to examine the safety and PK of rifampicin 35mg/kg with EFV and dolutegravir (DTG).  
Dolutegravir, an integrase strand transfer inhibitor (InSTI), is now recommended first-line alongside a 
backbone of two NRTIs in many African countries. DTG is arguably better tolerated than EFV, there is little or 
no population level resistance and it has a higher barrier to evolution of resistance. DTG is a substrate of drug 
efflux pumps, such as breast cancer resistance protein (BCRP) and P-gp, and is predominantly metabolized by 
uridine 5’-diphospho-glucuronosyltransferase 1A1 (UGT1A1), with CYP3A4 as a minor route.198 Co-
administration of standard dose rifampicin with DTG results in a clinically significant reduction in DTG 
exposure but this can be overcome by doubling the DTG dose to 50mg twice daily or 100mg once daily 
(though the former is preferable).198,199  There is no data on high dose rifampicin with DTG but this will also be 
studied in SAEFRIF.141 Standard dose rifampicin and HIV protease inhibitor (PI) administration is not 
recommended due to significant interaction, which cannot be easily overcome (other than super-boosted 
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lopinavir/ritonavir) and there are no plans to test the administration of high-dose rifampicin with protease 
inhibitors (PIs).  
In summary, rifampicin and ART drug-drug interactions are an important consideration in the treatment of 
HIV/TB and data is needed on the safety and PK of high-dose rifampicin with ART (specifically DTG and EFV 
which are the most widely used agents in Africa) and on  long-term HIV virological outcomes.  
1.5.4 Are host-directed therapies important for HIV-associated TBM?  
We know that inflammatory response contributes to poor outcomes in TBM.60 Limiting damaging 
inflammation may be just as important as controlling the infection and recent research has yielded fascinating 
results thanks to the use of ‘omics’ technologies, as further described in the chapter 3 review paper ‘Recent 
developments in pathogenesis and diagnostics of tuberculous meningitis’.  
Adjunctive corticosteroids are currently recommended for TBM based on the results of a meta-analysis: at 
follow-up from 3- to 18-months, steroids reduced deaths by almost one quarter (RR 0.75, 95% CI, 0.65 to 
0.87; nine trials, 1337 participants).200 Disabling neurological deficit is common in survivors, and unfortunately 
steroids may have little or no effect on this outcome (RR 0.92, 95% CI 0.71 to 1.20; eight trials, 1314 
participants). The Thwaites et al 2004 trial followed participants for five years, and the effect on death was no 
longer apparent at this time-point (RR 0.93, 95% CI 0.78 to 1.12; one trial, 545 participants).201  
The Thwaites et al. 2004 trial is the only study has reported results by HIV status. The study included 98 PLHIV 
and the sub-group analysis by HIV status was underpowered and did not quite achieve statistical significance 
(stratified RR, 0.78; 95% CI, 0.59 to 1.04; P=0.08), Figure 
1.21.202 In light of this inconclusive result in PLHIV, a 
randomized placebo-controlled trial of the same 
dexamethasone regimen is underway in Vietnam and 
Indonesia (NCT03092817) with a longer follow-up duration 
of 24-months to observe for any late adverse effects of 
steroids in people with an already compromised immune 
system (e.g. Kaposi’s sarcoma, other cancers, fungal or 
invasive bacterial infections).  
Figure 1.21. Kaplan-Meier survival estimate amongst PLHIV according to dexamethasone treatment group.202 
TBM is associated with a hypercoagulable inflammatory state with platelet dysfunction and cerebral infarction 
occurs in at least a quarter of cases. Aspirin is increasingly being studied in an effort to avert stroke and the 
ensuing death or long-term disability.203,204,205 A recent promising pilot study in Vietnam demonstrated a 
reduction in new infarcts and death with 1000mg aspirin in addition to the standard corticosteroids. The 
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effect of 1000mg aspirin was most marked in people with definite TBM, new infarct or death occurred in 
10.7% (3/28) versus 34.4% (11/32) with corticosteroids alone (p=0.06). A dose-dependent inhibition of 
thromboxane A2 and upregulation of pro-resolving protectins in the CSF was identified as a possible 
mechanism of action.206 Larger studies are planned in both adults and children. Thalidomide and other host 
directed therapies are touched upon in the review paper in chapter 3. I have not gone on to discuss 
pathogenesis and host-directed therapy in detail, as whilst it is an extremely important and relevant topic it is 
beyond the scope of this thesis.  
1.6 What are the pressing questions about improving the treatment of TB meningitis 
in Uganda? 
Specific considerations relevant to HIV/TBM outlined in the chapter 7 research paper Intensified Antibiotic 
Treatment for Tuberculous Meningitis (Box 1) and a multitude of research questions relevant to TBM in Africa 
in general outlined in Table 1.6 below. Currently, high-dose rifampicin appears to be the most promising 
option for intensification of TBM treatment. There is however scant data on the safety and PK of high-dose 
rifampicin in PLHIV in Africa and no CSF PK data. Therefore, the most pressing question that I addressed in my 
PhD research is whether high-dose rifampicin can be safely used in advanced HIV disease and whether high-
dose intravenous or oral rifampicin achieve therapeutic CSF levels. I plan to address through a phase II open-
label RCT, the study design and results are outlined in chapter 8.   
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Table 1.6. Research questions relating to the treatment of TBM in Africa 
 RCT = randomised controlled trial IV = intravenous mAb = monoclonal antibody IL = interleukin LZD = linezolid H = isoniazid  
Items shown in bold are those which I hope to address through my PhD research.  
Area Questions applicable to Africa 
Evidence available from 
Uganda or elsewhere 






TB meningitis  
Is high-dose rifampicin safe and well-
tolerated in Ugandans? 
Rifatox,175  Rifavirenz 197  
dose 20mg/kg/day is safe 
1. Rifashort study in PTB is
investigating R 35 mg/kg
2. Phase II RCT of 30-40 mg/kg
Can high-dose rifampicin be safely used 
in people with advanced HIV disease? 
Rifavirenz 197 R 20mg/kg 
outpatient study, median 
CD4 120 to 144.  
PanACEA MAMs study 
N=24 HIV+ CD4 >200, only 
n=4 received R 35mg/kg178 
1. RCT of high dose rifampicin versus
standard therapy in hospitalised
PLHIV
Can people with AIDS and critical illness 
adequately absorb oral rifampicin or is 
an IV regimen preferable? 
Yunivita180 compared IV to 
PO rifampicin included n=6 
PLHIV (Indonesia) 
1. PK study with IV and oral rifampicin
in hospitalised PLHIV
What are the blood and CSF PK 
characteristics of high-dose rifampicin 
in Ugandans with TB and HIV? 
Dian181 N=4 PLHIV  
R 30 mg/kg (Indonesia) 
1. PK study of R 35 mg/kg in
hospitalised PLHIV with CSF
sampling
2. PK results from Rifashort (blood) 
Can high-dose rifampicin improve 
clinical outcomes from TBM? 
Svennson et al.152 PK-PD 
meta-analysis (Indonesia) 
1. Phase III RCT R 35 mg/kg in TBM
Can higher dose isoniazid (in rapid 
acetylators) improve outcomes? 
Ding164  PK-PD study, found 
H exposure predicted 
survival 
1. Phase III trial planned in China 
Can linezolid improve outcomes? 
Sun207  non-randomized 
study: faster GCS & temp 
resolution with LZD 
1. Phase IIB RCT (LASER), phase II RCT
(ALTER), phase III RCT (INTENSE-
TBM) in Africa
What is the optimal regimen for MDR-
TBM, tuberculomas, spinal TB? 
Expert opinion, case 
reports only.208 
1. Rare subgroups of disease would
require multicentre approach 
How do other co-infections or co-
morbidities contribute to poor 
outcomes in TBM? 
Post-mortem studies from 
South Africa describe co-
infections in PLHIV209   
1. Prospective cohorts with detailed 
clinical, microbiological, 
radiological work up, and post
mortem examination
Does high-dose rifampicin affect 
dolutegravir levels more than standard 
dose rifampicin?  
nil 
1. SAEFRIF study planned R 35mg/kg






Are corticosteroids safe in PLHIV? What 
is the risk of cryptococcal disease or 
Kaposi’s sarcoma? 
9-month data on n-98
Thwaites 2004 trial202 
African studies suggest
elevated risk of Kaposi’s
sarcoma with steroids210,211
1. Vietnamese ACT HIV trial 
2. Observational studies describing
incidence of cancers and fungal 
infections in HIV/TBM 
Is there an alternative effective host-
directed therapy for TBM? 
Thalidomide,212   
statins, TNF-α mAb, IL-1Ra 
used at case report level 
1. Animal models
2. Phase II trial of other novel options
Is aspirin effective in averting stroke in 
PLHIV/ TBM? 
Aspirin 81mg and 1000mg, 
phase II (Vietnam)206 
1. Phase III trial (INTENSE, Uganda)
2. Phase II trial (LASER-TBM, S. Africa)
Supportive care 




1. Cross sectional study to understand
cause of hyponatraemia
What is the best management for 
hydrocephalus in Uganda? 
Nil 
1. Begin with observational study
describing prevalence and
outcomes
Is deep vein thrombosis prophylaxis 
indicated?  
Nil 
1. Begin with observational study
describing prevalence and
outcomes
Is prophylactic fluconazole warranted in 
PLHIV + TBM receiving corticosteroids? 
Nil 
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2 Chapter 2: Overview of PhD Aim, Hypotheses, Objectives, 
Setting and Methodology 
2.1 Aim 
The overarching aim of this research was to identify better ways of diagnosing and treating TBM in sub-
Saharan Africa.  
2.2 Hypotheses 
1. The next generation assay Xpert MTB/Rif ‘Ultra’ is significantly more sensitive than Xpert MTB/Rif for
the detection of M. tuberculosis in CSF. However, Xpert Ultra’s sensitivity will be imperfect and it will
fail to diagnose a small number of cases of TBM that are evident by CSF culture, post-mortem
examination, or metagenomic next generation sequencing.
2. Urine diagnostics such as urine TB-LAM and urine Xpert Ultra will be useful adjunctive tools in
diagnosing TBM and will identify patients at the greatest risk of death.
3. Intensified treatment of TBM with intravenous rifampicin (20 mg/kg) or high-dose oral rifampicin (35
mg/kg) will result in significantly increased blood and CSF exposure during the critical early days of TB
treatment as compared to common control (10mg/kg oral rifampicin).
4. High-dose rifampicin will be safe in people with advanced HIV disease and may improve functional
outcomes and survival at 8- and 24-weeks.
2.3 Objectives 
1. To assimilate available retrospective data on adults with suspected TBM in Uganda and to describe
the TBM population in terms of baseline characteristics, method of diagnosis and clinical outcomes.
2. To review the literature on novel diagnostics for TBM and summarise key findings in a review paper
3. To prospectively determine the diagnostic accuracy of Xpert Ultra for the diagnosis of TBM in a
Ugandan population. To explore whether metagenomic next generation sequencing can help
differentiate suspected TBM cases who are negative by Xpert MTB/Rif Ultra.
4. To investigate the utility of urine diagnostics, specifically urine TB-LAM and urine Xpert Ultra, in the
diagnosis and prognostication of TBM.
5. To review the literature relating to the rationale and best options for intensified antibiotic treatment
for TBM and summarise findings in a review article.
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6. To determine, through a phase II open-label randomised controlled trial, whether higher-dose
rifampicin, delivered orally at 35mg/kg/day or delivered intravenously at 20 mg/kg/day provide blood
and CSF exposure profiles that are favourable compared to the 10 mg/kg standard dose oral rifampicin.
7. To describe the safety of high-dose rifampicin, and clinical outcomes including functional status and
survival, overall and by treatment arm.
8. To deliver a series of public engagement events to increase the community and district healthcare
worker’s awareness of TBM, advanced HIV disease, and the research available.
2.4 Study Setting 
The Republic of Uganda is a country in East-Central Africa 
bordered by Kenya, South Sudan, Democratic Republic of 
Congo and Rwanda, Figure 2.1. Uganda is listed as a WHO ‘high’ 
TB prevalence country and TB is a major driver of morbidity and 
mortality, particularly in PLWHIV. An autopsy study at Mulago 
Hospital discovered disseminated TB in 32% (17/53) of all 
autopsies, and 46% (16/35) HIV-positive cadavers.1 In an 
outpatient setting at the Infectious Diseases Institute clinic in 
Kampala, TB remains the most frequent cause of death in 
PLWHIV (24%, 17/70) despite >15-years of ART roll-out.2  
Figure 2.1. Map of the Republic of Uganda 
The TB and HIV epidemic in Uganda are inextricably intertwined with a HIV prevalence of 40% amongst TB 
cases with a known HIV status.3 Of HIV-positive TB cases, 97% report being on ART, though the timing of ART 
initiation, adherence to ART and virological suppression is not reported.3  
In 2019, there were 88,000 (range 52-134,000) cases of TB, giving an incidence of 200/100,000 population. 
This included ~ 35,000 cases amongst PLWHIV, resulting in 8,500 
(range 5100 to 13000) deaths in PLWHIV.3 The incidence of TB is 
declining slowly, Figure 2.2. The Ugandan national TB reporting 
system captures data on TB cases as ‘pulmonary’ or ‘extra-
pulmonary’ and reports that 94% of notified cases were pulmonary 
in 2019. So, whilst we can estimate that there was ~ 5280 cases of 
extrapulmonary TB in 2019, there is no national level data on TBM 
incidence or outcomes.  
Figure 2.2. TB incidence rate in Uganda 2000 - 2018
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2.5 Study Team 
Professor Alison Elliott, based at the Medical Research Council – Uganda Virus Research Institute and London 
School of Hygiene and Tropical Medicine Uganda Research Unit, is my primary supervisor and has overseen 
the PhD process from initial fellowship application, through PhD upgrading and write up of the thesis. I 
regularly attended Professor Elliott’s lab meetings to discuss ideas, share progress and receive guidance and 
inspiration.   
This research was based within the activities of the Infectious Diseases Institute (IDI) Meningitis Clinical 
Research Team, Figure 2.3, led by Dr David Meya 
(Makerere University) and Professor David Boulware 
(University of Minnesota, UoM) who was also my PhD 
supervisor. The team is made up of Physicians, Medical 
Officers, Nurses, Research Assistants, Laboratory 
Technicians, and an HIV Counsellor. The team’s outputs 
are the result of a 10-year collaboration between IDI 
and UoM, and include the conduct of several clinical 
trials (COAT – Cryptococcal Optimal Antiretroviral 
Timing, and ASTRO – Adjunctive Sertraline for the 
Treatment of Cryptococcal Meningitis) and the 
generation of an extensive amount of research around 
meningitis diagnostics and clinical management of 
cryptococcal meningitis. More recently the team has 
expanded its scope to cover TB meningitis.  
Figure 2.3. IDI Meningitis Clinical Research Team 
The team conduct their activities on the Infectious Diseases and Neurology wards of Kiruddu National Referral 
Hospital (formerly part of Mulago National Referral Hospital and now an independent entity) in Kampala and 
the General Medicine wards at Mbarara Regional Referral Hospital. After hospital discharge patients are 
followed-up at the Infectious Diseases Institute Clinic in Kampala and in the Outpatient Department in 
Mbarara Hospital. The hospital laboratories have access to a GeneXpert machine but other laboratory 
capabilities were limited so samples were transported to the Makerere University Microbiology Laboratory 
(CSF analysis) or Makerere University TB Laboratory (CSF TB culture) or to the IDI Translational Laboratory 
(Xpert MTB/Rif Ultra) and IDI Core Laboratory for blood work (complete blood count, renal and liver function 
tests) and storage. In Mbarara the Joint Clinical Research Centre Laboratory was used.  
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2.6 Methodology 
I utilised a broad range of research methodologies during my PhD to appropriately address the 8 objectives 
described in above. The methodologies and statistical techniques used are described in detail in the 
respective research papers. Broadly, the research methodologies can be broken down into five components 
as detailed below.  
2.6.1 Literature Review 
I conducted literature reviews to familiarize myself with the background evidence in the field of TBM 
outcomes, diagnostics and intensified TBM treatment. This culminated in a number of papers: 
• Systematic review and meta-analysis on outcome of TBM (Appendix 1)
• Review article on recent updates in pathogenesis and diagnostics of TBM (chapter 3)
• Review article on Intensified antimicrobial therapy for TBM (chapter 7).
2.6.2 Diagnostic Research 
2.6.2.1 Retrospective cohort study on TB Meningitis Diagnosis and Outcomes in Uganda 
To more fully understand the nature of TBM in Uganda I utilized existing data collected by the IDI Meningitis 
Research Team during prior studies between 2010 – 2016. I identified patients who may have had TBM by 
looking at those patients in whom tests for cryptococcal meningitis were negative, as well as searching for 
variables that related to TB diagnostic testing, TB treatment or ‘suspected TBM’ being listed by the study 
doctor. Where there was uncertainty I revisited archived research files to clarify the patient history and data. 
After extensive reviewing of research notes and data cleaning I generated a retrospective TBM dataset, 
containing 195 patients treated for TBM (suspected or confirmed diagnosis), which I used to analyse and write 
up the research paper in chapter 4 ‘Tuberculous meningitis diagnosis and during the Xpert MTB/Rif era: a 6.5-
year cohort study in Uganda’.  
2.6.2.2 Prospective Diagnostic Research on CSF and Urine  
Throughout my PhD research period I undertook ward rounds with the study team on the Infectious Diseases 
Ward at Kiruddu National Referral Hospital in Kampala. On a daily basis we assessed adults presenting with 
suspected meningitis (e.g. headache or altered mental status), sought informed consent (from the patient or 
their caregiver) and thereafter made a clinical assessment and collect baseline data and a CSF sample, as well 
as a urine sample. We performed imaging as clinically indicated and where possible. We returned diagnostic 
results to the local ward team and followed the patient through to the time of hospital discharge or death. 
CSF samples from patients with suspected TB were used for the prospective diagnostic accuracy study of CSF 
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Xpert MTB/Rif Ultra (chapter 5). Urine samples were used to explore the utility of urine diagnostics for TBM 
diagnosis and management (chapter 6).  
2.6.3 Therapeutic Research: A Phase II Randomised Controlled Trial of High Dose Oral and 
Intravenous Rifampicin in TB Meningitis 
During the first 6 months of the PhD I invested time in developing the protocol, standard operating 
procedures (SOPs) and case report forms (CRFs) for the Rift trial, a phase II open-label randomized controlled 
trial investigating high-dose rifampicin for adult TBM. The trial primary endpoints were: 1) pharmacokinetic 
parameters (serum total and peak exposure and CSF concentration), 2) composite safety endpoint (grade 3-5 
AEs, serious AEs or discontinuation of rifampicin for >5 days) during the 8-week intervention period. The study 
was powered for primary endpoints with a sample size of 60 across the three arms. Secondary endpoints 
were primarily exploratory and included clinical outcomes: 1) mortality at 8 and 24 weeks, 2) time to 
normalization of conscious level, 3) functional status by modified Rankin score). I published the clinical trial 
protocol as a paper on Wellcome Open Research, featured in the Appendix 5.  
Thereafter, I navigated the regulatory approvals from the UK and Ugandan authorities, including three rounds 
of Institutional Review Board submissions at Mulago Hospital and LSHTM, Uganda National Council of Science 
and Technology approval and Ugandan National Drug Authority approval. Donation of study drug was sought 
from Sanofi. The trial began enrolment on 14th January 2019 and recruited through til 17th December 2019. 
The individual follow-up period was 6 months, so the final participant completed follow-up on the 26th May 
2020. The Rift main trial paper is included in chapter 8.  
2.6.4 Public Engagement 
I realized that there was a major need for public engagement work around meningitis to address a number of 
challenges: 
1. Firstly, I observed how people present to hospital with very advanced disease, often after weeks of
illness, by which time the TBM is advanced (Medical Research Council, MRC stage II/III), irreversible
brain damage already exists and the chance of any therapeutic intervention having an impact is
limited.
2. Secondly, even after presentation to hospital some patients languish at regional hospitals or private
hospitals for days or weeks without having a lumbar puncture, appropriate treatment being initiated
or onwards referral to the research team for diagnostic or therapeutic research being made.
3. Thirdly, there is a misperception in the community that lumbar punctures kill people (often because
they are only performed at the terminally stage of the illness for the reasons mentioned above) and
this misperception can lead to a delay in consent for the LP on arrival at hospital.
4. Lastly, misconceptions are held by some community members about the aims and nature of clinical
research relating to fears about being experimented upon and exploited.
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These are challenging problems to address and no work had been done on public engagement around 
meningitis research previously in Uganda. I was successful in winning three public engagement grants, the 
first a small public engagement grant from LSHTM, the second an Endeavour award from Makerere-UVRI 
Infection and Immunity (MUII) Centre of Excellence, and the third a continued development public 
engagement award from LSHTM. The overall aim of the public engagement work was to increase dialogue 
between the community and research team to increase awareness of HIV-associated meningitis the ongoing 
clinical research, and to dispel myths and anxiety around lumbar punctures. 
Along with the research team, and with guidance from the Infectious Diseases Community Advisory Board, I 
put together a series of different events over 15 months. These events included a circus in an informal 
settlement in central Kampala to engage with hard-to-reach individuals, continued medical education sessions 
with regional healthcare workers, testimonials from trial participants broadcast on CBS national radio, a 
television show on NTV national TV including a trial participant and an ‘Event of Hope’ research results 
dissemination with trial participants and other stakeholders. The activities are detailed in an open letter in 
chapter 9 published on the African Academy of Sciences Open Research.  
2.7 Ethics 
All elements of the research were conducted in-line with Good Clinical Practice in Research and the 
Declaration of Helsinki. Ethical approvals were obtained from Mulago Hospital Institutional Review Board 
(MREC 1260) and the LSHTM Ethics Committee (14388).  
Informed written consent (signature or thumbprint where illiterate) was obtained from participants or their 
surrogate (if participant lacked mental capacity due to altered mental state, which is common in brain 
infections). Clinical examination and study procedures were undertaken by experienced and appropriately 
trained study staff. Study drugs were administered by research nurses and drug management was overseen 
by the IDI research pharmacist and the Ugandan National Drug Authority.  
2.8 Data Management and Quality Assurance 
Data was collected using the DataFax system which relies on paper case report forms (CRFs) that were 
scanned, emailed to a server, and data entered by intelligent character recognition. After an initial automated 
error-checking, secondary review for accuracy was performed by the DataFax team at the Infectious Diseases 
Institute, Uganda. A detailed data management plan was written and reviewed by the data management team 
at LSHTM. To ensure data collected was of the highest quality a monitoring plan was implemented which 
involved both internal monitoring by IDI and external monitoring by Mrs Mirriam Akello and Mrs Sarah 
Coutinho from Makerere-UVRI Infection and Immunity Centre of Excellence.  
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3 Chapter Three: Recent advances in Pathogenesis and 






Year of publication 
Annual publications, PubMed.  Search terms 
tuberculous meningitis OR TB meningitis in 
title/abstract 
The Tuberculous Meningitis International Research Consortium is comprised of basic scientists, translational 
and clinical researchers interested in TBM and meets biennially. Along with fellow multi-disciplinary members 
of the consortium I led the writing of a review paper on ‘Recent advances in pathogenesis and diagnostics of 
tuberculous meningitis’. This paper involved pulling together a group of ten authors from seven different 
countries. The article has become part of a ‘collection’ of 11 articles published on the Wellcome Open 
Research platform by the consortium (https://wellcomeopenresearch.org/collections/tbmeningitis). I laid out 
the framework for the article, wrote the section on molecular diagnostics and harmonised and edited the 
other sections. I handled the submission process and the response to reviewer comments. Literature search 
was conducted on PubMed using the terms tubercul* meningitis OR TB meningitis within the dates 
10/10/2014 and 10/10/2019, yielding 742 titles/abstracts which were the sifted for relevance. 
The article specifically focusses on insights from the last 5 years and does not aim to be a comprehensive or 
systematic review of all literature relating to TBM. The article serves as a broad overview and introduction to 
immunology and diagnostics and introduces topics relevant to the rest of the thesis. 
The number of publications relating to 
TBM has steadily increased since the 
turn of the century, equating to 
almost 2000 in total. The increasing 
use of ‘omics’ techniques in the last 5-
10 years is increasingly illuminating 
the complex pathogenesis of this 
disease and will hopefully lead to 
better diagnostics and treatments. 
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The pathogenesis of Tuberculous meningitis (TBM) is poorly 
understood, but contemporary molecular biology technologies have 
allowed for recent improvements in our understanding of TBM. For 
instance, neutrophils appear to play a significant role in the 
immunopathogenesis of TBM, and either a paucity or an excess of 
inflammation can be detrimental in TBM. Further, severity of HIV-
associated immunosuppression is an important determinant of 
inflammatory response; patients with the advanced 
immunosuppression (CD4+ T-cell count of <150 cells/μL) having higher 
CSF neutrophils, greater CSF cytokine concentrations and higher 
mortality than those with CD4+ T-cell counts > 150 cells/μL. Host 
genetics may also influence outcomes with LT4AH genotype 
predicting inflammatory phenotype, steroid responsiveness and 
survival in Vietnamese adults with TBM. Whist in Indonesia, CSF 
tryptophan level was a predictor of survival, suggesting tryptophan 
metabolism may be important in TBM pathogenesis. These varying 
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approach to anti-bacillary or immunomodulatory treatment in TBM is 
truly the best way forward. Of course, to allow for proper treatment, 
early and rapid diagnosis of TBM must occur. Diagnosis has always 
been a challenge but the field of TB diagnosis is evolving, with 
sensitivities of at least 70% now possible in less than two hours with 
GeneXpert MTB/Rif Ultra. In addition, advanced molecular techniques 
such as CRISPR-MTB and metagenomic next generation sequencing 
may hold promise for TBM diagnosis. Host-based biomarkers and 
signatures are being further evaluated in childhood and adult TBM as 
adjunctive biomarkers as even with improved molecular assays, cases 
are still missed. A better grasp of host and pathogen behaviour may 
lead to improved diagnostics, targeted immunotherapy, and possibly 
biomarker-based, patient-specific treatment regimens.
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            Amendments from Version 1
In this version we have taken on board the suggestions of 
reviewer 1. We have further developed the evidence on 
TBM pathogenesis including host genotype and brain injury 





The pathogenesis of Tuberculous meningitis (TBM) is poorly 
understood. Mechanisms by which Mycobacteria disseminate 
from lung to the brain, key factors driving a dysregulated host 
response, and the pathogen specific factors influencing pres-
entation and severity, compared to other forms of TB, are 
not well described. In recent years application of contemporary 
molecular biology ‘omics’ techniques to clinical samples, greater 
availability of advanced neuroradiology, emphasis on immune-
mediated contributions to pathology, and use of refined experi-
mental models of TBM have better illuminated its pathogenesis. 
A better grasp of these processes may also lead to improved 
diagnostics, targeted immunotherapy as well as a biomarker- 
based, patient-specific approach to personalized treatment. Diag-
nosis has been traditionally insensitive (AFB smear) and slow 
(culture). This has improved with the addition of GeneXpert 
MTB/Rif (Xpert) which gave sensitivities similar to culture 
in 2 hours (versus 2–4 weeks with culture). Subsequently, 
GeneXpert MTB/Rif Ultra (Ultra), a re-engineered version, has 
shown better sensitivities than culture in some settings. Yet, none 
of these technologies has adequate negative predictive value 
to ‘rule-out’ TBM. In this article we review important recently 
published studies that have informed our current understanding 
of TBM pathogenesis and diagnostics. We do not seek to 
present a comprehensive review of the history of TBM patho-
genesis and diagnostics as a number of detailed papers that have 
addressed this recently1–3. Rather we provide a commentary 
of key studies published within the last 5 years and summarise 
knowledge gaps and future considerations to enable progress 
in the field.
TBM pathogenesis
Dissemination to the central nervous system
Understanding of the microbial and immune processes that 
allow M. tuberculosis to disseminate from the respiratory epi-
thelium to reach the meninges remains incomplete2,4. The 
foundations of what is known were laid through natural history 
and autopsy studies in the pre-chemotherapy era. The necessary 
steps to develop TBM include the pathogen surviving its ini-
tial encounter with the innate immune system at the respiratory 
epithelium and establishment of primary infection in the lung 
parenchyma with characteristic granulomatous inflammation5–7. 
Spread beyond the lungs likely occurs through the blood and 
may be preceded by local invasion to the lymphatic system. 
Donald and Schoeman have highlighted the possibility of 
coincident miliary TB in cases of TBM, particularly in young 
children, where tubercles of different sizes and ages have 
been described on the meninges and confirmed by magnetic 
resonance imaging (MRI)8,9. In children, miliary TB and TBM 
develop most often within 3 months of primary infection, when 
fresh anatomical changes are still found in the primary lung 
focus10. In addition to children, people living with HIV (PLWHIV) 
are another vulnerable group who may be unable to control 
the infection in the lungs and therefore at risk of coincident 
miliary TB and TBM secondary to haematogenous dissemina-
tion of M.tb8,11. The contemporaneous nature of TBM and miliary 
TB potentially challenges the “Rich focus” model (of a single 
meningeal/sub-cortical granuloma rupturing years after initial 
haematogenous dissemination discharging acid-fast bacilli into 
the sub-arachnoid space)12.
Host immune response to TB infection in the CNS
The host immune response to TB bacilli in the sub-arachnoid 
space gives rise to a granulomatous inflammation predominantly 
affecting the basal meninges. Inflammatory exudates may obstruct 
the passage of cerebrospinal fluid (CSF), leading to hydrocepha-
lus. Small and medium-sized intracerebral arteries can become 
inflamed and occluded, leading to cerebral infarcts. The major-
ity of TBM pathology is believed to result from the host inflam-
matory response, which has been reviewed in depth elsewhere;2 
several pro- and anti-inflammatory cytokines such as tumour 
necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin (IL) 
1β, IL-6, IL-8, and IL-10 are shown to be induced in TBM13,14. 
Disequilibrium of pro- and anti-inflammatory cytokines influ-
ence the severity and course of TBM. Current understand-
ing of key established mechanisms known to play a role in host 
immune response in TBM are summarised in Figure 12,15.
In the recent literature, the long-standing belief that exces-
sive inflammation is the cause of death in TBM was brought 
into question by a recent immunopathogenesis study in Vietnam. 
In HIV-negative adults, associations between death and both lower 
CSF cytokine concentrations and lower CSF leucocyte counts 
(median 59 × 103 cells/mL (IQR 13–240 × 103 cells/mL) in those 
who died versus 135 × 103 cells/mL (IQR, 48–298 × 103 cells/mL) 
in survivors) were noted16. These data support the notion that 
poor outcome from TBM, in the context of immunosuppres-
sive treatment (adjunctive corticosteroids), is associated with an 
inadequate pretreatment inflammatory response in HIV-negative 
individuals. In a study of 120 Vietnamese adults with TBM 
included in a trial of adjunctive aspirin treatment, it was shown that 
there was an aspirin dose-dependent inhibition of thromboxane A
2
 
and upregulation of pro-resolving CSF protectins, resulting 
in potential reduction in new infarcts and deaths by day 60 of 
treatment in microbiologically confirmed TBM patients17. A fur-
ther study investigated concentrations of host protective lipid 
mediators (specialized proresolving mediators, SPMs) in CSF. 
Prostaglandins and cysteinyl leukotrienes were found to be 
reduced in more severe cases, while the lipoxygenase 5-derived 
13-series resolvin (RvT)2, RvT4, and 15-epi-lipoxin B4, were
significantly increased in survivors. These data suggest SPMs
may play an important role in TBM pathogenesis18.
Among 608 Indonesian adults with suspected TBM, higher 
CSF and blood neutrophil counts (HR 1.10 (95%CI 1.04–1.16) 
per 10% increase and HR 1.06 per 109 neutrophils/L increase; 
Page 3 of 20
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Figure  1.  Illustrative  summary  of  the  pathogenesis  of  tuberculous  meningitis  (TBM).  Reproduced with permission from author and 
Journal of Leukocyte Biology2. A: Mycobacterium tuberculosis bacilli (M.tb) disseminate from the primary site of infection in the lung to seed 
the brain. The bacilli traverse the blood brain barrier (BBB) and blood cerebrospinal fluid barrier (BCSFB) through various virulence factors 
that enable the invasion of and migration through cerebral vascular endothelial cells, or are carried into the CNS by infected peripheral innate 
immune cells. B: In the CNS antigen recognition and internalization by microglia, neurons and astrocytes occurs, mediated by numerous 
host genetic factors. C: The resulting immune response stimulates the release of proinflammatory cytokines and chemokines and other 
immune mediators that contribute to the breakdown of the BBB and the influx of innate and adaptive immune cells from the periphery. D: A 
prolific inflammatory response ensues. The inflammatory exudate in the basal cisterns contributes to cerebral vascular pathology and the 
development of hydrocephalus and raised intracranial pressure. Vasogenic edema due to an influx of proteins through the leaky BBB, and 
cytotoxic edema as a result of cellular damage contribute to the raised pressure. The overall decrease in cerebral blood flow puts the brain 
at risk of ischemia, infarction and poor patient outcomes. In some cases the infection is controlled in discrete tuberculomas or abscesses, 
which may resolve with treatment and time.
(95% CI 1.03–1.10), respectively) were associated with mortality19. 
Flow-cytometry on blood in a subset of 160 HIV-negative adults 
with TBM showed lower αβT and γδT cells, NK cells and 
MAIT cells in TBM subjects compared to 26 pulmonary TB 
adults (2.4 to 4-fold, all p < 0.05) and 27 healthy controls 
(2.7-7.6-fold, p < 0.001), but higher neutrophils and classi-
cal monocytes (2.3 - 3.0-fold, p < 0.001). CSF flow cytometry 
of TBM patients showed a predominance of αβT and NK cells, 
associated with better survival, as well as the presence of MAIT 
cells, previously undescribed in CSF20. Indonesian HIV-negative 
TBM patients showed a strong myeloid blood response and a 
remarkably broad lymphoid CSF response including innate lym-
phocytes, however there was little correlation between blood 
and CSF compartments20.
These recent studies in Vietnamese and Indonesian adults with 
TBM, aimed at gaining insights into mechanisms of the inflam-
matory response in disease pathogenesis, used novel and high- 
resolution methods to look at lipid mediator profiles and 
immune cell populations. Data indicated specific lipid mediator 
signatures and cell populations that are associated with dis-
ease severity before treatment and mortality; these should be 
considered for host-directed therapy of TBM.
Host genetic and metabolic factors.
More efficient and cost-effective genomics platforms have 
enabled of late better understanding of variable host responses 
in TBM through the study of host genetics. Polymorphisms in 
CD43 encoding a surface glycoprotein involved in M.tb adhesion 
and proinflammatory cytokine induction and PKP3-SIGIRR-
TMEM16J gene region encoding a negative regulator of 
TLR/IL-1R signalling have both been linked to survival in 
TBM21,22. However, the greatest interest has been around the 
role of leukotriene A4 hydrolase (LTA4H). LTA4H catalyzes 
the final step in the synthesis of leukotriene B4 (LTB4), a 
potent chemoattractant and pro-inflammatory eicosanoid. 
A common functional promoter variant rs17525495 in the 
LTA4H gene can predict survival and dexamethasone respon-
siveness in HIV-uninfected adults with TBM16,23. This human 
candidate gene association study was guided by findings 
in a zebra fish model where LTA4H was found to deter-
mine the balance of pro-inflammatory and anti-inflammatory 
eicosanoids in response to mycobacterial infection16,24. In a 
retrospective study in Vietnamese HIV-uninfected adults with 
TBM, while LTA4H rs17525495 TT and CC genotypes were 
both associated with susceptibility to mycobacterial infection, 
the associations involved opposing inflammatory states: high 
inflammation for the TT genotype and low inflammation for the 
CC genotype. CT genotype had an intermediate inflammatory 
response and were more likely to survive TBM. Dexamethasone 
treatment improved survival in TT genotype patients with hyper-
inflammatory response but was possibly harmful to CC patients 
with hypo-inflammatory response23. A later prospective study 
in Vietnam reported that in TBM HIV-uninfected adults, LTA4H 
genotype influences cytokine inflammatory response and corre-
lates with TBM severity, Figure 216. More importantly, this study 
confirmed that the LTA4H genotype determined corticosteroid 
responsiveness and survival. 
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Figure 2. Kaplan-Meier survival curves stratified by LTA4H genotype. Figures A and B show survival in 763 patients with tuberculous 
meningitis in Vietnam16, with human immunodeficiency virus (HIV) infection (A), and without HIV infection (B). In HIV-infected patients, 
case-fatality rates were 34.8% (16 of 46) in those with TT genotype, 42.1% (61 of 145) in CT genotype, and 38.8% (52 of 134) in CC genotype. 
In HIV-uninfected patients, case-fatality rates were 7.1% (3 of 42) in TT, 21.4% (40 of 187) in CT, and 18.7% (39 of 209) in CC. Figures C and 
D show survival in 375 patients with tuberculous meningitis in Indonesia19. These patients are HIV-uninfected with severe (GCS ≤ 13) (C) or 
milder (GCS 14–15) disease (D). In a recessive model, TT genotype versus CT/TT combined had HR 0.81 (95% CI 0.41-1.62, p = .550) in 
severe and 0.31 (95% CI 0.04-2.25, p = .156) in milder disease.
Interestingly, LTA4H genotype did not predict outcomes in 
Indonesian adults with TBM, but there was a trend towards 
improved survival with TT genotype compared to CC or CT 
genotype, Figure 219. A clinical trial is currently underway in 
Vietnam (NCT03100786) to evaluate LTA4H genotype-directed 
corticosteroid therapy, an exciting example of personalised 
medicine in TBM25.
Although prior studies have considered sodium, glucose and 
lactate as related to TBM pathogenesis, recent developments in 
the application of targeted metabolomics have provided greater 
insight in the role of tryptophan, a potential key metabolite in 
TBM. This amino acid required for protein biosynthesis is a 
precursor to serotonin and melatonin (serotonin pathway) and 
kynurenine and quinolinic acid (kynurenine pathway). The latter 
is stimulated at the expense of the former by pro-inflammatory 
cytokine such as IL-6, TNF-alpha and IFN-gamma via indoleamine 
2, 3-dioxygenase. In a recent study of serum and CSF metabolites, 
low levels of tryptophan were associated with survival26. One 
theory regarding this association could be the neuroprotective 
effects of the associated kynurenine pathway downstream 
metabolites. Either this pathway, or the 11 genetic foci related 
to CSF tryptophan metabolism could have novel clinical 
implications for TBM26.
HIV co-infection and immune reconstitution inflammatory 
syndrome
HIV infection is a strong independent predictor of death from 
TBM (hazard ratio, 3.94; 95% confidence interval (CI), 
2.79–5.56)27. The role of adjunctive corticosteroids in HIV-
associated TBM is inconclusive (relative risk of death with 
adjunctive steroids, 0.78; 95% CI, 0.59 to 1.04; P=0.08)28 and a 
randomized placebo-controlled trial is underway (NCT03092817) 
to address the use of steroids in HIV-associated TBM. Patho-
genesis studies in PLWHIV are required to identify the unique 
pathogenic determinants of poor prognosis. Thuong et al. 
compared the pretreatment CSF cells and cytokine profiles of 
764 HIV-positive and HIV-negative participants in Vietnamese 
TBM clinical trials. HIV-positive individuals had higher mean 
CSF neutrophil percentage (17% vs 5%; P < .0001) and global 
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cytokine expression (aside from IL-10 which inhibits response to 
M. tuberculosis) than their HIV-negative counterparts. PLWHIV
with CD4+ T-cell counts <150 cells/μL showed higher median
CSF neutrophil percentage (25%), than those with a count
≥150 cells/μL (neutrophils 10%; P=0.021) and patients without
HIV infection (neutrophils 5%; P<0.0001). Of patients with
a CD4+ T-cell count of <150 cells/μL, 44% (105 of 238) died,
compared with 13% (5 of 39) with a count of ≥150 cells/μL
and 19% (83 of 439) without HIV infection16. These findings,
amongst others, suggest a role for neutrophils in the immun-
opathogenesis of HIV-associated TBM.These findings, amongst
others, suggest a role for neutrophils in the immunopathogenesis
of HIV-associated TBM29.
Marais et al. conducted longitudinal analyses of paired blood 
and CSF samples in South Africans with HIV-associated 
TBM, describing the relationships between the development of 
immune reconstitution inflammatory syndrome (IRIS) and CSF 
leucocytes, the concentrations of >30 blood and CSF inflamma-
tory mediators, and blood transcriptional profiles. They found 
TBM-associated CNS IRIS to have an inflammatory signature 
characterized by neutrophil and inflammasome-mediated proin-
flammatory responses30,31. The neutrophil-dependent inflamma-
tory activation could be detected in peripheral blood before the 
start of TB treatment and therefore has potential to predict who 
will develop IRIS.
Brain Injury Markers.
The study of neurodegenerative-associated proteins to describe 
extent and type of brain injury post TBM has recently been 
explored through omics analysis, approaches which strive to 
understand genetic or molecular profiles of humans, particularly 
in paediatric TBM. In lumbar CSF of children with TBM, S100B 
and NSE (structural proteins of the CNS, and biomarkers of 
CNS tissue damage) at disease onset were associated with poor 
outcome, as was highest concentration overall and an increas-
ing profile over time in S100B, NSE, and GFAP neuromarker 
concentrations increased over time in those who died (whilst 
inflammatory markers decreased), and were overall highest in 
those with cerebral infarction32. It is of interest that despite 
markers of inflammation reducing, proteins traditionally 
associated with neurodegenerative processes continued to rise.
In ventricular CSF of children with TBM, transcriptome analysis 
has revealed significant enrichment of transcripts associated with 
neuro-excititoxicity predominantly driven by glutamate release 
and NMDA binding and receptor uptake33. Upregulation of genes 
associated with nitric oxide, cytochrome c, brain injury proteins 
like myelin basic protein, and proteins including tau, amyloid- 
beta and apo- lipoprotein were also seen33; many of which have 
also been described in in neurodegenerative conditions such as 
Alzhiemer’s disease and traumatic brain injury34.
These findings raise the possibility of ongoing brain injury 
which in TBM seem to occur following ischaemic injury, despite 
resolving acute inflammation32. Further studies, including those 
which investigate the longer-term pathogenic processes in 
TBM are required to validate these results and understand 
further neurological sequelae including those which may indicate 
a post-infectious process in TBM.
Neuroimaging in pathogenesis studies
Technical advances and increasing availability of imaging 
modalities has recently enabled research in which imaging is 
used to assess pathogenic mechanisms in TBM in vivo in ani-
mal and human subjects. In a blood and CSF biomarker study of 
childhood TBM tuberculomas, magnetic resonance imaging has 
been used to note an association between tuberculomas and ele-
vated interleukin (IL) 12p40, interferon-inducible protein 10, 
and monocyte chemoattractant protein 1 concentrations, whereas 
infarcts were associated with elevated TNF- α, macrophage 
inflammatory protein 1α, IL-6, and IL-832. Specific sequences 
can also be used to describe morphology of structural damage and 
correlate this to meaningful clinical measures. For instance 
poorer Diffusion Tensor Imaging (DTI) parameters of white mat-
ter integrity in the anterior cingulate gyrus parahippocampal 
gyrus and globus pallidus are associated with worse neuropsy-
chological performance35. A further study by the same group 
used Diffeomorphic Anatomical Registration Through Exponenti-
ated Lie Algebra (DARTEL) voxel-based morphometry (VBM) to 
assess the integrity of grey matter in these same TBM patients36. 
Patients with TBM performed significantly poorer on the digit 
symbol, similarities, block design, matrix reasoning, and letter-
number sequencing subtests of the Wechsler Adult Intelligence 
Scale compared to healthy adults. These changes correlated 
with smaller grey matter volumes in the right thalamus, right 
superior temporal gyrus, right precuneus, right middle tempo-
ral gyrus, left putamen, right caudate nucleus, and right middle 
temporal gyrus36. These studies suggest that structural damage 
can be cortical as well as subcortical which may in turn be related 
to degree of long-term impairment. This has implications for 
understanding long term outcomes particularly neurocognitive 
impairment in TBM, which in light of these findings may share 
features with other forms of dementia (including vascular and 
HIV associated neurocognitive impairment) where a subcortical 
pattern of neurocognitive impairment (including frontal and 
executive functions) can be observed.
A rabbit model study of childhood TBM, utilized ionized 
calcium binding adapter molecule (Iba-1) to approximate micro-
glial activation with flurodeoxyglucose-positron emission tom-
ography (FDG-PET) and demonstrated the presence of activated 
microglia and macrophages localized to TB lesions37. In 
humans, case reports and a prospective study have advocated 
the use of FDG-PET as a diagnostic tool, as it has been effec-
tive in detecting extra-cranial evidence supportive of a TBM 
diagnosis38–40. The role of FDG-PET in unravelling time course 
of inflammation in TBM remains to be seen, although it has 
played a role in understanding Alzheimer’s, a disease in which, 
similar to TBM, inflammation plays a key pathogenic role41,42.
Pathogen factors: bacillary load, pathogen strain and 
virulence factors
TBM patients generally have low bacterial loads in CSF which 
causes difficulties in both diagnosis and ability to study bacterial 
load evolution-related pathophysiology. The time-to-positivity 
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of a culture and cycle threshold (Ct) of nucleic acid amplifica-
tion tests such as GeneXpert MTB/Rif (Xpert) can provide an 
indication of likely bacterial burden43. Over 50% of diagnosed 
cases are microbiologically undetectable and defined as ‘prob-
able’ or ‘possible’ TBM which obviously limits this approach44. 
Marais et al. showed that in patients where M.tb was cultured 
from CSF taken before and after two weeks of anti-tuberculosis 
treatment, there was a 9.3-fold increased risk of subsequently 
developing TBM-IRIS, although the sample size is small with 
15 TBM-IRIS patients compared with 6 non-TBM-IRIS 
patients45. Thuong et al. found that among 692 Vietnamese 
adults with TBM, pre-treatment CSF M.tb load (by Xpert Ct) 
was correlated with increased CSF neutrophil counts, increased 
cytokine production, and new neurological events after treatment 
initiation, but not death43.
In addition, epidemiological trends of M.tb lineage from TBM 
(n=73) and pulmonary TB (n=220) patients in Thailand showed 
that the Indo-Oceanic lineage is more frequently found in 
TBM patients (41% versus 13% in PTB)46. This association did 
not hold true in Indonesia, though specific genetic variations were 
identified which were associated with TB phenotype, including 
one (Rv0218) whose encoded protein may play a role in host- 
pathogen interaction47.
Host-pathogen interactions
It is estimated that the global burden of latent TB infection (LTBI) 
is approximately 23.0% (95% CI 20.4%–26.4%), amounting to 
approximately 1.7 billion people48. Innate immune responses 
are critical to control TB infection yet also contribute to tissue 
damage. This delicate balance is illustrated in the damage response 
framework which provides a theory of microbial pathogenesis 
that incorporates the contributions of both host and microbe to 
host damage that stems from host-microbe interaction49,50. This 
framework likely applies to TBM based on evidence of both 
failed immunity and excessive inflammation being linked to 
increased TBM pathology, see Figure 323,51,52. Both the microbe 
and the host contribute to host damage and where an individual 
patient’s immune response lies on the continuum of the 
damage response framework parabola determines the nature of 
the disease process16,43,53. Evidence from recent studies shows 
LTA4H genotype, CSF cytokines and CSF immune cells such 
as neutrophils are determinants of inflammatory state, which 
impacts both bacterial growth and host damage and thus leads 
to different outcomes. The current one-size-fits-all approach to 
TBM treatment fails to recognize divergent pathologies and may 
explain the poor outcomes in certain populations. Being able to 
identify where on the parabola an individual lies and tailoring 
therapy to achieve the optimal milieu is an approach that 
Figure 3. Outcomes of the host – M. tuberculosis interaction depicted by the basic parabola of the damage-response framework. On 
the left side of the parabola, shaded in blue, the immune system fails to limit mycobacterial growth and invasion which results in host damage. 
On the right side, shaded in red, the immune response is excessive and the resultant inflammation and host-damage. The proportion of the 
parabola lying below the black line represents disease latency, which is not associated with clinically evident host damage. On the blue side 
therapeutic interventions could be targeted at stimulating an immune response, whilst on the red side therapeutic interventions could aim to 
dampen immune response.
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warrants further investigation. LTA4H genotype is an example 
of using host genotype to predict inflammatory response and to 
tailor treatment by host directed therapy. Omics technology 
are now being used to identify additional host genetic markers 
and treatment targets in TBM.
TBM diagnostics
Host-based diagnostic biomarkers
Traditional diagnostic techniques for TBM include CSF smear 
microscopy for acid fast bacilli (rapid and cheap but insensi-
tive in most settings, 10–15%) and CSF culture (improved sen-
sitivity of 50–60% but results in 2–6 weeks with a biosafety 
lab level three requirement)3. Given the limitations of tradi-
tional, diagnostic tests for TBM that focus on bacillary detection, 
there is interest in the utilization of host-based diagnostic 
biomarkers for diagnosis of TBM, Figure 4. Adenosine deami-
nase (ADA), produced by lymphocytes, is an important regulator 
of follicular helper T-cells. ADA is commonly used for diagno-
sis of TB from other, typically extra-pulmonary locations and 
numerous studies have considered ADA for diagnosis of 
TBM54. One 2017 meta-analysis found ADA to have a pooled sen-
sitivity of 89% (95% CI 84–92%) with pooled specificity 91% 
(95% CI, 87–93%)54. Yet ADA use for TBM diagnosis has been 
limited by the high cost of the test, required sophisticated lab 
infrastructure, study heterogeneity, inadequate negative predictive 
values, and variable test performance.
A number of studies have considered unstimulated CSF 
interferon gamma (IFN-γ) levels as a diagnostic test, in general, 
a high number of false positive results has limited the utility of 
CSF IFN-γ55,56. For instance, in one study of 39 controls 
(n=12 viral, n=16 purulent, n=11 cryptococcal meningitis) 
and 30 subjects with TBM while median IFN-γ levels where 
higher amongst subjects with TBM, diagnostic accuracy was 
inadequate56. At the strongest cut-point (81pg/mL) determined 
by receiver operator curve analysis, positive predictive value was 
only 81% with positive results occurring in 2/12 (17%) with 
viral meningitis, 3/16 (19%) with purulent meningitis, and 
1/11(9%) with cryptococcal meningitis56.
Interferon gamma release assays (IGRAs) are commonly used 
to infer LTBI. A 2016 meta-analysis of six studies performing 
CSF IGRA’s found a pooled sensitivity and specificity of 
77% (95% CI 69%-84%) and 88% (95% CI 74%-95%), respec-
tively, for TB meningitis, though reference standards varied by 
study57. Limitations of IGRA include high cost, the need for 
advanced lab infrastructure, frequent “indeterminate” results, and 
false positives associated with other causes of meningitis. Addi-
tional host biomarkers including delta-like ligand 1, vitamin D 
binding protein, and fetuin have been evaluated in CSF though 
none were found to have satisfactory performance58. Numer-
ous CSF antibodies to M.tb in CSF has also been evaluated. 
Huang and colleagues found pooled sensitivities of 91% 
Figure  4.  Novel  Host  and  Pathogen  biomarkers  for  diagnosis  of  tuberculous  meningitis54–60.  LAM = lipoarabinomannan, RNA = 
riboneucleic acid, VOC = volatile organic chemicals, IGRA = inferferon gamma resease assay, DLL1 = delta-like ligand 1, VDBP = vitamin d 
binding protein, ADA = adenosine deaminase. * This image focuses only on novel host or TB biomarkers for diagnosis of TBM and does not 
incorporate traditional tools such as culture or AFB smear, or newer nucleic acid amplification tests in use commonly such as GeneXpert or 
GeneXpert Ultra, or experimental techniques such as metagenomic next generation sequencing.
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(95% CI 71–98%) for anti-M37Ra across five studies, 84% (95% 
CI 71–92%) for anti-antigen-5 across eight studies, and 84% 
(95% CI 71–92%) across 12 studies for anti-M37Rv, again using 
a variety of reference standards (making the pooled estimates 
somewhat flawed)59. Use of blood antibody assays are discour-
aged for the diagnosis of TB, and their utility in CSF is limited 
by heterogeneity and the lack of a uniform reference standard 
across research studies as well as a lack of commercial assays.
Though on the surface, many of these markers look to have 
promise, uptake has been limited. Heterogeneity in study design 
and widely variable study performance has limited the consensus 
regarding the utilities for most host-based tests. Further, many 
of these tests require sophisticated laboratory infrastructure, 
are costly, and in some cases are not commercially available. 
None of these tests are routinely used and as far as the authors 
are aware, none are actively being studied further. 
Biomarkers in children
The often-dismal outcome of TBM is contributed to by 
delayed diagnosis and/or initiation of treatment, especially in 
high burden settings4. Currently available diagnostic tests per-
formance is especially poor in young children with TBM. Thus, 
diagnosis of childhood TBM is mostly based on a combination 
of clinical findings, CSF analysis and radiological findings61. 
Even so, there are often multiple missed opportunities prior to 
a diagnosis of childhood TBM62. Since it can be challenging 
to identify bacilli in paediatric extrapulmonary TB, the use 
of host or pathogen biomarkers to aid diagnosis is being 
explored. Host biomarker-based tests have shown promise in 
extrapulmonary TB outside of the CNS and therefore have 
potential applications in TBM63. Recent technological advances 
have made it possible to screen for many biomarkers in as little 
as 3 μl of sample using the Luminex multiplex cytokine beaded 
arrays, albeit in research context currently, rather than routine 
clinical practice.
A three-marker CSF biosignature comprising IL-13, VEGF 
and cathelicidin LL-37, diagnosed childhood TBM with a 
sensitivity of 52%, specificity of 95%, with positive and nega-
tive predictive values of 91% and 66% respectively. Cut-off 
values for VEGF, IL-13 and cathelicidin LL-37 were 
42.92 pg/mL, 37.26 pg/mL and 3221.01 pg/mL respectively15. 
Further evaluation of this three-marker CSF biosignature in a 
different cohort revealed positive and negative predictive values 
of 90% and 59.5% respectively, however with different cut-off 
values for VEGF, IL-13 and cathelicidin LL-37 of 9.4 pg/ml, 
524.9 pg/ml and optical density of 0.045 respectively64. In a 
study investigating potentially useful host biomarkers in CSF 
for childhood TBM (23 children with TBM and 24 controls), 
28 proteins including IFN-γ, TNF-α, MPO, MMP-8, MMP-9, 
MIP-4 and CXCL9 amongst others, when analysed individually, 
showed areas under the receiver-operating curve (AUC) ≥0.80. 
When combined, biomarkers IFN-γ, MPO and VEGF showed 
good accuracy (AUC = 0.97, up to 91.3% sensitivity 
and up to 100% specificity), as well as ICAM-1, MPO, CXCL8, 
and IFN-γ (AUC of 0.97, up to 87.0% sensitivity and up 
to 95.8% specificity). Cut-off values for VEGF, IFN-γ, 
MPO, ICAM-1 and CXCL8 were >9.4 pg/ml, >99.5 pg/
ml, >25823.0 pg/ml, >1372.0 pg/ml and >394.8 pg/ml, 
respectively64.
Despite the potential of CSF-based biosignatures, collection 
of CSF is invasive, and blood or urine-based inflammatory 
biosignatures require exploration. In a study evaluating serum 
biomarkers, the combination of CRP, IFN-γ, IP-10, CFH, 
Apo-A1 and SAA showed moderate diagnostic accuracy for 
clinically-defined TBM, including both ‘definite’ and ‘probable’ 
TBM (AUC of 0.75, sensitivity of 69.6% and specificity of 
62.5%). A three-biomarker combination of adipsin, Aβ42 
and IL-10 showed improved accuracy (AUC of 0.84, sensitivity 
of 82.6% and specificity of 75.0%). Cut-off values for CRP, 
IFN-γ, IP-10, CFH, Apo-A1, SAA, adipsin, Aβ42 and IL-10 were 
>80721.0 ng/ml, <61.5 pg/ml, <57.2 pg/ml, >350185.0 ng/ml,
>287512.0 ng/ml, >59894.0 ng/ml, <2393.0 ng/ml, <278.4 pg/ml
and <7.0 pg/ml, respectively. Although sample size was small,
these biomarkers warrant further exploration65.
Pathogen-based diagnostics
The absence of a perfect gold standard for use in TBM diag-
nostic studies means that the results must be interpreted with an 
awareness of the pros and cons of the reference standard used. 
The 2010 uniform TBM case definition which defines cases 
as ‘definite’, ‘probable’, ‘possible’ or ‘not TBM’ is the most 
standardised tool to use when defining a case definition61. This 
case definition was derived by expert consensus rather than 
being data-driven and, although designed to be applicable to any 
age, HIV infection status or geographical setting, may perform 
better in some contexts than others. In HIV-negative populations 
a reference standard of ‘definite, probable or possible’ is often 
used, however in PLWHIV including ‘possible’ in the reference 
standard can be imprecise due to the wide variety of infectious 
and non-infectious aetiologies that can fall into this category. 
It must also be noted that the potential to score points is 
affected by the ability to comprehensively investigate patients 
with brain, chest and abdominal imaging as well as microbiologi-
cal sampling from outside the CNS; in resource constrained set-
tings the ability to score a high number of points may therefore be 
compromised. We do strongly advocate the use of the case 
definition to standardise results, allow for greater comparison 
between studies and meta-analysis of data; use of other standards 
must be interpreted with a degree of caution.
Nucleic-acid amplification tests.
To address the limitations of conventional microscopy and 
culture techniques, NAATs have emerged as important tools for 
rapid and accurate diagnosis of TBM44. A recent meta-analysis 
evaluating NAATs in TBM reported heterogeneity in results with 
a pooled sensitivity of 82% against culture and 68% against a 
clinical reference standard66. This variability, especially in 
in-house NAATs, is subject to difference in volume of sample, 
method of extraction, choice of targets used, presence of 
inhibitors in the sample and lack of optimal reference standard. 
Traditional NAATs require expensive equipment, stringent 
operational conditions and technical expertise limiting their use in 
routine clinical practice in lower-resource, high endemic settings. 
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To circumvent these challenges, loop mediated isothermal ampli-
fication (LAMP) assays were developed and can be conveniently 
carried out under isothermal conditions in an ordinary labora-
tory water bath or heating block within one hour. Though LAMP 
has outperformed PCR in an Indian study on TBM67, the assay is 
still in its infancy and needs further validation. Another method 
to potentially reduce the overall cost of NAAT would be to 
utilize magnetic bead assay technology, thus obviating the need 
of gel electrophoresis system or expensive dyes.
Xpert is a rapid (90 min run-time) fully-automated cartridge- 
based real-time PCR assay that detects the presence of M.tb 
complex DNA, as well as rpoB gene mutations responsible for 
rifampicin resistance. The pooled sensitivity and specificity of 
Xpert against culture in 33 studies on TBM, was 71.1% and 
98%, respectively68. Xpert has been shown to significantly 
increase microbiological confirmation of TBM in Uganda over a 
6.5-year period but its impact on clinical outcomes in 
unknown69. Individual studies have also found inferior perform-
ance for Xpert compared to multiplex PCR70 or Amplicor assay71 
in diagnosing TBM although these results have not been con-
firmed. The next generation, GeneXpert MTB/Rif Ultra (Ultra) 
has an 8-fold lower limit of detection than Xpert (16 CFU/ml 
versus 113 CFU/ml) attributable to a larger chamber allowing 
double the volume of sample to reach the PCR reaction and two 
additional DNA probes (IS1081 and IS6110)72. In a Ugandan 
study of Ultra using cryopreserved CSF, Ultra demonstrated a 
sensitivity of 95% against a composite microbiological refer-
ence and 70% against probable/definite TBM in comparison to 
45% and 43%, respectively for each Xpert and culture73,74. 
In 2017, Ultra was endorsed by the WHO as the best ini-
tial test for TBM and is being rolled out currently worldwide, 
superseding Xpert75. 
In January 2020, two larger prospective studies evaluating 
Ultra were published. In the Ugandan study, 204 (96% HIV- 
positive) adults with suspected meningitis had CSF Xpert Ultra 
performed. Compared with a reference of definite/probable 
TBM, test sensitivities were 77% (95% CI 63 – 87%) for Ultra, 
56% (95% CI 44 – 70%) for Xpert, and 61% (95% CI 45 – 76%) 
for mycobacterial culture76. In this study ‘possible TBM’ 
cases were not included in the reference standard as this 
category is non-specific in HIV co-infection due to concomitant 
infectious and non-infectious brain pathologies associated 
with advanced immunosuppression. In the second study, 
Donovan et al employed a different study design and randomised 
205 Vietnamese adults (15% HIV co-infected) with meningitis 
to either Ultra or Xpert testing. Against a reference standard 
of definite, probable, or possible TBM, test sensitivities were 
47% (95%CI, 34 – 60%) for Ultra, 40% (95%CI, 28 – 53%) 
for Xpert, and 48% (95%CI, 38 – 58%) for mycobacterial 
culture77. Specificity of Ultra for TBM diagnosis was 
high in both studies. The sensitivity of Ultra statistically 
superior to that of Xpert in Uganda but not in a Vietnamese 
predominantly HIV-negative population. How can we rationalise 
and interpret these differing results? Firstly, diagnostic tests 
cannot be expected to perform identically in all settings. Differ-
ences in tested CSF volume, CSF processing, HIV co-infection, 
genetics influencing host response to M.tb, and M.tb lineages 
(the number of copies of IS1081 and IS6110 genes varies by 
lineage) could all contribute to these different results, as 
could the differences in study design (e.g. head-to-head com-
parison versus randomizing samples) and smear microscopy 
sensitivity and reference standards used. Secondly, and most 
importantly, regardless of the differences in the exact perform-
ance of Ultra, the key point is that while Ultra demonstrates 
some improvement on the performance of Xpert, its negative 
predictive value is not sufficiently high to exclude TBM when 
the result is negative.
Another commercial NAAT, the MTBDRplus assay, has 
been evaluated only in few cases of TBM and needs further 
validation78. Accurate and rapid detection of drug resistance 
is another challenge, rifampicin resistance detection by Xpert 
has imperfect sensitivity (93%) and where detected and ideally 
requires confirmation by sequencing or culture70,79. Ultra uses 
melt curve analysis to improve detection of rifampicin resist-
ance but both are about 95% sensitive80,81. Ultra will not be able 
to adequately define rifampin resistance in samples with a 
low quantity of bacilli (trace category positive)82. In summary 
NAATs, are a major diagnostic advance but they cannot yet 
fully replace culture methods. Ultra is too insensitive to rule out 
TBM, and like Xpert, should be considered as the first test and 
not the last in TBM diagnosis83. Ultra is an important step in the 
right direction but the result should be considered in the context 
of the clinical probability of TBM84.
CRISPR-MTB and metagenomic next generation sequencing. 
Clustered regularly interspaced palindromic repeat (CRISPR) 
associated proteins (Cas) have the ability to cleave DNA at spe-
cific sites and are being used widely in gene-editing and more 
recently in infectious disease diagnostics. When combined with 
DNA amplification, the CRISPR system can detect nucleic 
acid molecules at extremely low abundance. There is one recent 
report of utilizing the CRISPR system for detection of M.tb 
(CRISPR-MTB). The study included 26 CSF specimens and 
found CRISPR-MTB to have a sensitivity of 73% compared to 
54% for Xpert and 23% for culture against a reference standard of 
‘clinical TBM’. The specificity of the test was 98% when tested 
against 63 non-TB cases. CRISPR-MTB is isothermal and 
can be performed in under 2 hours using only 500 μl of CSF. 
CRISPR-MTB remains to be tested against Ultra and requires 
a higher level of laboratory expertise, resources, and time than 
the Xpert platform but may be an advance in TB diagnostics 
if these findings can be confirmed in other settings with more 
standardized reference stanrdards85.
Metagenomic next generation sequencing (mNGS) is a rapidly 
developing technology that has proved useful in determining 
aetiologies for CNS infections that have evaded detection by con-
ventional techniques. Further, mNGS, as opposed to organism- 
specific molecular tests has the ability to detect any low abun-
dance infection with a single test86. A recent small study applied 
mNGS to stored CSF samples from 23 TBM cases and 
found a sensitivity of 67% (8/12) against a reference standard of 
definite TBM, higher than AFB stain (33%, 4/12), PCR (25%, 
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3/12) and culture (8%, 1/12)87. Paucibacillary conditions such as 
TBM where the bacillary load may fall below the LOD of com-
mercial NAATs, or where mutations exist around specific PCR 
primer binding sites may find particular use for mNGS. Tar-
geted enrichment of low abundance genes with Finding Low 
Abundance Sequences by Hybridization (FLASH), a novel 
CRISPR-Cas9 technology can increase DNA read abundance by 
up to 105-fold before sequencing occurs88. Combining FLASH 
and mNGS technologies could improve detection of TB DNA 
and associated antimicrobial resistance mutations mutations89. 
A first pilot of FLASH technology in TB demonstrated up to 
a 100-fold increase in TB read abundance, detection of 6/6 
cases of TBM positive with Ultra and detection of an additional 
case of TBM that had been missed by Xpert, Ultra and MGIT 
culture90. Here again, large studies need to be performed to 
better understand this technology’s performance and the cost, 
laboratory infrastructure, and degree of expertise will need to be 
improved upon to permit widespread usage.
Pathogen-based biomarkers. A urine lateral flow assay (LFA) 
that detects M.tb lipoarabinomannan (TB-LAM), a 17 kDa 
glycolipid found in the outer cell wall of MTB, has recently 
been recommended by the World Health Organization for the 
diagnosis of HIV-associated TB in HIV-positive inpatients 
(Alere Determine TB-LAM, Abbott, Chicago, USA). The unique 
characteristic of the test is that its sensitivity increases as 
CD4 T-cell count falls, with a sensitivity of 56% in those with 
CD4 <100 cells/ml60. Yet, in CSF, despite some initial optimism 
related to an autopsy-based study in Uganda, the Alere TB-LAM 
has shown poor sensitivity on lumbar CSF in Uganda91,92, along 
with a larger Zambian study which examined culture positive 
TBM in Zambia (TB-LAM sensitivity 22% (23/105))91,93. The 
Alere TB-LAM is also limited by is susceptibility to individual 
reader interpretation of the darkness of the test line compared 
to the reference card (Figure 4). A novel LAM assay (Fujifilm 
SILVAMP TB-LAM, Fujifilm, Japan) is able to detect con-
centration of LAM at approximately 30-fold lower than Alere 
TB-LAM due to design differences, including a silver ampli-
fication step and gives a result in one hour94. The Fujifilm LAM 
was recently tested on 968 urine samples (600 with definite 
pulmonary TB) in South Africa and showed a sensitivity of 70% 
(95% CI 53 - 83%) compared to 42% (95% CI 32 - 52%) for the 
Alere TB-LAM against a microbiological reference standard94. 
There is no data on this assay for diagnosis of TBM published 
to date.
Clinical prediction rules.
Work is underway to develop a more accurate multivariable clini-
cal prediction rule derived from large international cohorts using 
individual patient data95. The hope is that a data-driven scoring 
system will be developed for use in a range of clinical settings 
by using common, readily available clinical or laboratory 
parameters to aide in clinical decision making.
Discussion
In the last five years, the pathogenesis of TBM has been better 
elucidated, in part thanks to detailed immunological studies on 
clinical samples preemptively stored during clinical trials. These 
advances highlight the importance of collecting and storing sam-
ples appropriately for future research to maximize scientific 
outputs, as highlighted in the paper on sampling strategies in 
this collection. HIV infection is a major predictor of mortality in 
TBM and advanced HIV infection (CD4 T cell count <150 cell/μl) 
appears to drive a dysregulated, hyperinflammatory pheno-
type with very poor outcomes. In HIV-endemic sub-Saharan 
African settings around 90% of all adult TBM occurs amongst 
HIV-positive individuals69,96, often with either untreated 
advanced HIV or having recently initiated ART - both driving a 
hyperinflammatory response. In Vietnamese adults with TBM, 
LTA4H genotype is a strong predictor of mortality though this 
finding was not duplicated in Indonesia.
Recent insights have shown that neutrophils play a significant 
role in the immunopathogenesis of TBM, and that both a pau-
city and an excess of inflammation can be equally damaging in 
TBM. It has become increasingly clear that a ‘one-size-fits-all’ 
approach is too simplistic in TBM treatment, as in other infec-
tions such as pulmonary TB and sepsis97,98. The damage-response 
framework may provide a useful structure for understanding host-
pathogen interactions in TBM, illustrating how immune response 
could be exploited for therapeutic purposes. Additional anti- 
inflammatory therapy with aspirin17,99 or more targeted immu-
notherapy could have a role in persons with an excessive 
inflammatory response; whilst individuals with an inadequate 
response might do better without corticosteroid treatment or 
might even benefit from immunomodulating therapy to boost 
their immune response100. Future trials of novel specific host-
directed therapies are needed and must include immune markers to 
allow for post-hoc identification of subgroups benefitting from 
the initiated therapy. Because of the lack of correlation between 
blood and CSF compartments we advocate inclusion of both 
blood and CSF markers when studying adjuvant therapies.
The field of TBM diagnosis is rapidly evolving with GeneXpert 
MTB/Rif Ultra being the most promising test to date for diag-
nosis of TBM. Ultra is rapid and has potential to confirm more 
cases of TBM at lower bacillary loads, though whether this 
will improve outcomes remains to be determined. Most impor-
tantly, Ultra does not appear to have adequate predictive value 
to ‘rule-out’ TBM and so it cannot meet the potential of an 
ideal TBM diagnostic test to avoid long, toxic TBM therapy in 
persons without TBM. Novel sequencing technologies hold 
potential to provide increased understanding of pathogen genom-
ics and behavior and further illuminate host response, which may 
in turn lead to novel diagnostic and therapeutic targets. Sequenc-
ing technologies are increasingly available in TB endemic 
settings but will need further improvements in affordability 
and speed in addition to more data on accuracy to unlock their 
potential as diagnostic tools for TBM. It is now a realistic hope 
that a test (or set of tests) will one day be available that will be 
able to confirm or rule out TBM, provide M.tb resistance 
information, and direct clinicians to targeted, adjunctive host-
directed therapy within hours.
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4 Chapter Four: Tuberculous Meningitis Diagnosis and Outcomes During 
the Xpert MTB/Rif Era: Findings from a 6.5-year Cohort in Uganda 
(research paper) 
Foreword 
At the beginning my PhD in 2017 there was no literature on TBM in Uganda, and a collection of case series 
from other African countries, see Table 4.0. My understanding of the condition locally was based on clinical 
experience and anecdotes from colleagues. So, my first aim was to use available data to describe the 
demographics of the local TBM population, method of diagnosis and clinical outcomes. No national level data 
on TBM is collected by the Ministry of Health and the government hospitals generally do not have a medical 
records system which readily allows for retrospective review of notes. I therefore used data collected by the 
IDI meningitis research team during diagnostic studies and in the screening process for meningitis clinical 
trials at Mulago and Mbarara Hospitals in the period 16th November 2010 to 28th May 2017. Data was stored 
in a number of databases at the University of Minnesota or in research files at IDI archive in Kampala. I 
identified TBM cases by searching for variables relating to TB diagnostics and TB treatment to generate a TBM 
dataset of n=195 treated cases, which I analysed and wrote up as a retrospective cohort.  
This paper describes the demographics of TBM cases, the nature of their diagnosis, and hospital survival over 
three time periods: 1) the period before Xpert MTB/Rif was available; 2) the period around the introduction of 
Xpert MTB/Rif when the assay was only run on stored samples and results were not available to guide clinical 
management; 3) the period when Xpert MTB/Rif was used as a real-time diagnostic tool to guide clinical 
management. It was not possible to comment on annual number of TBM cases or incidence of TBM as 
screening intensity varied over the 6.5-year time period depending on whether a trial was active. This 
research paper was in fulfilment of PhD objective #1 - to assimilate available retrospective data on adults with 
suspected TBM in Uganda and to describe the TBM population in terms of baseline characteristics, method of 
diagnosis and clinical outcomes. The findings of this paper were presented as a poster at the Royal Society of 
Tropical Medicine and Hygiene Research in Progress conference in Moshi, Tanzania in 2018. 
I found that 12% (195/1672) of patients who received a lumbar puncture at Mbarara and Mulago Referral 
hospitals were treated for TBM in the 2010-2017 period and 96% were PLHIV. Despite ART coverage in 
Uganda improving rapidly during the study period, from 0% of patients presenting to hospital on ART in 2010 
to 61% being on ART in the most recent period, the degree of immune suppression at presentation did not 
improve significantly and median CD4+ T cell count was 78 cells/µl overall. The introduction of Xpert MTB/Rif 
had a marked impact on the proportion of TBM cases which are microbiologically confirmed: from 3% (1/33, 
with AFB smear only) to 41% (60/147, with Xpert MTB/Rif and culture). TBM In-hospital mortality declined 
84 
from 57% in the earliest period to 41% (51/124) in the most recent period where Xpert MTB/Rif has been 
used in real-time to guide decision-making. There are multiple confounding factors that may have contributed 
to this observed difference in hospital outcomes, alongside missing outcome data, so it is not possible to draw 
any conclusions about the impact of Xpert MTB/Rif on TBM survival. However, it is clear that even with the 
routine use of Xpert MTB/Rif and culture, the majority of TBM patients (59%, 87/147) are still treated on 
clinical suspicion alone despite negative TB tests and case-fatality in hospital is concerningly high. There was 
therefore a need for more sensitive, affordable, rapid diagnostic test to support clinical decision-making and 
prompt treatment initiation, with the hope of reducing death and disability. In light of this, I went on to 
prospectively investigate whether Xpert Ultra would be more sensitive than Xpert MTB/Rif in TBM diagnosis 
and whether other point of care biomarkers such as lactate has a role in HIV/TBM diagnosis (chapter 5), and 
thereafter whether urine TB diagnostics (Alere LAM, Xpert Ultra) have a role in TBM management (chapter 6).  
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Introduction
Tuberculous meningitis (TBM) is the second most common 
cause of adult meningitis in sub-Saharan Africa1,2, account-
ing for one to five percent of the 10.4 million tuberculosis (TB) 
cases reported worldwide in 20163. Despite treatment, TBM 
outcomes are poor with 19–28% mortality in HIV-uninfected 
persons and 40–67% mortality in HIV-infected patients in 
addition to long-term disability is frequent among survivors4–6.
Insidious symptom onset in persons with TBM leads to delay 
in seeking care and increasing disease severity at presentation 
correlates with higher mortality7. Further, the paucibacillary 
nature of TBM increases the difficulty in confirming diagno-
sis once care is sought, also contributing to high mortality8. 
Cerebrospinal fluid (CSF) smear microscopy for acid-fast bacilli 
(AFB smear) has poor sensitivity (~10–20%) in routine practice7. 
Culture has improved sensitivity (~50–60%) but is not widely 
available in many resource constrained settings and com-
monly takes at least 2–3 weeks for liquid culture growth, 
which is too slow to guide decision-making at the time of 
presentation8. 
In 2013, the World Health Organization endorsed the Xpert 
MTB/RIF (Xpert) assay (Cepheid, Sunnyvale, California, USA), 
a cartridge-based, polymerase chain reaction assay with a run 
time of 113 minutes, as the preferred initial test to investigate 
TB meningitis on the basis of a meta-analysis of 13 studies9. 
Of the two major studies included in the meta-analysis, Patel 
and colleagues reported 67% sensitivity against microbiologi-
cally proven TBM and 36% against consensus clinical case  
definitions, while Nhu and colleagues showed 59% sensitiv-ity 
against the same case definitions10–12. Additionally, use of a 
larger volume of centrifuged CSF improves sensitivity of  
Xpert10,13. Yet, inadequate negative predictive value means that a 
negative Xpert result has limited influence on clinical decision 
making14.
There is evidence that use of Xpert for diagnosis of pulmonary 
TB reduces diagnostic delay, increases the rate of same day treat-
ment, and decreases usage of empiric treatment15,16. However, 
for pulmonary TB, Xpert has not been shown to decrease  
mortality16–18. Yet, lessening diagnostic delay in persons with  
TBM may be more likely to lead to improved outcomes as 
compared to pulmonary TB given the high early mortality of 
TBM19. Whether routine use of Xpert for investigation of  
suspected TBM has made an impact on diagnosis or mortality  
has not yet been investigated.
Herein we describe TBM diagnosis and outcomes over a  




Uganda is a high burden HIV setting, with a prevalence of 6.2% 
among adults aged 15 to 64 years with an estimated 60% viral 
load suppression in 2017 among all HIV-infected adults20. Adults 
presenting with suspected meningitis (headache and neck stiffness 
+/- vomiting, fever, seizures, focal neurological deficits, or altered 
consciousness), to Mulago National Referral Hospital, Kampala, 
and Mbarara Regional Referral Hospital, were assessed for eligi-
bility for enrolment in two consecutive randomised clinical trials 
investigating cryptococcal meningitis. The first trial Cryptococcal 
Optimal Antiretroviral Timing (COAT) investigated early versus 
delayed antiretroviral therapy in HIV-related cryptococcal men-
ingitis (www.clinicaltrials.gov: NCT01075152) and the second,  
Adjunctive Sertraline for the Treatment of Cryptococcal Menin-
gitis (ASTRO-CM) evaluated whether sertraline when added to 
standard amphotericin-based therapy for cryptococcal meningi-tis, 
lead to improved survival (NCT01802385). Screening began on 
22nd November 2010 and continued until 28th May 2017. After  an 
informed consent process for trial screening a diagnostic  
lumbar puncture was performed and baseline demographics 
and clinical information were recorded on all. Participants with  
non-cryptococcal meningitis were not enrolled into the clinical  
trials but followed until hospital discharge. 
Any patient who received testing for TBM (CSF AFB smear, Xpert 
or mycobacterial culture) during this period was eligible to be 
included in the diagnostic accuracy analysis. Any patient who was 
ultimately treated for TBM was eligible to be included in one of 
the three TBM cohorts, from which data as used to compare rates of 
microbiological confirmation and outcomes. Cohort was deter-
mined by what type of TB testing they individual had undergone.
            Amendments from Version 1
Title
The title has been changed to: Tuberculous meningitis diagnosis 
and outcomes during the Xpert MTB/Rif era: a 6.5-year 
retrospective cohort study in Uganda
Methods:
As per reviewer suggestions we have expanded on the nature of 
the parent trials. To clarify who was eligible to be included in the 
diagnostic analysis and TBM cohort (n=195) we have added to 
the methods that “any patient from the 1672 patients screened 
who received testing for TBM (AFB smear, Xpert or culture) was 
eligible to be included in the diagnostic analysis and any patient 
who was treated for TBM was eligible to be included in the TBM 
cohort”. 
We have added a 2x2 table and a study schematic to make the 
flow of patients clearer as per the suggestion of Dr Wasserman 
and Dr Davis. It is not a classic Consort diagram as this 
population were not enrolled into a clinical trial. 
We have added a detail to the methods section to define empiric 
TBM treatment “TBM treatment given in the absence of a positive 
microbiologic result, based on a high index of clinical suspicion, 
was defined as ‘empiric TBM treatment’”.
Results
The reviewers kindly pointed out a typographical error in the 
manuscript. The number of microbiologically confirmed cases is 
74 (not 76) and the text has been amended accordingly. 
Regarding the sensitivity of Xpert and Ultra against a composite 
reference standard a 2x2 table has been added to accompany 
Figure 2. 
Discussion
In light of all three reviewer’s comments we have expanded the 
discussion to further acknowledge the other potential confounding 
factors and concluding that it is not possible to draw a conclusion 
about whether Xpert has reduced TBM mortality in this setting.
See referee reports
REVISED
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Figure 1. Timeline illustrating evolution of diagnostic testing.
Microbiologically proven (definite) TB meningitis was defined as 
any positive AFB smear, culture or Xpert result from CSF test-
ing. TBM treatment given in the absence of a positive microbio-
logic result, due to high index of clinical suspicion, was defined 
as ‘empiric TBM treatment’. Consensus uniform case definitions 
were used to categorise patients as definite, probable, possible or 
not TBM11. TBM treatment included 12 months of antitubercu-
lous therapy with 6–8 weeks of adjunctive corticosteroids as per 
Ugandan guidelines21. 
Cohort definitions and diagnostic tests used
Cohort one (16th November 2010 until 28th May 2013) received 
only CSF AFB smear testing (Figure 1). If available, 1mL 
cryopreserved CSF was later tested with Xpert MTB/Rif 
when Xpert became available. Cohort two (1st April 2011 until 
10th November 2013) underwent CSF AFB smear and Xpert 
MTB/Rif on a 1ml sample of uncentrifuged CSF. Testing was 
performed at physician discretion when there was lymphocytic 
pleocytosis and/or high degree of clinical suspicion. In the 
period of overlap of cohort one and two (April 2011–May 2013), 
Xpert testing was not being done on a routine basis; subjects 
were included in cohort two when Xpert was done in real-time 
and in cohort one if Xpert was not done, or only done at a 
later date on cryopreserved specimens.
In cohort three (11th November 2013 until 28th May 2017) all 
cryptococcal antigen negative (IMMY, Norman, Oklahoma, 
USA) patients were systematically investigated for the pres-
ence of TB meningitis, irrespective of physician discretion. 
Subjects had comprehensive testing for TBM with CSF AFB 
smear (Mulago Hospital only), Xpert MTB/Rif on large volume 
centrifuged CSF13 and CSF Mycobacteria Growth Inhibitor Tube 
culture (MGIT, Becton Dickinson, Franklin Lakes, USA). AFB 
smear was discontinued in Mbarara in 2013 as the sensitivity 
was deemed too low to justify further use. In patients with a 
confirmed diagnosis of cryptococcal meningitis (CM), if TBM 
co-infection was suspected, patients would be investigated 
for TBM at the physician’s discretion. 
Assessment of outcome
In-hospital outcome was determined from case report forms, 
hospital medical records or follow-up telephone calls with the 
patient or their surrogate where hospital outcome was unknown. 
The outcome was categorised as discharged alive, deceased prior 
to hospital discharge or unknown (i.e. self-discharged against 
medical advice in an imminently terminal patient, hospital 
outcome undetermined, transferred to another facility).
Statistical methods
Comparisons of categorical and continuous demographic and 
clinical characteristics by cohort were performed using Fisher’s 
exact tests and Kruskal-Wallis tests, respectively. Sensitivity 
of Xpert MTB/Rif was evaluated against a composite reference 
standard (any positive CSF test - AFB smear, Xpert or culture 
i.e. definite TBM according to the uniform case definition)11.
A separate analysis was conducted against the uniform case
definition of probable or definite TBM11. Concordance between
Xpert MTB/Rif and culture was evaluated with a kappa
statistic and McNemar’s test. Invalid tests (e.g. culture
contamination, Xpert error) were counted as negative results.
Mortality was first compared by cohort for participants with a
known outcome using Fisher’s exact test. Data for patients with
unknown outcome was imputed to assume first that 50% within
each cohort died, or that 75% died (both within the expected
mortality range for this population). Odds ratios and 95%
confidence intervals were computed from multivariable logistic
regression models with these imputed data, adjusted for
1) ART status, and 2) ART status and definite TBM diagnosis.
Imputations were repeated with new random assignments to
confirm results. Analyses were conducted using SAS version
9.4 (The SAS Institute, Cary, NC) and p-values <0.05 were
considered statistically significant.
Ethics
Institutional review board approvals for the studies and the 
associated screening process were obtained locally in Uganda 
[ASTRO: Mulago Hospital Research Ethics Committee (approval 
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number, MREC 429); COAT: Makerere University School of 
Medicine Research and Ethics Committee (approval number, REC 
Ref No. 2009–022)], from the University of Minnesota (USA), 
and by the Uganda National Council of Science and Technology. 
Written informed consent for screening or participation in the 
studies was obtained from all participants or from their surrogates 
(e.g. family member or guardian) where the patient had altered 
mental status and did not have the capacity to provide consent.
Results
Participant characteristics
Over the study period, 1672 patients with meningitis symptoms 
were assessed and underwent lumbar puncture: 1058 (63%) had 
a positive CSF cryptococcal antigen test, 558 (33%) had nega-
tive CSF cryptococcal antigen test (data missing, n=56). A total 
of 195 subjects were treated for TBM, see Figure 2. Overall 61% 
were male, median age was 35 years (IQR 30–42), 96% were 
HIV-positive, median CD4 count was 78 cells/μL (IQR 26–191) 
and the majority (69%) presented with British Medical 
Research Council severity grade II disease, see Table 1. Base-
line characteristics were similar between cohorts with the 
exception of antiretroviral (ART) experience; 0% of participants 
were on ART in cohort one compared to 61% in cohort three 
(P<0.01).
Among the 74 cases of microbiologically proven TBM in this 
population with advanced HIV infection, 34% (25/74) had an 
acellular CSF (white cells <5 cells/μL) at presentation, and 
4% (3/74) had a normal CSF profile (CSF cells <5 cells/μL, 
protein <45 mg/dL, and glucose >2.2mmol/l).
Method of diagnosis
Microbiological confirmation of TBM was made in 38% 
(74/195) of cases. The proportion of cases with microbiologi-
cally confirmed TBM (definite TBM) increased significantly, 
from 3% (1/33) in cohort one to 87% (13/15) in cohort 2 and 
41% (60/147) in cohort 3 (P<0.01). Categorisation by uniform 
case definition is summarised in Table 2.
There was a marked difference in physician threshold for 
empiric TBM therapy between the two clinical sites. In cohort 
three, Mulago Hospital recorded 44 cases of which 77% (34/44) 
were microbiologically confirmed and 23% (10/44) were 
empirically treated, whilst Mbarara Hospital recorded 103 
cases of which 25% (26/103) were microbiologically confirmed 
and 75% (77/103) were empirically treated.
Diagnostic accuracy of Xpert MTB/Rif
Xpert MTB/Rif was positive in 51 of 455 tested (11%), 
MGIT culture positive in 39 of 321 (12%) tested, AFB 
stain positive on 5 of 818 tested (1%), as summarised in 
Table 2.
Diagnostic accuracy of Xpert and MGIT were analysed in 
cohort three, when both assays were done routinely, and 60 par-
ticipants had a microbiologically confirmed diagnosis (compos-
ite reference standard). Sensitivity of Xpert was 63% (38/60) 
against the composite reference standard and 54% (38/71) against 
the uniform case definition (probable or definite TBM). Sensi-
tivity of MGIT culture was 65% (39/60) against the composite 
reference standard of definite microbiologic-confirmed TBM 
Figure 2. Illustration of flow of patients from the screening population into the TBM cohort.



















N in TBM case cohort 33 15 147 195
Demographics
Sex 195 0.58
      Male 18 (55%) 8 (53%) 92 (63%) 118 (61%)
Age 195 0.33
      Median (IQR) 33 (29, 38) 35 (29, 40) 35 (30, 43) 35 (30, 43)
HIV details
HIV status, n (%) 195 1.00
      HIV-positive 32 (97%) 15 (100%) 141 (96%) 188 (96%)
ART status, n (%) 179 <0.01
      On ART 0 (0%) 4 (27%) 80 (61%) 84 (47%)
      ART naive 32 (100%) 11 (73%) 52 (39%) 95 (53%)
CD4 131 0.30




      I 9 (27%) 4 (31%) 20 (14%) 33 (17%)
      II 22 (67%) 7 (54%) 102 (70%) 131 (69%)
      III 2 (6%) 2 (15%) 23 (16%) 27 (14%)
*P-values from Fisher’s exact tests for categorical variables and Kruskal-Wallis tests for continuous variables.
and 55% (39/71) against uniform case definition for probable or 
definite TBM.
Concordance between Xpert MTB/Rif and MGIT culture was 
analysed in the 118 with both Xpert and MGIT culture results 
available (Table 3). Either Xpert or MGIT culture was positive 
in 56 patients, of which only 30% (17/56) were positive by both 
modalities (kappa 0.23 95% CI [0.04, 0.41], p=0.01) (Figure 3). 
Neither method diagnosed significantly more cases than the other 
(p=0.42). 
Outcomes
Hospital outcome was known for 142 participants, 53 had 
unknown outcomes or self-discharged against medical advice. 
Median time to death was 3 days (IQR 1–9 days) among those 
known to have died, and median length of hospitalization was 7 
days (IQR 4–10 days) for participants known to have survived 
to hospital discharge. Among those with known outcomes, there 
was a non-significant decline in mortality from 57% in cohort 
one to 41% in cohort three (p=0.27) (Table 4). Assuming that 
50% of those with unknown outcome died, and adjusting for 
ART status and definite TBM diagnosis at hospitalization, the 
odds of dying were approximately twice as high for cohort 
one (aOR 1.7 95% CI [0.7, 4.4]) and cohort two (1.8 [0.6, 5.6]) 
as compared to cohort three. Assuming that 75% of those with 
unknown outcome died, adjusted odds of death increase fur-
ther, cohort one (4.0 [1.5, 10.9]) and cohort two (2.0 [0.6,6.7]) 
compared to cohort three (Table 4, Figure 4).
Discussion
Rapid molecular diagnostics have been predicted to reduce TB-
related mortality22 but little is reported about the impact of Xpert 
on TBM-related mortality. Here we report diagnosis and clinical 
outcomes among hospitalized Ugandans treated for TB menin-
gitis over a 6.5-year period. In-hospital mortality was high in the 
cohort overall (44% 95% CI [36,52%]), similar to other research 
settings with high HIV prevalence7,19,23,24. The adjusted 
model found that odds of in-hospital mortality were almost 
two-fold higher in the earliest cohort, tested by CSF smear micro-
scopy only, compared to that of the most recent cohort in which 
Xpert (and culture) were routinely performed. Though severity 
of TBM at presentation was similar over the study period 











Total number 471 71 1130 1672
    Cryptococcal Antigen positive 269 31 758 1058
    Cryptococcal Antigen negative 187 38 333 558
TBM diagnostic tests performed
CSF AFB smear microscopy*
    N AFB performed 466 71 281 818
    N AFB positive 1 (0%) 0 (0%) 4 (2%) 5 (1%)
CSF TB culture
    N TB culture performed 0 0 321 321
    N TB culture positive 0 0 39 (12%) 39 (12%)
CSF Xpert MTB/Rif
    N Xpert performed (realtime) 0 71 384 455
    N Xpert positive 0 13 (18%) 38 (10%) 51 (11%)
Uniform case definition
    Definite 1 (3%) 13 (87%) 60 (41%) 74 (38%) <.01
    Probable 5 (15%) 2 (13%) 11 (7%) 18 (9%)
    Possible 22 (67%) 0 (0%) 53 (36%) 75 (38%)
    Not 5 (15%) 0 (0%) 23 (16%) 28 (14%)
Prior to November, 2013 any patient not prospectively tested with Xpert was considered in Cohort 1 *AFB smear 
was initially performed on all meningitis patients regardless of CSF Cryptococcal antigen result. From October 
2013, it was only performed on those with a negative Cryptococcal antigen, and was later stopped altogether in 







positive 17 22 39
negative 17 62 79
Total 34 84 118
P-value from McNemar’s test
N=118 (with both Xpert and culture results)
Wellcome Open Research 2018, 3:64 Last updated: 31 JUL 2018
94 
Figure 3. Venn diagram Illustrating the overlap of positive MGIT culture and Xpert test results in the n=118 samples tested with both 
assays. A total of 118 adults were tested with both MGIT culture and Xpert, of which 22 were positive by MGIT culture, 17 by Xpert and 17 by 
both tests. Neither test performed better than the other, p=0.423 by McNemar’s. A kappa statistics value of 0.23 95%CI [0.04, 0.41], p=0.01, 

















N in TBM case cohort 33 15 147 195
Outcome of hospitalization
   Unknown 26 (79%) 4 (27%) 23 (16%) 53 (27%)
   Known 7 (21%) 11 (73%) 124 (84%) 142 (73%)
      Discharged Alive 3 (43%) 4 (36%) 73 (59%) 80 (56%) 0.27
      Died 4 (57%) 7 (64%) 51 (41%) 62 (44%)
Odds Ratio (Mortality) and 95% CI (on imputed data)
   Assuming 50% of unknowns died
      Adjusted for ART status 1.5 (0.6,3.6) 2.0 (0.7,6.2) 1
       Adjusted for ART status and 
confirmed TBM
1.7 (0.7,4.4) 1.8 (0.6,5.6) 1
   Assuming 75% of unknowns died
      Adjusted for ART status 3.3 (1.3,8.4) 2.5 (0.8,7.8) 1
       Adjusted for ART status and 
confirmed TBM
4.0 (1.5,10.9) 2.0 (0.6,6.7) 1
Overall median (IQR) time in hospital was 7 (4, 10) days among those who were known to be discharged alive, 
and 3 (1, 9) days among those who were known to have died in hospital
*P-value from Fisher’s exact test comparing KNOWN discharged alive vs KNOWN died; Odds ratios are the odds 
of being discharged alive, assuming 50% and 75% of those with unknown outcome died
and TBM treatment recommendations have not changed for 
Uganda, there are multiple other potential confounding fac-
tors due to the nature of the study. Improved access to ART, 
strengthening in healthcare services, increased awareness of TBM 
amongst communities and healthcare workers or changes in 
employment of empiric treatment all may have occurred over the 
study period and if present, may have impacted our findings. Due 
to these potential confounding factors, it is not possible to draw 
a conclusion about whether Xpert has reduced TBM mortality in 
this setting.
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The proportion of ART experienced subjects increased 
significantly over time with improved access to ART treatment in 
Uganda and because the parent trial in cohort one enrolled only 
ART naïve subjects25. Although ART status was not associated 
with mortality, we adjusted for ART in multivariable models due 
to the large discrepancy in ART status between cohorts. 
Nonetheless the impact of ART use is likely to have played 
a role in the observed decline in mortality.
Despite a non-significant decline in mortality, a current case- 
fatality rate of 41% remains unacceptably high and highlights 
the remaining work required to achieve the WHO goal of reduc-
ing TB-related deaths by 90% by 203026. Initiating treatment 
in the early stage of disease is the single most important factor 
in improving outcomes7. Earlier presentation to the hospital is 
essential for prompt diagnosis and treatment initiation, yet, 83% 
of our cohort presented with MRC grade II or III disease.
Once the patient presents to care, an affordable, rapid, and reli-
able test that can effectively confirm or rule out TBM is crucial 
for prompt diagnosis. In this predominantly HIV-positive TBM 
cohort, sensitivity of Xpert was 63% against the composite 
reference standard. Thus, even though results were available 
rapidly, Xpert missed over one in three cases. The next gen-
eration assay Xpert MTB/Rif Ultra has an analytic limit of 
detection of 15 colony forming units (CFU)/ml, compared to 
113 CFU/ml for Xpert27. Ultra appears to be significantly more 
sensitive than Xpert or culture for the diagnosis of TBM (95% 
Figure 4. Illustration of odds of dying in cohort one and two compared to cohort three in a multivariate model. Odds ratios (and 95% 
confidence intervals) for death by the end of hospitalization comparing cohorts 1 and 2 to cohort 3, computed from multivariable logistic 
regression models with imputed data, adjusted for (1) ART status, and (2) ART status and definite TBM diagnosis. Data for patients with 
unknown outcome was imputed to assume that 50% within each cohort died, or that 75% died. In all models, neither ART nor definite TBM 
status had a significant association with in-hospital mortality, adjusted for cohort.
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5 Chapter Five: Diagnostic Accuracy of Xpert MTB/RIF Ultra for 
Tuberculous Meningitis in HIV-infected Adults: A Prospective 
Validation (research paper) 
Foreword 
The findings of the retrospective cohort study in chapter 4 supported the idea that molecular diagnostics can 
improve microbiological confirmation of TBM, and may be a contributory factor in improving survival from the 
disease. It is known that TBM diagnostic delay leads to poor outcomes and therefore near-point-of-care 
diagnostics are particularly needed to reduce time to treatment initiation.1 However, with only a quarter of 
treated TBM cases in chapter 4 having a positive CSF Xpert MTB/Rif (26%, 38/147 in cohort 3, Nov 2013 to 
May 2017), it suggested that a more sensitive molecular test was urgently needed. The lack of a reliable POC 
TBM diagnostic test contributes to missed or delayed diagnosis in some patients and over treatment in 
others, with associated drug toxicity, drug-drug interactions, pill burden and the risks of corticosteroids in an 
already immunocompromised population.  
The next generation Xpert MTB/Rif Ultra (Xpert Ultra) assay, re-engineered to be more sensitive in 
paucibacillary forms of TBM than Xpert MTB/Rif, was recommended by the WHO in 2017.2 The diagnostic 
performance of Xpert Ultra needs to be evaluated in different populations and types of TB so that clinicians 
and policy-makers know how to interpret the results.  
The evaluation of novel diagnostics in TBM is complicated by the fact that there is no single ‘gold standard’ 
test to use as a reference. Typically, in pulmonary TB, novel tests are measured against mycobacterial culture 
alone, but in TBM we know this is only 26-67% sensitive so its use as a gold standard leads to misclassification 
of the index test.3 A composite microbiological reference standard (e.g. a combination of TB-specific tests) is 
more accurate than culture alone or alternatively the consensus uniform clinical case definition (as described 
in section 1.3.2 and Appendix 2) should be used.4 Though, should we use probable/definite or 
possible/probable/definite as the reference standard in TBM? Which one is likely to represent the most 
genuine TBM cases? Each of these options has its own limitations and presenting a combination of these 
possibilities gives the reader the most complete picture of test performance, albeit with caveats. In the prior 
study of Xpert Ultra on cryopreserved CSF samples (described in section 1.3.5) we used ‘probable/definite’ as 
the reference standard as we were concerned that ‘possible’ TBM would be a non-TB-specific heterogeneous 
category which might include a variety of other infectious and non-infectious aetiologies in advanced 
immunosuppression. As such, including ‘possible’ in the reference standard would give rise to a falsely low 
sensitivity of the TB index test. The recent Heemskerk et al. multi-center diagnostic study of modified ZN 
stain, used ‘possible/probable/definite’ as the reference standard. Inclusion of the ‘possible’ category in the 
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reference standard in this study, which included one-third PLHIV, gave rise to a (perhaps falsely) low 
sensitivity of Xpert of 25% and culture of 32%.5   
The ideal is to perform a full diagnostic work-up with the aim of identifying an alternative explanation for the 
patient’s symptoms; when an alternative diagnosis is confirmed microbiologically (stain, culture, or NAAT), 
serologically, or histopathologically, that individual leaves the ‘possible or probable’ group and enters the 
‘not’ TBM group, thereby making the uniform case definition a more accurate reference standard. The 2010 
uniform case definition states “the list of alternative diagnoses that should be considered include: pyogenic 
bacterial meningitis, cryptococcal meningitis, syphilitic meningitis, viral meningoencephalitis, cerebral malaria, 
parasitic or eosinophilic meningitis (Angiostrongylus cantonesis, Gnathostoma spinigerum, toxocariasis, 
cysticercosis), cerebral toxoplasmosis and bacterial brain abscess (space-occupying lesion on cerebral 
imaging) and malignancy (e.g. lymphoma)”.4 Unbiased metagenomic next generation sequencing (mNGS) 
might therefore be particularly helpful in identifying alternative aetiologies of disease in the ‘possible’ or 
‘probable’ group, allowing reclassification as ‘not’ TBM. Equally, biased sequencing with prior enrichment of 
M. tuberculosis DNA might identify TB that had been missed in the ‘possible or probable’ group allowing it to
be classified as ‘definite’.
In this prospective study of 204 patients with suspected TBM at two referral hospitals in Uganda I aimed to 
accurately assess of the diagnostic accuracy of Xpert Ultra by optimising the reference standard through 
inclusion of the Biofire Filmarray meningoencephalitis PCR (for 14 viral and bacterial pathogens), post-mortem 
examination in people who died without a confirmed diagnosis, and storage of CSF samples for mNGS. This 
research paper tested hypothesis #1: Xpert Ultra is significantly more sensitive than Xpert MTB/Rif for the 
detection of M. tuberculosis in CSF. However, Xpert Ultra’s sensitivity will be imperfect and it will fail to 
diagnose a small number of cases of TBM that are evident by CSF culture, post-mortem examination, or 
metagenomic next generation sequencing.  
In this study I confirmed that Xpert Ultra is significantly more sensitive that Xpert MTB/Rif against both the 
reference standards used when testing fresh CSF samples of patients with suspected TBM. The sensitivity of 
Xpert Ultra was 77% (95% CI, 63-87%) against the reference standard of probable/definite TBM and negative 
predictive value was 93% (95%CI, 87-96%). The specificity of Xpert Ultra was 96% (95%CI, 91-98%) when the 
Ultra result was excluded in assigning the case definition. A total of 4 post-mortem examinations were 
performed of which one had macroscopic evidence of meningitis and one had evidence of disseminated TB. If 
these two cases were categorised as definite TBM then the sensitivity and negative predictive value of Xpert 
Ultra would be 89% and 97% respectively against the composite reference standard, and 74% and 92% 
respectively against probable/definite TBM. 
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In the univariate analysis the following baseline factors were associated with definte TBM: low GCS, CSF 
white cell pleocytosis, low CSF glucose, high CSF lactate, high CSF protein. Every doubling in CSF lactate 
resulted in a ~6-fold increase in the odds of definite TBM. In the multivariate analysis low CSF glucose 
remained strongly associated with definite TBM – every doubling of CSF glucose resulted in a 70% decrease 
in the odds of definite TBM. It was not possible to examine CSF lactate in the multivariable model. 
At the time of writing, 84 of the mNGS results for the 204 patients in the prospective Xpert Ultra cohort were 
available. Among the 9 participants with ‘probable’ TBM who were included in the ‘probable/definite’ TBM 
reference standard there were no alternative pathogens and no missed M. tuberculosis infections identified 
by mNGS (mNGS results were available for 5/9 participants). Therefore, the number of participants in the 
‘probable’ TBM reference category remained unchanged by mNGS and Xpert Ultra’s diagnostic accuracy 
results stand as they are in the published paper. Although reads to cytomegalovirus (CMV, 10 reads per 
million (rpm)), Epstein Barr virus (EBV, 4 rpm) and pegivirus (5998 rpm) were identified in the ‘probable’ 
group these were deemed to be non-clinically significant. In the ‘possible’ TBM group mNGS were available 
for 27 patients including 3 clinically significant infections (Wesselbrons virus 1414 rpm, Varicella Zoster virus 
98933 rpm, CMV 68503 rpm).  
Of the 39 cases in the ‘definite’ TBM group who were positive by Xpert Ultra we have mNGS results available 
for 17 patients. mNGS detected M. tuberculosis DNA in 65% (11/17, 2 to 540 rpm) but did not identify M. 
tuberculosis DNA in 35% (6/17) definite TBM cases. We therefore cannot hold out a great deal of hope that 
mNGS is going to be more sensitive than Xpert Ultra in the detection of M. tuberculosis DNA, though 
improvements in the collection, storage and the sequencing process may improve its performance in future.  
As described in section 1.3.5.3, the mNGS research is part of a wider ongoing collaboration between Dr Meya 
and Professor Boulware’s Ugandan team and Dr Michael Wilson at UCSF. The mNGS sample processing and 
bioinformatic work was not undertaken by myself, rather by Dr Prashanth Ramachandran (Dr Wilson’s post-
doctoral researcher) and the results of the wider sequencing study are being finalised and written up by Dr 
Ramachandran currently. To date, three relevant abstracts [a) viral pathogens in a TBM cohort, b) a combined 
host and pathogen classifier, c) enrichment techniques for TB] have been presented at the American 
Academy of Neurology conference, Appendix 6a-c and are referred to in the chapter 10 discussion. 
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Articles
Xpert MTB/RIF Ultra for the diagnosis of HIV-associated 
tuberculous meningitis: a prospective validation study
Fiona V Cresswell, Lillian Tugume, Nathan C Bahr, Richard Kwizera, Ananta S Bangdiwala, Abdu K Musubire, Morris Rutakingirwa, Enock Kagimu, 
Edwin Nuwagira, Edward Mpoza, Joshua Rhein, Darlisha A Williams, Conrad Muzoora, Daniel Grint, Alison M Elliott, David B Meya, 
David R Boulware, on behalf of the ASTRO-CM team
Summary
Introduction Tuberculous meningitis accounts for 1–5% of tuberculosis cases. Diagnostic delay contributes to poor 
outcomes. We evaluated the performance of the new Xpert MTB/RIF Ultra (Xpert Ultra) for tuberculous meningitis 
diagnosis.
Methods In this prospective validation study, we tested the cerebrospinal fluid (CSF) of adults presenting with 
suspected meningitis (ie, headache or altered mental status with clinical signs of meningism) to the Mulago National 
Referral Hospital and Mbarara Regional Referral Hospital in Uganda. We centrifuged the CSF, resuspended the cell 
pellet in 2 mL CSF, and tested 0·5 mL aliquots with Xpert Ultra, Xpert MTB/RIF (Xpert), and mycobacterial growth 
indicator tube (MGIT) culture. We quantified diagnostic performance against the uniform case definition of probable 
or definite tuberculous meningitis and a composite microbiological reference standard.
Findings From Nov 25, 2016, to Jan 24, 2019, we screened 466 adults with suspected meningitis and tested 204 for 
tuberculous meningitis. Uniform clinical case definition classified 51 participants as having probable or definite 
tuberculous meningitis. Against this uniform case definition, Xpert Ultra had 76·5% sensitivity (95% CI 62·5–87·2; 
39 of 51 patients) and a negative predictive value of 92·7% (87·6–96·2; 153 of 165), compared with 55·6% sensitivity 
(44·0–70·4; 25 of 45; p=0·0010) and a negative predictive value of 85·8% (78·9–91·1; 121 of 141) for Xpert and 
61·4% sensitivity (45·5–75·6; 27 of 44; p=0·020) and negative predictive value of 85·2% (77·4–91·1; 98 of 115) 
for MGIT culture. Against the composite microbiological reference standard, Xpert Ultra had sensitivity of 
92·9% (80·5–98·5; 39 of 42), higher than Xpert at 65·8% (48·6–80·4; 25 of 38; p=0·0063) and MGIT culture at 
72·2% (55·9–86·2; 27 of 37; p=0·092). Xpert Ultra detected nine tuberculous meningitis cases missed by Xpert and 
MGIT culture.
Interpretation Xpert Ultra detected tuberculous meningitis with higher sensitivity than Xpert and MGIT culture in 
this HIV-positive population. However, with a negative predictive value of 93%, Xpert Ultra cannot be used as a rule-
out test. Clinical judgment and novel highly sensitive point-of-care tests are still required.
Funding Wellcome Trust, National Institute of Health, National Institute of Neurologic Diseases and Stroke, 
Fogarty International Center, and National Institute of Allergy and Infectious Diseases.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Worldwide, Mycobacterium tuberculosis affected more than 
10 million people in 2018, with devastating con sequences, 
including around 1·5 million deaths.1 Tuberculous 
meningitis, the most serious form of tuberculosis in­
fection, accounts for 1–5% of new cases of tuberculosis 
and results in death or substantial disability in more than 
half of those affected.2 Outcomes are particularly poor 
in patients with HIV co­infection, which can triple the 
risk of death from tuberculous meningitis, reaching 
approximately 50%.3 Another major driver of poor out­
comes is diagnostic delay.4
Cerebrospinal fluid (CSF) smear microscopy with 
Ziehl–Neelsen staining for acid­fast bacilli is the 
cheapest and most widely available test for tuberculous 
meningitis diagnosis, but it is insensitive in most 
settings with out expert microscopists.5–7 Culture takes a 
minimum of 2 weeks to provide results (too slow for 
clinical utility), has only moderate sensitivity (30–60%), 
and is not readily available in most settings within 
low­income tuberculosis­endemic countries.8,6 Xpert 
MTB/RIF (Xpert; Cepheid, Sunnyvale, CA, USA)—a 
rapid, automated, cartridge­based mol ecular test—was 
endorsed by WHO in 2015 as the best initial test for 
tuberculous meningitis.9 Xpert has been deployed in 
130 of 145 countries eligible for concessional pricing 
as of 2016.10 Xpert provides 45–67% sensitivity to 
detect microbiologically proven tuberculous meningitis, 
meaning a negative result does not provide adequate 
confidence that tuberculous menin gitis is not present.8,11 
Thus, empirical antituberculous therapy for tuberculous 
meningitis, with its associated drug toxicities, drug–
drug interactions, pill burden, and cost, is still commonly 
used, often unnecessarily.
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Subsequently, Xpert MTB/RIF Ultra (Xpert Ultra) was 
developed, which has a larger chamber (50 µL) for DNA 
amplification than Xpert, allowing twice the volume of 
sample to reach the PCR reaction. Xpert Ultra also has 
two new multicopy DNA targets (IS6110 and IS1081), 
incorporates fully nested nucleic acid amplification, 
and uses melting temperature­based analysis instead of 
real­time PCR to improve the accuracy of rifampicin­
resistance detection. In vitro, these changes have made 
the limit of detection of M tuberculosis seven times 
lower (16 vs 113 colony forming units [CFUs] per mL).12,13 
Another important benefit of Xpert Ultra is the 
shortened run time of 84 min (compared with 112 min 
for Xpert), enabling an extra five tests to be run on each 
module in a working day, equating to an extra 40 tests 
per day on an eight­module unit. To upgrade from Xpert, 
only new software and the Xpert Ultra cartridges are 
required—the same instrument can be used. Previous 
studies have shown that Xpert Ultra’s sensitivity is 
markedly improved over Xpert’s in smear­negative 
pulmonary tuberculosis (63% vs 46%),14 HIV­associated 
pulmonary tuberculosis (90% vs 77%),14 and paediatric 
tuberculosis (74% vs 63%).15 The largest study to 
date of Xpert Ultra in tuberculous meningitis used 
cryopreserved CSF samples and found sensitivities of 
95% (95% CI 77–99) for Xpert Ultra and the same 
sensitivity of 45% (24–68) for each of Xpert and 
mycobacterial growth indicator tube (MGIT) culture 
against a composite microbiological reference standard.8 
Against the uniform clinical case definition of probable 
or definite tuberculous meningitis,16 sensitivity was 
70% (47–87; 16 of 23 patients) for Xpert Ultra and 
43% (23–66; ten of 23) for both culture and Xpert.8 Four 
additional small studies on CSF (containing a minimum 
of four and a maximum of 43 samples) corroborated the 
increased sensitivity of Xpert Ultra.17–20 Additional larger 
studies using real­time CSF samples and prespecified 
reference standards are needed to better inform the 
current understanding of Xpert Ultra’s performance in 
tuberculous meningitis.
The aim of this study was to prospectively assess 
the diagnostic accuracy of Xpert Ultra for tuberculous 
Research in context
Evidence before this study
We searched PubMed Central for reports of Xpert MTB/RIF Ultra 
(Xpert Ultra) for the diagnosis of tuberculosis using the terms 
(“Xpert MTB/RIF Ultra” or “Xpert Ultra”) and (“tuberculosis” or 
“TB” or “tuberculous meningitis” or “TBM” or “extrapulmonary”). 
The search was done on Feb 14, 2019, with no search date or 
language restrictions.
In-vitro studies of Xpert MTB/RIF (Xpert) and Xpert Ultra assays 
have been done on sputum samples spiked with decreasing 
numbers of Mycobacterium tuberculosis H37Rv colony-forming 
units (CFUs), which found the limit of detection to be 16 CFUs 
per mL for Xpert Ultra versus 113 CFUs per mL for Xpert—a 
seven-times reduction in the limit of detection. 
This improvement signified a promising step for the diagnosis 
of paucibacillary tuberculosis. Since then, several prospective 
and retrospective studies have evaluated Xpert Ultra in 
diagnosis of adult pulmonary tuberculosis (four), paediatric 
tuberculosis (two), extrapulmonary tuberculosis (two), 
paucibacillary tuberculosis (one), and tuberculous 
meningitis (one), all of which have found Xpert Ultra to be more 
sensitive than Xpert. The largest prospective diagnostic accuracy 
study to date, including 1753 participants with suspected 
pulmonary tuberculosis, found Xpert Ultra to have superior 
sensitivity to Xpert in smear-negative pulmonary tuberculosis 
(63% vs 46%) and in HIV-associated pulmonary tuberculosis 
(90% vs 77%), albeit with a more modest difference 
of 5·4 percentage points in the general pulmonary tuberculosis 
population. To date, only Bahr and colleagues have specifically 
focused on tuberculous meningitis, testing 129 cryopreserved 
CSF samples from HIV-positive Ugandan adults and 
finding sensitivities of 70% (16 of 23 patients) for Xpert Ultra 
and 43% (ten of 23) for Xpert against a uniform reference 
standard of probable or definite tuberculous meningitis. 
The sensitivity against a composite microbiological reference 
standard was 95% (21 of 22) for Xpert Ultra and 45% (ten of 22) 
for Xpert (p=0·0010).
Added value of this study
To our knowledge, this prospective study is the largest to date 
to investigate the diagnostic performance of Xpert Ultra for 
tuberculous meningitis. It corroborates the findings from 
cryopreserved CSF samples and adds to the data on use of Xpert 
Ultra in HIV-positive populations and in paucibacillary forms of 
tuberculosis. We tested each sample with Xpert and Xpert Ultra 
to allow direct head-to-head comparisons of the performance 
of the two assays. To optimise the uniform case definition 
reference standard, we endeavoured to exclude other 
non-tuberculosis causes of meningitis by testing CSF with 
a meningoencephalitis PCR panel (testing for 14 viral, 
bacterial, and fungal pathogens) and offering post-mortem 
examinations when possible for participants who died without 
a microbiologically confirmed diagnosis.
Implications of all the available evidence
Our results support the WHO recommendations to use Xpert 
Ultra as the initial test for suspected tuberculous meningitis. 
With its run-time of 84 min, Xpert Ultra, in the context of 
appropriate infrastructure, holds potential to provide same-day 
results and facilitate prompt tuberculous meningitis treatment. 
Nonetheless, Xpert Ultra’s imperfect negative predictive value 
(92·7% [95% CI 87·6–96·2] vs the uniform clinical case 
definition in this study) means that clinical judgment must 
override a negative Xpert Ultra result and empirical tuberculosis 
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meningitis compared with Xpert using fresh CSF 
specimens from an HIV­positive population.
Methods
Study design and population
In this diagnostic accuracy study, we prospectively eval­
uated adults (aged ≥18 years) presenting consecutively to 
Mulago National Referral Hospital, Kampala, and Mbarara 
Regional Referral Hospital, Mbarara, Uganda, with 
suspected meningitis (headache for >3 days or altered 
mental status [Glasgow Coma Scale <15] with clinical signs 
of meningism at examination—ie, neck stiffness or 
Kernig’s sign). The period of enrolment ran from 
Nov 26, 2016, to Jan 24, 2019, at Mulago National Referral 
Hospital and from Nov 25, 2016, to June 13, 2017, at 
Mbarara Regional Referral Hospital. Ethical approval was 
obtained from the Mulago Hospital, London School of 
Hygiene & Tropical Medicine, and University of Minnesota 
institutional review boards and Uganda National Council 
of Science and Technology, and informed consent was 
obtained from participants or their surrogate (in patients 
with altered mental status) as part of the screening process 
for a meningitis clinical trial (NCT01802385) that 
subsequently rolled into an observational diagnostic study. 
The study was conducted in line with the Standards for 
Reporting Diagnostic Accuracy Studies.21
Procedures
Given the high prevalence of cryptococcus and the similar 
initial presentations between cryptococcal meningitis and 
tuberculous meningitis, fingerstick cryptococcal antigen 
lateral flow assay (LFA; Immy, Norman, OK, USA) was 
done at the participant’s bedside. Thereafter, lumbar 
puncture was done for all participants, CSF opening 
pressure was recorded, and CSF was collected into a 
sterile tube with a target volume of more than 6 mL. At 
the bedside, CSF glucose and lactate were measured from 
a drop of CSF collected into an Eppendorf tube using a 
handheld OneTouch glucose meter (OneTouch; Lifescan, 
Inverness, UK) and a point­of­care lactate meter (Nova 
Biomedical; Waltham, MA, USA). Xpert and Xpert Ultra 
results were returned to the study team within 24 h to 
guide treatment decisions.
Clinical history, physical examination, and detailed 
neurological assessment findings were recorded as rec­
ommended by the Tuberculous Meningitis International 
Research Consortium.22 Other diagnostic tests, including 
urine tuberculosis lipoarabinomannan (Alere Determine; 
Alere, Waltham, MA, USA), chest radiograph, abdominal 
ultrasonography, brain imaging, and sputum Xpert, were 
done as clinically indicated and when locally available.
Microbiological testing
Laboratory CSF testing included white blood cell count, 
lymphocyte percentage, differential Gram stain, aerobic 
bacterial culture, Ziehl–Neelsen acid­fast bacilli stain 
(Kampala only), total protein, CSF cryptococcal anti gen, 
and Biofire FilmArray menin goencephalitis PCR panel 
(bioMérieux; Durham, NC, USA) for 14 meningo­
encephalitis pathogens (Streptococcus pneu moniae, Neisseria 
meningitidis, Listeria monocytogenes, Haemophilus influenzae, 
Strepto coccus agalactiae, Esche richia coli, herpes simplex 
virus types 1 and 2, cyto megalovirus, varicella zoster virus, 
human herpes virus 6, enterovirus, human parechovirus, 
and cryptococcus). All samples that were negative for 
CSF cryptococcal antigen underwent com prehensive 
tuber culosis diagnostic studies. Samples positive for 
cryptococcal antigen under went fungal culture and, in the 
event of fungal growth, quantitative fungal culture count.
For tuberculosis analysis, the CSF was centrifuged at 
3000 g for 20 min to concentrate bacilli into the cell pellet. 
Supernatant was pipetted out to leave a residual volume of 
2 mL in which the cell pellet was re­suspended by 
vortexing. The resuspended cell pellet was then divided 
into four 0·5 mL aliquots for Xpert, Xpert Ultra, MGIT 
culture, and cryopreservation at −80°C in case of invalid 
results from Xpert or Xpert Ultra or for future sequencing 
work. The aliquots for Xpert and Xpert Ultra were mixed 
with 1·5 mL of sample reagent, shaken vigorously, allowed 
to sit for 15 min, and then run on the Cepheid platform. 
The 0·5 mL aliquot for MGIT culture was added to the 
MGIT tube and incubated in a Bactec 960 instrument 
(Becton Dickinson; Franklin Lakes, NJ, USA). The 
algorithm for CSF diagnostic testing is illustrated in the 
appendix (p 2). Where the volume of CSF was below 6 mL, 
a stepwise approach was used to maximise the likelihood 
of yielding a diagnosis for the participant, as shown in the 
appendix (p 4). At the clinician’s discretion, participants 
with a positive test for CSF cryptococcal antigen were 
allowed to undergo tuber culous meningitis testing as 
cryptococcosis coinfection with tuberculous meningitis 
does occur, although rarely.23 In Mbarara, tuberculosis 
testing was done at the Médecins Sans Frontières 
Epicentre laboratory. In Kampala, testing was done at the 
Makerere University Micro biology Laboratory, Makerere 
University Mycobacteriology (BSL­3) laboratory (MGIT 
culture), and the Infectious Diseases Institute Trans­
lational laboratory (Xpert and Xpert Ultra). Clinical 
information was not available to the performers of the 
index or reference tests. The same laboratory technologist 
performed Xpert and Xpert Ultra, but MGIT results were 
read and reported by a different technologist.
Xpert results are reported as follows: M tuberculosis not 
detected; invalid, if the internal quality control checks 
fail; or, if M tuberculosis DNA is detected, a semi­
quantitative category of very low, low, medium, or high 
is given. Xpert Ultra results are reported in the same way 
but with the addition of the trace semi­quantitative 
category for the lowest bacillary loads (less than 
approximately 113 CFUs per mL). Rifampicin resistance 
is reported as indeterminate for tests positive in the 
trace category as the DNA quantity is too low to 
adequately detect rifampicin resistance conferring 
mutations.
See Online for appendix
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For participants who died during hospitalisation at 
Mulago hospital and did not have a microbiologically 
confirmed diagnosis, the families were invited to provide 
informed consent for post­mortem examination in the 
Makerere University mortuary by a trained pathologist. 
Post­mortem examinations were unavailable in Mbarara. 
Additionally, CSF samples collected from participants 
with cryptococcal meningitis and who survived without 
tuberculosis therapy (ie, negative controls) were run on 
Xpert Ultra from the same parent study (NCT01802385).
Statistical analysis
We assessed the diagnostic accuracy of Xpert Ultra against 
two reference standards. For the primary reference 
standard, we used the consensus uniform case definition 
of probable (≥10 points on the diagnostic scoring system 
when brain imaging is not available or ≥12 points when 
brain imaging is available) or definite (microbiologically 
confirmed M tuberculosis) tuberculous meningitis.16 We 
also used a composite microbiological reference standard 
of any positive CSF test (Ziehl–Neelsen stain microscopy, 
Xpert, Xpert Ultra, and MGIT) for M tuberculosis. Here, 
we included the index test (Xpert Ultra) in the reference 
standard as the existing tests are imperfect, and we judged 
the likelihood of false­positive detection of M tuberculosis 
DNA in the CSF of an HIV­positive person with aseptic 
meningitis in a tuberculosis­endemic area to be extremely 
low.
Baseline clinical characteristics were compared between 
those with definite tuberculous meningitis and the re­
maining participants, who were classified as other menin­
gitis, via Wilcoxon rank­sum test for continuous variables 
and Pearson’s χ² squared or Fisher’s exact test for 
categorical variables. We directly compared the sensitivity 
of Xpert Ultra with that of Xpert or MGIT using McNemar’s 
test for paired categorical data. For the comparison of two 
diagnostic test performances against the primary reference 
standard, we used the Cochran–Mantel–Haenszel statistic 
for comparing matched catego rical data across two strata 
of diagnostic tests versus the uniform case definition.16 
Negative predictive value was calculated against the 
primary reference standard, both with and without the 
Figure 1: Flow diagram showing the diagnostic outcomes of the study population
Xpert=Xpert MTB/RIF. MGIT=mycobacterial growth indicator tube. HSV=herpes simplex virus. CSF=cerebrospinal fluid. *Five participants with confirmed tuberculous 
meningitis had a positive CSF cryptococcal antigen test, of whom two had culture-confirmed cryptococcal meningitis. †Culture or PCR positive. ‡Two HSV type 1, 
two HSV type 2, two varicella zoster virus, and one cytomegalovirus. §One confirmed Streptococcus pneumoniae on PCR, four clinical diagnosis of bacterial meningitis 
based on CSF picture (ie, high CSF white blood cell count with neutrophil predominance suggestive of bacterial meningitis).
466 participants screened
262 with cryptococcal meningitis
and no suspicion of disseminated
tuberculosis 
204 tested with Xpert Ultra
39 positive for tuberculous meningitis by Xpert Ultra165 negative for tuberculous meningitis by Xpert Ultra
162 negative by Xpert and MGIT culture 3 positive by Xpert or MGIT culture
2 MGIT culture only
1 MGIT culture and Xpert
9 negative by Xpert and MGIT culture 30 positive by Xpert or MGIT culture
18 MGIT culture and Xpert
6 MGIT culture only
6 Xpert only
204 with final diagnosis
42 with tuberculous meningitis*
3 negative by Xpert Ultra
39 positive by Xpert Ultra





2 cerebral vascular accident
1 progressive multifocal
   leukoencephalopathy
1 benign intracranial hypertension
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Xpert Ultra result being used to assign the uniform case 
definition category. Calculation of specificity and positive 
predictive value was done against the composite endpoint 
and the uniform case definition using 2 × 2 tables. We 
counted invalid tests (eg, culture contamination or Xpert 
error) as negative results. Additionally, a sensitivity analysis 
was done including only participants who received all 
three tests. We did univariate and multivariable logistic 
regression analysis to identify variables that correlate with 
microbiological confirmation of tuberculous meningitis. 
Variables which showed association in the univariate 
analysis (likelihood ratio test p<0·1) were eligible to be 
included in the multivariable model. Variables that were 
not normally distributed were log transformed.
Sample size calculation was done using the composite 
microbiological refe rence standard. For the paired analysis 
comparing the sensitivity of Xpert Ultra with that of Xpert 
or MGIT among participants positive for tuberculous 
meningitis, we assumed a third of pairs would give 
discordant results and that the sensitivity of Xpert Ultra 
would be 25% higher than that of Xpert and MGIT.8 
Under these assumptions, we required 39 tuberculous 
meningitis cases to give 80% power with α set to 5%. 
Assuming the prevalence of tuberculous meningitis 
would be 20%, we aimed to recruit 200 participants.
We did a post­hoc analysis of the sensitivity of all assays 
according to the British Medical Research Council (MRC) 
tuberculous meningitis grade of disease severity grade 
against both reference standards (appendix p 12).
Stata version 13.1 was used for statistical analyses.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
During the study period, 466 HIV­positive adults pre­
sented with suspected meningitis and consented to 
diagnostic lumbar puncture. Of these, 262 participants 
were diagnosed with cryptococcal meningitis and had no 
suspicion for disseminated tuberculosis warranting CSF 
tuberculosis diagnostics, so were excluded from this 
study. 204 were tested for tuberculous meningitis with 
Xpert Ultra (figure 1), of whom 195 (96%) were HIV 
positive with a median CD4 T cell count of 46 cells/μL 
(IQR 11–130). This number included 39 (19%) patients 
who had a positive CSF cryptococcal antigen test but 
were still tested for tuberculous meningitis because of 
suspected tuberculosis coinfection, and an additional 
31 (15%) of those tested for tuberculous meningitis tested 
positive for cryptococcal antigen in serum but negative in 
CSF. Biofire meningoencephalitis PCR was done on 
80 CSF samples; not all samples were tested owing to a 
technical issue with the machine. We collected a median 
of 11 mL (IQR 7–15) of CSF per participant, which left a 
median of 8 mL (5–11) of CSF to be spun down 
for tuberculosis testing after routine microbiology and 
chemistry testing had been done. Collected CSF was 
clear in 186 (91%) participants, with the remaining 
18 (9%) having turbid CSF. Brain imaging was rarely 
done (ie, in 18 participants) because of a lack of 
functioning CT scanners in the study sites. No adverse 
events were attributable to the diagnostic testing (data 
not shown).
At baseline, lack of white blood cell pleocytosis and 
con centrations of glucose, protein, and lactate differed 
significantly between those with and without micro­
biologically confirmed tuberculous meningitis (table 1). 
The demographic, clinical, and diagnostic details of 
the 42 participants with micro biologically confirmed tuber­
culous meningitis are shown in the appendix (pp 5–6).
Of the 204 participants who underwent tuberculous 
meningitis diagnostic testing, Xpert Ultra was positive in 
39, of whom Xpert was also positive in 24 and MGIT 
culture in 24 (figure 1). Xpert Ultra was negative in 
165 participants, of whom 162 were negative and three 
were positive by the composite microbiological reference 






Age, years 32 (29–38) 35 (28–42) 0·43
Sex ·· ·· 0·73
Female 19 (45%) 68 (42%) ··
Male 23 (55%) 94 (58%) ··
HIV status ·· ·· ··
Positive 41 (98%) 154 (95%) 0·47
Negative 1 (2%) 6 (4%) ··
Unknown 0 2 (1%) ··
On antiretroviral therapy 23 (55%) 99 (62%) 0·48
Headache duration, days 14 (7–21) 14 (5–21) 0·40
Glasgow Coma Scale 13 (10–14) 14 (13–15) 0·0012
CD4 count, cells per μL* 57 (13–108) 46 (10–188) 0·83
CSF opening pressure, cmH2O 20 (10–32) 18 (13–26) 0·91
Acellular CSF <5 cells per μL 11 (26%) 99 (61%) <0·0001
CSF white blood cells per μL† 170 (70–283) 100 (40–275) 0·085
CSF lymphocytes 100% (84–100) 100% (80–100) 0·61
CSF total protein, g/L 1·2 (0·9–2·0) 0·3 (0·2–0·8) <0·0001
CSF glucose, mmol/L 1·2 (0·9–2·0) 2·9 (1·9–4·4) <0·0001
CSF lactate, mmol/mL‡ 9·5 (4·6–11) 3·6 (2·4–5·1) <0·0001
Alive at hospital discharge 25 (60%) 101/143 (71%)§ 0·18
Values are n (%), n/N (%), or median (IQR), unless otherwise stated. p values are from Wilcoxon rank-sum for 
continuous data and Fisher’s exact test for categorical data. Patients with definite tuberculous meningitis were positive 
for tuberculous meningitis by the composite microbiological reference standard. Patients with other meningitis were 
the remaining participants, including 112 with unknown causes and 50 with known causes of meningitis (see figure 1). 
*63 participants had CD4 count data (12 in the definite tuberculous meningitis group and 51 in the other meningitis 
group). †Median values in participants with more than five white blood cells per μL of CSF. ‡Lactate concentrations 
were available for 18 participants in the tuberculous meningitis definite group and 70 in the other meningitis group. 
§19 participants had unknown status at discharge in the other meningitis group.
Table 1: Baseline characteristics of participants who underwent tuberculous meningitis testing
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tuberculous meningitis that were not identified by Xpert 
or MGIT culture (figure 2). We diagnosed probable 
or definite tuberculous meningitis in 51 (25%) of 
204 participants when including the Xpert Ultra result in 
assigning the uniform case definition. When the Xpert 
Ultra result was excluded, 44 (22%) participants were 
classified as having probable or definite tuberculous 
meningitis. Of the 42 participants with definite tuber­
culous meningitis, five (12%) tested positive for 
cryptococcal antigen in CSF, including two (5%) who had 
positive fungal cultures (quantitative cryptococcal culture 
520 000 and 20 000 CFUs per mL; figure 1).
We identified alternative causes of meningitis in 
49 (30%) of the 162 participants without confirmed 
tuberculous meningitis (figure 1). In four patients without 
confirmed tuberculous meningitis who died in hospital, 
post­mortem examinations were done and causes of 
death were herpes simplex virus meningoencephalitis, 
pro gressive multifocal leukoencephalopathy, and dissemi­
nated tuberculosis without obvious CNS involvement in 
one patient; progressive multifocal leukoencephalopathy 
(PML) in one patient; pneumonia with no obvious CNS 
pathology in one patient; and meningoencephalitis with 
macroscopic appearance that was compatible with tuber­
culous meningitis, with histopathological confirmation 
awaited, in one patient.
Among the 42 participants with definite tuberculous 
meningitis, 17 (40%) died in hospital, with a median time 
to death of 4 days (IQR 2–6). Among the 162 patients in 
the other meningitis group, hospital outcome was known 
for 143, of whom 19 (13%) died in hospital.
When compared with the uniform case definition 
(probable or definite tuberculous meningitis), sensitivities 
were 76·5% (95% CI 62·5–87·2) for Xpert Ultra, 
55·6% (44·0–70·4) for Xpert, and 61·4% (45·5–75·6) for 
MGIT (table 2). Against the composite microbiological 
reference standard, sensitivities were 92·9% (80·5–98·5) 
for Xpert Ultra, 65·8% (48·6–80·4) for Xpert, and 72·2% 
(55·9–86·2) for MGIT culture (table 2). Xpert Ultra was 
superior to Xpert in detecting tuberculous meningitis 
when either the composite micro biological reference 
standard or uniform case definition was used (table 2). 
Xpert Ultra was significantly more sensitive than MGIT 
culture when the uniform case definition was used but 
not when the composite micro biological reference 
standard was used (table 2). The negative predictive value 
of Xpert Ultra was 92·7% (87·6–96·2) against the 
uniform case definition (table 2). When including only 
the 117 participants who had received all three tests, no 
major difference in performance of any of the tests was 
observed (appendix p 7).
Of the 39 positive Xpert Ultra results, 14 were categorised 
as trace, ten as very low, seven as low, five as medium, and 
none as high; three results were unknown. Of the 14 Xpert 
Ultra trace samples, only four were positive on Xpert 
(three very low and one low) and six were positive on 
culture. Median time to CSF culture positivity was 14 days 
Figure 2: Venn diagram of positive diagnostic tests in the composite 
microbiological reference standard
The Venn diagram displays 42 participants with microbiologically confirmed 
tuberculous meningitis by either Xpert, Xpert Ultra, or MGIT culture. 















p value† Sensitivity vs 
uniform case 
definition
p value‡ Negative predictive 
value vs uniform case 
definition
Specificity vs uniform 
case definition
Xpert Ultra 204 92·9% (80·5–98·5); 
39/42
·· 76·5% (62·5–87·2); 
39/51




Xpert 166 65·8% (48·6–80·4); 
25/38
0·0063 55·6% (44·0–70·4); 
25/45




MGIT culture 142 72·2% (55·9–86·2); 
27/37
0·092 61·4% (45·5–75·6); 
27/44




Values are percentage (95% CI); numerator/denominator unless stated otherwise. Xpert=Xpert MTB/RIF. MGIT=mycobacterial growth indicator tube. *The composite 
microbiological reference standard included a positive CSF test on any of Ziehl–Neelsen stain microscopy, Xpert, Xpert Ultra, and MGIT culture. Specificity (and the positive 
predictive value) versus the composite endpoint is by definition 100% as the index test is included in the reference standard of definite tuberculous meningitis. If the Xpert 
Ultra result is excluded when assigning the case definition, the specificity of Xpert Ultra is 96% (95% CI 91–98; 153 of 160 patients) and the positive predictive value is 82% 
(66–93; 32 of 39). †McNemar’s test comparing the sensitivity of Xpert or MGIT culture with that of Xpert Ultra. ‡Cochran–Mantel–Haenszel test comparing the distribution of 
Xpert or MGIT results with that of Xpert Ultra results against the uniform clinical standard of definite or probable tuberculous meningitis.
Table 2: Diagnostic performance of Xpert, Xpert Ultra, and MGIT culture for the diagnosis of tuberculous meningitis
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(IQR 10–15). Median time to positivity by Xpert Ultra semi­
quantitative category was 15 days (13–15) for trace, 15 days 
(12–15) for very low, 12 days (9–21) for low, and 9 days (8–9) 
for medium (appendix pp 3, 8).
No cases of rifampicin resistance were identified with 
either Xpert or Xpert Ultra. Positive samples classed in the 
Xpert Ultra trace category have in determinate rifampicin 
resistance because more than 16 CFUs per mL of 
M tuberculosis and amplification of rpob DNA is required 
to generate rifampicin susceptibility results;13 thus all 
14 trace positive results had indeterminate rifampicin 
resistance in our study. Culture­based drug susceptibility 
testing was not done. MGIT culture reported contaminated 
results in 13 (9%) of 142 cultures performed.
When analysing by MRC grade, the sensitivity of Xpert 
Ultra against the composite microbiological reference 
standard was 100% in grade 1 disease, 96% in grade 2 
disease, and 82% in grade 3 disease. Using the uniform 
case definition, the sensitivity of Xpert Ultra was 100% in 
grade 1 disease, 74% in grade 2 disease, and 69% in grade 3 
disease. The observation of decreasing sensitivity with 
advancing disease MRC severity grade held true for Xpert 
and MGIT (appendix p 9).
The CSF from 45 participants with confirmed crypto­
coccal meningitis and no clinical suspicion of tuber­
culosis coinfection were all negative on Xpert Ultra, 
suggesting false positivity (eg, laboratory contamination) 
is a rare occurrence (specificity 100%, 95% CI 92–100).
Univariate analysis found that Glasgow Coma Scale 
score of less than 15, CSF pleocytosis, and lower CSF 
glucose, higher CSF protein, and higher CSF lactate 
concentrations were all positively associated with 
micro biological confirmation of tuber culous meningitis 
(table 3). Log2 CSF lactate con centration was not included 
in the multivariate analysis because of the large amount 
of missing data. In the multivariable logistic regression 
model, lower log2 CSF glucose concentration remained 
positively asso ciated with microbiological confirmation 
of tuberculous menin gitis, although the multivariable 
model analysis was restricted to 101 participants with a 
complete dataset for the variables included in the model 
(table 3). The median volume of CSF spun down for 
tuberculosis testing was 8 mL (IQR 5–11) and each 
doubling (ie, log2 increase) of CSF volume spun down 
increased the odds of tuberculosis confirmation by 
40%, although this did not achieve statistical significance 
(table 3).
Of the nine participants who were positive only by 
Xpert Ultra, six had started antiretroviral therapy 
within the 6 weeks preceding the study (median 
duration 28 days, IQR 17–35), a timing consistent with 
unmasking immune reconstitution inflammatory 
syndrome.
Discussion
In this HIV­positive population with suspected menin gitis, 
Xpert Ultra showed higher sensitivity to detect tuberculous 
meningitis than either Xpert or MGIT culture against both 
considered reference standards, although the difference 
was not significant when Xpert Ultra was compared with 
MGIT culture against the composite microbiological 
reference standard. These findings from fresh CSF corro­
borate our earlier findings from cryopreserved CSF, 
supporting the robustness of these data.8
Importantly, more than a third (14 [36%] of 39) of 
positive Xpert Ultra results were in the trace category 
Univariate model Multivariable model
n Odds ratio (95% CI) p value n Adjusted odds ratio (95% CI) p value
Age, per year 204 0·98 (0·95–1·01) 0·26 ·· ·· ··
Male sex 204 1·14 (0·58–2·26) 0·70 ·· ·· ··
Duration of headache, per day 168 1·00 (0·98–1·01) 0·95 ·· ·· ··
Glasgow Coma Scale score
15* 72 1 (ref) ·· 35 1 (ref) ··
11–14 97 3·62 (1·39–9·39) 0·0083 46 3·71 (0·84–16·48) 0·084
≤10 33 5·50 (1·82–16·62) 0·0025 21 4·71 (0·93–23·82) 0·061
Log2 CD4 count, cells per µL 63 0·94 (0·71–1·34) 0·66 ·· ·· ··
On antiretroviral therapy 202 1·34 (0·67–2·66) 0·40 ·· ·· ··
Log2 CSF volume, mL 198 1·20 (0·84–1·72) 0·32 ·· ·· ··
Log2 CSF volume spun down, mL 96 1·40 (0·84–2·35) 0·20 ·· ·· ··
CSF pleocytosis† 189 4·94 (2·28–10·72) <0·0001 101 2·04 (0·33–12·74) 0·44
Log2 CSF glucose, mmol/L 122 0·31 (0·18–0·54) <0·0001 101 0·33 (0·17–0·65) 0·0010
Log2 CSF lactate, mmol/L‡ 88 5·76 (2·45–13·52) <0·0001 ·· ·· ··
Log2 CSF protein, mg/dL 166 2·10 (1·52–2·89) <0·0001 101 1·02 (0·56–1·87) 0·25
Variables that were significant (p<0·1) in the univariate model were included in the multivariable model. Odds ratios for log-transformed variables are per log2 increase. 
CSF=cerebrospinal fluid. *p=0·0001 with the likelihood ratio test. †>5 lymphocytes per µL of CSF. ‡CSF lactate was excluded from the multivariable model because of the 
amount of missing data.
Table 3: Univariate and multivariable analyses of factors potentially associated with microbiological confirmation of tuberculous meningitis
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(correlating to <100 CFUs per mL), which is usually 
below the limit of detection of Xpert and potentially 
below the limit of detection of tuberculosis culture. Of 
these 14 trace positive samples, only four were positive 
by Xpert and six by culture. The ability to detect non­
viable organisms is another reason why detection of 
tuberculosis might be improved with molecular tests 
versus culture.
As part of the uniform case definition, we did not 
include participants with possible tuberculous meningitis 
(n=74) in our analysis because of the non­specific nature 
of this category in this study population with advanced 
HIV—eg, due to concurrent neurological pathology such 
as PML (study population median CD4 T cell count 
46 cells/μL, IQR 11–130).
With increasing market penetration of the Xpert plat­
form in countries with high tuberculosis burden24 and a 
turnaround time of 84 min, Xpert Ultra is the best point­
of­care test for tuberculous meningitis currently available 
and has been endorsed by WHO as the best initial test for 
tuberculous meningitis.25 Yet, our study shows a moderate 
76·5% sensitivity of Xpert Ultra against a uniform case 
definition of probable or definite tuberculous meningitis, 
giving a negative predictive value of 92·7%. In other 
words, nearly a fifth of patients (nine [18%] of 51) with 
clinical phenotypes and CSF profiles highly suggestive of 
tuberculous meningitis and negative for all other tested 
pathogens were negative by Xpert Ultra (and by Xpert and 
culture). Four of these participants died from their illness, 
one with macroscopic post­mortem findings compatible 
with tuberculous menin gitis. Our belief is that a pro­
portion of these are false­negative results, but this remains 
to be determined in future studies. CSF could also be 
tested with Xpert Ultra on multiple days if safe to do so 
and a false­negative result is suspected; we have employed 
this strategy with success in several patients (outside of 
this study). Markers of host response should also be 
considered as potential future adjunctive diagnostic tests, 
although to date, none have been successful.26 Currently, 
clinical judgment remains relevant when making treat­
ment decisions regarding tuberculous meningitis.11
Multivariable analysis showed low CSF glucose to be 
associated with microbiologically confirmed tuberculous 
meningitis. CSF lactate could not be taken through to the 
multivariable model because of the amount of missing 
data but was found to be strongly associated with 
microbiologically confirmed tuberculous menin gitis in 
the univariate model and thus warrants further investi­
gation as a diagnostic marker. Handheld glucometers and 
lactate meters are true point­of­care tests, with results 
available at the bedside within a matter of seconds. A low 
CSF glucose concen tration (<2·2 mmol/L, <40 mg/dL, or 
CSF to plasma glucose ratio <50%) in a patient with 
symptoms and signs suggestive of tuber culous meningitis, 
once bacterial menin gitis and cryptococcus have been 
excluded, is a good indication to consider antituberculous 
therapy regardless of tuberculosis­specific test results. 
The potential for using CSF glucose and lactate as com­
ponents of a comprehensive diagnostic algorithm focused 
on probability of diagnosis should be explored in future 
studies.
We believe that using Xpert Ultra on CSF samples is 
highly specific for the diagnosis of tuberculous menin­
gitis, although the absence of a perfect reference standard 
makes this difficult to prove. Furthermore, the inclusion 
of Xpert Ultra in the composite reference standard risked 
incorporation bias and is a limitation of this study. 
Yet, unlike sputum from the lungs, which can remain 
positive in the trace category on Xpert Ultra even years 
after treatment of prior pulmonary tuberculosis,27 CSF is 
a sterile body fluid that is replenished four to five times a 
day.28 Presence of M tuberculosis in the CSF progresses to 
death if untreated. In this study of hospitalised patients 
with advanced HIV who were from a tuberculosis­
endemic country and had symptoms of subacute 
meningitis, we feel that the probability of a false­positive 
DNA­based test is negligible.
The median total volume of CSF spun down for 
tuberculosis testing was 8·0 mL; however, this volume 
was then divided into four, with a median volume of 
approximately 2·0 mL per diagnostic test. We used an 
algorithm for stepwise dropping of tests when the CSF 
volume collected was less than 6 mL so the minimal 
input CSF volume would always be at least 2·0 mL per 
diagnostic test to maximise the likelihood of obtaining an 
accurate result for the patient. Each doubling of CSF 
volume spun down increased the odds of tuberculosis 
confirmation by 40%, although this association was not 
significant. Xpert has been noted in some studies to have 
improved performance when higher CSF volumes are 
used; this study cannot inform whether the same is true 
for Xpert Ultra.5,6 The stepwise use of tests on low­volume 
samples resulted in small samples receiving fewer tests 
and thus imperfect matching, with CSF from 204 patients 
tested with Xpert Ultra compared with only 166 with 
Xpert. There were also the common problems of culture, 
beyond diagnostic delay; only 142 culture results were 
received (including 13 that were contaminated) because 
of a number being lost when sent to an external 
mycobacterial laboratory.
11 (26%) of 42 patients with microbiologically con­
firmed tuberculous meningitis had an acellular CSF 
(fewer than five white blood cells per µL). All those with 
acellular CSF also had CSF opening pressure and total 
protein within the normal range and lower median CSF 
lactate concentrations (CSF lactate 4·6 mmo/mL vs 
9·5 mmol/mL in the definite tuberculous meningitis 
group). We previously reported that one in three patients 
with definite tuberculous meningitis have acellular 
CSF, a finding that has also been noted in other HIV­
positive cohorts outside of Asia.29 This observed 
absence of an inflammatory response in patients with 
microbiologically confirmed tuberculous meningitis 
could be explained by immune paresis secondary to 
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advanced HIV disease (CD4 count was available in two 
of 11 patients and was three cells per µL and six cells 
per µL, respectively), or by early presentation (three of 
11 patients had MRC grade 1 disease). Mortality was 
high in this subgroup despite the apparent absence of 
CSF inflammation, with six (55%) patients dying in 
hospital. Low CSF white blood cell count has been 
associated with death in a multivariate prognostic model 
in Vietnamese adults with tuberculous meningitis, and 
it is becoming increasingly clear that both absence 
of inflammation, as well as excessive inflammation, are 
deleterious in tuberculous meningitis.2,30
The sensitivity of all assays was highest in early disease 
(MRC grade 1), and sensitivity decreased as disease 
severity progressed. Although the numbers are small and 
the analysis of sensitivity by MRC grade was post hoc, 
this finding supports the notion that an increasing 
immune response (ie, inflammation) aimed at controlling 
bacillary load is the mediator of disease. Thereby, an 
inverse relationship might actually exist between CSF 
bacillary load and disease severity in this population. This 
hypo thesis warrants further investigation in immunology 
studies and highlights the importance of finding 
the optimal host­directed therapy to control damaging 
inflammation in this population.
When translating these results to the field, it is important 
to consider that in many hospital laboratory settings, 
centrifuging the CSF might not be feasible, in which case 
we would advise loading 2 mL of CSF directly into the 
Xpert Ultra cartridge to maximise the bacillary load, as 
dilution with sample reagent is not required for 
CSF. Additionally, although our cohort cannot inform 
diagnostic performance in an HIV­negative population, 
our paired analysis of specimens shows that Xpert 
Ultra performs better than Xpert in an HIV­positive 
population. Whether Xpert Ultra can improve outcomes 
of tuberculous meningitis or lessen unnecessary exposure 
to tuberculous meningitis medications remain to be 
determined. In this prospective study, with real­time Xpert 
Ultra results available to the clinical team within 24 h, in­
hospital mortality was 40% (17 of 42 patients) compared 
with 50% (11 of 22) in our previous study on cryopreserved 
CSF in which results were not available to guide 
management decisions.7,8 We cannot say whether this 
observed reduction in mortality is attributable to the 
availability of real­time Xpert Ultra results because this 
study was not designed to study the effect of Xpert Ultra 
on clinical outcomes. Additionally, this study included 
two clinical sites (Mulago and Mbarara hospitals), whereas 
the previous study was done solely in Mbarara hospital. 
Furthermore, given the time between this study and 
the previous study, additional potential confounding 
factors might be present that contribute towards the 
mortality difference. In addition to access to improved 
point­of­care diagnostics, earlier presentation to hospital, 
better supportive care, and optimised antimicrobial and 
anti­inflammatory treatments are required to reduce the 
high case­fatality in this population. Larger structural 
factors, such as poverty and weak health systems, also 
continue to play a role in the high mortality of tuberculosis 
and HIV coinfection and need to be addressed. At present, 
regular use of empirical therapy continues to be required 
for tuberculous meningitis.
In conclusion, Xpert Ultra offers a substantial improve­
ment in rapid and accurate diagnosis of tuberculous 
meningitis, and is superior to Xpert. However, Xpert Ultra 
does not represent a perfect rule­out test. Clinical judgment 
and empirical therapy remain important to improve 
outcomes for patients with tuberculous meningitis. In this 
exciting era of rapidly evolving molecular diagnostics and 
biomarkers, the development of a highly sensitive point­of­
care test that can facilitate rapid treatment and give 
clinicians confidence in rationalising the use of empirical 
tuberculosis treatment is a realistic goal.
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6 Chapter Six: Standardized Urine-based Tuberculosis Screening 
with TB-LAM and Xpert MTB/Rif Ultra in Ugandan Adults with 
Advanced HIV disease and Meningitis (research paper) 
Foreword 
In chapter 4 and 5 I have shown that introduction of the Xpert MTB/Rif assay has had a marked impact on 
microbiological confirmation of TBM and that the Xpert Ultra assay is more sensitive than Xpert MTB/Rif when 
testing the CSF of patients with suspected TBM. However, CSF analysis is not without operational challenges 
including the following: 1) lumbar punctures (LPs) are not necessarily available in smaller hospitals in Uganda 
and other LMIC settings due to a lack of expertise and equipment; 2) LPs can be delayed whilst brain imaging 
is awaited; 3) LPs can be medically contraindicated due to space occupying lesions, thrombocytopaenia or 
coagulopathy; 4) LPs carry risks including nerve damage, bleeding, infection, and cerebellar herniation. A non-
CSF dependent diagnostic test that can support TBM treatment decisions would be incredibly valuable, 
especially if it also had value in prognostication.  
Urine-based TB diagnostics have the potential to reduce missed TB diagnoses and mortality in patients with 
advanced HIV disease and disseminated TB.1 Urine is an easily obtainable sample and can be tested using 
either a lateral flow assay for TB-lipoarabinomannan (Alere LAM) or Xpert Ultra. To date, urine LAM and Xpert 
Ultra have not been explored specifically in a suspected meningitis population and there are a number of 
questions of interest:  
1. Can urine TB diagnostics help to differentiate aetiologies of meningitis and support TBM treatment
decisions?
2. What’s the prevalence of disseminated TB detectable by urine testing in hospitalised patients with
suspected meningitis?
3. Does urine TB test positivity serve as prognostic tool in TBM?
I sought to explore some of these questions in a pilot study of adults presenting with suspected meningitis 
(including cryptococcal meningitis, TBM or meningitis of unknown cause) to Kiruddu National Referral 
Hospital and Mbarara Regional Referral Hospital. This research paper explores hypothesis #2: urine 
diagnostics such as urine TB-LAM and urine Xpert Ultra will be useful adjunctive tools in diagnosing TBM and 
will identify patients at the greatest risk of death.  
The key finding of this exploratory study was that there was evidence of disseminated TB by positive urine TB 
test (Alere LAM or Xpert Ultra) in a surprisingly high proportion of all meningitis cases: 22% (44/198) of 
cryptococcal meningitis, 50% (20/40) of definite TBM, 50% (11/22) probable TBM, 17% (15/88) of 
other/unknown cases. So, a positive urine Alere LAM or Ultra in isolation cannot reliably support TBM 
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treatment decisions, but might be more useful when considered alongside the cryptococcal antigen result. 
Given that urine Alere LAM and urine Xpert MTB/Rif are only moderately sensitive the true burden of 
disseminated TB disease could be even higher than that detectable by urine. The findings therefore suggest 
that TBM is commonly part of a disseminated TB disease picture, rather than a single compartment infection, 
in PLHIV and this may be relevant when considering optimising management, as further discussed in chapter 
10. In patients with definite TBM, urine Ultra may have prognostic value, though this needs to be further
investigated through a larger study with appropriate adjustment for CD4+ T-cell count and other baseline
factors.
The key results in this paper were presented in a poster at the Conference on Retroviruses and Opportunistic 
Infections in Boston, March 2020.  
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Background. Diagnosis of extrapulmonary tuberculosis (TB) remains challenging. We sought to determine the prevalence of 
disseminated TB by testing urine with TB-lipoarabinomannan (TB-LAM) lateral flow assay and Xpert MTB/RIF Ultra (Ultra) in 
hospitalized adults.
Methods. We prospectively enrolled human immunodeficiency virus (HIV)-positive adults with suspected meningitis 
in Uganda during 2018–2020. Participants underwent standardized urine-based TB screening. Urine (60 mcL) was tested with 
TB-LAM (Alere), and remaining urine was centrifuged with the cell pellet resuspended in 2 mL of urine for Xpert Ultra testing.
Results. We enrolled 348 HIV-positive inpatients with median CD4 of 37 cells/mcL (interquartile range, 13–102 cells/mcL). 
Overall, 26% (90 of 348; 95% confidence interval [CI], 21%–30%) had evidence of disseminated TB by either urine assay. Of 243 par-
ticipants with both urine TB-LAM and Ultra results, 20% (48 of 243) were TB-LAM-positive, 12% (29 of 243) were Ultra-positive, 
and 6% (14 of 243) were positive by both assays. In definite and probable TB meningitis, 37% (14 of 38) were TB-LAM-positive and 
41% (15 of 37) were Ultra-positive. In cryptococcal meningitis, 22% (40 of 183) were TB-LAM-positive and 4.4% (6 of 135) were 
Ultra-positive. Mortality trended higher in those with evidence of disseminated TB by either assay (odds ratio = 1.44; 95% CI, 
0.83–2.49; P = .19) and was 6-fold higher in those with definite TB meningitis who were urine Ultra-positive (odds ratio = 5.67; 95% 
CI, 1.13–28.5; P = .04).
Conclusions. In hospitalized Ugandans with advanced HIV disease and suspected meningitis, systematic screening with urine 
TB-LAM and Ultra found a high prevalence of urine TB test positivity (26%). In those with TB meningitis, urine tests were positive 
in over one third. There was little concordance between Ultra and TB-LAM, which warrants further investigation.
Keywords.  HIV; meningitis; TB-LAM; tuberculosis; Xpert MTB/RIF Ultra.
Tuberculosis (TB) is a major cause of death in people with 
human immunodeficiency virus (HIV). Human immuno-
deficiency virus-associated TB is often disseminated, de-
fined as having 2 or more noncontiguous sites resulting from 
lymphohematogenous dissemination of Mycobacterium tuber-
culosis [1, 2]. Postmortem studies have shown that >90% of 
cases involve multiple organ systems including spleen, liver, 
multiple lymph node groups, kidneys, or central nervous 
system [3]. Diagnosis of disseminated TB is taxing due to chal-
lenges in accessing clinical samples from the affected sites. In 
addition, in the context of HIV-associated meningitis, of which 
cryptococcal meningitis is the most common cause [4, 5], dis-
seminated TB may not be considered due to the considerable 
overlap in the clinical presentation of the 2 diseases: ie, fevers, 
night sweats, cough, and wasting. There are case reports and 
case series of cryptococcal meningitis coinfection with TB 
[6, 7], including TB meningitis [8], but no published studies 
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systematically screened for TB among HIV-positive adults pre-
senting with neurological infections. It is unknown to what 
extent undiagnosed disseminated TB infection contributes to 
the high mortality in HIV-infected patients with neurological 
infections.
Urine-based TB diagnostics have the potential to re-
duce missed TB diagnoses and reduce mortality in pa-
tients with advanced HIV disease. Urine is easily obtainable 
and can be tested using either a lateral flow assay (LFA) for 
TB-lipoarabinomannan (TB-LAM) or the Xpert MTB/RIF 
assay (Xpert; Cepheid, Sunnyvale, CA). Tuberculosis-LAM 
is emerging as the key urine-based TB diagnostic. Published 
data, including a 2016 Cochrane review, demonstrate that the 
first-generation Alere Determine TB-LAM Ag assay (TB-LAM; 
Alere, Waltham, MA) has a sensitivity of 40%–70% and a 
specificity of ≥98% in TB/HIV-coinfected patients with CD4 
counts <100 cells/μL [9–11]. The STAMP trial evaluated the use 
of the Alere Determine TB-LAM Ag assay and Xpert MTB/RIF 
among HIV-positive patients hospitalized in Malawi and South 
Africa [12] and demonstrated reduced all-cause 56-day mor-
tality with urine-based TB-LAM screening in certain high-risk 
subgroups of those with CD4 T-cell counts <100 cells/μL, se-
vere anemia (hemoglobin <8 g/dL), or clinically suspected TB. 
These findings corroborate those of an earlier study that found a 
4% (95% confidence interval [CI], 1%–7%) reduction in 8-week 
all-cause mortality in hospitalized HIV-positive adults with 
urine TB-LAM screening [13]. STAMP found that TB-LAM 
provided a 2-fold higher diagnostic yield than urine Xpert 
MTB/RIF. As a result, the World Health Organization (WHO) 
has recently updated their guidelines to support the expanded 
use of the Alere TB-LAM assay in all patients hospitalized with 
symptoms and signs of TB, CD4 count <200 cells/μL (irrespec-
tive of symptoms), or clinically advanced HIV disease, or who 
are seriously ill [14] .
Due to the limited sensitivity of urine Xpert MTB/RIF, urine 
screening with Xpert is not currently recommended by the 
WHO. In 2017, however, Cepheid introduced the re-engineered 
Xpert MTB/RIF Ultra (Ultra) with technical enhancements re-
sulting in 7-fold improved analytical sensitivity and addition of 
a “trace” category for the lowest bacillary load [15]. Two diag-
nostic accuracy studies of Ultra on cerebrospinal fluid (CSF) 
in HIV-positive Ugandan adults with suspected TB meningitis 
found Ultra to be significantly more sensitive than Xpert MTB/
RIF against a composite reference standard [16, 17]. However, 
publications on Xpert Ultra use in urine have thus far been lim-
ited, and include a case report [18] and a small number of sam-
ples in diagnostic accuracy studies of Ultra in extrapulmonary 
samples [19, 20], without evaluation as a screening tool. In 
a Ugandan study, the performance of urine Xpert Ultra in 
diagnosing pulmonary TB was assessed, and researchers 
found that Xpert Ultra had significantly higher sensitivity than 
TB-LAM, with 50% sensitivity in patients with CD4 <100 cells/
µL [21]. This study, which also included HIV-negative patients, 
used sputum-based diagnostics as the reference standard. The 
suboptimal sensitivity of urine diagnostics in pulmonary TB di-
agnosis is perhaps not surprising because sputum studies are 
often discordant with urine diagnostics if the TB has not dis-
seminated beyond the lungs, as may often be the case in HIV-
negative patients [22]. In our study, we sought to determine the 
prevalence of disseminated TB infection by testing urine with 
the Alere TB-LAM LFA and Xpert Ultra in HIV-positive adults 
presenting with suspected meningitis.
METHODS
Study Population
We conducted a prospective cohort study as part of screening 
for an observational meningitis diagnostic study and a TB 
meningitis randomized controlled trial (RifT trial: ISRCTN 
15668391). Consecutive HIV-infected adults presenting with 
suspected meningitis to Mulago National Referral Hospital, 
Kampala or Mbarara Regional Referral Hospital were screened 
for infectious meningitis etiologies using a stepwise diag-
nostic algorithm, as described elsewhere [23], after provision 
of written informed consent. Inclusion criteria for diagnostic 
testing were HIV-positive adults (≥18  years) presenting with 
suspected meningitis (eg, headache or altered mental status, 
clinical signs of meningism). From March 27, 2018 to February 
6, 2020, urine-based screening for TB was conducted using an 
Alere Determine TB-LAM LFA assay (TB-LAM; Alere) and 
Xpert Ultra (Cepheid). Urine TB testing was conducted for all 
patients within 48 hours of admission to hospital. Tuberculosis 
screening was performed irrespective of TB symptoms, past or 
current TB therapy, or CD4 T-cell count among consented par-
ticipants. Cryptococcal meningitis was diagnosed by positive 
CSF cryptococcal antigen (CrAg) LFA at the bedside and later 
confirmed by culture. Participants with suspected or confirmed 
TB meningitis were categorized according to the 2010 uni-
form case definition; with “definite TB meningitis” comprising 
those with microbiologically confirmed M tuberculosis in CSF 
and “probable TB meningitis” comprising those who score ≥10 
points (or ≥12 points if brain imaging is performed) on clinical, 
CSF, and imaging criteria but who are negative for TB on CSF 
testing [24]. Due to its low specificity in a high HIV-burden set-
ting “possible TB meningitis” was not included as a discrete di-
agnostic category.
Study Procedures
A suggested minimum of 30 mL of midstream, early morning 
urine was collected from participants able to provide a sample. 
In the laboratory, 60  μL of unconcentrated urine was tested 
with the TB-LAM according to the manufacturers’ instructions, 
and test samples were classified according to the reference card 
with grade 1 or above considered positive according to the 
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was measured using calibrated Falcon tubes, the volume was re-
corded, and the urine was processed for Ultra testing. The urine 
was concentrated by centrifugation at 3000 ×g for 15 minutes at 
room temperature. Surplus urine was decanted off leaving 2 mL 
in which the cell pellet was resuspended and loaded into the car-
tridge for Xpert Ultra testing. No buffer was used. Tuberculosis-
LAM and Xpert Ultra testing were performed simultaneously 
by a laboratory technologist blinded to the patient history, and 
the TB-LAM result was reported independently without aware-
ness of the Ultra result. Both results were reported in real-time 
to the clinical team.
Clinical management, including timing of commencement 
of anti-TB therapy and additional TB investigation, was at 
the discretion of the attending physician; wherever possible, 
anti-TB therapy was started as soon as possible for all patients 
with a positive TB-LAM and/or Xpert Ultra result, and addi-
tional work-up, including collection of additional clinical sam-
ples where possible for TB microbiology (Xpert Ultra and/or 
Mycobacteria Growth Inhibitor Tube [MGIT] culture; Becton 
Dickinson, Franklin Lakes, NJ), chest radiography, and abdom-
inal ultrasound, was performed where indicated and feasible.
Baseline demographics, clinical characteristics including an-
tiretroviral therapy (ART) use, and laboratory data were col-
lected as part of the screening process. Consented participants 
were followed up until hospital discharge or through >10 weeks 
if enrolled into a meningitis clinical trial.
Ethics
All participants (or a surrogate in cases of mental incapacity) pro-
vided written informed consent for urine testing, lumbar punc-
ture, CSF testing, CSF storage, and data collection. Approval for 
the studies was obtained from the Mulago Hospital Research 
Ethics Committee (MHREC1260 and MHREC1246), Uganda 
National Council for Science and Technology, University of 
Minnesota, and the London School of Hygiene and Tropical 
Medicine.
Statistical Analysis
Statistical analysis is primarily descriptive with the primary 
endpoint of interest being the prevalence of disseminated TB 
detected by urine testing. We compared baseline character-
istics across meningitis etiologies, with Kruskall-Wallis tests 
comparing continuous variables and χ 2 tests comparing catego-
rical variables. We compared the proportion of positive Urine 
TB-LAM results and the distribution of TB-LAM grade across 
meningitis etiologies using a χ 2 test. We compared congruency 
in positive TB-LAM versus Xpert Ultra tests by McNemar’s 
test, and we compared the distribution of urine Xpert Ultra 
semiquantitative grade across meningitis etiologies using a 
χ 2 test and Fisher’s exact test (as appropriate according to 
sample size). We tested the relationship between urine volume 
and a positive Xpert Ultra result using a χ 2 test with volume 
dichotomized at the median 24 mL (range, 4.5–45 mL). We re-
ported the proportion surviving hospitalization by each urine 
TB diagnostics result, and we compared test results and mor-
tality using univariable logistic regression. P values were not 
adjusted for multiple testing. All analyses were conducted using 
SAS (version 9.4; SAS Institute, Cary, NC).
RESULTS
Patient Demographics
We enrolled 348 HIV-positive hospitalized participants, 58% 
(201 of 348) of whom were men. The median age was 35 years 
(interquartile range [IQR], 29–42). The study participants had 
advanced HIV disease (median CD4 = 37 cells/μL; IQR, 13–102 
cells/mcL), despite 48% (167 of 347) reporting ART use at the 
time of presentation (implying virologic failure, suboptimal ad-
herence, or recent initiation). The majority of participants had 
cryptococcal meningitis (57%, 198 of 348); 18% (62 of 348) had 
definite or probable TB meningitis according to the uniform 
clinical case definition [24]. Cerebrospinal fluid features by 
meningitis etiology are shown in Table 1.
Diagnostic Yield of Urine Tuberculosis-Lipoarabinomannan and Ultra
Overall, 26% (90 of 348; 95% CI, 21%−30%) of the study parti-
cipants had evidence of disseminated TB by positive TB urine 
assay: 23% (75 of 327; 95% CI, 18%−27%) positive by urine 
TB-LAM, and 11% (29 of 264; 95% CI, 7%−15%) positive by 
urine Xpert Ultra. In cryptococcal patients, 22% (40 of 183) had 
evidence of disseminated TB by urine TB-LAM and 4.4% (6 of 
135) by urine Xpert Ultra. In definite TB meningitis patients,
37% (14 of 38) had a positive urine TB-LAM and 41% (15 of
37) had a positive urine Xpert Ultra. In probable TB meningitis
patients, 41% (9 of 22) had a positive urine TB-LAM and 21% (4 
of 19) had a positive on urine Xpert Ultra. In a composite of def-
inite and probable TB meningitis, 37% (23 of 62) had a positive
urine TB-LAM and 34% (19 of 56) had a positive Xpert Ultra
(Table 2 and Supplemental Figure 1). Among urine TB-LAM-
negative subjects, the number needed to test with Xpert Ultra to 
diagnose an additional case of disseminated TB was 13 persons
(95% CI, 8.0−22.9).
Concordance Between Tuberculosis-Lipoarabinomannan and Ultra
Overall, 243 participants had both urine TB-LAM and Xpert 
Ultra results available for paired analysis. Of 63 participants 
with a positive urine TB assay, 76% (48 of 63)  were positive 
by TB-LAM and 46% (29 of 63) were positive by Xpert Ultra 
(P = .01). Only 22% (14 of 63) of those with a positive urine TB 
test were positive by both TB-LAM and Ultra (Figure 1). The 
overlap of TB-LAM and Ultra was greater among those with 
definite TB meningitis. Of the 35 definite TB meningitis partici-
pants tested with both assays, 51% (18 of 35) had positive urine 
test, 34% (12 of 35) were urine TB-LAM positive, and 43% (15 
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Table 2. Urine TB Diagnostic Test Results by Disease Category
Urine TB Testing Details Cryptococcal Meningitis TBM (Confirmed) TBM (Probable) Unknown Othera P Valueb
N 198 40 22 88
Urine TB-LAM
Tested with TB-LAM, N 183 38 22 84
Urine TB-LAM positive, n (%) 40 (21.9%) 14 (36.8%) 9 (40.9%) 12 (14.3%) <.01
LAM Grade 1 25 (13.7%) 5 (13.2%) 4 (18.2%) 7 (8.3%)
LAM Grade 2 9 (4.9%) 0 (0.0%) 4 (18.2%) 4 (4.8%)
LAM Grade 3 5 (2.7%) 7 (18.4%) 1 (4.5%) 0 (0.0%)
LAM Grade 4 1 (0.5%) 2 (5.3%) 0 (0.0%) 1 (1.2%)
Urine Xpert Ultra
Tested with Xpert Ultra, N 135 37 19 73
Urine Xpert Ultra positive, n (%) 6 (4.4%) 15 (40.5%) 4 (21.1%) 4 (5.5%) <.001
Semiquantitative trace 1 (0.7%) 4 (10.8%) 1 (5.3%) 0 (0.0%)
Semiquantitative very low 1 (0.7%) 4 (10.8%) 0 (0.0%) 1 (1.4%)
  Semiquantitative low 2 (1.5%) 4 (10.8%) 3 (15.8%) 0 (0.0%)
Semiquantitative medium 0 (0.0%) 2 (5.4%) 0 (0.0%) 1 (1.4%)
  Grade unknown 2 (1.5%) 1 (2.7%) 0 (0.0%) 2 (2.7%)
Either TB Test Positive
TB-LAM and/or Xpert Ultra positive 44 (22%) 20 (50%) 11 (50%) 15 (17%) <.001
Abbreviations: TB, tuberculosis; TB-LAM, TB-lipoarabinomannan; TBM, tuberculous meningitis. 
aIncludes possible and nontuberculous meningitis diagnoses.
bP value assessed by χ 2 distribution of LAM positivity and Ultra positivity across disease groups.
Table 1. Participant Baseline Demographics, Clinical, and CSF Findings by Disease Category
Characteristics Cryptococcal Meningitis TBM (Confirmed) TBM (Probable) Unknown Othera
N 198 40 22 88
Age, years 35 [29–42] 32 [28–36] 38 [30–48] 37 [30–44]
Women 79 (40%) 17 (43%) 11 (50%) 40 (45%)
HIV Factors
CD4+ T cells/μL 23 [8–70] 72 [41–111] 55 [22–186] 205 [45–340]
Currently on ART 91 (46%) 17 (43%) 8 (38%) 51 (58%)
Months on ARTb 2.3 [0.6–29.4] 2.2 [0.7–27.9] 1.5 [0.5–11.3] 6.9 [1.6–73.9]
Clinical
Fever 77 (52%) 34 (97%) 20 (91%) 46 (68%)
Headache 190 (98%) 34 (94%) 15 (68%) 61 (76%)
Duration of headache 14 [7–21] 14 [8–21] 14 [7–21] 14 [7–30]
Focal neurologic deficit 7 (4%) 15 (38%) 8 (36%) 21 (24%)
Wasting 81 (42%) 23 (58%) 13 (59%) 35 (41%)
Glasgow come score <15 70 (35%) 36 (92%) 19 (86%) 45 (52%)
Seizure 41 (30%) 11 (38%) 4 (21%) 23 (38%)
Weight, kg 52 [45–60] 55 [45–58] 53 [50–60] 50 [50–59]
Cough 56 (39%) 25 (74%) 10 (53%) 39 (61%)
Night sweatsc 31 (25%) 22 (85%) 13 (72%) 24 (44%)
Baseline CSF Results
Opening pressure, cm H2O 23 [14–32] 19 [10–29] 15 [10–24] 18 [12–23]
Opening pressure <20 cm H2O 66 (38%) 16 (52%) 10 (67%) 40 (62%)
Total WBC count cells μL <5 [<5–50] 30 [<5–220] <5 [<5–200] <5 [<5–30]
Total WBC count <5 μL 117 (60%) 17 (45%) 11 (52%) 61 (71%)
CSF protein, mg/dL 69 [36–100] 128 [61–200] 88 [31–151] 68 [28–111]
CSF WBC <5 μL and protein <45 mg/dL 51 (28%) 5 (15%) 4 (20%) 26 (36%)
Abbreviations: ART, antiretroviral therapy; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; IQR, interquartile range; TBM, tuberculous meningitis; WBC, white blood cells. 
NOTE: Data are n (%) or median [IQR].
aIncludes possible and nontuberculous meningitis diagnoses.
bAmong those on ART at diagnosis.
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18 of positive tests). Overall, 17 persons with microbiologically 
confirmed TB meningitis had negative urinary tests (Figure 2).
Urine Diagnostics as a Predictor of In-Hospital Mortality
Among those who are known to have died in hospital, the me-
dian time to death was 7 days (IQR, 3–12 days). Among parti-
cipants with disseminated TB with either urine assay positive, 
the mortality was 33% (27 of 82), compared with 25% (59 of 
232) among those with negative urine assays (odds ratio = 1.44; 
95% CI, 0.83–2.49; P = .19). The mortality was also higher (al-
beit nonsignificantly) among participants with positive urine
TB-LAM (32% positive LAM vs 26% negative LAM, P = .32)
and among urine Xpert Ultra positive participants (36% vs 24%, 
P = .18). However, among those with definite TB meningitis,
there was 50% mortality (7 of 14) in those with positive urine
Xpert Ultra compared with 23% (3 of 20)  in those with neg-
ative urine Xpert Ultra (odds ratio = 5.67; 95% CI, 1.13–28.5;
P = .04). With either urine TB-LAM or Ultra positive, the odds 
of dying were 3-fold higher (odds ratio = 3.00; 95% CI, 0.71–
12.7; P = .14) in those with definite TB meningitis (Table 3).
Relationship Between Urine Volume and Ultra Positivity
Among patients with urine volume measured and recorded, 
13% (8 of 64) of patients with <24 mL tested positive by Ultra, 
and 9% (6 of 65)  of patients with ≥24  mL tested positive by 
Ultra (P = .55). The distribution of urine volume among those 
with definite TB meningitis was the same as the rest of the 
study population, thus larger centrifuged volumes did not yield 
a higher prevalence of detecting TB.
We tested for differences in the demographics, clinical, or 
laboratory parameters of patients who were positive by a single 
urine assay or both assays. We explored available laboratory 
parameters by urine test positivity, and there were no significant 
differences in baseline CD4 count, hemoglobin, or creatinine 
level in patients who had discordant results (Supplementary 
Table 1).
DISCUSSION
We have demonstrated that the prevalence of urine TB test 
positivity is 26% amongst HIV-infected patients presenting to 
hospital with suspected meningitis and advanced HIV disease 
in Uganda. The urine TB-LAM assay had more positive results 
(23%) than urine Xpert Ultra (11%), yet Xpert Ultra positivity 
was associated with higher risk of mortality (36% in-hospital 
mortality), particularly in those with TB meningitis (50% 
in-hospital mortality). Uganda has a high TB incidence rate 
(200 of 100 000 population in 2018); our findings may be gen-
eralizable to many other countries in sub-Saharan Africa with 
similar TB incidence rates [25].
Cryptococcosis and TB coinfection (including TB men-
ingitis) has been described in case reports, and in the 
Cryptococcal Optimal ART Timing (COAT) trial where  18% 
(32 of 177) of participants with cryptococcal meningitis were 
treated for concurrent active TB disease during the 46-week 
study period [26]. However, this is the first study in which dis-
seminated TB has been systematically screened for in an HIV-
associated meningitis cohort. Among the 198 cryptococcal 
meningitis patients, one quarter had a positive urine TB test, 
TB-LAM (22%) or Xpert Ultra (4.4%). The true prevalence of 
disseminated TB could be higher than this given that urine TB 
testing may not detect all forms of disseminated TB. Given the 
considerable overlap in symptoms between cryptococcal men-
ingitis and disseminated TB in advanced HIV disease, it is likely 
that without routine screening for TB, some of these diagnoses 
would be missed, and therefore they may contribute to the high 
mortality associated with cryptococcal meningitis. Consistent 
with other studies, in-hospital mortality was high in our cryp-
tococcal meningitis subgroup and trended towards there being 
34 14 15
Xpert Ultra
N = 180 negative
 by both assays
TB-LAM
Figure 1. Venn diagram of overlap between tuberculosis (TB)-positive urinary as-
says. Of 243 persons with both TB-lipoarabinomannan (TB-LAM) and urine Xpert 
Ultra results, 63 were positive by either TB urinary assay, 76% (48 of 63) of whom 
were positive by TB-LAM and 46% (29 of 63) by Xpert Ultra (P = .01). Only 22% (14 
of 63) of those with a positive urine TB test were positive by both TB-LAM and Ultra. 
Among the 195 persons with a negative TB-LAM, 15 (7.7%) were positive by Xpert 
Ultra, with a number needed to test with Ultra to diagnose an additional case of 





CSF Xpert Ultra positive
(Definite TBM)
TB-LAM
Figure 2. Venn diagram illustrating overlap of tuberculosis-lipoarabinomannan 
(TB-LAM) and urine Ultra among those with definite TB meningitis (TBM). Of 35 
persons with definite TBM tested with both assays, a total of 18 (51%) had positive 
urine test, 12 (34%) were urine TB-LAM positive, and 15 (43%) were urine Ultra 
positive with an overlap of 9 of 18 (50%) positive participants being positive by both 
assays. Overall, 49% (17 of 35) with definite TBM, diagnosed by positive CSF Xpert 
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persistent increased mortality in coprevalent disseminated TB 
infection despite clinical teams having real-time access to TB 
urine diagnostic results; however, this study was not designed 
nor powered to determine an impact of coprevalent TB on 
mortality.
We investigated the clinical utility of TB urine diagnostics in 
TB meningitis, a condition that is notoriously challenging to 
diagnose even with molecular CSF diagnostics. Overall, 50% 
(20 of 40; with both urine tests) of definite TB meningitis par-
ticipants had either a positive TB-LAM or urine Xpert Ultra. 
Among probable TB meningitis cases, patients with highly 
suggestive clinical features but in whom rapid CSF diagnostics 
(acid-fast bacilli [AFB] smear and CSF Xpert Ultra) were neg-
ative, 41% were urine TB-LAM positive and 21% urine Ultra 
positive. A lack of sensitive and timely diagnostics has histor-
ically made TB meningitis diagnoses extremely difficult, and 
therefore treatment for probable TB meningitis rests upon the 
presence of symptoms or signs indicative of meningitis, CSF 
features plus suggestive imaging criteria or confirmed evidence 
of extra-neural TB. The uniform case definition agreed by con-
sensus in 2010 does not include the TB-LAM assay as “evidence 
of extra-neural TB” [24], but our data suggest that this may 
be warranted. In this study a positive urine TB test was inter-
preted as evidence of extra-neural TB when assigning points in 
the uniform case definition. Urine TB diagnostics have the po-
tential to improve our classification of TB meningitis cases and 
warrant investigation in a larger study. Although not routinely 
used as part of a TB meningitis diagnostic work-up, urine is an 
easily obtained sample, and TB-LAM and Ultra are relatively 
low cost; therefore, we advocate their use as adjunctive tests in 
the investigation of patients with suspected TB meningitis.
Urine Xpert Ultra has previously been used to diagnose 
disseminated TB in a case report [18] and has been evalu-
ated as a marker of pulmonary TB in a cross-sectional study 
[21], but this is the first time that urine Xpert Ultra has been 
evaluated as a screening test for disseminated TB in a pro-
spective cohort and correlated with survival. Urine Xpert 
Ultra was positive in 11% of our (tested) cohort overall, 
demonstrating that urine is an additional viable clinical 
sample for use with Ultra. It is interesting to note that in pa-
tients with definite TB meningitis, Xpert Ultra and TB-LAM 
were positive in a similar proportion of patients (41% and 
37% respectively), whilst there were considerably more pos-
itive TB-LAM tests than Xpert Ultra tests in patients with 
cryptococcal meningitis  (22% and 4% respectively). Our 
data raise several questions about the MTB antigen load 
required for respective test positivity, the performance of 
urine Xpert Ultra at different degrees of immunosuppres-
sion, the impact of renal TB infection versus TB bacteremia 
on test performance, and the specificity of TB-LAM in pa-
tients with disseminated fungal diseases or other opportun-
istic infections [27].
In our subgroup analysis, in-hospital mortality was 6-fold 
higher  (50% vs 15%; odds ratio = 5.67; 95% CI, 1.13–28.5; P 
= .04) in patients with definite TB meningitis and a positive 
urine Xpert Ultra in comparison to patients with definite TB 
meningitis and a negative urine tests. These data suggest that 
urine Ultra testing may be a useful test to identify TB menin-
gitis patients with at particularly higher risk of death and thus 
requiring more intensive TB therapy or alternative or adjunc-
tive host-directed immunotherapy. Future research is needed to 
explore whether urine Ultra positivity and the increased mor-
tality relates to burden of MTB infection, host factors, or both.
Overall, there was little concordance between urine Xpert 
Ultra and TB-LAM positivity, only 22% of those positive by 
either test were positive by both assays. A similar observation 
was made in the STAMP trial, in which only 23% of patients 
had both urine TB-LAM and urine Xpert MTB/RIF posi-
tivity [12]. The reasons for this are unclear. We observed no 
statistically significant differences in the demographics, clin-
ical, or laboratory parameters of patients who were positive 
by a single urine assay or both assays, although our study was 
not powered to detect a clear association between these vari-
ables and urine assay positivity. We need to further investigate 
the lack of concordance between TB-LAM and urine Xpert 
Ultra and to explore whether this relates to the following: (1) 
Table 3. In-Hospital Mortality by Urine Diagnostic Result and Meningitis Aetiology by Univariate Logistic Regressiona
Study  
Population














Overall 32% (22 of 68) 26% (60 of 229) 1.35 (0.75–2.42) .32 36% (10 of 28) 24% (51 of 214) 1.78 (0.77–4.09) .18 1.44 (0.83–2.49) .19
Cryptococcal 32% (12 of 38) 27% (36 of 133) 1.24 (0.57–2.72) .59 50% (3 of 6) 23% (28 of 121) 3.32 (0.63–17.4) .16 1.41 (0.67–2.96) .37
TBM, definite 38% (5 of 13) 32% (7 of 22) 1.34 (0.32–5.61) .69 50% (7 of 14) 15% (3 of 20) 5.67 (1.13–28.5) .04 3.00 (0.71–12.7) .14
TBM, probable 50% (4 of 8) 38% (5 of 13) 1.60 (0.27–9.49) .60 0% (0 of 4) 50.0% (7 of 14)
Other/unknown 11.1% (1 of 9) 19.7% (12 of 61) 0.51 (0.06–4.48) .54 0% (0/4) 22% (13/59) 0.34 (0.04–2.84) .32
Abbreviations: CI, confidence interval; TB, tuberculosis; TB-LAM, TB-lipoarabinomannan; TBM, tuberculous meningitis.
aData represent mortality by TB test status. Hospital outcome was unknown for 34 participants (7.5% of cryptococcal, 7.5% TBM definite, 5% TBM probable, 17% unknown/other menin-
gitis). Among those who are known to have died in hospital, the median time to death was 7 days (interquartile range, 3–12 days).





/ofid/article-abstract/7/4/ofaa100/5811128 by guest on 05 M
ay 2020
125 
Advanced Human Immunodeficieny Virus Disease • ofid • 7
variation in the M tuberculosis burden required for test pos-
itivity; (2) interpatient differences in the renal parenchymal 
changes associated with renal TB or HIV-related nephropathy; 
or (3) differences in host immunity that may impact on the 
degree of immune complexing of circulating TB-LAM antigen 
and thereby its potential to cross the basement membrane 
[28]. Such a study could include immunological and renal 
parameters (such as proteinuria or urine-protein to creati-
nine ratio) to investigate whether the degree of immunodefi-
ciency or glomerular pathology may contribute towards the 
likelihood of excreting M tuberculosis bacilli or the TB-LAM 
glycolipid—the latter is only 17.5 kDa without immune com-
plexing but 150–1000  kDa when complexed with anti-LAM 
antibodies—into the urine.
One strength of our study is that we studied a large cohort of 
348 adults and this is the first time that urine TB diagnostics have 
been evaluated in a prospective manner among HIV-associated 
meningitis patients. However, we do recognize limitations to 
our study. Due to either suboptimal volume of urine sample 
or due to Ultra test availability, not all patients had TB-LAM 
and Xpert Ultra test results available for analysis. In instances in 
which urine volume was limited, TB-LAM testing was priori-
tized as per WHO guidelines, and overall more TB-LAM tests 
were conducted because bedside TB-LAM tests were consist-
ently more available than Ultra. To ensure a fair comparison of 
the diagnostic performance of TB-LAM and urine Xpert Ultra, 
the concordance and diagnostic yield of each test was only com-
pared in 243 participants who had both test results available. 
Second, due to the high rates of urinary incontinence in this 
critically ill population, not all participants managed to provide 
the suggested >30 mL of urine. Low urine volume may have im-
pacted the sensitivity of Ultra, although we did not detect a dif-
ference in TB test positivity in urine samples above and below 
the median 24-mL volume. Third, our study was exploratory 
and not powered to detect a clear association between TB-LAM 
and/or Xpert Ultra positivity and death. Although there was a 
trend towards worse outcomes in patients with evidence of dis-
seminated TB, our data herein provide estimates necessary for 
future sample size calculations. Finally, due to the study setting 
and population (critically ill meningitis patients), we were un-
able to perform an extensive array of other TB diagnostics tests 
such as imaging or sputum collection to corroborate the urine 
results. However, urine TB-LAM has a high specificity (≥98% 
in TB/HIV-coinfected patients), and although there is a lack of 
published data on the specificity of urine Ultra, Ultra has a high 
specificity when used on other clinical samples [11, 15]; there-
fore, in this study population with advanced HIV disease in a 
setting known to have a high prevalence of TB, we believe the 
risk of false-positive results is minimal. The duration of urine 
Xpert Ultra positivity after prior TB treatment is unknown, but 
given the continuous filtration of the kidneys and that urine 
is normally a sterile fluid, it is unlikely that nonviable bacilli 
would persist months or years after prior treatment, although 
further study of this point is warranted.
CONCLUSIONS
In conclusion, we have demonstrated a 26% prevalence of pos-
itive urine TB tests in patients presenting with HIV-associated 
meningitis. Our results support the expanded use of TB urine 
diagnostics in patients with meningitis to optimize timely diag-
nosis and treatment of TB, especially, but not only, in settings 
such as sub-Saharan Africa where TB infection prevalence is 
extremely high. Further studies are required to investigate 
whether disseminated TB is an independent risk factor for death 
in cryptococcal meningitis and whether enhanced TB treatment 
can improve outcomes. We have also shown that urine TB diag-
nostics are of use in TB meningitis; first as rapid, noninvasive 
adjunctive tests for suspected TB meningitis and second, pos-
sibly, as a prognostic tool in patients with HIV-associated TB 
meningitis. Further research is required to investigate the lack 
of concordance between urine TB-LAM and urine Xpert Ultra.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
Supplementary Table 1. Demographic, HIV, clinical, and laboratory fac-
tors by urine TB diagnostic result.
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7 Chapter Seven: Intensified Treatment of Tuberculous Meningitis 
(review paper) 
Foreword 
As detailed in the introduction (section 1.3) the optimal antibiotic therapy for TBM remains to be determined. 
TBM treatment recommendations are not evidence-based from PK-PD research in TBM patients, simply an 
extrapolation of trial data from pulmonary TB in the pre-HIV era. There is a drive to generate data specifically 
from TBM patients (including children and PLHIV) and investigate the impact of using intensified treatment, 
including higher doses of first-line TB drugs, additional of adjunctive antibiotics and different routes of 
administration.  
In order to immerse myself in the field I conducted a literature review and led the writing of a review paper, 
along with expert co-authors from Radboud University, Netherlands and Johns Hopkins University, USA who 
work in the field of intensified TB treatment trials and PK-PD research. The search strategy can be found in 
the Appendix 4. This research paper is in fulfilment of PhD objective 5: to review the literature relating to the 
rationale and best options for intensified antibiotic treatment of TBM and summarise findings in a review 
paper.  
The paper summarises the rationale for intensification of treatment, the properties of antituberculous drugs 
that might make them useful agents in the treatment of CNS TB and special populations including children, 
drug-resistant TB and PLHIV. There have been a number of clinical trials on intensified TBM treatment 
completed, and more underway or planned, which are also summarised in the review paper Table 3. 
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ABSTRACT
Introduction: Meningitis is the most severe manifestation of tuberculosis, resulting in death or disability
in over 50% of those affected, with even higher morbidity and mortality among patients with HIV or drug
resistance. Antimicrobial treatment of Tuberculous meningitis (TBM) is similar to treatment of pulmonary
tuberculosis, although some drugs show poor central nervous system penetration. Therefore, intensifica-
tion of antibiotic treatment may improve TBM treatment outcomes.
Areas covered: In this review, we address threemain areas: available data for old and new anti-tuberculous
agents; intensified treatment in specific patient groups like HIV co-infection, drug-resistance, and children;
and optimal research strategies.
Expert commentary: There is good evidence frompreclinical, clinical, andmodeling studies to support the
use of high-dose rifampicin in TBM, likely to be at least 30 mg/kg. Higher dose isoniazid could be beneficial,
especially in rapid acetylators. The role of other first and second line drugs is unclear, but observational data
suggest that linezolid, which has good brain penetration, may be beneficial. We advocate the use of
molecular pharmacological approaches, physiologically based pharmacokinetic modeling and pharmaco-
kinetic-pharmacodynamic studies to define optimal regimens to be tested in clinical trials. Exciting data
from recent studies hold promise for improved regimens and better clinical outcomes in future.
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1.1. Brief epidemiology of tuberculous meningitis
Tuberculosis (TB) is the leading infectious disease killer worldwide.
Tuberculous meningitis (TBM), its most dramatic manifestation,
makes up 1–2%of all TB cases in settingswhere theHIV prevalence
is low [1,2]. However, in settings where HIV is common, dissemi-
nated TB and TBMmake up amuch greater proportion of TB cases
[3]. A meta-analysis of post-mortem studies in low-resource set-
tings showed evidence of active TB in 43% of deceased HIV-
infected individuals, and one study noted meningeal involvement
in 28% of those with disseminated TB [4,5]. It is therefore not
surprising that TB is the second leading cause of adult meningitis
in many countries with high HIV prevalence [6,7]. TBM tends to
strike those at the extremes of age. It is particularly common in
young children under 5 years of age [8–10], and often the leading
cause of childhood bacterial meningitis in TB-endemic areas [11].
1.2. Pathogenesis and presentation of tuberculous
meningitis
Much remains unclear about the pathogenesis of TBM, but old
histopathological studies suggest that pulmonary infection is
followed by hematogenous dissemination of bacilli, including
the meninges covering the brain, forming so-called ‘Rich foci’
[12]. Months to years later, disease may reactivate; Rich foci
rupture into the subarachnoid space with the dissemination of
bacilli into the cerebrospinal fluid (CSF) and development of
basal meningitis [13]. In children, the meningitis usually occurs
as part of disseminated primary disease rather than a later re-
activation, and the same may be true of HIV-infected adults
where host-defense mechanisms are diminished [3]. A basal
meningitis results in formation of a dense exudate on the brain-
stem, which can envelop cerebral arteries and cranial nerves and
obstruct the flow of CSF. Entrapment of cranial nerves by the
exudate can lead to ophthalmoplegia or other cranial nerve
palsies, while obstruction of the CSF flow can lead to hydroce-
phalus. As themost severe consequence, the exudate can lead to
vasculitis of blood vessels of the circle of Willis, the vertebroba-
silar system, and the perforating branches of the middle cerebral
artery, resulting in brain infarctions. To dampen this immuno-
pathology, standard treatment now includes the use of adjuvant
corticosteroids [14,15].
TBM presents initially as subacute meningitis, with an insi-
dious onset of low-grade fever, malaise, weight loss, and
CONTACT Reinout van Crevel reinout.vancrevel@radboudumc.nl Department of Internal Medicine, Radboud University Medical Center, PO Box 9101, 6500
HB, Nijmegen, The Netherlands
Supplemental data for this article can be accessed here.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
https://doi.org/10.1080/17512433.2019.1552831
© 2018 Informa UK Limited, trading as Taylor & Francis Group
132 
gradually worsening headache, followed by confusion, develop-
ment of focal neurological symptoms like eye movement disor-
ders or limb paralysis and progressive coma. In small children,
early symptoms are non-specific including cough, fever, failure to
thrive, irritability or apathy, followed by loss of consciousness,
and focal neurological signs [16]. Recognition and diagnosis of
TBM remain a huge challenge. In the absence of a widely avail-
able, rapid, and reliable diagnostic test for extrapulmonary man-
ifestations of TB, clinicians face a management challenge in
deciding when anti-tuberculous therapy should be offered.
1.3. Prognosis of tuberculous meningitis
It is widely recognized that TBM is the most severe form of TB –
death and severe neurological sequelae are common. Reported
outcomes vary drastically by geographical region, prevalence of
HIV co-infection, drug resistance patterns, and time period. We
reviewed tuberculous meningitis studies published up to
6 June 2018, to examine the risk of death, and neurological seque-
lae amongst survivors. Full search strategy and search terms are
shown in the supplementary material. After manual screening of
abstracts, we included 84 studies; 12 included all ages, 35 included
adults only, and 37 included children only. We present data from
both retrospective and prospective studies which commenced
enrolment within the past 30 years (from 1988 onwards) and
which enrolled at least 100 participants (n = 28; 4 all ages, 16
adults, 8 children) plus two additional smaller studies which add
to limited evidence within a drug-resistant population in Table 1.
For adults with TBM, risk of death ranged from 7% to 50%
[35,36] for in-hospital mortality, up to 58% [37] at five years’
follow-up. Amongst survivors, risk of neurological sequelae ran-
ged from 14% to 45% [35,38]. Amongst studies including only
HIV-infected adults, mortality was 41–58% [37,39]. The majority
of studies were performed in Asia, with evidence from East and
West Africa notably lacking. A study in Uganda [40] examined
a TBM population with 96% HIV prevalence and reported 44%
in-hospital mortality. Seven studies recruited patients with
drug-resistant TB; those with isoniazid monoresistance demon-
strated a mortality of 31–56% [41,42] whereas those with rifam-
picin resistance or multi-drug resistant TB had a mortality of up
to 95% [42].
With regard to pediatric TBM, eight studies recruited exclu-
sively children; those up to October 2012 are more compre-
hensively reviewed in a meta-analysis from Chiang et al. [43],
who reported a risk of death of 19% (95% CI 14.0–26.1) and
a risk of neurological sequelae among survivors of 54% (95%
CI 42.6–64.9) amongst 1636 children studied. Within our
included studies, risk of death ranged from 8% to 29%
[44,45] for in-hospital mortality (excluding a small case series
of patients with MDR-TB [46]), and up to 34% overall [44].
Amongst survivors, risk of severe disability was up to 40%
[47], and all-severity disability up to 88% [48].
1.4. Towards better treatment of tuberculous meningitis:
outline of this review
Development of better treatments is a priority in light of the high
mortality and neurological disability associated with TBM.
Prompt diagnosis and effective antimicrobial treatment are
critical to limit bacillary multiplication and associated immuno-
pathology in the central nervous system (CNS). Host-directed
therapies targeting immunopathology are an important area of
research but outside of the scope of this review [49].
In this review, we focus on intensified antibiotic treatment
of TBM. First, we discuss the rationale and options for intensi-
fication of antibiotic treatment as well as available data for key
anti-tuberculous agents. Secondly, we address the relevance
and considerations of intensified treatment in HIV co-infection,
drug-resistant TBM, and pediatric populations. Thereafter, we
explore ways to accelerate understanding in this field through
the application of state-of-the-art and intelligent research
tools. We conclude by highlighting knowledge gaps and iden-
tifying key areas for future research.
2. The concept of intensified antibiotic treatment
2.1. The challenge of treating tuberculous meningitis
TBM is more challenging to treat than pulmonary TB (PTB) for
a number of reasons. Most importantly, in contrast to antibio-
tics used to treat PTB, antimicrobials for CNS TB must cross the
blood-brain barrier (BBB), and blood-cerebrospinal fluid barrier
(BCSFB), and remain in the brain or CSF and be present at the
site of infection at sufficient concentrations for a sufficient per-
iod of time to kill the TB bacilli (Figure 1) [50–54]. The BBB and
the BCSFB separate the extracellular CNS fluid compartment,
the interstitial fluid and the CSF from the blood compartment,
and transporters, like P-glycoprotein, in endothelial cells actively
pump substances out of the brain and into the blood or CSF,
thereby protecting the CNS from the free entry of potentially
neurotoxic substances [55,56]. Despite the presence of these
barriers designed to keep foreign materials such as xenobiotics
out, resulting in some first-line TB drugs, especially rifampicin
and ethambutol, penetrating the BBB and BCSFB poorly,
national and international guidelines for antimicrobial treat-
ment for TBM follow the model for PTB, with a 2-month inten-
sive phase followed by a continuation phases of treatment,
using the same first-line TB drugs and identical dosing, just
prolonged for 9–12 months duration [57–59] The World
Health Organisation guidelines suggest replacing ethambutol
with streptomycin but this has not been widely adopted and
there is little evidence to warrant this [60].
There are at least three other reasons that TBM treatment is
difficult. First, the anatomical distribution and quantity of
bacilli and their metabolic state (and, thus, likelihood of
being killed by anti-tuberculous drugs given their particular
mechanisms of action) – and the changes in these factors over
time with treatment – are poorly characterized in TBM, making
it difficult to develop a new treatment model specific for TBM.
Further, the integrity of the BBB and BCSFB related to infection
and inflammation, as well as blood supply to the compart-
ments where Mycobacterium tuberculosis resides, are likely to
change significantly over the course of treatment as antibio-
tics and anti-inflammatory medications are given. This may
affect the penetration of antibiotics to their site of action.
Lastly, it is not clear how mechanisms of bacterial killing
(protein synthesis inhibition, disruption of cell wall synthesis,
bacterial enzyme inhibition) influence host inflammatory
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responses and, in turn, vasculitis, strokes, and risk of death.
Host, bacterial, and treatment effects are thus intertwined and
must be taken into account when investigating optimal treat-
ments for TBM.
2.2. Strategies to optimize TBM treatment
In the absence of basic information on the interaction of host,
bacteria and treatment effects, there may be different strategies
to optimize TBM treatment. One strategy might be prolonging
treatment, as is often advocated. However, in one meta-analysis
evaluating treatment duration, the risk of relapse was extremely
low (~0.8%) and virtually identical in patients who got
<6 months versus >6 months of therapy, suggesting that
there is no evidence base to support longer treatment as
a means to improve response to TBM treatment [61].
Amore promising strategy is to increase drug exposures in the
CNS. This may be achieved by increasing doses of poorly pene-
trating drugs, adding, or replacing drugs with anti-tuberculous
agents that have better BBB and BCSFB penetration characteris-
tics [62], modification of physicochemical properties of TB drugs,
intracerebral injection, olfactory route delivery, tight-junction
modulation (e.g. by osmotic opening, liposome or nanoparticle-
mediated permeation) and, finally, inhibition of efflux mechan-
isms that pump drugs out of the brain [55,63–65]. Considering
the limited availability of some of these interventions in general
and particularly in settings where TB is most common, increasing
doses of poorly penetrating drugs and the use of agents with
improved penetration may form the most obvious way to inten-
sify and improve TBM treatment.
To find the optimal dose of drugs for TBM, whether they
penetrate poorly or relatively well across barriers, robust
information on the relationship between doses and expo-
sures achieved (pharmacokinetics, PK) and between expo-
sures and efficacy or safety (pharmacodynamics, PD) is
indispensable. Ideally, the ‘right’ dose results in maximum
efficacy, with limited adverse effects (Figure 2). Dose-
response or preferably exposure-response evaluations are
part of the drug development process. However, historically,
for most TB drugs currently in use (Table 2), far less attention
has been paid to establishing the relationship between drug
concentrations and responses for optimal dose-finding.
Furthermore, there has been little interest in exploring PK-
PD differences among TB disease-type subsets, such as
patients suffering from TBM or TBM-HIV coinfection. The
paradigm that inadequate exposure results in suboptimal
clinical response is nevertheless generally accepted for TB
drugs and has been described in multiple studies [66–72].
Nonetheless, such a relationship could not always be identi-
fied [73–75], and for most TB drugs dose-response curves
such as presented in Figure 2 are lacking, especially with
sterilizing effect as a clinical endpoint. The search for the
‘right’ high-dose of rifampicin is an illustrative example of
how a better understanding of TB drug PK and PD could be
used to improve treatment regimens.
Figure 1. Schematic overview of the relation between the blood-brain barrier (BBB), made up by brain endothelial cells, and the blood-CSF barrier (BCSFB), made up
by choroid plexus epithelial cells. The ependymal lining of the cerebral ventricles forms the barrier between brain (and its interstitial fluid, ISF) and CSF. According to
this simplified paradigm, there is free exchange of drug between the brain ISF and CSF, and CSF drug concentrations approximate the free drug concentration in
plasma that is able to penetrate the BBB, BCSFB, or both. Displayed efflux transporters may actively disturb this equilibrium, by actively transporting drugs into the
blood or CSF.
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2.3. Rifampicin
Rifampicin is an essential component of TBM treatment.
Rifampicin-resistant TBM is 69–100% fatal [41,76–78]. Up to
now, no agents have been identified that can replace it for
treatment of TBM. However, rifampicin has poor CSF penetra-
tion, and at current treatment doses, CSF concentrations of
rifampicin barely exceed the minimal inhibitory concentration
(MIC) against M. tuberculosis [79]. When interpreting rifampicin
CSF concentration data, it is important to keep in mind that
rifampicin in highly protein bound and that only the unbound
or ‘free’ rifampicin is biologically active. In the absence of
meningeal inflammation, only the ‘free’ rifampicin crosses
the BCSFB. Therefore, the difference of total rifampicin con-
centrations between plasma and CSF is usually much bigger
than the difference between ‘free’ or active rifampicin concen-
trations, and the CSF: plasma ratio of total rifampicin will
underestimate penetration of unbound (active) rifampicin.
As to the PD of rifampicin, it has been shown that the
efficacy of this drug is exposure or concentration dependent,
which means that it correlates with exposure to the drug (area
under the concentration – time curve, AUC0-24h) and/or its
peak concentration (Cmax) [80]. An increase in rifampicin
dose will increase the AUC0-24h and Cmax in plasma and at
the sites of action in supra-proportional fashion (owing to
saturable hepatic clearance), and this is hoped to enhance
activity against M. tuberculosis.
In search of higher yet safe doses of the cornerstone TB drug
rifampicin, several studies have been performed. Studies using
an in vitro pharmacodynamics system (IVPDS) or ‘hollow fiber
model’ and studies in mousemodels have suggested that higher
doses of rifampicin are associated with better results and shorter
treatments in PTB [80–82]. Until 2011, 14 clinical trials had eval-
uated high-dose rifampicin [83]. Before 1985, 13 of these trials
were published. These trials evaluated regimens with doses of
rifampicin up to 1200 mg (20 mg/kg) and different dosing inter-
vals (once, twice, thrice, six times per week, and daily). Several
trials suggested an advantage in terms of likelihood of culture
conversion among patients with PTB receiving at least 900 mg of
rifampicin. Hepatotoxicity was rarely observed, and no trend in
the occurrence of hepatotoxicity with the rifampicin dose was
evident. However, attempts to use high dose rifampicin (900 mg
or 15 mg/kg and more) intermittently rather than daily were met
with a high incidence of flu-like syndrome, an allergic reaction
which is ascribed to the intermittency of dosing rather than the
height of the dose. Therefore, high dose rifampicin should be
administered on a daily basis [83,84].
More recently, several trials have evaluated the high dose
rifampicin as a strategy for treatment shortening for pulmon-
ary TB. Increasing doses of rifampicin up to 40 mg/kg daily
were associated with a nine-fold increase in total exposure to
rifampicin in plasma compared to the standard 10 mg/kg dose
and were safe and tolerable over two weeks [85,86]. From the
same data, a significant exposure–response relationship could
be derived between rifampicin exposure and early bactericidal
activity [72]. In another recent clinical trial, a higher daily
rifampicin dose of 35 mg/kg administered over a longer per-
iod of 12 weeks together with standard doses of isoniazid,
pyrazinamide, and ethambutol decreased the time to culture
conversion compared to standard treatment [87]. PK-PD ana-
lysis revealed that higher exposures to rifampicin were the
intermediary link to the decreased time to culture conversion
and showed that this effect of rifampicin did not plateau at
the 35 mg/kg dose [88]. Higher doses of rifampicin up to
20 mg/kg have also been studied and were safe and tolerable
for other diseases such as brucellosis [89], leishmaniasis [90],
and other indications [91].
Along with the studies on PTB, high dose rifampicin has also
been evaluated as a strategy to reducemortality in TBM. Alvarez–
Uria administered 900 mg (~20 mg/kg) of oral rifampicin for
a median of 7 days to adults with TBM in India; no safety issues
were reported in this setting [92]. In the first in a series, in an
open-label, randomised phase II clinical trial in Indonesia, a 33%
higher dose of rifampicin administered intravenously (600 mg or
13mg/kg iv) for 2 weeks resulted in a three-fold higher exposure
to rifampicin in plasma and CSF during the first critical days of
treatment than 450 mg given orally. In this small study, 6-month
mortality was reduced by greater than 50% [79]. A clear concen-
tration–effect relationship could be identified, with the ‘effect’
being survival at 8-weeks (Figure 2) and threshold values asso-
ciated with decreased mortality could be derived through PK-PD
modeling, even though data suggested that the exposures that
maximized efficacy had not been reached yet [93]. Since
Figure 2. Concentration-response curves displaying the effect of rifampicin plasma AUC0-6h (left) and Cmax (right) exposure on survival, and the corresponding
exposure threshold values associated with maximal survival. Te Brake et al. aimed to deduce concentration thresholds predictive of good treatment response in TBM.
For this classes of 20 mg.h/L for AUC0-6h and 5 mg/L for Cmax were constructed (and included a minimum of three participants in each class), the percentage survival
within each class was calculated. Eight-week survival was used as the response parameter. Concentration-response curves were generated by non-linear regression
fitting.
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intravenous rifampicin is not widely available and must be admi-
nistered in a hospital setting, a follow-up pharmacokinetic study
evaluated doses of 17 or 20 mg/kg of oral rifampicin, which
resulted in total exposures in plasma approximately similar to
the values after 13 mg/kg iv, but average peak plasma and CSF
concentrations were lower with large interindividual variability
[94]. In literature, reported rifampicin MICs for susceptible strains
ranged from 0.06 to 0.4 mg/L [95,96]. CSF concentrations after 17
or 20 mg/kg oral rifampicin ranged from 0.125 to 1.06 mg/L [94]
and can, therefore, be considered to have reached MIC, but not
by much.
In a third phase II trial, this time double-blinded, randomized,
and placebo-controlled, 60 adult TBM patients were assigned to
10, 20, or 30 mg/kg oral rifampicin combined with standard
companion TB drugs for 30 days. The double and triple dose of
oral rifampicin led to three and five-fold higher total exposures in
plasma in the critical early days of treatment with proportional
increases in highest recorded CSF concentrations and without an
increase in the incidence of grade 3/4 adverse events. Six-month
mortality was 7/20 (35%), 9/20 (45%), and 3/20 (15%) in the 10,
20, and 30mg/kg groups, respectively (p = 0 · 12) [97]. In contrast
to the Indonesian studies, a large trial involving 817 TBMpatients
in Vietnam evaluating to an intensified regimen with 15 (rather
than 10) mg/kg of rifampicin plus levofloxacin versus standard of
care for 8 weeks did not demonstrate a survival benefit for higher
doses of rifampicin [98], except for patients with isoniazid-
monoresistant TBM [41]. It was postulated that the lack of effect
in this study can be explained by the relatively modest dose
increase of rifampicin [99].
Thus, the preponderance of the evidence points to
a treatment benefit with higher doses of rifampicin, but this
benefit is likely only to be seen with significant dose increases.
Additionally, rifampicin has been shown in vitro to have a variety
of anti-inflammatory effects – inhibiting the production of lipo-
polysaccharide-induced pro-inflammatory mediators including
nitric oxide, cyclooxygenase-2, tumor necrosis factor-α, and inter-
leukin-1β and prostaglandin E₂ [100], as well as reducing micro-
glial activation. Whether such anti-inflammatory benefits are
dose-related requires further research.
With regards to other rifamycin antibiotics, rifabutin has
been effective in rabbit pneumococcal meningitis, but neither
it nor the other licensed rifamycin – rifapentine – have been
tested in clinical TBM [101].
2.4. Other first-line drugs (isoniazid, pyrazinamide,
and ethambutol)
Isoniazid has high early bactericidal activity that kills actively
growing bacteria within the first 24 h and causes substantial
decreases in culturable sputum bacilli in PTB over the first
2 weeks of treatment [102]. Isoniazid has excellent CSF penetra-
tion [92,93,103–105]. It is a valuable component of TBM treat-
ment, as evidenced by a two-fold higher risk of death in
isoniazid-monoresistant compared to drug-susceptible TBM
[42,76]. Adding a second bactericidal agent (like levofloxacin)
does not appear to confer a survival benefit unless the patient
is infected with an isoniazid-resistant strain [98]. Isoniazid is
metabolized by the genetically polymorphic N-acetyltransferase
2 (NAT2). This enzyme exhibits two main phenotypes of activity:
fast and slow. This acetylator status has been linked to both
treatment outcome and hepatotoxicity in PTB. In TBM, exposures
to isoniazid in plasma and CSF were found to be higher among
slow acetylators [106]. Increasing the dose of isoniazid, e.g., to
10–15 mg/kg daily as in treatment for multi-drug resistant TB,
may be an option for intensified treatment of TBM, though this
remains to be proven.
Pyrazinamide also penetrates well into CSF [107] according
to unpublished data from the Ruslami [79] and Yunivita [93,94]
Indonesian studies. The drug only displays limited early bacter-
icidal activity in drug-sensitive PTB (first 2–4 days of therapy),
which is considered the most critical period in TBM treatment
[108,109]. Activity thereafter (days 4–14) seems comparable
with rifampicin and isoniazid [108,109]. In observational studies,
pyrazinamide appeared to reduce the risk of death and neuro-
logic sequelae in children with TBM allowing shortening of TBM
treatment to 6 months [110]. However, while some pyrazina-
mide appears to be good, more is not necessarily better, at
least in selected patient populations. In one study involving
patients with HIV infection (median CD4 count of 41 cells/
mm3), high pyrazinamide exposures in CSF were independently
associated with increased risk of death and neurotoxicity, even
after adjusting for BBB integrity [37,111]
The main function of ethambutol is to protect companion
drugs against emergence of resistance, but ethambutol has poor
CSF penetration, even early in treatment [104,107,112,113].
Considering this probably limited contribution, debate has arisen
regarding the choice of a fourth drug in treatment of drug-
sensitive TBM. But efforts to replace ethambutol, or add-on
a drug to the first-line regimen have been ineffective so far
[79,114] Thus, isoniazid and rifampicin are essential drugs for
drug-sensitive TBM, pyrazinamide is helpful, there is not a clear
role for ethambutol.
2.5. Second-line drugs: fluoroquinolones
Fluoroquinolones have excellent CSF penetration [115,116],
and high activity against drug-susceptible bacteria as well as
many drug-resistant bacteria. Analysis of fluoroquinolone
exposure versus response revealed worse outcomes among
TBM patients with lower and higher plasma and CSF expo-
sures than for patients with intermediate exposures (U-shaped
exposure-response) [117].
In a phase II trial with factorial design, TBM patients were
randomized to a higher intravenous dose of rifampicin and
subsequently to a standard dose of moxifloxacin, a double
dose of moxifloxacin or no moxifloxacin [79]. Use of moxiflox-
acin was not associated with a survival benefit in this trial. The
higher dose of moxifloxacin was used considering that higher
exposures to moxifloxacin may be more effective in TB treat-
ment based on studies in vitro and in mice, and rifampicin
decreases the exposure to moxifloxacin by approximately 30%
[118]. Similarly, in a large trial of intensified anti-tuberculous
therapy in Vietnam, levofloxacin failed to improve survival
unless the disease was caused by bacteria resistant to isonia-
zid [41,98]. A meta-analysis of the use of fluoroquinolones in
the management of TBM used data from 1115 patients and
concluded that fluoroquinolones cannot be recommended at
present, though the evidence was of moderate to low quality
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[119]. In light of two RCTs that have failed to show a benefit of
quinolones in combination with current first-line anti-
tuberculous agents [98,120], further trials of quinolones are
only likely to be warranted in combination with novel agents.
2.6 Second-line and repurposed drugs: aminoglycosides,
cycloserine, ethionamide, clofazimine, and linezolid
Streptomycin distribution into brain and CSF is limited [107],
and while its use in the 1940s decreased mortality from 90%
to 40–80%, this was only with long, complicated, painful
treatment with repeated intrathecal injections over months
[121], and its contribution to improving outcomes once multi-
drug regimens were available was small and only seen with
intrathecal administration [115,122]. The same constraints
apply to amikacin and kanamycin, with limited entry to CSF
described in adult and pediatric studies [103,107].
Cycloserine and ethionamide achieve high concentrations
in CSF, and the latter has been used successfully as
a replacement for ethambutol to enhance TBM regimens in
children [92,123,124]. Both can cause CNS adverse effects
including psychiatric disturbances and there are dose-
limiting gastrointestinal toxicities for ethionamide.
Ethionamide can be changed for the chemically similar
prothionamide, and cycloserine for terizidone (containing
two molecules of cycloserine) can be used interchangeably
in PTB, although there is limited evidence in TBM. Clofazimine
does not penetrate CSF well but in a single mouse study
showed widespread brain tissue distribution [125,126].
Studies in rats suggest that para-aminosalicylic acid can cross
the BBB and BCSF barriers [127], in humans the CSF concen-
trations of PAS are low, even in the presence of meningi-
tis [107].
Linezolid is an approved predominantly bacteriostatic drug,
which has shown efficacy against multidrug-resistant (MDR) and
extensively drug resistant (XDR) TB [128–130], Two recent
reviews support linezolid’s efficacy for treating pulmonary MDR
or XDR TB, though the optimal dosing that maximizes efficacy
while minimizing risk of toxicities (bone marrow suppression
and peripheral neuropathy) is not firmly established [128–130].
Janssen and the TB Alliance’s Nix-TB trial investigated a shorter,
all-oral three-drug regimen for XDR-TB, consisting of bedaqui-
line, pretomanid and linezolid (600 mg BID, later changed to
1200 mg QD) for six months [131,132]. Dose reduction or inter-
ruption due to myelosuppression or neuropathy occurred only
after a treatment period of 2–3 months and 4–6 months, respec-
tively, supporting a short-term linezolid intervention in TBM.
Linezolid seems successful in reaching the CSF, with CSF/
serum concentration ratios varying from 0.7 to 1.0 in studies
among patients with CNS infections without TB [133–135]. The
impressive efficacy of linezolid in the management of critically
ill patients with non-TB CNS infections (e.g. penicillin-
nonsusceptible Streptococcus pneumoniae, vancomycin-
resistant enterococci, methicillin-resistant Staphylococcus aur-
eus) was reviewed by Ntziora et al. [136].
Only two studies have evaluated the effect of linezolid in
patients with TBM, both in China [137]. In a non-randomized
study among adults with severe TBM, 16 patients received
adjunctive linezolid (600 mg BID, median duration 32 days)
[138]. Compared to the control group, patients showed better
improvement in Glasgow Coma Scale, temperature recovery,
and normalisation of CSF parameters, and safety was accep-
table. No pharmacokinetic data were collected. Secondly, in
a small retrospective cohort, children without clinical improve-
ment after two weeks of standard treatment were given line-
zolid while other children continued on standard treatment
only, the addition of linezolid was associated with improved
clinical outcome, shortened fever clearance time, and reduced
hospital stay. These results suggest that linezolid may be an
effective additional drug for treatment of TBM, which is safe
when given for a short duration (<4 weeks) [138].
2.7. New drugs: bedaquiline, delamanid,
and pretomanid
Bedaquiline appears to have poor penetration into CSF,
though data are limited, and binding to tubing make drug
measurement following lumbar puncture challenging [139].
Delamanid achieves CNS concentrations that are several-fold
higher in brain than in plasma in rats [140], but there are no
clinical data. Mass spectrometry imaging of rats following
intraperitoneal administration of pretomanid demonstrated
distribution of pretomanid to certain areas of the brain in
uninfected animals [141]; brain or CSF distribution in infected
animals or humans has not been assessed.
Thus, the second-line or new drugs with the highest like-
lihood of providing meaningful benefit include the following:
cycloserine or ethionamide (though these drugs carry high-risk
of toxicity), linezolid (optimal dosing to be determined), and
possibly the nitroimidazoles (e.g. delamanid or pretomanid). It
is hoped that new compounds in the TB drug development
pipeline (https://www.newtbdrugs.org) will have characteris-
tics associated with high probability of achieving effective
concentrations in the brain and CSF, for example, high CNS
multiparameter optimization desirability scores [62,142].
3. Intensified treatment for specific populations
3.1. HIV co-infection
Mortality from TBM is 2 to 3-fold higher in HIV co-infected
individuals. Mortality depends on stage of disease at presenta-
tion and is modified by HIV infection, with estimates of death
in HIV-uninfected adults of 15%, 30%, and 50% and HIV-
infected adults of 25%, 50%, and 80%, for Medical Research
Council stage I, II, or III disease, respectively [143,144].
Antiretroviral therapy (ART) naïve patients who present with
TBM are at high risk of severe adverse events, most likely due
to immune reconstitution inflammatory syndrome (IRIS), if
they initiate ART immediately [37], yet delayed ART initiation
puts them at risk of opportunistic infections and other com-
plications of AIDS. There are two reasons why intensified
antibiotic therapy might be especially relevant for HIV-
infected TBM patients.
Firstly, a number of studies have reported that HIV-positive
patients achieve lower plasma concentrations of the orally
administered first-line anti-tuberculous drugs than their HIV-
negative counterparts, particularly those with more advanced
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HIV [145–147]. Possible explanations relate to HIV enteropa-
thy, diarrhea, and wasting (latter leading to under-dosing
using current weight-based algorithms) [145,146,148,149].
A recent meta-analysis of rifampicin pharmacokinetic data for
931 individuals concluded that HIV status affects the total
exposure to rifampicin in the early days of treatment (AUC
37.2 mg.h/L in HIV-positive versus 56.7 mg.h/L in HIV-negative,
p = 0.003) but not later in therapy [150]. The lower plasma
rifampicin exposure in HIV-positive individuals in the initial
days of therapy may be particularly relevant in TB meningitis,
which carries a high early mortality.
Secondly, compared to those without HIV co-infection, HIV-
infected TBM patients generally have less meningeal inflam-
mation, as shown lower CSF white blood cell count or protein
[151–154]. When meninges are inflamed the tight junctions
between cells of the choroid plexus are disrupted allowing
plasma proteins and protein-bound drugs (like rifampicin) to
penetrate the CSF more readily [155]. One may, therefore,
hypothesize that reduced meningeal inflammation in HIV-
associated TBM may result in lower levels of anti-tuberculous
drug penetrating the BCSFB, although this has not been stu-
died. However, if this hypothesis is valid, then intensified
therapies that penetrate effectively into the CNS, regardless
of degree of meningeal inflammation, will be important in
HIV-associated TBM.
Theoretically, intensified antibiotic treatment might lower
the risk of IRIS in TBM. IRIS is a condition that results from
rapid restoration of pathogen-specific immune responses
to M. tuberculosis resulting in exuberant inflammation [156].
Although such paradoxical reactions have also been described
in HIV-uninfected patients, the incidence is much greater (up
to 47%) in HIV-infected patients on initiating ART [156,157].
TBM-associated IRIS presents as a recurrence or deterioration
of neurological symptoms and typically occurs within the first
three weeks and up to 3 months after ART is initiated, recom-
menced or switched [156,158]. The risk of IRIS in TBM is much
higher (RR 9.3, 95% confidence interval 1.4 to 62.2) in patients
with positive baseline CSF culture compared to those with
negative CSF cultures [156]. Culture positivity reflects a -
higher M. tuberculosis antigen burden, more rapid eradication
of M. tuberculosis antigen by intensified treatment may theo-
retically reduce the risk of subsequent IRIS on ART initiation. It
should be emphasized, however, that corticosteroids are cur-
rently the only proven therapy for paradoxical reactions,
including IRIS, and that the onset of paradoxical reactions
does not warrant intensification of antimicrobial therapy [158].
There are two other important considerations in HIV-TB co-
infection with regards to intensified treatments. Firstly, there are
significant drug–drug interactions between rifamycins andmany
ART drugs. Rifampicin causes induction of cytochrome P-450
(CYP) enzymes, phase II metabolizing enzymes, and drug trans-
porters, reducing concentrations of many companion drugs
[159,160]. Little is known about the maximal inductive capacity
of rifampicin and whether high dose rifampicin would cause
more significant drug–drug interactions, though a few small
studies suggest maximal induction already occurs at standard
doses of rifampicin [161–163]. The second consideration is the
overlapping toxicity profile of many ART and anti-tuberculous
agents. For example, linezolid and zidovudine can both cause
significant myelosuppression, aminoglycosides and tenofovir
can cause renal toxicity, fluoroquinolones and efavirenz can
cause hepatoxicity. Whilst such toxicity is relatively easy to moni-
tor and manage in higher income settings, in lower income
settings with the scarcity of laboratory tests and personalized
drug regimens, drug toxicity can pose a major management
dilemma. Current understanding and knowledge gaps regarding
TBM-HIV are summarised in Box 1.
3.2. Drug-resistant TBM
The treatment of TBM can be complicated by various forms of
drug resistance of M. tuberculosis. This can be resistance to just
one TB drug (monoresistance), multi-drug resistance which
refers to resistance to both isoniazid and rifampicin, and
extensively-drug resistant TB in which there is also resistance
against any fluoroquinolone and at least one injectable TB
drug [164].
Isoniazid monoresistance appears to be the most frequent
form of drug-resistant TBM. Heemskerk et al. reported isonia-
zid monoresistance, rifampicin monoresistance and multidrug
resistance in 27%, 0.3%, and 5% of 322 TBM patients in
Vietnam [41]; and the study by Vinnard et al. showing 10%,
2%, and 19% of 324 TBM patients with the same resistance
patterns in New York, USA [42]. HIV-infected patients with TBM
are at a higher risk of rifampicin-resistant TBM [42,143].
The consequences of resistance to rifampicin and/or iso-
niazid are enormous, with mortality rates of up to 100%
[42,76–78]. An important reason for this high mortality is the
slow detection of drug resistance. The availability of Xpert
MTB/RIF and, more recently, Xpert MTB/Rif Ultra tests is rele-
vant in this respect, as these tests enable the detection
of M. tuberculosis complex and rifampicin resistance within
a few hours. Still, the suboptimal sensitivity of these assays
in CSF and the lack of susceptibility information on other TB
drugs remain a challenge.
If rapid detection of drug-resistant TBM is possible, a drug
regimen can be designed based on the resistance pattern. In
TBM with monoresistance to isoniazid, available data suggest
that use of levofloxacin with a higher dose of rifampicin can
improve survival [41]. The best regimen for the treatment of
MDR TBM is unknown. Of the first-line agents, pyrazinamide is
often added in MDR-TB treatment in general, and this drug
shows a high penetration into CSF. It should be realized,
however, that MDR-TB isolates are often resistant to pyrazina-
mide as well and further work is needed to characterize gen-
otypes in varying geographic regions [165]. Furthermore, in
line with MDR-TB treatment for PTB, high dose isoniazid
(10–15 mg/kg daily) can be considered in case of low-level
resistance to isoniazid with mutations in the Inh A promoter
region, outside of the katG gene.
The second-line drugs with good penetration into the CSF,
are the fluoroquinolones, ethionamide/prothionamide, cyclo-
serine/terizidone, and linezolid, as discussed above. Again, it
should be noted that ethionamide/prothionamide and cyclo-
serine/terizidone are associated with CNS disturbances and
these may be additive when combined. Use of pyridoxine is
recommended to prevent CNS effects. Ethionamide/prothio-
namide also cause gastrointestinal intolerance. There is some
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Box 1. Implications of HIV coinfection in TBM.
Known Implications Evidence
Two to three-fold increased risk of death in HIV
co-infection
● Drivers of increased mortality not well characterized and require further
research
● HIV-associated TBM, in particular, may benefit from intensified therapy
Thao [183]
Marais [177]
Diagnosis more challenging: differential diagnosis
is broader and CSF picture can be atypical
● Diagnostic algorithms for TBM have poor sensitivity and specificity in HIV
co-infection
● Delayed treatment initiation due to diagnostic uncertainty may be impli-
cated in poor outcomes
● Additional diagnostic tests such as urine TB-LAM may be useful in the






ART initiation should be delayed til week 8 in
TBM.
● Provide dose-adjusted fluconazole in cryptococcal antigenemia and co-
trimoxazole prophylaxis if CD4 < 200
● Increased pill burden and additional risk of liver toxicity, renal dysfunc-




Increased risk of immune reconstitution inflammatory
syndrome (IRIS)
● IRIS has 30% associated mortality
● Complicates ART initiation and increases steroid requirements
● Alternative host-directed therapies are required
Marais [177]
Pepper [185]
Overlapping drug toxicities with ART e.g. liver injury,
peripheral neuropathies, rash
● Significant drug-related adverse events are 3.8-fold more likely in HIV-TB
co-infection than TB mono-infection This includes drug-induced hepatitis
which occurs in 10% of HIV-negative and 20% of HIV-positive TB patients.
● Individualized therapy to avoid or manage toxicity is challenging in
resource-constrained settings (individually formulated drugs are not
widely available) so TBM treatment is often interrupted. Interruption of
anti-TB drugs in TBM correlates with death




Increased risk of drug-interactions with ART ● PIs: risk of virological failure due to significant reduction in PI exposures
with rifampicin co-administration. Rifabutin recommended instead of
rifampicin, though not widely available and little data in TBM. In the
absence of rifabutin or alternative ART some use double dose lopinavir/
ritonavir, though side effects are considerable.
● INIs: require dose-adjustment with increased pill burden and possible
increase in toxicity
● NNRTIs: nevirapine is contraindicated due to marked reduction in expo-
sure with rifampicin co-administration, switch required. Efavirenz levels





Increased risk of disseminated TB disease, or HIV-related
organ pathology and associated complications
● HIV-positive people frequently have disseminated TB at the time of TBM,
including granulomatous hepatitis, which can worsen on initiating anti-
tuberculous therapy. Medical course may be more complicated due to




Use of adjunctive corticosteroids is not of proven benefit
in HIV-associated TBM
● Corticosteroids can be potentially harmful in people with advanced HIV as
they may exacerbate fungal infections and Kaposi’s sarcoma.







Driver of lower exposure to rifampicin in early days of
TB treatment in HIV-infection are not known
● Undetermined whether HIV-related intestinal immune activation, HIV
enteropathy, wasting or alteration in drug transporters are contributory
factors in the observed lower rifampicin exposures in HIV, nor whether
ART use can modify exposures.
● Further pharmacokinetic studies in HIV-TBM are needed





Unknown whether levels of other anti-tuberculous drugs
are reduced in HIV co-infection
● Possible reduced clearance of pyrazinamide and isoniazid in HIV co-
infected patients with high levels of immune activation
Vinnard [191]
McIlleron [159]
Differential degree of meningeal inflammation in HIV-
associated TBM
● Reduced meningeal inflammation in HIV likely to result in reduced levels
of antimicrobial drug penetration into CSF compartment
Cresswell [151]
Nau [155]
Theoretical risk of strongyloides super-infection with
high-dose corticosteroids
● Concurrent antihelminthic treatment may be required to prevent
overwhelming strongyloides infection in endemic regions (albendazole or
ivermectin). Trial underway in Asia.
Donovan [190]
PI = protease inhibitors, INI = integrase inhibitors, NNRTI = Non-nucleoside reverse transcriptase inhibitors
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cross-resistance between ethionamide/prothionamide with
isoniazid if the inhA mutation is present.
Based on the above, a combination of TB drugs for MDR-
TBM could consist of pyrazinamide, a fluoroquinolone (moxi-
floxacin or levofloxacin), ethionamide/prothionamide, and
cycloserine. This does not add up to the recommended five
effective agents yet and a combination of ethionamide/
prothionamide and cycloserine may only be tolerated for
a short term. Linezolid and high dose isoniazid (in case of low-
level resistance) are alternatives, and some clinicians may
consider aminoglycosides as a fifth drug despite their poor
penetration across the BBCSF barrier. There is no clear option
for further intensification. Clearly, there is an urgent need for
comparative trials on combinations of the available and pro-
mising drugs in drug-resistant TBM, though RCTs in drug-
resistant TBM would face significant logistical challenges due
to low patient numbers at any given center.
3.3. Paediatric TBM
As noted above, compared to adults, children often have
nonspecific presentations. Prodromal symptoms in older chil-
dren include fever, headache, anorexia, and vomiting. In
younger children, presentation is often one of the nonspecific
symptoms including failure to thrive, poor appetite, and
vomiting. Despite the importance of early initiation of anti-
TBM therapy, treatment is often delayed, as a diagnosis in the
pediatric population is challenging. In addition to the risk of
death (which appears to be lower in children than adults) and
neurologic sequelae [43], TBM in children occurs in the con-
text of a developing brain. Intellectual impairment is common,
and there is a risk of developmental sequelae related to TBM
that is unique to children, as the condition affects children
during important neurodevelopmental stages [166,167]. Given
the high risk of functional and neurodevelopmental impair-
ment following pediatric TBM, any improvement in treatment
has the potential not only for reducing the risk of death and
functional disability but also for improving quality of life in
young children by improving long-term neurocognitive
outcomes.
Clinical trials of anti-inflammatory therapy with steroids
or thalidomide have been conducted [168–170], but up to
now there have been no clinical trials of antimicrobial treat-
ments in pediatric TBM. Likewise, almost all data describing
CSF concentrations of TB drugs in TBM are from adults. Best
treatment practices, therefore, must be extrapolated largely
from adult trials, with doses adjusted for differences in drug
disposition in children. Recognizing that standard-
recommended pediatric dosing of first-line drugs achieves
subtherapeutic concentrations (for targets established for
PTB) in a high proportion of children [171–173], it is clear
that optimal treatment of TBM or CNS TB will require higher
doses of the most life-saving drugs, most notably rifampicin.
Based on adult PK targets for rifampicin associated with
improvements in mortality and knowledge of the develop-
mental pharmacology of this drug, rifampicin should almost
certainly should be dosed at 30 mg/kg or higher in children
[174]. Second-line drugs have not been examined for
efficacy expressly in pediatric TBM, though linezolid which
was associated with improved clinical outcomes in adults,
may have a role in pediatric TBM [137].
While WHO recommends treating paediatric TBM with
2 months of isoniazid, rifampicin, pyrazinamide, and etham-
butol followed by 10 months of isoniazid and rifampicin, there
is variability in guidelines given the paucity of clinical trials
data to inform practice, and in some settings treatment dura-
tion is shorter. In South Africa, for example, children are mostly
treated for six months using high-dose isoniazid, high-dose
rifampicin, standard-dose pyrazinamide, and ethionamide (the
latter in place of ethambutol) [124], based on cohort data
showing the efficacy of this regimen. While adult trials can
lend clues about the best antimicrobial treatment for pediatric
TBM, independent trials in children may be especially valuable
to look at pediatric-specific outcomes such as neurocognitive
and functional outcomes. Phase II and III clinical trials of
enhanced antimicrobial treatments for pediatric TBM are
enrolling or soon to start [175].
4. Summary and conclusions
Meningitis is the most dramatic and devastating manifestation
of TB, leaving upwards of 50% of those affected dead or
disabled. While in this review we addressed the possible role
of intensified antibiotic treatment, we acknowledge that
a number of other factors are also highly relevant. Timely
diagnosis and treatment is the most important factor related
to patient outcome, and there is a need for earlier presenta-
tion to hospital, more sensitive rapid diagnostics, and optimal
supportive care [176]. Secondly, more effective or tailored
host-directed therapy could help control the immunopathol-
ogy associated with TBM. Importantly, we must kill the bug to
cure the patient, and intensified antibiotic treatment with
drugs and doses that reach the site of disease well and slow
or arrest infection-related pathology is an intervention that
could be applied broadly once compelling evidence of
reduced death or disability has been provided by
a randomized clinical trial, of which there are number in the
pipeline (Table 3). In fact, in some settings, this is already
done. As an example, Table 4 contains a treatment regimen
for critically ill patients with suspected TBM who are admitted
to the intensive care unit in the Netherlands (Table 4). More
research is needed to examine the role of higher doses of
current drugs or use of alternative drug regimens, but some
candidate drugs for use and/or optimization are emerging, as
discussed in this review.
A number of priorities for future studies stand out. First,
data support the use of a much higher dose of rifampicin for
TB in general and for TBM in particular. Toxicity does not seem
to be higher compared to standard treatment, noting that the
anticipated survival benefit would outweigh a higher potential
risk of drug toxicity. Besides high-dose rifampicin, a second
approach that needs further study is the use of new drugs,
especially linezolid, giving its good penetration and promising
clinical effects, although this is based on two observational
studies. Delamanid and pretomanid also merit further evalua-
tion. A third priority is research in HIV-infected patients, chil-
dren, and drug-resistant TBM. HIV-infected patients are at
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Table 3. Summary of clinical studies investigating intensified antimicrobial treatments for TBM.
Published






















LVX 750 mg, ETD
750 mg, Z 1500 mg,




21.5% (95%CI 7.3–35.7%) absolute
reduction in 12 month mortality with
regimen B
PK: No PK data











M 400 mg or 800 mg
or E 750 mg
Standard doses of
Z and H used in all
participants
14 days Clinical:
Reduction in 6-month mortality in IV
rifampicin recipients (aHR 0.42; 95%CI
0.2–0.9). No increased toxicity
PK: 3-fold increase in plasma AUC0-24h,
Cmax and CSF Cmax with 600 mg IV
rifampicin






Standard of care (A):
R 10 mg/kg, H 5 mg/
kg, Z 25 mg/kg,
E 20 mg/kg
Intensified regimen (B):
R 15 mg/kg, LVX
20 mg/kg
H 5 mg/kg, Z 25 mg/
kg, E 20mg/kg
8 weeks Clinical:
No reduction in mortality overall (HR
0.94; 95%CI 0.7-1.2, P = 0.66).
Subgroup analysis of isoniazid-
resistant TBM found that intensified
therapy was significantly associated
with improved survival (HR 0.34, 95%
CI 0.15 to 0.76, p = 0.01) [41]
No increased toxicity.
PK: PK data awaited








A: R 450mg (standard
dose, ~10mg/kg)
B: R 900mg (double
dose, ~20mg/kg)
C: R 1350mg (triple
dose, ~30 mg/kg)
Standard dose H,
Z and E used in all
arms
30 days Clinical: Six month mortality: 7/20
(35%), 9/20 (45%), 3/20 (15%) in arms
A, B and C respectively (p = 0.12)
No increase in grade 3 or 4 AEs
PK: 3 and 5-fold higher total plasma
exposures with double and triple dose
rifampicin. Proportional increases in
CSF concentrations.





A: Standard of care
B: Standard of care
plus adjunctive LZD
600 mg twice daily
32 days
(median)
Clinical: Those who received LZD had
more rapid resolution of coma and
normalisation of temperature as well
as higher CSF glucose and lower CSF
white cell count. AEs limited: 12.5% in
LZD group (including
myelosuppression (n = 1) and optic
neuropathy (n = 1), both resolved on
discontinuing LZD)
PK: no PK done








A: Standard of care
(SOC)
B: SOC plus CIP
C: SOC plus LVX
D: SOC plus GFX
270 days Clinical: Worse outcomes amongst
participants with low or high plasma
or CSF exposures, rather than
intermediate exposures (U-shaped
exposure-response)
PK: CSF penetration (ratio CSF AUC0-24h:
plasma AUC0-24h) greatest for
levofloxacin (0.74, 95%CI 0.58–1.03).










A: R 750 mg (~17 mg/
kg)
B: R 900 mg (~20 mg/
kg)
C: R 600 mg i.v.
14 days Clinical: The study focused on
pharmacokinetics and safety/
tolerability and was not designed or
powered to study outcome or
relationships between exposures and
outcome.
PK: 750 mg and 900 mg resulted in
similar total exposures to rifampicin in
plasma as compared with 600 mg IV,
but peak plasma concentrations
remain higher with i.v. administration.
(Continued )
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much higher risk of dying, with lower average drug exposure
and a higher risk of treatment complications like IRIS, drug
interactions, and toxicity. Clinical trials in children are a high
priority, as there are no published clinical trials in this popula-
tion to date, and extrapolation of findings in adult patients is
difficult in light of different PK-PD and disease characteristics.
The considerable incidence of resistant TBM warrants further
research in improved identification of drug-resistant patho-
gens and comparative trials on combinations of available
and promising drugs. A fourth priority is the use of innovative
research strategies, including molecular pharmacology,
Physiologically based pharmacokinetic (PBPK) models, adap-
tive trial designs, and smart quantitative pharmacology,
including PK-PD assessments.
Finally, barriers to implementation of high-quality care for
TBM should be examined, prioritized, and addressed. Delays in
the presentation to hospital, lumbar puncture and treatment
initiation all contribute to poor outcomes. Intensified therapies
for TBM holds the potential to make the greatest impact on
mortality only if such barriers are addressed in parallel. The
global TBM research consortium convenes every 1–2 years
and has issued standard case definitions for research [177],
standardized methods for enhanced quality and comparability
of TBM studies [178], and produced a recent general overview
of TBM [49]. We hope this will catalyze high-quality research in
the field and translation of research findings to clinical practice.
5. Expert commentary
TBM is a highly variable disease, with multiple competing
causes of neurologic damage or death. Much remains
unknown about immunopathogenesis in different popula-
tions and different disease stages, and how best to minimize
the immunopathology. Additionally, the optimal antimicro-
bial chemotherapy regimen remains to be defined, and we
have discussed a number of promising options and the
immediate clinical trial landscape in this review. However,
cases are rare in any one institution, and significant resources
are required to care for any adult or child with TBM. Thus,
there is much to gain from optimizing design and analysis of
clinical trials in TBM. In addition, standardizing of pharmaco-
kinetic approaches across studies will allow for pooling of
data or easier comparisons between studies. We believe
Table 3. (Continued).
Upcoming or current TBM clinical trials of intensified therapy
Trial name Start Country Trial design/
population
















C: Oral R 35 mg/kg
H, Z and E given at
standard doses in all
arms
8 weeks 1. PK parameters in plasma and CSF
(Cmax, AUC, T > MIC)
2. Safety
3. 8 and 24-week mortality
4. Functional status (Rankin scale) at 2
and 24 weeks







120 A: high dose
R (standard dose H,
Z, E)




C: standard of care
8 weeks 1. PK parameters (plasma, CSF)
2. Functional outcome (Modified Rankin
Scale)
3. Safety




2018 Indonesia Phase II RCT 36 Rifampicin 1350 mg
(~30 mg/kg) with
A: no LZD
B: LZD 600 mg daily
C: LZD 1200 mg daily
H, Z and E given at
standard doses to
all participants












600 A: Standard of care




Z and E given at
standard doses
8 weeks 1. 6 month survival time
2. Time to normalisation of
consciousness (GCS 15)
3. Neurocognitive outcomes
4. safety and tolerability endpoints
5. PK-PD endpoints
6. Cost effectiveness
ACTG A5384 2019 TBD Phase II RCT
2 arm, parallel
design
300 A: 2 months R35H10
LZD1200Z, 4 months
R35H10
B: Standard of care
6 months 1. 18 month survival time
2. Modified Rankin scale at week 12, 24,
26, 48 and 72
3. Grade 3–5 adverse events
4. Neurocognitive function
5. Time to GCS = 15
6. Pharmacokinetic parameters
R = rifampicin, H = isoniazid, Z = pyrazinamide, E = ethambutol, ETD = ethionamide, CIP = ciprofloxacin, GFX = gatifloxacin, LVX = levofloxacin,
LZD = linezolid, M = moxifloxacin
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there are a variety of innovative strategies that may add to
the quality and scientific output of TBM research (Box 2).
Firstly, we can take advantage of preclinical tools to aid us
in designing regimens. Molecular pharmacological research
using, for example, human liver microsomes, hepatic cell
lines, brain capillary endothelial cell lines, and transporter
overexpression models can help identify whether TB drugs
are substrates, inhibitors and/or inducers of specific meta-
bolic enzymes or drug transporters, including those transpor-
ters that control access of molecules to the brain or CSF
[179]. It can predict drug–drug interactions mediated by
metabolic enzymes or drug transporters, reveal possible
synergy between drugs in combinations, and assess tissue
penetration/accumulation characteristics [179]. PBPK model-
ing is another value in silico tool; it combines mechanistically
scaled in vitro experimental data about PK and drug distribu-
tion to relevant compartments to simulate in vivo behavior,
and can take into account the distribution of demographic
and disease characteristics in the target population. In this
way, PBPK modeling allows for prediction of drug concentra-
tions in specific tissue compartments, such as the brain or
CSF, and helps translate exposure predictions to other doses
and populations. Thus, PBPK modeling can improve the effi-
ciency and accuracy of drug, dose, and regimen selection up
front.
A second important aspect is the trial design itself. Modern
trial designs that are adaptive in nature and allow for testing of
multiple regimens, with mid-trial selection of those arms that
show enough promise to continue will help avoid late-phase
trial failures which are costly in so many ways [87]. In trials for
TBM, however, the optimal way to assess regimens mid-study is
not clear and is made challenging by relatively low patient
numbers and variability in presentation and disease severity.
Thirdly, irrespective of the trial design, integration of PK
and PK-PD assessments into study design can enrich the
information upon which decisions are made. For example,
measurements of drug concentrations in the CSF can be useful
in models linking site-of-action PK with outcomes, provided
samples are collected properly. Optimal sampling strategies
should be employed to choose the best times to collect
plasma samples and (generally) the single CSF sample per
study participant. Timing of CSF sampling can differ among
study participants so that CSF concentrations over a dosing
interval can be characterized more fully using population PK
modelling. Advanced pharmacometrics (pharmacokinetic-
pharmacodynamic (PK/PD) modelling) is also crucial to max-
imize both study design and learning from rich and complex
data that emerges from interventional trials. Examples include
Table 4. Suggested intensified TBM regimen and administration for high resource settings.
Individual
drugs Dose Formulation Administration
Isoniazid* 5 mg/kg p.o. or i.
v.
Tablet 200 mg or injection fluid 100 mg/ml, 3 ml Orally
i.v. bolus: in 3–5 min
i.v. infusion: add the dose to 100 ml NaCl 0.9%, administer
within 0.5 h
Rifampicin* 30–35 mg/kg p.o
or 15 mg/kg i.v.
Capsule (150 or 300 mg), tablet (600 mg) or powder for
infusion fluid 600 mg (Rifadin®, Sanofi-Aventis)
Orally
i.v. infusion: dissolve 600 mg in 10 ml water for injection, add
the correct dose to 250 ml NaCl 0.9%, administer in 1.5 h.
Minimal volume is 100 ml, administration in 0.5 h.
Pyrazinamide* 30 mg/kg p.o. Tablet 500 mg Orally
Moxifloxacin* 600 mg p.o. or i.v.
**
Tablet 400 mg or infusion fluid,1.6 mg/ml, 250 ml
(Avelox®, Bayer)
i.v. infusion: infuse in no less than 1 h. No dilution needed.
Optional fifth drug
Linezolid* 600 mg bd p.o. or
i.v.
Tablet 600 mg, or infusion fluid, 2 mg/mL, 300 mL Orally, twice daily
i.v. infusion: administer within 30–120 minutes, no dilution
needed.
Amikacin 15 mg/kg i.v. Injection fluid 250 mg/ml, 2 ml i.v. infusion: add the dose to 100–200 ml NaCl 0.9%, administer in
0.5–1.0 h.
Other
Dexamethasone 0 · 4 mg/kg i.v.
(grade 2/3), or
0 · 3 mg/kg i.v.
(grade 1) TBM
Dexamethasone disodium phosphate, 5 mg/ml, 1 ml i.v. bolus: in 2–3 min
i.v. infusion: add the dose to 50–500 ml NaCl 0.9%
This regimen is used in the intensive care unit at Radboud university medical center, The Netherlands. All doses of drugs can be individualized by measurement of
drug concentrations in plasma or CSF (Therapeutic Drug Monitoring, TDM)
*In patients without risk of malabsorption e.g. ileus medication can be given by mouth or by nasogastric tube in patients unable to take medication by mouth.
** Higher dose of moxifloxacin is used to counteract the effect of rifampicin, which decreases the exposure to moxifloxacin by approximately 30% [118].
Of note, Intravenous compatibility of these drugs has not been tested, neither when combined in one infusion fluid nor when co-administered by Y-side. Only
dexamethasone is compatible with amikacin infusion when administered through a Y-side. Therefore, the drugs should be administered separately from each other
and the injection port/infusion system should be flushed with NaCl 0.9% after each administration.
Box 2. Innovative research strategies and methodology.
(1) Preclinical tools
● Molecular pharmacological research
● Physiologically based pharmacokinetic (PBPK) modeling
(2) Adaptive trial design
(3) Integration of PK and PK-PD assessments
(4) Tools for determination of CNS drug distribution
● PET imaging
● Post-mortem measurement of drug in brain
● Animal models
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the assessment of paediatric doses of high dose rifampicin in
TBM based on adult data [174], and the evaluation of PK–PD
relationships with high dose rifampicin in PTB.
When interpreting CSF concentration data, it is also impor-
tant to keep in mind that unbound drug is the active drug,
and highly bound drugs may have vastly different concentra-
tions in plasma and CSF but similar free concentrations in the
two compartments. Of note, CSF concentrations do not always
correlate with concentrations in the brain. While we com-
monly only have access to CSF to learn about CNS drug
distribution, post-mortem measurement of drug in brain can
provide critical information about distribution of specific drugs
into granulomas and those areas affected by vasculitis and
other TB-related brain pathologies. Although animal models
may be helpful in this regard, most animal models introduce
TB meningitis by intracranial injections, possibly compromis-
ing the comparison with human BBB and BCSFB integrity and
CNS drug entry.
To simplify TBM trials, having validated alternative end-
points could aid efficiency substantially – including CSF mar-
kers, neurocognitive or functional outcomes, microbiologic
endpoints. A difference in normalization of routine CSF para-
meters like glucose or more advanced (e.g. metabolomic [180]
or proteomic [181]) markers could be used as surrogate mar-
kers of clinical response. Obviously, it is also important to
correct the effect of intensified treatment for other factors
associated with outcome (age, HIV-status, disease severity,
inflammatory phenotype, etc.) to more accurately represent
the relationship between the antimicrobial treatment and
clinical outcomes [182].
6. Five-year view
In the era of ‘omics’ it is encouraging to see that we are
beginning to understand more about the immunopathogen-
esis of TBM [157,180,192]. This may lead to discovery of novel
targets for host immunomodulation or antimicrobial effect, as
well as identification of repurposed drugs with potential activ-
ity in TBM. In five years a number of the enrolling trials of
intensified antimicrobial therapy for TBM, listed in Table 3, will
have yielded important information on the PK and clinical
impact of higher dose rifampicin and linezolid in TBM. We
will also have new insights into previously under-studied
populations with TBM including children in India and Malawi
and HIV co-infected adults in sub-Saharan Africa.
Key issues
● Timely diagnosis and treatment is the most important factor
related to patient outcome, and there is a need for earlier
presentation to hospital and more sensitive rapid diagnostics.
More effective or tailored host-directed therapy will help
control the immunopathology associated with TBM.
● Intensified antibiotic treatment with drugs and doses that
reach the site of disease sufficiently to slow or arrest infec-
tion-related pathology is an intervention that could be
applied quickly and broadly if proven to improve clinical
outcomes in randomised trials.
● More research is needed to examine the role of higher
doses of current drugs or use of alternative drug regimens.
Data support the use of a much higher-dose of rifampicin
for TB in general and for TBM in particular. Linezolid, given
its good brain penetration and promising clinical effects in
two observational studies also warrant further investigation.
● Research in HIV-positive patients, children, and drug-
resistant TBM is a priority.
● Use of innovative research strategies are essential, including
molecular pharmacology, physiologically based pharmacoki-
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8 Chapter Eight: High Dose Intravenous and Oral Rifampicin in the 
Treatment of Tuberculous Meningitis: A Phase II Open Label 
Randomised Clinical Trial (research paper) 
Foreword 
Rifampicin is the cornerstone drug in TBM treatment, as evidenced by the fact that meningitis patients with 
rifampicin-resistant M. tuberculosis strains have a near-universal fatal outcome, even with second-line drugs 
in resource-rich settings.1-3 Mortality is much lower in patients with isoniazid monoresistant TBM.4  
As described in the introduction, there is a growing body of evidence that higher dose rifampicin is safe, 
improves blood and CSF rifampicin exposures and survival in predominantly HIV-negative Indonesians with 
TBM.5,6 This phase II clinical trial seeks to fill the knowledge gap that exists relating to: 1) the safety of high-
dose rifampicin in advanced HIV disease and 2) PK parameters from advanced HIV disease, and specifically 
rifampicin CSF PK data of which there is none from Africa.  
This chapter tests the following hypotheses: 
• Hypothesis #3: Intensified treatment of TB meningitis with intravenous rifampicin (20mg/kg) or high
dose oral rifampicin (35mg/kg) will result in significantly increased blood and CSF exposure during the
critical early days of TB treatment as compared to common control (10mg/kg oral rifampicin)
• Hypothesis #3: High dose rifampicin will be safe in people with advanced HIV disease and may
improve functional outcomes and survival at 8- and 24-weeks.
The full clinical trial protocol has been summarised in a protocol paper, which has been published on 
Wellcome Open Research and is included in Appendix 5. The safety data collected during the 8-week 
intervention period are presented as a primary endpoint, and the individual details of all the adverse events 
during the 24-week follow up period are presented in the supplementary material. 
This phase II clinical trial provided reassuring data on the safety of high-dose rifampicin in Ugandans with 
advanced HIV-related immunosuppression. The PK data also revealed how sub-optimal the CSF rifampicin 
concentrations are with standard TB treatment, with around half of enrolees having undetectable CSF levels. 
A two-fold increase in rifampicin dose administered intravenously and a 3.5-fold increase in oral dose had a 
marked impact on both serum and CSF rifampicin exposures, with almost all enrolees having CSF 
concentrations above the rifampicin MIC (1 mg/L). Given that oral rifampicin 35 mg/kg achieved good CSF 
concentrations with no excess toxicity and is a less complex intervention than intravenous rifampicin, it would 
be the most appropriate option to examine in a phase III clinical trial.  
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Background: High dose rifampicin may improve outcomes of tuberculous meningitis (TBM). Little 
safety or pharmacokinetic (PK) data exist on high-dose rifampicin in HIV co-infection, and no 
cerebrospinal fluid (CSF) PK data exist from Africa. We hypothesized that high-dose rifampicin would 
increase serum and CSF concentrations without excess toxicity. 
Methods: In this phase II open-label trial, Ugandan adults with suspected TBM were randomised to 
standard-of-care control (PO-10, rifampicin 10mg/kg/day), intravenous rifampicin (IV-20, 
20mg/kg/day), or high-dose oral rifampicin (PO-35, 35mg/kg/day). We performed serum and CSF PK 
sampling on day 2 and 14. The primary outcomes were total exposure (AUC0-24), maximum 
concentration (Cmax), CSF concentration (CCSF) and grade 3-5 adverse events.  
Findings: We enrolled 61 adults, 92% were HIV-positive, median CD4 count was 50cells/µL (IQR 46 – 
56). On day 2, geometric mean plasma AUC0-24hr was 42.9h×mg/L with standard-of-care 10mg/kg 
dosing, 249h×mg/L for IV-20 and 327h×mg/L for PO-35 (P<0.001).  In CSF, standard-of-care achieved 
geometric mean AUC0-24hr 0.27mg/L compared with 1.74mg/L (95%CI 1.2–2.5) for IV-20 and 
2.17mg/L (1.6–2.9) for PO-35 regimens (p<0.001). Achieving CSF concentrations above rifampicin 
minimal inhibitory concentration occurred in 11% (2/18) of standard-of-care, 93% (14/15) of IV-20, 
and 95% (18/19) of PO-35 participants. Higher serum and CSF levels were sustained at day 14. 
Adverse events did not differ by dose (p=0.34)  
Interpretation: High-dose intravenous or oral rifampicin was safe, resulted in ~6-8-fold higher 
exposures than standard of care, and therapeutic CSF levels. Current international guidelines result 
in sub-therapeutic CSF rifampicin concentration for 89% of Ugandan TBM patients. 
Funding: Wellcome Clinical PhD Fellowship (210772/Z/18/Z) 
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Research in Context 
Evidence before this study: We searched PubMed Central for reports on high dose rifampicin in 
antituberculosis therapies including the following search terms: "high dose" OR "intensified" AND 
“rifampicin” OR “antitubercul*” AND “tubercul*” OR "mening*" OR “TB”, on 2nd September 2020. 
Rifampicin was first identified as a key antituberculous agent in 1972 and at this time the minimum 
effective dose (600 mg) was used as rifampicin was relatively expensive. Since then, limited advances 
have been made in the treatment of drug-sensitive TB and there is a need to dose-optimise existing 
agents. This has promoted rifampicin dose-optimisation studies by the PanACEA consortium who 
have recently concluded that 40mg/kg rifampicin is the maximum tolerable dose in humans. This is 
particularly relevant for TBM as only about 5% of plasma rifampicin penetrates into the 
cerebrospinal fluid (CSF). Recent studies have shown that with the current dosing (10 mg/kg) 
rifampicin is often undetectable in the CSF of patients with TBM. 
Several key clinical trials have also investigated high-dose rifampicin in TBM in a largely HIV-negative 
population. An Indonesian phase II trial administered high-dose intravenously (IV) (~13 mg/kg IV) or 
standard dose oral rifampicin (10mg/kg) with or without moxifloxacin for 2-weeks. Intravenous 
rifampicin led to a 3-fold increase in plasma and CSF pharmacokinetic (PK) parameters and reduced 
6-month mortality (adjusted Hazard Ratio 0.42; 95% CI 0.20-0.91; p=0.03). Two subsequent
Indonesian phase II trials established the safety and PK of oral rifampicin up to a dose of 30 mg/kg. A
pharmacokinetic-pharmacodynamic model combining data from 148 participants in three
Indonesian trials predicted that increasing the oral rifampicin dose from 10 to 30 mg/kg would result
in an increase in 6-month survival from ~50 to ~70% and that higher doses would further improve
survival.
In contrast, the phase III randomised, double-blind, placebo-controlled trial of 817 adults with TBM 
in Vietnam investigating oral rifampicin (15 mg/kg) and levofloxacin compared with standard 
treatment, found improved survival in people with isoniazid monoresistance but no effect overall. A 
nested pharmacokinetic-pharmacodynamic study of 237 participants within this trial did not find an 
exposure-response relationship within the range of rifampicin exposure achieved, though the 
observed exposures in the intensified arm (geometric mean 82.5 h×mg/L) were considerably lower 
than the total exposure predicted to improve survival in the Indonesian model (300 h×mg/L).  
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The added value of this study: This is the first randomised controlled trial of high-dose rifampicin in 
TBM in adults in sub-Saharan Africa. We show that a 3.5-fold increase in the oral rifampicin dose 
results in an 8-fold increase in serum and CSF exposure with no excess toxicity. With standard dosing 
only 11% of participants achieve a CSF rifampicin concentration above the minimal inhibitory 
concentration for rifampicin (1 mg/L), compared to 95% with rifampicin 35mg/kg and 96% with 
20mg/kg IV. Oral administration of rifampicin 35mg/kg/day appears to achieve similar exposures as 
intravenous rifampicin and would be a less complex intervention to study in phase III trials and 
implement programmatically.     
HIV-positive individuals with advanced immunosuppression are at considerably higher risk of adverse 
drug reactions, 4-fold increased risk of drug induced liver injury, complications of polypharmacy and 
drug-drug interactions. Prior trials examining high-dose rifampicin have only included a handful of 
HIV-positive people with CD4 T-cell counts >200 cells/µl. This is the first safety and PK data for 
considerably higher dose rifampicin in HIV-associated TB and advanced immune suppression 
(median CD4 T-cell count 50 cells/µl).  
Implications of all the available evidence: Our data, taken together with existing data from Indonesia, 
show a clear increase in rifampicin exposure in the blood and CSF with higher dose rifampicin whilst 
maintaining an acceptable toxicity profile. Our data provide reassurance that it is safe to use oral 
rifampicin 35mg/kg in HIV-positive adults. The next step is to examine the impact of 35mg/kg oral 
rifampicin on survival and neurological disability in an appropriately powered phase III study in adults 
with TBM.  
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Introduction 
The HIV epidemic has dramatically changed the epidemiology of meningitis in sub-Saharan Africa and 
M. tuberculosis is now one of the leading causes.1 Tuberculous meningitis (TBM) is fatal in 16% (95%
confidence interval (CI), 10-24%) of HIV-negative adults and 57% (95%CI, 48-67%) of people living
with HIV (PLHIV).2 Long-term disability is seen in around a third of survivors regardless of HIV
serostatus.2 The treatment of TBM has been extrapolated from trials defining short course
pulmonary TB treatment in the 1970s, which used rifampicin dosed at 600mg (8-12mg/kg) daily and
did not explore substantially higher doses of rifampicin (Rifampin®) due to its high cost in that era.3
Rifampicin is a key drug in TB treatment, it is highly bactericidal and has important sterilising activity,
and low plasma exposures have been linked with treatment failure, relapse and evolution of
resistance.4 There is a growing body of evidence in pulmonary TB suggesting that high-dose
rifampicin accelerates the rate of bacillary clearance and the maximum well-tolerated oral dose is 40
mg/kg/day.5,6,7,8,9 Rifampicin is highly protein-bound so only around 5% of plasma rifampicin
penetrates across the blood-cerebrospinal fluid (CSF) barrier, and at the current 10mg/kg dose the
majority of TBM patients have undetectable rifampicin in their CSF, the site of disease.10,11
Inadequate central nervous system (CNS) drug penetration may be an important contributory factor
to early mortality. Improved survival may be achieved by ‘intensified therapy’: addition of drugs with
good CNS penetration, modifying drug doses and/or route of administration to maximise early
mycobactericidal activity in the CNS.11
In the Vietnamese intensified TBM treatment trial, the intervention arm contained oral rifampicin 15 
mg/kg/day and levofloxacin 20 mg/kg/day compared to standard TB treatment (containing 
rifampicin ~10 mg/kg/day).12 The intensified regimen showed no differential effect on mortality 
overall, though there was a survival benefit in those with isoniazid-resistant disease.13 The recently 
published pharmacokinetic (PK)-pharmacodynamic (PD) sub-study reported that whilst there was an 
approximate doubling of plasma and CSF rifampicin exposures in the intensified arm there was no 
detectable association between rifampicin exposure and survival within the moderate range of 
exposures observed.14 Conversely, data from 148 participants in three phase II Indonesian TBM trials 
investigating intravenous rifampicin and oral rifampicin dosed at 10, 20 and 30 mg/kg/day, combined 
in a model-based meta-analysis found a strong relationship between rifampicin exposure and 
survival in HIV-negative TBM patients.15,16,17 Simulations predicted an increase in 6-month survival 
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from approximately 50% to 70% upon tripling the oral rifampicin dose to ~30 mg/kg, and that even 
higher doses would further improve survival.17  
There is however a stark lack of clinical trial data on the safety and PK of high-dose rifampicin in HIV 
co-infection. PK data from Asia cannot necessarily be extrapolated to African populations due to 
differences in HIV serostatus, comorbidities, body size, and pharmacogenomics. PLHIV are at high 
risk of drug-related toxicity including a 4-fold increased risk of drug-induced liver injury,18 
complications relating to polypharmacy, and drug-drug interactions.19 There is therefore an urgent 
need to generate data on safety and PK of higher dose rifampicin in African adults with TBM, 
particularly in PLHIV who experience the greatest burden of disease.  
To date, the regimen with the most marked impact on survival is intravenous rifampicin at a of dose 
once daily 13 mg/kg.10 Intravenous rifampicin is not susceptible to first-pass metabolism, so a higher 
and less variable drug exposure may be achieved.20 However, intravenous rifampicin is not readily 
available in many TB endemic settings and co-formulation of oral TB drugs is essential to reducing pill 
burden. Therefore, in this first interventional trial in adults with suspected TBM in sub-Saharan 
Africa, we sought to test the hypothesis that in a predominantly HIV-positive population high-dose 
rifampicin, administered orally or intravenously, is safe and increases blood and CSF exposures and 
attainment of PK targets.  
Methods 
Study population and setting 
Participants were recruited from two centres in Uganda: Kiruddu National Referral Hospital, Kampala 
and Mbarara Regional Referral Hospital, Mbarara; public hospitals which act as referral hospitals for 
the Central and Western districts respectively. A full description of the trial protocol has been 
published elsewhere.21 Eligible patients were adults (>18 years of age) with suspected TBM, and 
either microbiological confirmation of meningeal TB (positive CSF AFB smear or CSF Xpert MTB/Rif 
Ultra) or a low CSF glucose (CSF:plasma ratio <50% or CSF glucose <65 mg/dl or <3.6 mmol) with 
TBM treatment planned. Patients were ineligible if they had jaundice or known liver cirrhosis; >3 
doses of TB treatment within the previous 3 days; discontinued TB treatment in the prior 14 days; 
known allergy to rifamycins, isoniazid, pyrazinamide, ethambutol; known current/previous rifampicin 
drug-resistant M. tuberculosis infection; concurrent cryptococcal meningitis; known to be currently 
163 
taking any drug that has a clinically relevant interaction with rifampicin (including HIV protease 
inhibitors or nevirapine); could not attend follow-up visits, pregnant or breastfeeding; known 
porphyria; known chronic renal failure with creatinine clearance <10 ml/min; or lack of written 
informed consent. Participants were subsequently classified in accordance with the TBM uniform 
case definition.22 
Randomisation 
Participants were stratified at study entry by site and British Medical Research Council (MRC) disease 
severity grade (grade I or II/III). Participants were randomly assigned in a 1:1:1 ratio to one of three 
trial arms. The randomisation list was generated by a computer-generated permutated block 
randomization algorithm of different sized blocks and sealed envelopes labelled with the 
randomisation code contained the study arm assignment. Due to the urgent need to begin 
treatment to reduce mortality, enrolment was not delayed whilst waiting for enrolment blood test 
results, and participants were withdrawn and replaced a posteriori if their baseline alanine 
transaminase (ALT) was >3x upper limit of normal (ULN).  
Procedures and Laboratory Investigations 
CSF was tested at the bedside for Cryptococcal antigen (CrAg LFA, IMMY, Norman, USA), glucose 
(One Touch Select), and lactate (Nova Biomedical; Waltham, USA). In the local microbiology 
laboratory, CSF underwent Gram’s stain, bacteriological culture, cell count and differential, protein 
estimation, and Xpert MTB/Rif Ultra (Cepheid, Sunnyvale, CA). Blood tests were sent to the 
Infectious Diseases Institute Core Laboratory in Kampala and the Joint Clinical Research Centre 
Laboratory in Mbarara, Uganda. Baseline bloods included HIV Ab/Ag test, liver function tests, renal 
function tests, complete blood count, and b-HCG for women. Safety bloods including liver function 
tests were sent on days 3, 7, 14, 28, and 56, approximately. For pharmacokinetic measurements, we 
collected blood samples on day two (+/-1) at the following time points: pre-dose and 2-, 4- and 8-
hours post-dose. In case of intravenous infusion, the first 2-hour sampling point occurred at the end 
of the infusion. We collected a single CSF sample on day 2, randomized between 2- to 8-hours post 
dose with collection windows randomized as 2-4, 4-6, or 6-8-hours post dose. On day 14 (+/-2), we 
collected a single blood and CSF sample between 2 to 8 hours post-dose for PK analysis. 
Pharmacokinetic samples were transferred immediately to the Kiruddu Hospital Microbiology 
Laboratory in Kampala or JCRC laboratory in Mbarara protected from light where they were 
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centrifuged at 3000g for 10 minutes. Following centrifugation, serum or CSF was aliquoted into 1ml 
cryovials and immediately cryopreserved at -80 OC for later analysis. 
Study treatment 
The intervention period in this open label phase II trial was 8 weeks. Participants were randomized to 
one of three antituberculous therapies: 1) IV-20, high-dose intravenous (IV) rifampicin (20 
mg/kg/day) administered over 2 hours, alongside oral isoniazid (5 mg/kg), pyrazinamide (25 mg/kg) 
and ethambutol (20 mg/kg); 2) PO-35, high dose oral rifampicin (35 mg/kg/day), administered as 
standard fixed dose combination quadruple antituberculous tablets (RHZE) (containing ~10mg/kg of 
rifampicin) along with additional 25 mg/kg dose given as 300 mg oral rifampicin capsules; 3) 
standard of care (SOC, control arm) fixed-dose combination RHZE tablets (containing ~10 mg/kg/day 
of rifampicin) according to WHO weight-bands. Detailed dosing tables are provided in the 
supplementary materials. Where participants were unable to swallow, oral medication was 
dispersed and given via a nasogastric tube. In the IV-20 arm, after 14 days of IV rifampicin 
participants were switched to high dose oral rifampicin (35mg/kg) for the remaining 6 weeks of the 
intervention period, as per PO-35 arm. Study drugs were administered under directly observed 
therapy during hospitalisation. Adjunctive corticosteroids were given routinely as dexamethasone 
0.4 mg/kg/day IV for week 1, 0.3 mg/kg/day IV for week 2 and thereafter as oral prednisolone 
80mg/day and weaned to a stop over the following 6 weeks. Corticosteroids underwent more rapid 
weaning or discontinuation if clinical indicated.21 All participants received a 3-day albendazole course 
to mitigate Strongyloides hyperinfection risk secondary to high dose steroids, and PLHIV received 
cotrimoxazole prophylaxis. Antiretroviral therapy (ART) naïve PLHIV, or those who had discontinued 
ART, initiated ART after completion of the intensive phase of TB treatment (week 8) in accordance 
with Ugandan guidelines. Current protease inhibitor or nevirapine-based ART was an exclusion 
criterion due to clinically significant interactions with rifampicin.  
Outcome Assessment and Follow-Up 
Participants were reviewed daily during hospitalisation for neurological status and adverse events 
(AE) ascertainment, before being discharged around day 14 unless their medical condition warranted 
prolonged hospitalisation. After hospital discharge, participants were reviewed by the study team as 
outpatients at weeks 4, 8, 12, 18, and 24. Where possible a detailed neurocognitive assessment was 
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performed at the week 8 and 24 visit. After 24-weeks of follow-up the participants were referred to 
local TB services to complete a total treatment duration of 9-12 months.  
Primary endpoints were 1) pharmacokinetic parameters in serum (AUC0-24, Cmax) and CSF 
concentration (CCSF); 2) composite safety endpoint during the 8-week intervention period 
(comprising any of the following: a) grade 3-5 AEs including drug-induced liver injury; b) serious AEs 
(SAEs); or c) discontinuation of rifampicin for >5 days for any cause. Secondary endpoints included 
survival to 8- and 24-weeks, time to normalisation of conscious level (GCS=15), functional status by 
modified Rankin scale score at 8 and 24-weeks, quantitative neurocognitive performance Z score at 
8 and 24 weeks, incidence of TB immune reconstitution inflammatory syndrome.   
Pharmacokinetic analysis 
Total rifampicin concentrations were analysed by validated high-performance liquid chromatography 
with ultraviolet detection (HPLC-UV) in the Infectious Disease Institute Translational Laboratory using 
an LC-2010C HT system (Shimadzu, Kyoto, Japan). Chromatographic analysis occurred on a Phenyl-
Hexyl, 150 × 3 mm ID, 3µm particle size, analytical column (Thermoscientific, USA). The assay was 
internally validated and performed well in an external international quality control (QC) programme, 
accuracy of the QC samples was 94 - 102% depending on the concentration. The intra-assay and 
inter-assay coefficients of variation were 2.9 - 3.6% and 3.4 - 4.8% respectively. The calibration curve 
for rifampicin in plasma covered a range from 0.25 to 15 mg/L. Samples with concentrations above 
the upper limit of quantitation were diluted with blank plasma before re-analysis. The accuracy and 
repeatability of this approach was validated. Further details are provided in the supplementary 
materials.  
The PK parameters Cmax and area under the time-concentration curve up to 8 hours post dose (AUC0–
8) were determined using a standard non-compartmental approach with Phoenix WinNonLin
(Certara, Princeton, USA) using the log-linear trapezoidal rule. The AUC0-24 was determined using a 
published population PK model,23 modified for IV administration in IV-20 using NONMEM (Icon 
Development Solutions, Ellicott City, Maryland). Tmax was defined as the time to reach maximum 
concentration. The rifampicin CSF concentration (CCSF) was the measured concentration in the 
interval of 2 to 8-hr post dose. Where rifampicin concentrations were below the lower limit of 
quantification (LLOQ, 0.25 mg/L), for the purposes of PK analysis a value of 0.125 mg/L (half of the 
LLOQ) was assigned. The difference in log-transformed exposure measures between study arms was 
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assessed in a general linear regression model with the pairwise difference of each arm with the 
control assessed by the Wald t-test with Bonferroni adjustment for multiple testing. The difference 
in Tmax between study arms was tested with Kruskal Wallis test. The between-arm difference in 
proportion of participants achieving a minimum published Cmax target of 8 mg/L,24 an AUC0-24hr of 
300 h×mg/L (an exposure generating about 65% of the maximum effect in the Indonesian model-
based PK-PD meta-analysis17), and a CSF concentration above the rifampicin MIC for the most 
prevalent M. tuberculosis strain in Uganda (M. tuberculosis Uganda II) was compared with a Chi-
squared test.25 
Statistical analysis 
We determined sample size following the assumption that PK parameters are normally distributed 
on the log scale and derived rifampicin log-transformed Cmax standard deviation from prior 
research.10 The statistical analysis adhered to the published protocol and statistical analysis plan.21 
We followed CONSORT guidelines, and the primary analyses were conducted by intention to treat 
(ITT). We compared the number and proportion of individuals who reported any kind of clinical 
grade 3-5 AE during the study period, and the composite safety endpoint, between arms with a chi-
squared test. We compared time to experiencing an AE and time to normalisation of conscious level 
(GCS=15/15) between treatment arms using a Fine and Gray competing risks proportional hazards 
regression model and cumulative incidence functions, with death considered a competing risk. 
Mortality at 8- and 24-weeks post-randomisation was compared between study arms using the risk 
difference from a generalised linear regression model with binomial distribution and identity link 
function. Kaplan-Meier curves were used to compare time to death. Participants who were 
withdrawn or lost to follow-up were censored at the time of their last contact. We compared the 
mean modified Rankin score at 8- and 24-weeks between trial arms using a linear regression model. 
In addition, we modelled repeated measures GCS profiles using a linear mixed model with random 
slope parameter. Data were collected using the DataFax system, and all statistical analyses were 
conducted using Stata version 13.1 (StataCorp, College Station, Texas, USA).  
Ethical considerations and oversight 
Written informed consent was obtained from all participants or their caregiver (where the individual 
lacked capacity to consent). Those enrolled via surrogate consent repeated the informed consent 
process at the earliest opportunity after regaining capacity. The trial was approved by the Infectious 
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Diseases Institute Scientific Review Committee, the Research Ethics Committees of the London 
School of Hygiene and Tropical Medicine and Mulago Hospital, the Uganda National Council of 
Science and Technology, the National Drug Authority and registered (ISRCTN42218549). An 
independent data safety committee reviewed the accruing safety data. The intravenous and oral 
rifampicin were donated by Sanofi. Fixed-dose combination antituberculous therapy was produced 
by Macleod’s pharmaceuticals.  
Role of the funding source 
The funders had no role in the study design, data collection, analysis, or interpretation of the results, 
nor writing of the manuscript.  
Results 
Study population 
From 14th January 2019 through 17th December 2019, 139 adults with suspected TBM were assessed 
for eligibility of which 61 were enrolled, including 31 (51%) with microbiologically confirmed TBM, 
see Figure 1. One participant in the PO-35 arm was withdrawn on day 2 due to baseline ALT >3x ULN. 
An additional participant was enrolled to replace the withdrawal, and randomised to the SOC care 
arm giving rise to 21 participants in that arm. One participant withdrew consent for follow-up on day 
7. One participant left the hospital against medical advice on day 3 and was lost to follow-up.
Participant baseline characteristics are described in Table 1. The majority of participants (56/61,
92%) were HIV-positive with a median CD4 count of 50 cells/µl (IQR 46–56), a median HIV viral load
of 4815 copies/ml, and 20 (33%) were on ART with a median duration of 36 days (IQR 16 to 61 days).
There were no cases of rifampicin-resistant disease identified by CSF or urine Xpert Ultra. The
characteristics at baseline were balanced between the three arms.
Primary outcomes 
Compared to the control, rifampicin administered IV at 20 mg/kg/day and orally at 35mg/kg/day 
resulted in greater than proportional increases in geometric mean serum peak and total exposure 
and CSF concentration. On day 2 in the control arm, serum Cmax was 6.0 mg/L (95%CI, 4.20-8.68) and 
AUC0-24 was 42.9 h×mg/L (95%CI, 29.2-63.0). With IV-20 arm, Cmax increased 6-fold to 36.2 mg/L 
(95%CI, 31.8-41.2) and AUC0-24 increased 5-fold to 217 h×mg/L (95%CI, 202-306; p<0.001 for each 
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comparison with control). In the PO-35 arm, Cmax increased 5-fold to 29.3 mg/L (95%CI, 23.0-37.5) 
and AUC0-24 increased ~8-fold to 327 h×mg/L (95%CI, 248-430; p<0.001 for each). In CSF, with 
standard-of-care treatment 56% (10/18) of participants had undetectable rifampicin (<0.25 mg/L) 
and geometric mean concentration was 0.27 mg/L (95%CI, <0.25–0.45). CSF rifampicin was 
detectable in all participants in the intensified arms. Geometric mean CSF concentrations were ~6-
fold higher with IV-20 at 1.74 mg/L (95%CI, 1.20-2.53) and 8-fold higher with PO-35 at 2.17 mg/L 
(95%CI, 1.64-2.86; p<0.001 for each). A CSF concentration at or above 1 mg/L, which is the 
rifampicin minimal inhibitory concentration for the predominant M. tuberculosis strain in Uganda,25 
occurred in 11% (2/18) with standard-of-care, 93% (14/15) with IV-20, and 95% (18/19) with PO-35 
(p<0.001). PK results are further described in Table 2 and Figure 2. 
At day 14, when rifampicin cytochrome enzyme autoinduction is approximately 90% established,23 
geometric mean exposures had decreased in the arms with oral (but not intravenous) rifampicin, but 
exposures in the intervention arms remained higher than those in the control arm. The median 
sample collection time post-dose was 2.67 hours (IQR 2.18–3.17) for serum and 2.83 hours (IQR, 
2.18–3.17) for CSF on day 14. The geometric mean concentrations increased from 4.58 mg/L (95%CI, 
2.67–7.86 mg/L; n=13) with standard-of-care to 34.2 mg/L (95%CI, 29.2–40.1; n=11; p<0.001) with 
IV-20 and 15.9 mg/L (95%CI, 6.85–36.9 mg/L; n=13; p=0.003) with PO-35mg/kg. In the CSF at day 14,
11% (1/9) of participants in the standard-of-care arm had detectable rifampicin (>0.25 mg/L), whilst
88% (7/8) with IV-20 and 89% (8/9) PO-35mg/kg arm had detectable CSF levels. Geometric mean CSF
concentrations were 0.57 (0.30-1.11, p=0.001) for IV-20 and 0.45 (95% CI 0.21–0.96, p=0.007) for
PO-35.
During the 8-week intervention period, grade 3 to 5 adverse events occurred in 15 (71%) of 
standard-of-care, 10 (50%) of IV-20, and 11 (55%) PO-35 participants (p=0.342).  No participants 
interrupted rifampicin for >5 days during the intervention period. The composite safety endpoint did 
not differ between trial arms (p=0.342), see Table 3. There was no difference in time to experiencing 
an AE when comparing the intervention arms to the control: IV-20 sub-distribution hazard ratio 
(SHR) 0.734 (95%CI, 0.33-1.65, p=0.456) and PO-35 1.04 (95%CI, 0.53-2.05, p=0.909). The most 
common grade >3 event was elevated ALT, which occurred in 7 (11.7%) of participants overall. This 
was attributed to drug-induced liver injury (DILI), which occurred in 4 (19%) participants in the 
standard-of-care arm, 1 (5%) with IV-20, and 2 (10%) with PO-35. ALT elevation was grade 3 in all 
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cases, except one episode of grade 4 ALT elevation in the standard-of-care arm. In all instances, liver 
enzymes improved after interrupting pyrazinamide whilst other TB drugs were continued. There 
were no episodes of fulminant hepatic failure. Isolated hyperbilirubinaemia, a recognised adverse 
effect of rifampicin, occurred in three participants (grade 4) during the intervention period, one of 
which was in the IV-20 arm and the other two were in the control arm.  
Secondary outcomes 
Overall, during the 8-week intervention period, 18 (29.5%) participants died; 5/21, 6/20 and 7/20 in 
the control, IV-20, and PO-35 arms, respectively. There was no evidence of an association with 
treatment arm (LR test p-value=0.595). By the end of the 24-week follow-up period, 24 (39.3%) of 
participants died; 7/21, 7/20, and 10/20 in the control, IV-20, and PO-35 arm, respectively. There 
was no evidence of an association with treatment arm (LR test p-value=0.333). Kaplan-Meier survival 
curves are shown in Figure 3. 
Mean modified Rankin scores (0 to 6 score on which 0 is asymptomatic and 6 is dead) at week 8 
were 2.06, 1.84, and 2.30 (p=0.75) and week 24 were 0.86, 0.81, and 1.14 in the standard-of-care, 
IV-20, and PO-35 arms, respectively (p=0.85). Time to normalization of Glasgow coma scale did not
differ compared to the control: IV-20 sub-distribution hazard ratio (SHR) 1.20 (95%CI, 0.58-2.48;
p=0.630) and PO-35 0.85 (95%CI, 0.41-1.77; p=0.658). In the linear mixed model of GCS profiles, GCS
increased by 0.13 (95% CI, 0.07–0.18; p=<0.001) per day, with no evidence of a difference by arm
(p=0.953), see supplementary materials.
Discussion 
In this randomised controlled trial of high-dose rifampicin involving predominantly HIV-positive 
adults with suspected TBM, both high-dose intravenous and oral rifampicin were safe and resulted in 
a far greater proportion of participants achieving CSF levels above the rifampicin MIC when 
compared to standard TB treatment. With the currently WHO-recommended TB therapy only 1 in 10 
participants achieved a CSF rifampicin concentration above the MIC. As well as being rapidly 
bactericidal, rifampicin is the key sterilising drug in the regimen, so achieving adequate levels at the 
site of disease is essential and attainment of the drug MIC should be considered a bare minimum.  
Critical illness is known to alter drug PK, and in the early days of TBM treatment patients may be 
comatose, have vomiting or require drugs to be given via a nasogastric tube, all of which may further 
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jeopardise effective early treatment. HIV infection also appears to alter rifampicin PK in the initial 
days of therapy. A recent meta-analysis of rifampicin PK data from 70 studies including 3477 
participants confirmed that during the initial days of standard TB treatment rifampicin total plasma 
exposure is indeed reduced in PLHIV (mean AUC0-24 was 37.2 h×mg/L in HIV-positive versus 56.7 
h×mg/L in HIV-negative adults, p=0.003), though this difference diminished at steady-state.24 Our 
participants in the standard-of-care arm had a serum geometric mean AUC0-24 of 42.9 h×mg/L, similar 
to the PLHIV and lower than the HIV-negative group in the meta-analysis.24 It is encouraging to see 
that even in a population with advanced HIV disease high blood and CSF rifampicin exposures were 
obtained with oral dosing of rifampicin at 35 mg/kg/day in this study.   
The increases in rifampicin dosing resulted in greater than proportional increases in serum and CSF 
exposure: a 2-fold dose-increase administered IV resulted in ~6-fold increases in exposure, and a 3.5-
fold oral dose-increase resulted in a ~8-fold increase in exposure. The supra-proportional increase in 
exposures observed here, and in other studies, is likely to be attributable to 1) saturation of the 
beta-esterase metabolizing enzymes and/or p-glycoprotein with a reduction in the first-pass effect 
and thereby increased bioavailability of oral drug; 2) saturation of the biliary excretion pathway.23,5 
Rifampicin induces its own metabolism via the pregnane X receptor, a phenomenon known as 
clearance autoinduction, resulting in lower exposure at steady state. Despite this phenomenon, we 
found that serum and CSF rifampicin concentrations in the interventional arms were still higher than 
those in the control arm at day 14 when clearance autoinduction is well established. The serum and 
CSF PK parameters in the intervention arms were comparable, although not formally tested.  
In relation to other intensification studies, the day 2 total serum rifampicin exposures achieved in 
the IV-20 and PO-35 arms were 3- and 4-fold higher respectively than that of the intensified arm of 
the Vietnamese trial by Heemskerk et al (AUC0-24 82.5 h×mg/L following rifampicin 15mg/kg/day).14 
The total exposure achieved with PO-35 (AUC0-24 327 h×mg/L) is comparable to the most recent 
Indonesian phase II trial, which tested rifampicin 30 mg/kg/day and reported an AUC0-24 of 294 
h×mg/L.15 Owing to the difficulty in consistently culturing M. tuberculosis, CSF does not lend itself to 
microbial kill studies. We therefore cannot draw any parallels with the mycobacterial clearance rates 
in high-dose rifampicin pulmonary TB studies but our data can contribute to a PK-PD model to 
understand the exposure-response relationship in this Ugandan HIV/TBM population. Recently, PK-
PD data from the Vietnamese intensification trial has sparked further interest in the importance of 
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isoniazid, which has high early bactericidal activity and excellent CSF penetration.14 Heemskerk et al 
found that low isoniazid exposure was predictive of death and linked to a fast metabolizer N-
acetyltransferase 2 phenotype.14 For an African population this may be less relevant, considering 
that the proportion of fast acetylators is lower as compared to Asians ethnicities. Apart from this, 
isoniazid monoresistance (up to 25% prevalence in some countries) cannot readily be detected at 
baseline with the Xpert MTB/Rif assay. Therefore, obtaining therapeutic concentrations of other key 
drugs, especially rifampicin, in the CSF is absolutely critical and can only be achieved by increasing 
the currently recommended rifampicin dose. 
Importantly, despite the substantial increase in rifampicin exposure in the intervention arms, there 
was no increase in toxicity, in-line with other studies of largely HIV-negative individuals.5,10,15,26 The 
adverse effects of rifampicin are well described and include hypersensitivity reactions featuring fever 
and rash, thrombocytopaenia, liver toxicity and hyperbilirubinaemia. Recent data from the PanACEA 
group suggests that rifampicin toxicity is largely idiosyncratic.9 Our findings support the notion that 
drug exposure is not a driver of toxicity in this population. This is reassuring data as PLHIV are at 
markedly increased risk of drug-related toxicity including cutaneous drug reactions, hypersensitivity, 
liver toxicity, and complications relating to polypharmacy and immune reconstitution.19,18 Due to the 
critically ill and immunocompromised nature of the trial population, grade 3-5 adverse events were 
experienced by over half (59%, 36/61) of participants but largely appeared to be a complication of 
the underlying disease process, and events were evenly distributed across study arms. Interruption 
of antituberculous therapy in the treatment of TBM is associated with increased mortality.27 We 
therefore used an algorithm for the management of DILI in which pyrazinamide was interrupted in 
isolation with regular monitoring of liver function tests, allowing other antituberculous agents to be 
continued. This was effective in all occurrences of DILI during the intensive phase of treatment. We 
did not observe any impact of high-dose rifampicin on 8 or 24-week mortality, nor functional 
outcomes by modified Rankin score. The phase II study was not powered for these clinical endpoints 
and thus an adequately powered trial is justified having established the safety of high-dose 
rifampicin in this population.  
HIV is central to both the incidence and pathogenesis of TBM. Although HIV status was not an entry 
criterion for the study, 92% of those eligible to enrol were PLHIV. Under half were on ART at 
enrolment, none were virologically suppressed, and median CD4 count was 50 cells/µl. Effective HIV 
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treatment can reduce the risk of TB by up to 80%, therefore earlier HIV diagnosis and effective long-
term treatment are key upstream interventions to reduce the incidence of TB.28 Other important 
upstream interventions include 1) TB preventative therapy and 2) screening for TB prior to ART 
initiation. It is noteworthy that a third of our participants were presenting to hospital with TBM in 
the weeks following ART initiation, suggesting that symptom-based TB screening had failed. Access 
to urine TB diagnostics (e.g. TB-lipoarabinomannan) in HIV clinic settings is important to reduce 
unmasking TB immune reconstitution inflammatory syndrome, which can be devastating in the CNS. 
The roll out of dolutegravir as first-line ART in Uganda began in 2018 and may support improved 
rates of virological suppression in the future. We dose-adjusted dolutegravir to 50 mg twice daily, 
which is safe and effective with standard dose rifampicin.29,30 A PK study is ongoing in Uganda 
(SAEFRIF4) to assess the impact of rifampicin 35 mg/kg on dolutegravir PK. 
We acknowledge that this study has a number of limitations. Due to critical illness and inability to 
stand, baseline weight was frequently estimated, which may have resulted in imprecision in the 
weight-based dosing. Ideally, we would have collected blood and CSF samples at more time points, 
especially in the clearance phase, to allow estimation of elimination rate and half-life. However, we 
prioritised participant safety and comfort so restricted blood sampling to daylight working hours and 
performed a single PK lumbar puncture. As with many TBM trials microbiological confirmation was 
only made in around half of participants. Due to the complexity of performing rifampicin MIC, the 
MIC was derived from population estimates within the same TB laboratory.25  
This phase II study provides important evidence that high-dose rifampicin increases CSF and serum 
exposures in a predominantly HIV-positive population. These data, taken together with data from 
Indonesian studies, justify a phase III trial to investigate safety in a wider population and the impact 
of high-dose on survival. We look forward to the outcome of a number of large trials already in the 
pipeline to examine the clinical impact of high-dose oral rifampicin in isolation (ISRCTN15668391), or 
with adjunctive linezolid and aspirin (NCT04145258, NCT03927313) in patients with TBM. Whether 
in future the optimised TBM treatment regimen will include high-dose rifampicin remains to be 
concluded.  
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Table 1. Baseline characteristics 
IV-20 arm PO-35 arm Control arm 
N randomised 20 20 21 
Age, median (IQR) years 33.5 (25.5 - 38.5) 32.5 (26.5 - 38.5) 34.0 (27 – 36) 
Gender, male N (%) 13.0 (65) 12.0 (60) 9.00 (42.9) 
Weight, median (IQR), kg 55 (47.5 - 58.5) 50.5 (50 – 55) 50.0 (45 – 55) 
HIV details 
HIV-positive, N (%) 18.0 (90) 18 (90) 20 (95.2) 
HIV-negative, N (%) 2 (10) 2 (10) 1 (4.80) 
55 (45 - 59) 50.5 (50 - 55) 50 (45 - 55) 
7840  
(4014 – 574462) 
6523  
(4815 – 92346) 
2333.5 
(945 – 19316) 
12 (60) 11 (55) 4 (19.0) 
Amongst those HIV positive: 
CD4 T cell count, median (IQR)cells/µl 
HIV viral load, median (IQR) copies/
ml 
Currently receiving ART, N (%) 
Antiretroviral therapy duration, 
median (range), weeks 28 (0 – 62.3) 26 (1.6 – 6.6) 61 (0.7 – 195.9) 
MRC TB meningitis grade, n (%) 
I 3 (15) 1 (5) 2 (9.5) 
II 13 (65) 16 (80) 12 (57.1) 
III 4 (20) 3 (15) 7 (33.3) 
Uniform case definition, n (%) 
Definite (microbiologically 
confirmed) 8 (40) 12 (60) 11 (52.4) 
Probable 4 (20) 4 (20) 6 (28.6) 
Possible 7 (35) 4 (20) 1 (4.8) 
Not 1 (5) 0 (0) 3 (14.3) 
CSF information, median (IQR) 
Opening pressure, mmH20 230 (155 - 320) 220 (135 - 300) 135 (100 - 230) 
White cells,cells/ µl) 24 (4 - 162.5) 4 (4 - 145) 4 (4 - 122.5) 
Protein, mg/dl 154.5 (105 - 186) 125 (73 - 188) 92 (30 - 164) 
Glucose, mg/dl 41 (21 - 68) 44 (21 - 66.7) 38 (18 - 64) 
Lactate, mmol/L 8.5 (7.30 - 9.80) 6.9 (2.9 - 11.1) 8 (5.2 - 10.4) 
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Table 2. Rifampicin Pharmacokinetic data by treatment arm 
IV-20 PO-35 Control P value a 
AUC0-8 (h×mg/L) b 








(21.7 - 42.8) 
<0.001 
Ratio to control 5.33 5.31 - 
P value d <0.001 <0.001 - 
AUC0_24 (h×mg/L) e 




(202 - 306) 
327 
(248 - 430) 
42.9 
(29.2 – 63.0) <0.001 
Ratio to control 5.80 7.62 - 
P value d  <0.001 <0.001 - 
n (%) achieving target of >300 h×mg/L 7 (36.8) 9 (47.4) 0 (0%) <0.001 j 
Cmax (mg/l) b 








(4.20 - 8.68) 
<0.001 
Ratio to control 5.99 4.86 - 
P value d <0.001 <0.001 - 





(1.83 - 3.85) 
4.05 
(2.17 - 7.33) 
2.83 
(2.08 - 8.25) 
0.002 g 
CCSF (mg/l) 




(1.20 - 2.53) 
2.17 
(1.64 - 2.86) 
0.27 h 
(0.17 - 0.45) 0.058 
Ratio to control 6.44 8.00 - 
P value d <0.001 <0.001 
n (%) with detectable CSF level  15 (100) 19 (100) 8 (44)  <0.001 f 
n (%) with concentration above 
rifampicin MIC (1 mg/L) 
14 (93.3%) 18 (94.7%) 2 (11.1%) <0.001 f 
Median (IQR) hours post-dose to CSF 
sample 4.70 (3.28 – 5.92) 4.55 (3.08 – 6.20) 
4.83 (3.78 – 
5.5) 
a) likelihood ratio p-value from general linear regression 
b) Standard two step non-compartmental analysis on Phoenix WinNonLin. Where concentration was still increasing at the last
sampling point it was not possible to determine Cmax 
c) AUC0-8 was based on AUC0-last if Tlast was sufficiently close to 8 hours 
d) Pairwise comparison between experimental arm and control arm from general linear regression
e) AUC0-24 derived using published population PK model in NONMEM23 
f) P value by chi squared test      g) P value by Kruskal Wallis test 
h) 10 participants had CSF levels below the lower limit of quantification (LLOQ = 0.25mg/l). A value of 50% of the LLOQ was assigned. 
j) P values by Fisher’s exact test   MIC = minimum inhibitory concentration 
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(n=21) P value 
TOTAL NUMBER OF EVENTS N (%) N (%) N (%) 
Grade 3 6 (30) 6 (30) 12 (57) 0.12 
Grade 4  3 (15) 4 (20) 4 (19) 0.91 
Grade 5  5 (25) 7 (35) 5 (24) 0.68 
NEUROLOGICAL EVENT  
Cerebrovascular accident 2 (10) 1 (5) 1 (4.8) 
Seizures 1 (5) 2 (10) 2 (9.5) 
Headache 0 (0) 0 (0.0) 1 (4.8) 
Hearing loss 0 (0) 1 (5) 0 (0) 
Neuropathy 0 (0) 0 (0) 1 (4.8) 
Altered mental status 2 (10) 1 (5) 2 (9.5) 
GENERALISED 
Fever 0 (0) 2 (10) 1 (4.8) 
Rash (Kaposi's sarcoma) 0 (0) 1 (5) 1 (4.8) 
GASTROINTESTINAL & HEPATIC 
Abdominal pain  0 (0) 1 (5.0) 0 (0) 
Dysphagia 1 (5) 0 (0) 0 (0) 
Elevated alanine transaminase 1 (5) 2 (10) 4 (19) 
Elevated bilirubin 1 (5) 0 (0) 2 (9.5) 
OTHER 
Anaemia 1 (5) 1 (5) 2 (9.5) 
Hypotension 1 (5) 0 (0) 0 (0) 
Thrombosis 0 (0) 0 (0) 1 (4.8) 
Elevated creatinine  1 (5) 1 (5) 1 (4.8) 
Urinary tract obstruction 0 (0) 1 (5) 0 (0) 
Respiratory distress 1 (5) 2 (10) 3 (14) 
Low sodium 1 (5) 1 (5) 0 (0) 
AEs in relation to pre-specified secondary endpoint  
N (%) with a grade 3-5 AE 10 (50) 11 (55) 15 (71) 0.343 
N (%) with a Serious AE 8 (40) 7 (35) 7 (33) 0.899 
N (%) of patient with discontinuation 
of rifampicin for >5 days in week 0-8  0 0 0 
Composite of 1 or 2 or 3 10 (50) 11 (55) 15 (71.4) 0.343 
Values are N (%). P values by Chi-square test. All Serious AEs were represented within the grade 3-5 AE row and 
already included in the composite endpoint  
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Figure 1. CONSORT diagram 
Assessed for eligibility n = 139
(Kampala n = 115, Mbarara n = 24) 
Completed 
follow up = 12 









Too unwell to 
undergo PK 
sampling n=1
Underwent PK sampling n=19
LTFU n = 1 
Footnotes:
* Reasons inclusion criteria not met were: research medical officer deemed that the clinical picture was not
suggestive of TB meningitis and/or CSF Xpert Ultra was negative and the CSF glucose was not below the inclusion
threshold (CSF:plasma ratio <50% or CSF glucose <65 mg/dl or <3.6 mmol)
Participants who were LTFU, withdrew consent or withdrawn were censored at their time of last contact
• One LTFU occurred on day 3 when the participant left hospital against medical advice
• One protocol-directed withdrawal was for baseline ALT >3x ULN (withdrawn on day 2, PK visit completed)
• One participant withdrew consent for further follow-up on day 7 after transferring to another facility
Underwent PK sampling n=19
Too unwell to 
undergo PK 
sampling n=1
Protocol-directed withdrawal n = 1 
Withdrew consent n=1
Completed 
follow up = 8 died= 10 
Completed 
follow up = 14 died= 7 
Did not meet inclusion criteria* n= 73
Met exclusion criteria n=5
• Jaundice or cirrhosis n=3
• >3 days antituberculous drugs n=1
• Pregnancy n=1
Underwent PK sampling n=21
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Figure 2 a-c. Pharmacokinetic parameters on day 2 
Distribution of rifampicin a) Area under the concentration-time curve from 0 to 24 hours post-dose (AUC0–24), b) maximum concentration in plasma (Cmax), c) CSF 
concentration (CCSF), the horizontal red line is the M. tuberculosis Uganda II MIC of 1 mg/L. The x axis shows the three trial arms: intravenous rifampicin 20 mg/kg, oral 
rifampicin 35 mg/kg, control rifampicin 10 mg/kg, in combination with standard doses of isoniazid, pyrazinamide, ethambutol and corticosteroids. Red dashed line represents 
geometric mean concentrations.  






















































































Figure 3. Kaplan-Meier survival 
Survival by trial arm. Follow-up time is 24 weeks. Withdrawals (n=2) and loss to follow up (n=1) were 
censored at their last time of contact. P value by log rank test. The study was not powered for 
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Figure 1. HIV antiretroviral therapy (ART) status. The blue segments represent participants with 
recent HIV diagnoses (within 3 months of trial enrolment). The yellow segments represent 
participants with HIV for greater than 3 months. TLE=tenofovir, lamivudine, efavirenz, TLD=tenofovir, 





























Table 1a-c. Dosing of rifampicin by trial arm 
R = rifampicin H = isoniazid Z = pyrazinamide E = ethambutol 
a) Intravenous rifampicin dosing by body weight























































































































































28.5 - 31.49 600 10 1.0 
31.5 – 34.49 660 11 1.1 
34.5 – 37.49 720 12 1.2 
37.5 – 40.49 780 13 1.3 
40.5 – 43.49 840 14 1.4 
43.5 – 46.49 900 15 1.5 
46.5 – 49.49 960 16 1.6 
49.5 – 52.49 1020 17 1.7 
52.5 – 55.49 1080 18 1.8 
55.5 – 58.49 1140 19 1.9 
58.5 – 61.49 1200 20 2.0 
61.5 – 64.49 1260 21 2.1 
64.5 – 67.49 1320 22 2.2 
67.5 – 70.49 1380 23 2.3 
70.5 – 73.49 1440 24 2.4 
73.5 – 76.49 1500 25 2.5 
76.5 – 79.49 1560 26 2.6 
79.5 – 82.49 1620 27 2.7 
82.5 – 85.49 1680 28 2.8 
85.5 – 88.49 1740 29 2.9 
88.5 – 91.49 1800 30 3.0 
b) Rifampicin dosing in high dose oral rifampicin arm
Weight Number of RHZE tabs 
(150/75/400/275 mg) 
Additional R 300mg 
tablets 
Total R dose 
(mg) 
30-37 kg 2 tabs 3 tabs 1200 
38-54 kg 3 tabs 4 tabs 1650 
55-70 kg 4 tabs 5 tabs 2100 
≥ 71 kg 5 tabs 6 tabs 2550 
c) Rifampicin dosing in the control arm
Weight Number of RHZE tablets (150 / 
75 / 400 / 275 mg) 
30-37 kg 2 tabs 
38-54 kg 3 tabs 
55-70 kg 4 tabs 
≥ 71 kg 5 tabs 
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Determination of Rifampicin concentration in plasma and CSF using HPLC-UV 
An in-house high-performance liquid chromatography with ultraviolet detection (HPLC UV) was used 
to determine the concentration of rifampicin in human plasma. Rifampicin (RIF) was extracted from 1 
ml of plasma after addition of rifapentine (internal standard) using solid phase extraction. HPLC 
analysis was carried out on a Shimadzu LC-2010C HT system (Kyoto, Japan) equipped with a controller, 
a quaternary gradient pump, an ultraviolet detector, an autosampler, a column oven, an on-line 
degasser and was remotely operated by class VP software. The analytical column was a Phenyl-Hexyl, 
150 mm × 3 mm ID, 3µm particle size (Thermoscientific, USA). The mobile phase comprised methanol 
(eluent1), acetonitrile (eluent2) and a mixture of 10 mM ammonium acetate buffer (pH 5.0 adjusted 
with acetic acid)/acetonitrile 98/2 (eluent3) using a gradient elution program. 5% methanol(eluent1) 
was pumped constantly over the total run time. The gradient started with 55% eluent 2 in 27 minutes, 
then 95% eluent 2 in 0.5 minutes where it was maintained for 7.5 minutes. The column was 
conditioned with 5% eluent 2 for five minutes before the next injection. The injection volume was 10 
µL. The UV detector was set at 254nm over the run time of 40 minutes. The flow rate was 0.45 ml/min 
at 40
o
C. Unknown concentrations were derived from linear regression analysis of the peak area ratios 
(analyte/internal standard) vs. concentration curve. The linearity was verified using estimates of 
correlation coefficient (r). The calibration curve for rifampicin in plasma covered a range from 0.25 to 
15mg/L.  
The method was validated according to the published FDA guidelines
1
. The average recovery of RIF 
from plasma was 100% while that of the internal standard was 104%. The within batch precision(%CV) 
of quality control samples and for dilutions of samples above the upper limit of quantification was 2.88 
to 3.57%, and the batch to batch precision was 3.41 to 4.78%. Accuracy was 94-102%. The samples 
were stable for at least 6hrs on the bench and 48hrs in the auto sampler. There was no interference 
with endogenous compound in the 5 plasma samples of volunteers tested. No interference with 
nevirapine, efavirenz, lopinavir, atazanavir, darunavir, etravirine, rifampicin, isoniazid, pyrazinamide, 
ethambutol, carbamazepine, phenytoin, saquinavir, vancomycin, ceftriaxone, tenofovir, amikacin, 
gentamycin, methotrexate, carboplatin and cefotaxime.  
Quality control samples spiked in CSF were run in five folds each and analyzed using calibrators spiked 
in plasma. The deviation from the expected value was between 0.1-15%. 
1. US FDA D. Bioanalytical method validation guidance for industry. 2018.
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Table 2. Individualised AE details. This table shows all the AEs in the 24-week follow up period. The safety endpoint was based on AEs during the intervention period 













Outcome of AE 
IV-20 110038 Kampala 16/02/2019 8 respiratory distress aspiration 3 no not related probably related probably related persistent, expect to resolve 
IV-20 110038 Kampala 22/04/2019 73 seizures 
generalized 
seizures 
5 yes not related probably related definitely related death, unrelated 
IV-20 110038 Kampala 25/03/2019 45 seizures 
generalized 
seizures 
3 yes not related definitely related definitely related resolved 
IV-20 110038 Kampala 16/02/2019 8 seizures partial seizures 3 no not related probably related probably related persistent, expect to resolve 
IV-20 110065 Kampala 13/03/2019 1 stroke TBM 5 yes not related definitely related definitely related death, unrelated 
IV-20 110102 Kampala 15/04/2019 0 altered mental status TBM 5 yes not related probably related definitely related death, unrelated 
IV-20 110135 Kampala 27/05/2019 0 stroke stroke 5 yes not related not related possibly related severity worsened to grade 5 
IV-20 110193 Kampala 15/09/2019 39 dysphagia candidiasis 3 yes not related definitely related not related resolved 
IV-20 110220 Kampala 30/08/2019 1 altered mental status TBM 5 yes not related definitely related definitely related severity worsened to grade 5 
IV-20 110326 Kampala 05/12/2019 2 elevated creatinine acute kidney injury 3 no not related possibly related possibly related resolved 
IV-20 110327 Kampala 11/12/2019 8 elevated ALT DILI 3 no 
probably 
related 
possibly related possibly related resolved 
IV-20 110332 Kampala 08/01/2020 29 low sodium TBM 4 yes not related not related probably related severity worsened to grade 5 
IV-20 120089 Mbarara 11/10/2019 9 low haemoglobin diarrhoea 4 no not related probably related not related resolved 
IV-20 120089 Mbarara 30/10/2019 28 hypotension sepsis 5 yes possibly related possibly related not related severity worsened to grade 5 
IV-20 120089 Kampala 31/10/2019 29 bilirubin, high Other 4 no 
probably 
related 
possibly related possibly related chronic, not expect to resolve 
PO-35 110014 Kampala 21/01/2019 0 elevated creatinine acute kidney injury 4 no not related not related probably related resolved 
PO-35 110014 Kampala 28/01/2019 7 elevated ALT DILI 3 no possibly related possibly related possibly related resolved 
PO-35 110071 Kampala 25/04/2019 35 abdominal pain Other 5 yes not related not related possibly related severity worsened to grade 5 
PO-35 110071 Kampala 29/03/2019 8 
urinary tract 
obstruction 
Other 3 no not related not related not related persistent, expect to resolve 
PO-35 110124 Kampala 24/05/2019 11 hearing loss hearing loss 4 no not related possibly related definitely related chronic, not expect to resolve 
PO-35 110145 Kampala 19/07/2019 37 fever TBM 5 no not related probably related definitely related severity worsened to grade 5 
PO-35 110188 Kampala 08/01/2020 160 dysphagia KS disseminated 5 yes not related not related definitely related severity worsened to grade 5 
PO-35 110214 Kampala 03/09/2019 12 low sodium TBM 3 no not related probably related definitely related chronic, not expect to resolve 
PO-35 110214 Kampala 15/09/2019 24 seizures TBM 5 yes not related probably related definitely related severity worsened to grade 5 
PO-35 110230 Kampala 14/09/2019 4 altered mental status TBM 5 yes not related definitely related definitely related severity worsened to grade 5 
PO-35 110269 Kampala 20/10/2019 4 stroke stroke 4 yes not related probably related definitely related chronic, not expect to resolve 
PO-35 110269 Kampala 24/10/2019 8 fever drug fever 4 no possibly related possibly related possibly related resolved 
PO-35 110269 Kampala 11/11/2019 26 low haemoglobin Other 3 no not related probably related probably related persistent, expect to resolve 
PO-35 110291 Kampala 07/04/2020 154 vomitting liver cirrhosis 4 yes not related not related not related chronic, not expect to resolve 
189 
PO-35 110316 Kampala 28/11/2019 6 rash KS disseminated 5 yes not related definitely related definitely related severity worsened to grade 5 
PO-35 110333 Kampala 16/12/2019 6 elevated ALT DILI 3 no possibly related possibly related probably related resolved 
PO-35 120099 Mbarara 10/11/2019 6 respiratory distress 
pneumonia, 
bacterial 
5 yes not related definitely related definitely related death, unrelated 
PO-35 120113 Mbarara 24/11/2019 3 seizures partial seizures 3 no not related possibly related probably related resolved 
PO-35 120113 Mbarara 29/11/2019 8 respiratory distress 
pneumocystis 
pneumonia 
5 yes not related probably related probably related severity worsened to grade 5 
Control 110061 Kampala 28/03/2019 21 elevated ALT DILI 3 no possibly related not related not related resolved 
Control 110061 Kampala 02/05/2019 56 rash KS disseminated 3 no not related definitely related not related persistent, expect to resolve 
Control 110061 Kampala 29/05/2019 83 bilirubin, high DILI 4 no possibly related possibly related possibly related resolved 
Control 110087 Kampala 06/04/2019 4 stroke stroke 5 no not related probably related definitely related severity worsened to grade 5 
Control 110109 Kampala 28/04/2019 3 altered mental status TBM 5 yes not related probably related definitely related severity worsened to grade 5 
Control 110144 Kampala 28/06/2019 16 seizures 
generalized 
seizures 
4 yes not related possibly related probably related resolved 
Control 110144 Kampala 24/06/2019 12 
neurosensory 
alteration 
TBM 3 no not related possibly related not related persistent, expect to resolve 
Control 110144 Kampala 01/08/2019 50 respiratory distress anaemia 3 yes not related possibly related probably related persistent, expect to resolve 
Control 110152 Kampala 29/06/2019 4 respiratory distress 
pneumonia, 
bacterial 
3 no not related probably related probably related resolved 
Control 110159 Kampala 05/08/2019 34 headache 
cryptococcal 
meningitis 
3 yes not related definitely related not related resolved 
Control 110177 Kampala 10/09/2019 50 elevated ALT DILI 3 no possibly related possibly related possibly related resolved 
Control 110195 Kampala 06/10/2019 55 fever sepsis 3 yes not related possibly related not related resolved with sequelae 
Control 110195 Kampala 07/10/2019 60 bilirubin, high Other 4 no 
probably 
related 
possibly related possibly related resolved 
Control 110195 Kampala 22/11/2019 102 respiratory distress Other 5 yes not related probably related probably related death, unrelated 
Control 110228 Kampala 11/09/2019 2 elevated creatinine acute kidney injury 3 no not related definitely related definitely related chronic, not expect to resolve 
Control 110228 Kampala 09/09/2019 0 altered mental status TBM 5 yes not related probably related definitely related severity worsened to grade 5 
Control 110250 Kampala 15/10/2019 13 elevated ALT DILI 4 no possibly related possibly related probably related resolved 
Control 110251 Kampala 27/11/2019 57 bilirubin, high Other 4 no 
probably 
related 
possibly related possibly related resolved 
Control 110287 Kampala 04/12/2019 34 elevated ALT DILI 3 no possibly related possibly related possibly related resolved 
Control 110330 Kampala 06/04/2020 123 heart failure heart failure 5 yes not related not related not related severity worsened to grade 5 
Control 110330 Kampala 27/12/2019 22 fever Other 3 yes not related probably related probably related resolved 
Control 110330 Kampala 04/02/2020 61 fever Other 3 yes not related not related not related 
persistent, expected to 
resolve 
Control 110344 Kampala 21/12/2019 4 seizures TBM 5 yes not related definitely related definitely related severity worsened to grade 5 
Control 120108 Mbarara 03/12/2019 15 thrombosis 
deep vein 
thrombosis 
3 no not related possibly related possibly related persistent, expect to resolve 
Control 120108 Mbarara 22/11/2019 4 respiratory distress aspiration 5 no not related not related possibly related severity worsened to grade 5 
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Figure 2. Liver function test trajectories in participants who experienced drug-induced liver injury 
The figures demonstrate that the timing of ALT 
elevation was between weeks 1 to 6 and was 
generally not accompanied by 















































































Figure 3. Adverse event competing risks regressions 
Time to experiencing an adverse event (AE) was compared between treatment arms using cumulative 
incidence functions and a Cox proportional hazards regression model. Death was considered a 
competing risk. There was no difference in time to experiencing an AE when comparing the 
intervention arms to the control: IV-20 sub-distribution hazard ratio (SHR) 0.734 (95%CI, 0.33-1.65, 
p=0.456) and PO-35 1.04 (95%CI, 0.53-2.05, p=0.909). 
Figure 4. Random effects linear mixed model of Glasgow coma scale score by study day. 
In the linear mixed model of GCS profiles, GCS increased by 0.13 (95% CI, 0.07–0.18; p=<0.001) per 












































9 Chapter Nine: A Journey of Hope: giving research 
participants a voice to share their experiences and improve 
community engagement around advanced HIV disease in 
Uganda (research paper) 
Foreword 
Public and community engagement is increasingly recognised as an important part of research 
activities. Three broad and often overlapping purposes of public engagement are defined as: 
1. Transmit – to inspire and inform, change, educate, build capacity and involvement, influence
decisions.
2. Collaborate – to collaborate, consider, create or decide something together
3. Receive – to use the views, skills, experience of the public to inspire and inform our own
capacity
It is important that public engagement attempts to encompass all three purposes to avoid it 
becoming a one directional broadcast of a message which may be disconnected with what the 
community want or need. I believe that our research participants are the greatest asset for 
community engagement – they have experienced the disease first-hand, they understand the 
challenges in accessing care that led to them having advanced HIV disease in the first place, they 
know how to communicate at a level that is accessible and meaningful for the public. As such I 
endeavoured to include research participants and other community members in all aspects of 
planning, creation and delivery of the engagement events.  
I was successful in securing three small grants to support public engagement activities, the first from 
LSHTM small grants for public engagement, the second from Makerere University Infection and 
Immunity Centre of Excellence and the third an LSHTM Continued Development Public Engagement 
award. Thereafter, I considered the audience with which it was important to engage, not only the 
community but also with healthcare workers and other stakeholders in the HIV field. The IDI 
community advisory board were instrumental in thinking about engagement methods and 
collaboration to maximise the impact of the activities.  
As a team we delivered a series of multifaceted events over a 14-month period, which have been 
described further in an open letter in African Academy of Sciences Open Research. The messages and 
events have also been summarised in a short video which can be accessed at 
https://www.youtube.com/watch?v=u0tar-jArPI&feature=youtu.be
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Over the last decade excellent progress has been made globally in HIV 
management thanks to antiretroviral therapy (ART) rollout and 
international guidelines now recommending immediate initiation of 
ART in people living with HIV. Despite this, advanced HIV disease (CD4 
less than 200 cells/mL) and opportunistic infections remain a 
persistent challenge and contribute significantly to HIV-associated 
mortality, which equates to 23,000 deaths in Uganda in 2018 alone. 
Our Meningitis Research Team based in Uganda is committed to 
conducting clinical trials to answer important questions regarding 
diagnostics and management of HIV-associated opportunistic 
infections, including tuberculosis and cryptococcal meningitis. 
However, clinical research is impossible without research participants 
and results are meaningless unless they are translated into benefits 
for those affected by the disease. Therefore, we held a series of 
community engagement events with the aims of 1) giving research 









27 Jul 2020 report report
Angela Kaida , Simon Fraser University, 
Burnaby, Canada
1. 
Deborah Baron , University of North2.
AAS Open Research AAS Open Research 2020, 3:33 Last updated: 29 OCT 2020
195
Corresponding author: Fiona V. Cresswell (fionacresswell@doctors.org.uk)
Author roles: Cresswell FV: Conceptualization, Funding Acquisition, Methodology, Project Administration, Resources, Writing – Original 
Draft Preparation, Writing – Review & Editing; Kasibante J: Methodology, Project Administration, Writing – Review & Editing; Martyn EM: 
Investigation, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; Tugume L: 
Investigation, Methodology, Writing – Review & Editing; Stead G: Investigation, Methodology, Project Administration; Ssembambulidde 
K: Investigation, Methodology; Rutakingirwa MK: Investigation, Methodology, Project Administration, Writing – Review & Editing; 
Kagimu E: Investigation, Methodology, Project Administration, Writing – Review & Editing; Nsangi L: Investigation, Methodology, Project 
Administration; Namuju C: Investigation, Methodology; Ndyetukira JF: Investigation, Methodology, Project Administration; 
Ahimbisibwe C: Investigation, Methodology, Project Administration; Kugonza F: Investigation, Methodology; Sadiq A: Investigation, 
Methodology; Namudde A: Methodology, Project Administration; Dobbin J: Investigation, Methodology, Project Administration, Writing 
– Review & Editing; Srishyla D: Investigation, Methodology; Quinn C: Investigation, Methodology, Project Administration, Writing –
Review & Editing; Kabahubya M: Investigation, Methodology, Project Administration; Muzoora C: Methodology; Watiti S: Investigation,
Methodology, Project Administration, Writing – Review & Editing; Meya DB: Conceptualization, Funding Acquisition, Investigation,
Methodology, Project Administration, Resources, Writing – Review & Editing; Elliott AM: Funding Acquisition, Investigation,
Methodology, Project Administration, Resources, Supervision, Writing – Review & Editing
Competing interests: No competing interests were disclosed.
Grant information: This work was supported by the African Academy of Sciences (AAS) through a Makerere University/Uganda Virus 
Research Institute Infection and Immunity Centre of Excellence (MUII-plus) endeavour award. MUII-plus is supported through the 
Developing Excellence in Leadership, Training and Science in Africa (DELTAS Africa) Initiative [DEL-15-004], which is an independent 
funding scheme of the AAS’s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for 
Africa’s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [107743] and the UK 
Government. FVC is supported by the Wellcome Trust through a Clinical PhD Fellowship [210772/Z/18/Z]. The events were funded 
through London School of Hygiene and Tropical Medicine (small grant for public engagement and continued development public 
engagement award) and Makerere University/Uganda Virus Research Institute Infection and Immunity Centre of Excellence endeavour 
award.  
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Copyright: © 2020 Cresswell FV et al. This is an open access article distributed under the terms of the Creative Commons Attribution 
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to cite this article: Cresswell FV, Kasibante J, Martyn EM et al. A Journey of Hope: giving research participants a voice to share 
their experiences and improve community engagement around advanced HIV disease in Uganda [version 2; peer review: 1 
approved, 1 approved with reservations] AAS Open Research 2020, 3:33 https://doi.org/10.12688/aasopenres.13104.2
First published: 27 Jul 2020, 3:33 https://doi.org/10.12688/aasopenres.13104.1 
messages of hope around advanced HIV disease with the community, 
2) dispelling myths and stigma around HIV, and 3) raising awareness
about the complications of advanced HIV disease and local clinical
research and recent scientific advances. The purpose of this Open
Letter is to describe our community engagement experience in
Uganda, where we aimed to give clinical research participants a
greater voice to share their experiences. These activities build upon
decades of work in HIV community engagement and lays a platform
for future research and engagement activities.
Keywords 
Public engagement, advanced HIV diseases, meningitis, clinical 
research
Carolina, Chapel Hill, USA
Any reports and responses or comments on the 
article can be found at the end of the article.
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Introduction
Substantial progress has been made in the treatment and 
prevention of HIV in the last decade thanks largely to the 
widespread roll out of antiretroviral treatment (ART) and 
recommendation to treat all people living with HIV (PLHIV) 
regardless of CD4 cell count. The ambitious UNAIDS 
“90-90-90” target states that, by 2020, 90% of PLHIV should 
be diagnosed, 90% of those diagnosed initiated on ART, and 
90% of those on ART should be virally suppressed (HIV viral 
load <50 copies/ml), aiming to reach the Sustainable Devel-
opment Goal of ending the HIV epidemic by 20301. The 
global efforts to achieve these targets are demonstrated by a 
55% decline of AIDS-related deaths between 2004 and 20182.
While unquestionable strides in starting people on ART have 
been made, gains in recent years are decreasing and 23,000 
people died from HIV-related illness in 2018 in Uganda alone2. 
This is in part due to the remaining challenge of advanced HIV 
disease, defined by the World Health Organisation (WHO) as 
having as CD4 cell count less than 200 cell/µL or clinical 
stage III or IV disease3. Uganda is making good progress 
towards the “90-90-90” targets, with 84% aware of their HIV 
status, 87% of those who are HIV positive on treatment and 
88% of those on treatment virally suppressed, however, stigma 
still acts as a barrier to seeking HIV testing and care4. Moreover, 
those who successfully test may not link to care early enough 
due to systemic barriers. Data suggest that in sub-Saharan 
Africa at least one-third of people starting on ART present 
with advanced HIV disease, a fact which requires addressing 
if global targets are to be reached5.
Our Meningitis Clinical Research Team based at the Infectious 
Diseases Institute (IDI) Kampala and Mbarara Regional Refer-
ral Hospital Uganda, is dedicated to reducing advanced HIV-
associated mortality by improving the diagnosis and treatment 
of common opportunistic infections, including cryptococcal 
and tuberculosis meningitis. Together cryptococcal disease and 
tuberculosis cause over half of HIV-related deaths6,7.
Public engagement seeks to overcome the disconnect between 
scientists and the community, making research more meaningful 
for the public and scientists alike. It can serve to improve 
uptake of research studies and can tackle suspicion about the 
intention of scientists. Three broad and often overlapping 
purposes (or pillars) of public engagement are: 1) to ‘transmit’ 
in order to inspire and inform, change, educate, build capac-
ity and involvement, influence decisions; 2) to ‘collaborate’ in 
order to consider, create or decide something together; 3) to 
‘receive’ in order to use the views, skills, experience of the public 
to inspire and inform our own capacity (Figure 1)8. The specific 
roles of the Meningitis Clinical Research Team in ‘transmitting’, 
‘receiving’ and ‘collaborating’ varied according to the type of 
outreach activity.
Globally, there is a strong history of community stakeholder 
engagement and activism among PLHIV. This is particu-
larly true in Uganda, where community engagement has long 
been a priority of civil society groups, such as The AIDS Sup-
port Organisation (TASO) based on the Greater Involvement of 
People Living with HIV/AIDS (GIPA) principles9. We aimed 
to build on these efforts and also believe it is critical to ensure 
research participants have a voice to share their experiences and 
an opportunity to become advocates of clinical research and 
the condition being studied; their messages may improve the 
wellbeing and save the lives of others in their communities. 
With the support of public engagement funding through 
London School of Hygiene and Tropical Medicine and 
Makerere University/Uganda Virus Research Institute Infec-
tion and Immunity Centre of Excellence, we designed and 
Figure 1. Purposes and pillars of public engagement.
     Amendments from Version 1
We have taken on board the reviewers constructive suggestions and 
modified the manuscript accordingly.
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implemented a series of multifaceted events between December 
2018 and January 2020. The overarching aims included giv-
ing clinical research participants (who are survivors of advanced 
HIV disease) a voice in sharing their experiences of clinical 
research and messages of hope around advanced HIV disease 
with the community. This included dispelling myths and 
stigma around HIV, raising awareness about local ongoing 
clinical research in the field and recent scientific advances. 
We addressed our aims by engaging a variety of audiences 
including healthcare workers through knowledge exchange ses-
sions, and thereafter the community and stakeholders in the HIV 
field through community advisory board meetings, radio, tel-
evision and two community events. In this letter, using the three 
pillars of public engagement (transmit, collaborate and receive), 
we discuss the planning, conduct and outcomes of our public 
engagement events.
Knowledge exchange with district healthcare workers. 
Audience: Health care workers. Purpose: Transmit, 
receive and collaborate
For PLHIV presenting with symptoms of meningitis or low 
CD4+ T cell count, the WHO recommends point-of-care 
cryptococcal antigen testing (a rapid test for a fungal infec-
tion, which causes meningitis in immunocompromised people). 
However, we noted that most patients were referred on to 
Kiruddu and Mbarara referral hospitals at a late stage of 
illness, without prior lumbar puncture (a clinical procedure 
performed to collect cerebrospinal fluid via a needle placed 
in the base of the back which is essential for diagnosing 
meningitis, also known as ‘spinal tap’) or cryptococcal antigen 
testing3. We visited 21 peripheral health centres in Kampala 
and 4 centres in Mbarara within the catchment area for Kiruddu 
and Mbarara hospitals respectively. These were mainly level 
IV healthcare facilities (HCIV) or district hospitals offering 
HIV prevention, care and treatment services to HIV-positive 
clients. In these interactive ‘knowledge exchange’ sessions the 
meningitis team had three aims. We transmitted information to 
the healthcare workers using posters, infographic leaflets and 
power point presentations detailing the aetiology, pathogenesis, 
clinical presentation, diagnostic challenges, available treat-
ment options and opportunities that clinical trials present in 
improving treatment and care of PLHIV. We also ‘received’ and 
‘collaborated’ with healthcare workers by discussing their 
experiences and challenges managing advanced HIV disease 
and potential solutions (e.g. helping with patient referrals 
and diagnostics such as providing CrAg tests) (Figure 2 and 
Figure 3). 
An average of 40 people attended each session and the audi-
ence comprised of healthcare workers including physicians, 
medical officers, clinical officers, nurses, laboratory person-
nel, and medical students. The evaluation of these sessions was 
performed by informal verbal feedback and discussions with 
staff who attended the teaching sessions. Staff appreciated 
having up-to-date teaching to ensure they would recognize 
advanced HIV disease, cryptococcal and tuberculosis men-
ingitis, and felt empowered to refer to the hospital. They also 
appreciated understanding what resources were available to 
ensure they could get the best care for their patients. A working 
relationship was established between the meningitis research 
team and health workers in the clinics we visited.
Community and stakeholder engagement
We recognise that challenges in healthcare seeking behaviour 
in advanced HIV are multifactorial, influenced by policy, 
healthcare systems, and community cultural, socioeconomic 
and geographical factors, to name but a few10. We therefore 
undertook a multifaceted approach to maximise community 
engagement and information dissemination around the Kampala 
region as follows.
Community Advisory Board Meetings. Audience: 
Community representative. Purpose: Receive and 
collaborate
The IDI Community Advisory Board (CAB; comprised of 
patient representatives, spiritual leaders, stakeholders and pri-
vate sector) met with our study team on two occasions to dis-
cuss the aims and potential content of our proposed community 
outreach activities (Figure 4). Our aim within these meet-
ings was to ‘receive’ opinions and suggestions from the CAB 
on our proposed outreach activities, and agree appropriate 
channels of information dissemination and adapting the content 
and language used to ensure cultural sensitivity Together, we 
agreed a schedule of events, including a circus event, a televi-
sion and radio shows, and a ‘Journey of Hope’ event. The mem-
bers of the CAB also activiely ‘collaborated’ in activities by 
attending events and a member of the CAB featured in the 
TV event.
Circus event in community center. Audience: Adults in 
the community who may be disengaged from HIV care. 
Purpose: Transmit
In this event the aim of meningitis research team was to 
transmit: engaging with hard-to-reach young adults who may be 
disengaged from HIV care or untested in order to raise aware-
ness about meningitis, the safety of lumbar punctures and ongo-
ing meningitis clinical research. Using a local social circus 
group, we attracted a large audience of around 250 people using 
Figure 2. Knowledge exchange session in Western Uganda.
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interactive community performances, music, acrobatics, jug-
gling, fire breathing and a drama sketch of a patient journey 
through meningitis illness (Figure 5). A trial participant (Mr JS), 
Dr Meya (Principal Investigator), Dr Stephen Watiti (an HIV 
advocate) and a Research Medical Officer did a structured 
question and answer (Q&A) session with the audience. We 
conducted formal exit interviews with the audience to ensure 
that the correct messages had been retained and to receive feed-
back from attendees. Quotes from exit interviews included “the 
event corrected wrong thoughts about meningitis, that it’s a 
Figure 3. Infographic leaflets distributed to share information about TB meningitis and the RifT clinical trial. The RifT clinical trial 
studied the safety, tolerability and pharmacokinetics of high dose rifampicin compared to standard of care TBtreatment of adult tuberculous 
meningitis in Uganda. 
Figure 4. Infectious Diseases Institute Community Advisory 
Board Meeting. Figure 5. Public audience drawn to the circus event.
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citizens and long-standing myths regarding HIV/AIDS. Few 
people with HIV can openly talk about their status and this 
stigma has led to challenges in reaching the UNAIDS 90-90-90 
targets, with 70,000 new HIV infections annually in Uganda and 
1 in 3 people presenting with advanced HIV disease13. The key 
message of this 1-hour television (TV) show, with a wide 
national audience was that ‘advanced HIV disease is prevent-
able and treatable’. The show was aired on National TV on 
the World AIDS day 2019 and featured Drs John Kasibante 
(Research Medical Officer) and Fiona Cresswell (Principal 
Investigator) and Mr Tugume, a former research participant 
(Figure 7). Mr Tugume openly educated people on life as a 
survivor of advanced HIV disease. He helped demystify key 
issues such as Undetectable = Untransmissible: early initiation 
of antiretrovirals to achieve viral suppression and to prevent HIV 
transmission to loved ones.
During the panel discussion questions arose like “can someone 
with HIV live with one who doesn’t have HIV and she doesn’t 
get the infection?”, to which Mr Tugume responded “yes, my 
wife is HIV-negative, we are raising our son who is also 
HIV-negative and are soon to have another child”. Mr Tugume 
also helped to reduce anxiety around lumbar punctures when 
asked “do people die from lumbar punctures?” and replied “No, 
I got many lumbar punctures when I was being treated for 
cryptococcal meningitis in Mulago, and here I am talking with 
you. They didn’t kill me but saved my life”. This is an example 
of collaborating with a former research participant to trans-
mit key information to the public. We also received queries and 
viewpoints from the public.
‘A Journey of Hope’ – Research participant and stakeholder 
event. Audience: Research participants, institutional 
leaders, stakeholders. Purpose: Transmit and 
collaborate
‘A Journey of Hope’ was a celebratory event bringing together 
clinical trial participants, the IDI Meningitis Research Team, 
key stakeholders including Centre for Disease Control, U.S. 
Mission Uganda, Chair of the Mulago Hospital Institutional 
Review Board, an internationally renowned HIV patient 
advocate Dr Stephen Watiti, Executive Director of IDI and 
the research office. The IDI Drama Group performed cultural 
Figure 7. Dr Kasibante, Dr Cresswell and Mr Tugume appear 
on NTV.
cultural disease or witchcraft”, “the event was very good and 
it helped people or the community to learn many things in 
this area”, “Lumbar punctures are not the cause of death in 
sick people”, “headache, tiredness, neck pain are symptoms 
of meningitis”.
Radio shows on Central Broadcasting Services. Audience: 
Community members in central districts of Uganda. 
Purpose: Receive, transmit and collaborate
Radio, described as “Africa’s medium of choice in the global 
age”, remains an important medium of communication in 
Uganda, in part due to its accessibility11. We harnessed the 
popularity of radio in attempting to access hard-to-reach 
populations and aired a series of events on Central Broadcast-
ing Services (CBS) radio, the largest radio station in Uganda. 
CBS is home to the most popular Breakfast show in Uganda, 
and a has a large following across different age groups12. The 
aim of this radio show was to allow the Research Medical 
Officers to ‘transmit’ important scientific content to the 
listeners, and also to ‘collaborate’ by co-creating the contents of 
the radio material with former trial participants, who were able 
to share their experiences - a focal point of the show. (Figure 6). 
In the week leading into World AIDS Day 2019 pre-recorded 
material including testimonials from three clinical trial 
participants who have survived advanced HIV disease were 
broadcast sharing key messages around symptoms of menin-
gitis, experiences with lumbar punctures and clinical research, 
their treatment and return to health. On World AIDS day itself, a 
Research Medical Officer on the team featured on the radio 
and fielded questions from the presenters and public around 
advanced HIV disease, consistent with the ‘receive’ pillar of 
the public engagement framework.
National Television Show. Audience: Community who 
may be disengaged from HIV care or carrying myths or 
stigma relating to HIV/AIDS. Purpose: Receive , transmit 
and collaborate
HIV continues to be the most stigmatizing infection in Uganda, 
in part due to the lack of evidence-based information reaching 
Figure 6. Study physician Dr Ssembambulidde records 
material for CBS radio broadcasts.
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Discussion
Whilst it is challenging to measure the exact impact of these 
activities we know that we engaged with around 500 healthcare 
workers, 250 members of the public face-to-face, several 
thousand members of the public through TV and radio, around 
80 research participants and a number of key stakeholders in 
the HIV field. Four former trial participants have come forward 
as strong advocates for living well with HIV and continue to 
spread messages of hope in their communities. We learned 
the importance of harnessing the voices and opinions of the 
public in planning and conduct of engagement activities and in 
the planning of future research activities aimed at combating 
advanced HIV disease. In addition to optimising medical 
management as stipulated in the WHO advanced HIV care 
package, we believe addressing late presentation requires a 
holistic approach, with engagement and education of healthcare 
workers and the community14,15.
While there has been a huge amount of positive work in 
community engagement in PLHIV in Uganda, sometimes 
public engagement is can be overlooked in academic research. 
There can be a focus on volume of publications in peer-reviewed 
scientific journals leading to a lack of value placed on dis-
semination to the wider public16. However, in an era of digi-
talisation where ‘fake news’ surreptitiously invades our 
media sources, it is more important than ever for researchers 
to take a stand and accurately disseminate research findings to 
populations who are most affected. As public-researcher inter-
action improves, so too will trust in science, which may 
encourage broader public participation in scientific pursuits such 
as clinical research. We also feel it is critical to give research 
participants a voice to share their experiences and become 
advocates of science in the community.
In this letter we have shared our attempt to close the gap 
between HIV clinical research and the wider public using 
research participants as partners in delivering a unique variety 
of novel engagement activities. Our work lays the foundation 
for future engagement activities and research into the benefits 
and best practice around public engagement activities.
Consent
Written informed consent was obtained from all individuals that 
are identifiable in the provided figures.
Data availability
Underlying data
No data are associated with article.
Acknowledgements
We would like to thank the research participants who contributed 
to the public engagement work and continue to be advocates in 
their communities. We would like to thank the IDI community 
advisory board, drama group and research office for their support 
in the planning and conduct of the activities.
dances and a dramatization around meningitis (Figure 8) to 
address stigma and myths surrounding lumbar punctures and 
meningitis management (‘collaborate’). A number of trial 
participants spoke about their experiences in clinical research. 
The event was also used as a platform to disseminate scien-
tific results to trial participants and important stakeholders 
(‘transmit’). The ‘Journey of Hope’ symbolised a very diffi-
cult journey for patients and their caretakers, many of whom 
had at times lost hope and were now celebrating with their 
families and former doctors, empowered to act as community 
advocates to improve understanding about advanced HIV. 
Attendees feasted and cut cake together to celebrate the progress 
made so far (Figure 9). We hope to repeat this successful 
event in the future on the completion of further clinical 
trials.
Figure 8. Dramatisation of meningitis illness by IDI drama 
group.
Figure 9. Cake cutting with the research team, study 
participants and IDI Executive Director.
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10  Chapter Ten: Discussion and Conclusion 
10.1 Summary of findings 
This section summarises the main findings presented in chapters 3 to 8 in relation to the pre-specified 
PhD hypotheses or objectives.  
10.1.1 Objective 1: To assimilate available retrospective data on adults with suspected 
TBM in Uganda and to describe the TBM population in terms of baseline 
characteristics, method of diagnosis and clinical outcomes 
The retrospective data analysis found that overall just over 1 in 10 (12%, 195/1672) of the patients 
presenting with suspected meningitis to Mulago National Referral Hospital and Mbarara Regional 
Referral Hospital, were treated for TBM in the 2010 – 2017 period, making it the second most 
common form of meningitis after cryptococcal meningitis, in-line with South African and Zimbabwean 
reports.1,2 
TBM was indeed largely seen in PLHIV, particularly those with advanced immunosuppression. In the 
chapter 4 retrospective cohort, 96% (187/195) of patients treated for TBM were PLHIV with a median 
CD4+ T cell count of 78 cells/µl, and in the chapter 8 prospective study in 92% (56/61) of enrolees 
were PLHIV with a median CD4+ T cell count of 55 cells/µl. Thanks to the massive scale up of HIV 
treatment programmes in Uganda, the proportion of TBM patients on ART increased dramatically 
(from 0% in the earliest group to 61% in the latest group) during the 2010 to 2017 retrospective 
cohort analysis, and in 2019 ART coverage was 48% (27/56) in Rift trial enrolees. Whilst we lacked 
data on HIV virological suppression from the chapter 4 retrospective cohort, no one was virologically 
suppressed in the chapter 8 Rift study population.  
HIV treatment characteristics were better described in the Rift study population; among the 56 HIV-
positive Rift enrolees, 30 were recent HIV diagnoses, of which (20, 67%) had initiated ART within the 3 
months prior to hospital admission. This suggests that delayed HIV testing and ART initiation has 
contributed to their advanced HIV disease. Amongst the 26 participants with longer-standing HIV, the 
majority (17, 65%) had discontinued their ART or had unknown ART history, suggesting the next 
biggest contributor to advanced HIV disease was poor engagement with HIV care and treatment.  
Microbiological confirmation of TBM increased with availability of the Xpert platform, from 3% (1/33) 
before Xpert to 41% (60/147) with routine use of Xpert and culture in the 2013-2017 period, as 
described in the chapter 4 retrospective cohort. Microbiological confirmation further increased to 
204 
51% (31/61) with the use of Xpert Ultra in the Rift enrolees in 2019 in chapter 8. This is in keeping 
with the microbiological-confirmation rate in other TBM trials.3 However, this means that around half 
of TBM cases are still treated empirically in the absence of a microbiological confirmation. 
Since the introduction of the Xpert platform in-hospital mortality may have declined. In the chapter 4 
retrospective cohort in-hospital, mortality was 57% in the pre-Xpert group and was 41% in group 
where Xpert was used routinely, despite MRC disease severity grade at presentation being stable. In 
the chapter 5 prospective Xpert Ultra study the in-hospital mortality was 40% (17/42) in those with 
definite TBM and in the chapter 8 Rift population, 24-week mortality was 39% (24/61). Whether the 
availability of the Xpert platform has directly impacted on clinical outcomes is unclear from the data I 
have available. Whilst there appears to be a temporal association between the introduction of Xpert 
and reduced TBM mortality there are a multitude of confounding factors which may have ultimately 
influenced outcomes, such as improved ART coverage or health system strengthening influencing 
supportive care received. Despite these marginal improvements in TBM-associated mortality over 
time, and whilst our reported mortality was a little lower than that in the in the meta-analysis in the 
Appendix 1 (pooled mortality in PLHIV 57%, 95% CI, 48-67%), the death-toll from TBM is still 
unacceptably high.  
A key driving factor of poor outcomes is late presentation to hospital.4 Only 10% of the Rift study 
population presented with MRC grade I disease, compared to about 40% in Vietnamese studies.5 By 
the time of presentation with MRC grade II/III disease, when mental status is altered +/- focal 
neurology, there may already be irreversible cerebral infarction, and even the best diagnostics and 
antimicrobial treatment may be unable to radically change the course of the disease. The difference 
in health seeking behaviour may therefore be a contributory factor to the difference in survival found 
between African and Asian settings in the TBM meta-analysis Appendix 1, mortality in African studies 
ranged from 23-80% and in Asian studies ranged from 2-67%.6 Ongoing engagement work is needed 
around health seeking behaviour to encourage earlier presentation to hospital, as well as recognition 
of meningitis at district health facilities with timely onwards referral.  
Whilst acknowledging the limitations that come with using retrospective data, the retrospective 
cohort in chapter 3 was valuable in understanding the TBM landscape in Uganda. The results from the 
retrospective data were consistent with data that I collected prospectively in the chapter 5 
prospective Xpert Ultra study and in the chapter 8 Rift trial population.  
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10.1.2 Hypothesis 1: Xpert MTB/Rif ‘Ultra’ is significantly more sensitive than Xpert 
MTB/Rif for the detection of M. tuberculosis in CSF. However, Xpert Ultra’s 
sensitivity will not be perfect and it may fail to diagnose a small number of 
cases of CNS TB that are evident by metagenomic next generation sequencing, 
CSF culture or post-mortem examination 
In the chapter 5 prospective study of 204 Ugandan adults (96% HIV-positive) with suspected 
meningitis, when compared with a reference of probable/definite TBM, test sensitivities were 77% for 
Xpert Ultra, 56% for Xpert, and 61% for MGIT culture. Xpert Ultra was more sensitive than Xpert when 
measured against both the uniform case definition of probable/definite (77% versus 56%, p=0.001) 
and the composite microbiological reference standard (93% versus 66%, p=0.006). Xpert Ultra missed 
3 cases that were culture positive (including one that was also Xpert positive). 
In the limited number of post-mortem examinations performed, one patient had the macroscopic 
pathological appearance suggestive of TBM (basal meningeal exudate) in a case which had been 
classified as ‘possible’ TBM. There were no false negative Ultra results identified amongst the 84 
mNGS results available from the Ultra study cohort. However, outside of the Xpert Ultra cohort mNGS 
has managed to identify M. tuberculosis DNA in two samples negative by Xpert Ultra (Appendix 6b 
and 5c).  
In the chapter 5 Xpert Ultra study I did not include ‘possible’ TBM in the reference standard as I 
believed that the ‘possible’ TBM category is a very non-TB-specific category in advanced HIV 
immunosuppression, especially in a setting where the diagnostic capacity to exclude other conditions 
is limited. This was borne out by results from the Biofire meningoencephalitis PCR panel which was 
used during the Xpert Ultra and study enabled 10 participants (13%, 10/80) to be re-classified as ‘not’ 
TBM prior to the Ultra analysis taking place. In addition, the preliminary results from the CSF mNGS 
identified viral pathogens in an additional 11% of ‘possible’ TBM samples tested (3/27) and the variety 
of viral pathogens identified in a wider sample set are described in the Appendix 6a.  
Data from the chapter 5 Xpert Ultra study also emphasized that TBM can present with a non-
inflammatory cellular CSF profile in this population. One quarter of patients with confirmed M. 
tuberculosis in CSF had an acellular CSF, so clinicians cannot rely on the classical lymphocyte 
pleocytosis to make a diagnosis of TBM in PLHIV, and other clinical or CSF parameters may be better 
predictors to use when making treatment decisions. In the univariate model the presence of CSF 
white cells (as a binary variable) was associated with definite TBM but the relationship became non-
significant in the multivariate model. The univariate model showed that that high CSF lactate was the 
strongest discriminator of confirmed TBM – with every doubling of CSF lactate there was a ~6-fold 
increase in odds of having definite TBM. CSF glucose was also a good discriminator, with every 
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doubling in CSF glucose there was a 70% decrease in the odds of having TBM. It was not possible to 
examine CSF lactate in the multivariable model due to the limited amount of lactate data but CSF 
glucose remained a strong predictor of definite TBM. Low GCS (11-14 and <10, compared to GCS 15) 
was strongly associated definite TBM in the univariate model and the trend remained in the 
multivariable model, albeit with p-values marginally above the 0.05 significance threshold.  
Overall, I can conclude that Xpert Ultra is significantly more sensitive that Xpert MTB/Rif in the 
diagnosis of TBM in our study population and only missed a handful of TBM cases that were identified 
by other means (3 MGIT culture positive, 1 suggestive post-mortem examination, none by mNGS 
within the chapter 5 study participants).  
10.1.3 Hypothesis 2: Urine diagnostics such as urine TB-LAM and urine Xpert MTB/Rif 
Ultra will be useful adjunctive tools in diagnosing TB meningitis and will identify 
patients at the greatest risk of death.  
Access to timely lumbar puncture is not universal in smaller hospitals in Uganda, and many other 
African settings. Therefore, a non-CSF-based diagnostic approach for TBM would be very valuable. 
With this in mind, I postulated that a positive urine TB test might help to rapidly differentiate TBM 
from other forms of meningitis and may have prognostic value. This prompted the chapter 6 
prospective observational study of 348 undifferentiated meningitis patients at two referral hospitals. 
This was an exploratory study and I did not aim to examine sensitivity or specificity of urine LAM or 
Ultra in this paper. 
Urine Alere LAM is only moderately sensitive at detecting TB (40-70% if CD4+ T cell count <100 
cells/µl), yet despite this there was a staggeringly high prevalence of disseminated TB (detectable by 
either Alere LAM or urine Ultra) across the cohort of hospitalised meningitis patients: 22% in 
cryptococcal meningitis, 50% in probable and definite TBM and 17% in other/unknown types of 
meningitis. The true prevalence of TB is likely to be even higher than that detectable by urine. In the 
22% (44/198) of  patients in the cryptococcal meningitis group who had a positive urine TB test I 
believe this represents disseminated TB rather than concurrent TBM and cryptococcal meningitis, 
which we know is a relatively rare phenomenon.7 Whilst there was a difference in prevalence of TB 
detectable by urine between the four meningitis groups (p<0.001), a urine LAM or Ultra result could 
not be used in isolation to make a diagnosis of TBM and should be interpreted in the context of the 
blood/CSF CrAg results and other CSF parameters (e.g lactate and glucose).  
The high burden of urine-detectable disseminated TB in the probable and definite TBM groups is 
noteworthy when considering pathogenesis and the 3-fold higher mortality from TBM in PLHIV 
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compared to HIV-negative TBM. It is evident that HIV-associated TBM is a multisystem disease, with 
concomitant disease in the kidneys, and therefore probably a number of other organs. Case-fatality in 
those with a positive urine Ultra was 50%, (7/14) whereas it was 15% (3/20) in those with a negative 
urine Ultra – a case-fatality similar to that of HIV-negative people with TBM. Patients with definite 
TBM who had a positive urine Ultra had a ~6-fold increased odds of dying (OR 5.67, 95% CI, 0.71-12.7, 
p=0.04) compared to those with a negative urine Ultra. There was no detectable association between 
urine Alere LAM positivity and in-hospital mortality (OR 1.34, 95% 0.32-5.61, p=0.69) but this needs to 
be examined with a larger sample size.  
Urine Alere LAM and Ultra results were moderately concordant, possible reasons are postulated in 
the chapter 6 discussion, and TB-LAM positivity representing non-tuberculous mycobacterial infection 
must also be considered and further investigated.   
10.1.4 Hypothesis 3: Intensified treatment of TB meningitis with intravenous 
rifampicin (20 mg/kg) or high dose oral rifampicin (35 mg/kg) will result in 
significantly increased blood and CSF exposure during the critical early days of 
TB treatment as compared to common control (10 mg/kg oral rifampicin)  
Through the phase II clinical trial outlined in chapter 8 I demonstrate that with standard of care TB 
treatment (including R 10 mg/kg), the serum geometric mean peak rifampicin concentration (6.0 
mg/L) fell below the recommended reference range (>8 mg/L)8 and the serum AUC/MIC (42.9 h×mg/L) 
fell well below the suggested 271 h required for a 1 log CFU reduction in murine studies.9 In CSF, the 
rifampicin concentration fell below the lower limit of quantification (<0.25 mg/L) in around half of 
participants and only two participants achieved a CSF rifampicin concentration above the MIC of the 
predominant strain in Uganda. The measured rifampicin exposures with standard TB treatment are 
sub-optimal, especially considering that rifampicin is the most important drug in TB therapy and 
meningitis is the deadliest manifestation of TB. A 2-fold rifampicin dose increase administered 
intravenously (20 mg/kg) yielded a roughly 6-fold increase in serum and CSF exposures. A 3.5-fold oral 
dose increase (35 mg/kg) yielded a roughly 8-fold increase in serum and CSF exposures. All the 
participants on the intervention arms had detectible CSF rifampicin and almost all (93% and 95% 
respectively) had levels above the rifampicin MIC.  
10.1.5 Hypothesis 4: High dose rifampicin will be safe in people with advanced HIV 
disease and may improve functional outcomes and survival at 8- and 24-weeks. 
When considering the immunocompromised nature of the study population and severity of the 
underlying disease, it is not surprising that grade 3-5 adverse events were commonplace in all arms 
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(71% of standard of care, 50% of IV-20 and 55% of PO-35, p=0.343). Overall, the most common grade 
>3 event was elevated ALT, attributed to drug induced liver injury (DILI), and occurred in 7/60 (11.7%)
of all participants, 4/7 of which were in the control arm. The majority of DILI occurred in the first
month of therapy, Figure 10.1. The observed incidence of hepatotoxicity is slightly higher than that
reported in the Vietnamese TBM trial (5.5% overall) and UK TB cohorts (~7%)10 but less than that in
the Indonesian trio of TBM trials (19, 20 and 27%).11-13 The relatively modest incidence of DILI within
the study is reassuring considering that HIV is known to be an independent risk factor for DILI (OR
4.40, 95% CI, 1.06-18.3).10
Figure 10.1. Alanine transaminase (IU/L) by study day in the Rift trial 
Rifampicin is known to cause hyperbilirubinaemia and an exposure-effect relationship exists. 
Unconjugated bilirubin rises after starting rifampicin because of inhibition of bilirubin hepatocellular 
uptake via OATP and/or glucuronidation by UGTA1A1.14 Bilirubin levels then decline to less than 
pretreatment values upon rifampicin continuation, suggestive of induction of net bilirubin clearance. 
Clinically detectable jaundice was not a common observation in Rift study enrollees, as the majority of 
elevations were low grade (1 to 3 x upper limit of normal, ULN). There were 3 episodes of isolated 
hyperbilirubinaemia in the study population and bilirubin elevations (>grade 3) also occurred in the 
context of DILI and were classified as DILI at the time of AE reporting.  
There were only two other events that were possibly, probably or definitely related to rifampicin – a 
persistent fever (possibly related) and hypotension as part of multi-organ failure (possibly related). I 
did not record subtle grade 1-2 tolerability events as these are challenging to ascertain in a person 
with altered mental state and a multitude of other disease-related symptoms, and they are of limited 
clinical relevance.  
Seizures occurred in around 8% (5/61) of the enrolees including 2 fatal seizures and use of certain 
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interactions with rifampicin and ART. Kaposi’s sarcoma was noted at as an AE in two participants after 
it progressed rapidly and was ultimately fatal several months down the line, though this is unlikely to 
be related to rifampicin and could have been exacerbated by the corticosteroids recommended as 
part of TBM treatment (which were promptly discontinued) or may have been the natural course of 
disease in profoundly immunosuppressed individuals. 
In this phase II study I did not detect a difference in modified Rankin score or survival at 8 or 24-
weeks, although the study was not powered to explore a survival benefit. We performed detailed 
neurocognitive studies at week 8 and 24 in those who were well enough to engage with the in-depth 
testing, the results of which I plan to report separately in future.  
Owing to the difficulty in diagnosing TBM, only half of the participants included in the study had a 
microbiologically-confirmed diagnosis and it is plausible that people without TBM were included, 
which might dilute the clinical effect of the intervention. I can conclude that, within the limited 
population studied, high-dose rifampicin was safe but no impact on survival or functional status was 
observed.  
10.2 Limitations 
The specific limitations are discussed in the individual research papers in chapters 3 to 8. Here I 
discuss the more general limitations of my work undertaken trying to improve the diagnosis and 
treatment of TBM in Uganda. I did my best to overcome the multiple obstacles placed by this 
problematic disease, the three main disease-related challenges are elaborated below.  
Challenges posed by the nature of the disease: 
Firstly, although TBM is the second most common aetiology of meningitis in Uganda it is relatively less 
common than cryptococcal meningitis, and in the absence of a reliable blood or urine antigen test 
many patients had to be screened and undergo lumbar puncture in ordered to identify cases. As such, 
recruitment into studies is relatively slow, which limited the size of the studies possible during a PhD 
across two sites. The phase II clinical trial in chapter 8 was adequately powered from a 
pharmacokinetic and safety perspective, but we need to further examine safety in a larger study and 
clinical outcomes in a multicenter phase III trial. A larger sample size would also have been useful for 
the urine TB diagnostic study in chapter 6 as the confidence intervals were wide and Xpert Ultra and 
Alere LAM’s potential as prognostic markers could have been more accurately examined with a larger 
study with appropriate adjustment for baseline factors (e.g. CD4+ T cell count) and I have not yet 
externally validated my findings. I plan to do this within the future research, as described later.   
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Secondly, the lack of a gold standard diagnostic test or other specific reference standard for TBM 
makes both the decision about who to enroll into clinical trials and how to most accurately evaluate 
diagnostics tests a challenge. The most balanced approach was to present the data stratified by the 
internationally recognised uniform case definition (definite i.e. microbiologically-confirmed, 
definite/probable, +/-possible), to explain the range of diagnostic tests undertaken, and state the 
caveats.  
Thirdly, unlike studies in pulmonary TB which use time to culture conversion or serial sputum colony 
counts, there is currently no validated M. tuberculosis quantitative assay or surrogate endpoints for 
use in TBM studies. Therefore, I was unable to examine the impact of high dose rifampicin on CSF 
bacillary clearance. Our endpoints were survival and function status by modified Rankin score at 8- 
and 24-weeks, and whilst clinical outcomes are ultimately the most important, they are potentially 
confounded by other non-TB multi-morbidities in a population with AIDS. Further I have not yet 
performed a PK-PD analysis of the Rift trial data, though I plan to do this in due course.  
Lastly, due to the severity of illness in the patient group collection of clinical samples was seldom 
straightforward which led to a proportion of patients having incomplete data. For example, in chapter 
5, lumbar punctures whereby only a small volume of CSF could be collected led to there being fewer 
culture and Xpert results than Xpert Ultra. Likewise, collecting urine from patients who were confused 
and incontinent was challenging and sometimes only enough for the Alere LAM was a collected 
leading to a mismatch between the number of LAM and Xpert Ultra performed. The pattern of 
missingness of urine data may not be random; sicker patients are more likely to be incontinent of 
urine and unable to give a sample, conversely the most unwell patients often have a urethral catheter 
which then facilitates urine sample collection. Overall, I doubt any major bias has been introduced. 
Operational limitations: 
As well as disease-related limitations there were also a number of operational challenges. It would 
have been ideal to perform a comprehensive work up to better characterize the extent of the TB 
disease and other co-infections, including sputum Xpert Ultra, TB blood and urine cultures, bacterial 
blood cultures, chest x-ray, abdominal ultrasound and brain imaging on everyone screened and 
enrolled. The hospital CT scanners were frequently out of service and transporting a neurologically 
obtunded patient to another center for imaging was deemed too risky in many patients. During the 
chapter 8 Rift study I prioritized routine CSF microbiology, Ultra and storage for future immunology 
work above MGIT culture where sample volume was limited. In hindsight a culture and individual-
level rifampicin MIC on every isolate would have more accurately examined the AUC/MIC parameter, 
at least within the culture-positive patients.  
211 
In Rift trial participants enrolled on DTG-based ART and receiving high-dose rifampicin, I had hoped to 
perform real-time DTG therapeutic drug monitoring (TDM) to provide reassurance that trough levels 
were in the therapeutic range. The IDI translational lab DTG assay is on the recently installed liquid 
chromatography mass spectrometry machine, but unfortunately this was having technical issues that 
have only recently been overcome, which precluded real-time DTG TDM. DTG was dose-adjusted to 
50 mg twice daily shortly after enrolment, but TDM should ideally be performed at week 4 as the 
rifampicin enzyme induction builds over the first 4 weeks of therapy. A number of stored samples can 
now be tested, however more definitive results will be provided by the SAEFRIF study underway in 
Uganda.15  
I had hoped that we would be able to perform post-mortem examinations in all patients who died in 
hospital but we only succeeded in performing four post-mortems. We discovered that autopsy 
studies are highly logistically challenging; post-mortems are not part of normal clinical or cultural 
practice so the majority of families were understandably reluctant to let their recently deceased loved 
one be transported to another facility for an alien procedure, especially when the burial normally 
takes place very quickly. This was compounded by the fact that there was only one pathologist in the 
country capable of performing the examination, and only during working hours. Minimally invasive 
autopsy may have been a more successful approach but precludes the macroscopic inspection of the 
brain.  
In this PhD I have focused specifically on the antimicrobial treatment but supportive care of critical 
illness, host-directed therapies and rehabilitation are also clearly vital considerations in improving 
treatment and outcomes from TBM.  
10.3 Implications of the findings 
10.3.1 TBM can be prevented by upstream HIV-related interventions including earlier 
HIV testing, treatment and TB screening within HIV services. 
The WHO End TB strategy aims to reduce TB deaths by 90% by 2030 compared with 2015.16 
Disseminated TB including TBM contributes heavily to the burden of TB deaths17 so meeting the End 
TB target requires the specific drivers of TBM to be addressed. I have illustrated here that the vast 
majority of TBM patients have advanced HIV, so preventing immunosuppression (as well as 
preventing HIV transmission in the first place) is likely to be the best approach to reduce the incidence 
of TBM. The majority of the Rift study population were late HIV diagnoses with an already AIDS-
defining CD4+ T cell count. HIV testing interventions may be able to identify PLHIV earlier and link to 
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treatment services before immunosuppression is advanced. Diagnosing HIV at the time of 
hospitalization with an opportunistic illness is a failure of community-based HIV testing services. 
Equally important is screening for TB in PLHIV. The WHO recommend a TB symptom screen (any of 
cough, fever, night sweats, or weight loss)18 in all PLHIV and urine Alere LAM testing19 prior to ART 
initiation if CD4+ T cell count is <100 cells/µl or if there are symptoms of TB regardless of CD4+ count. 
This allows underlying TB to be diagnosed and treated prior to ART initiation, thereby avoiding 
unmasking TB IRIS which can be fatal, particularly in the CNS.20,21 TB screening and treatment prior to 
ART initiation did not appear to have happened in the 20 Rift trial enrolees who had recently initiated 
ART, and represents a missed opportunity. In the participants who had been on ART <35 days with 
probable/definite TBM the CSF picture was in keeping with unmasking IRIS [median WBC 140 cell/µl 
(95% lymphocytes 5% neutrophils), protein 0.94 g/L, lactate 9.5, glucose 1.1 mmol] as was the CSF 
transcriptomic picture, which showed upregulation of interferon-gamma signalling, IL-12 signalling 
and neutrophil degranulation (oral presentation by C Quinn, Union Conference 2020). With the 
increasing implementation of the WHO HIV test and treat policy22 including a push towards same day 
ART in some settings, the TB screening process must be well embedded within HIV treatment 
practices to avoid cases of unmasking TBM IRIS.  
Even with prompt TB treatment at the time of hospitalization in a relatively well-resourced health 
service in South Africa, the early mortality from HIV/TB is 22% within 3 months.23 Therefore, 
community-based interventions which prevent active TB disease arising, or support early diagnosis, 
are likely to have the greatest impact. TB preventative therapy (TPT) in PLHIV is recommended by 
WHO and is being rolled out in Uganda, though with limited coverage currently (29% of household 
contacts of confirmed TB cases, 46% of PLHIV newly enrolled into care).24,25 This is an effective 
intervention at a population level26 but is a difficult intervention to implement in an already highly 
immunosuppressed population unless it is possible to first exclude active TB disease.  
The continued lack of access of Alere LAM in both the community HIV clinics and public hospitals is a 
contributing factor that must be prioritised by the National TB Control Programme. Empowering 
patients to seek care earlier and recognition of critically ill patients in community settings is also an 
important piece in the community engagement work around meningitis and advanced HIV disease. 
Likewise, bigger structural factors that drive the TB/HIV epidemic cannot be ignored.  
10.3.2 Xpert Ultra is the best first test for TBM but should not be the last test 
Xpert Ultra is the best CSF test currently available for TBM in a Ugandan setting, and probably in the 
rest of sub-Saharan Africa. However, Xpert Ultra cannot be used as a ‘rule-out’ test for TBM due to its 
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imperfect negative predictive value of 93% (95% CI, 88-96%). The Xpert Ultra test result must be 
interpreted with the pre-test probability of TBM in mind, as illustrated in Figure 10.2.  
Figure 10.2. Test 
threshold and test-
treatment threshold in 
relation to pre-test 
probability of TBM 
disease.27 
We may never have a single perfect CSF test for TBM and combining a number of tests including a 
host and pathogen biomarker might be the most promising approach. I have demonstrated that 
reliance on a classical CSF picture with lymphocyte pleocytosis is not possible in PLHIV as around 1 in 
4 confirmed cases have an acellular CSF. The univariate and multivariate model in the chapter 5 Xpert 
Ultra paper suggest that low CSF glucose and high CSF lactate are good markers of definite TBM, both 
of which can be easily, quickly and cheaply be measured at the bedside with a handheld meter. A CSF 
CrAg is also easily performed at the bedside to exclude cryptococcal meningitis. Urine Alere LAM is 
helpful (though also commonly positive in other forms of meningitis), and urine Xpert Ultra is 
supportive of a TBM diagnosis as it is less commonly positive in other forms of meningitis and may be 
useful as a prognostic indicator, though external validation is needed.  
In the same edition of Lancet Infectious Diseases as our chapter 5 paper was the Xpert Ultra study 
from the Vietnam group, which included 205 adults (15% PLHIV).28 Donovan et al. used a reference 
standard of definite, probable, or possible TBM, and reported sensitivities of 47% for Xpert Ultra, 40% 
for Xpert, and 48% for MGIT culture. They concluded that Xpert Ultra was not statistically superior to 
Xpert based on the reference standard used.28 How can we reconcile the different results between 
the two studies? Differences in CSF volume, CSF processing and study design might have contributed 
to the difference (in the Vietnam study patients were randomized to either Xpert or Xpert Ultra rather 
than head-to-head testing). Geographical differences in HIV status, genetics influencing host 
response, and TB lineage  (distinct have different copy number of IS6110 and IS1081) might also have 
contributed.29 The reference standard used in the Vietnamese study is also important; the sensitivity 
of Xpert Ultra increased to 58% when ‘possible’ TBM was dropped from the reference. Remarkably in 
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their study roughly one third of cases (35%, 29/82) in the ‘definite’ category was positive by ZN smear 
microscopy in isolation (whilst negative by MGIT culture, Xpert Ultra and Xpert). This unique 
phenomenon was attributed to their highly experienced resident microscopist and is unlikely to be 
replicated in any other centers worldwide. Thus, I believe the results from our two Ugandan studies 
are more generalizable to an African setting and were remarkably consistent – the negative predictive 
value of Ultra was 94% in the 2018 study30 with cryopreserved samples and 93% in the chapter 5 
prospective study. The negative predictive value is not good enough for Ultra to be used as a rule-out 
test but is an improvement on Xpert (86%).   
The inherent value of a having a microbiologically-confirmed diagnosis cannot be understated. Firstly, 
for patients, it may result in increased confidence in the diagnosis and consequently their willingness 
to comply with long and unpleasant treatment. Secondly, for clinicians, a confirmed diagnosis reduces 
the risk, time, and cost associated with investigating for other causes of the illness and gives a greater 
degree of confidence in treating this condition and its associated complications. Thirdly, for policy 
makers and other stakeholders it is important information for planning of preventative strategies and 
clinical services. Lastly, for researchers, a microbiologically-confirmed diagnosis can increase the 
scientific rigour of the study in hand. Everyone stands to gain from a better test being available and 
the search must continue.  
Use of the composite microbiological reference standard does not lend itself to accurately calculating 
the specificity as the index test is included in the reference standard (i.e. there can be no false 
positives). When the uniform case definition (excluding the Xpert Ultra result) was used to calculate 
the specificity of Xpert Ultra it was 96%. The specificities of Xpert and Xpert Ultra are extremely 
high,31 and CSF testing in TBM is not likely to experience the pitfalls that exist with sputum testing in 
people with prior pulmonary TB who can experience false positive trace calls, as further explained in 
the chapter 5 paper. So, a positive CSF Xpert Ultra should be interpreted as active TBM disease and 
treatment initiated immediately.  
Finally, the use of CSF test results becomes academic if lumbar puncture needles are not available, 
which is a common occurrence even at the National Referral Hospital, requiring the family to have 
available money to buy the needle from an outside pharmacy. Likewise, CrAg LFA tests are often not 
immediately available to differentiate cryptococcal meningitis from TBM. Health system 
strengthening to ensure consistent supply of lumbar puncture needles and POC diagnostics will be 
lifesaving.   
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10.3.3 HIV-associated TBM is a manifestation of disseminated TB disease so 
supportive care and interventions to optimise the host response are important 
alongside optimal antimicrobial therapy 
10.3.3.1 The prevalence of disseminated TB amongst patients with HIV-associated TBM 
Disseminated TB was highly prevalent in HIV-associated TBM - it was detectable by urine in 50% of 
patients with probable or definite TBM. The true proportion with disseminated TB might be more like 
70-80% given the only moderate sensitivity of urine diagnostics. Therefore, TBM may be towards the 
end of the spectrum of disseminated TB disease, as proposed in Figure 10.3. Recent in-depth clinical 
phenotyping of hospitalised adults with HIV/TB in Malawi and South Africa has shown that urine 
LAM/Xpert positivity is associated with a severely ill clinical phenotype32 and immune activation, 
which may contribute to mortality through tissue damage and organ dysfunction.33 We therefore 
cannot consider CNS infection and inflammation in isolation in HIV/TBM. 
Figure 10.3. Schematic illustrating the natural progression of disease in adults with and without HIV co-infection and the 
continuum of disseminated HIV disease which has TB meningitis towards the end. TBM = tuberculous meningitis. Shortly 
after HIV-1 infection and prior to substantial CD4 T cell depletion, the risk of active tuberculosis increases; during the early 
stages of HIV-1 infection, this risk can rise to approximately 10% per year; in advanced HIV-1, the risk of active tuberculosis 
can increase to 30% per year. While highly beneficial, antiretroviral therapy (ART) does not fully restore the tuberculosis-
specific immune response, and ART-treated HIV-infected persons exhibit increased tuberculosis risk despite viral 
suppression. ART can lead to clinical worsening of patients coinfected with opportunistic pathogens. When immune control 
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in the lung and lymphatics fail a mycobacteraemia arises and bacilli are disseminated to multiple organ systems including the 
spleen, kidneys and CNS (central nervous system). Adapted from Esmail et al.34  
10.3.3.2 Disseminated TB may be a risk factor for death in HIV/TBM 
It is well established that disseminated TB, as evidenced by a positive Alere LAM, is a risk factor for 
mortality in hospitalised HIV/TB patients. Meta-analysis of 10 studies including 1172 adults with 
HIV/TB confirmed a 2.5-fold increased mortality risk in patients with positive TB-LAM compared to 
those with negative urine LAM, even after adjusting for other risk factors for mortality such as CD4+ T 
cell count.35 Positive urine Xpert MTB/Rif is also associated with a 2-fold increased mortality risk, but 
there is no published data on urine Xpert Ultra and mortality risk.  
To the best of my knowledge, the impact of disseminated TB on TBM outcomes has not previously 
been explored. Case-fatality in definite TBM cases with evidence of disseminated TB disease by a 
positive urine Xpert Ultra was 50% (7/14), whereas it was 15% (3/20) in those with a negative urine 
Xpert Ultra. The increased mortality in those with HIV/TBM with disseminated TB may relate to multi-
system dysfunction and generalised immune dysregulation, rather than specifically CNS-related 
pathology. There was a similar but less marked trend with urine Alere LAM positivity. This is a small 
dataset and there is likely to be collinearity with extent of immunosuppression, so this proposition 
needs to be further explored in a larger study with appropriate adjustment for other baseline 
variables. 
Why might urine Xpert Ultra be a better predictor of mortality than Alere LAM in TBM and what does 
this tell us? Of the two urine tests, urine Xpert Ultra positivity is perhaps the most representative of 
renal TB infection which manifests as micro-abscesses in HIV/TB. Whereas urine Alere LAM 
antigenuria is indicative of glomerular filtration of circulating LAM or LAM fragments from 
mycobacteraemia or TB disease at a distant site, as well as renal TB itself.36,37 In theory, the Xpert 
assay is designed to detect M. tuberculosis DNA associated with bacilli rather than cell free DNA of 
low molecular weight, as the cartridge has an on-board internal wash step to reduce contamination 
by cell free DNA pre-amplification.38 Therefore, if urine Xpert Ultra positivity truly represents renal TB 
it may be a marker of the general systemic burden of TB, given that at post-mortem renal TB micro-
abscesses usually occurs when there is also evidence of multi-organ involvement.39-41  
10.3.3.3 Systemic immune dysregulation in disseminated TB 
Disseminated TB is accompanied by a generalised inflammatory response. Professor Meintjes’ group 
have recently done in-depth profiling of the hospitalised adults with HIV/TB in Khayelitsha Hospital, 
Cape Town, and found an association between disseminated TB and death which was driven by an 
immune profile dominated by soluble inflammatory mediators associated with the innate immune 
system and chemotactic signalling (IL1Ra, IL-6 and -8, MIP-1a and b, CCL3 and 4, IP-10, CXCL10, 
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CCL3).33 Similar findings were noted in the STAMP trial participants, those who died had more 
disseminated TB, higher concentrations of cytokines responsible for innate and pro-inflammatory 
signaling, elevated markers of inflammation such as C-reactive protein and hepcidin, more marked 
monocyte activation, and impaired ex vivo functional responses, including cytokine production and 
phagocyte function, and impaired CD8+ T-cell function.42 Higher levels of innate and chemotactic 
mediators reflect increased activation and recruitment of innate cells into the tissue in response to 
multi-organ infection. Whilst this is an appropriate response (though ultimately ineffective) it comes 
with significant immunologic and metabolic costs to the host, including tissue damage and organ 
dysfunction.33 The innate response goes from initially being protective to becoming harmful to the 
host and ultimately results in death. Interrupting this negative physiological cascade with an 
appropriate anti-inflammatory drug (as well as or instead of corticosteroids) whilst high-dose 
rifampicin takes its rapidly bactericidal effect on the infection may be more effective than targeting 
the bacteria alone.  
10.3.3.4 The role of co-infections  
The results from the Meintjes’ group suggest not only impairment of anti-TB host defenses in patients 
with disseminated disease and poor outcomes, but potentially also those against bacteria or other co-
infections in patients with HIV/TB. Given the general impairment in host defences in HIV/TBM, with 
the additional insult of high-dose corticosteroids, empirical prophylactic therapy may have a role, 
particularly antifungal prophylaxis with fluconazole. An ART-naïve Rift study participant who had 
negative blood and CSF CrAg at baseline went on to develop fulminant cryptococcal meningitis 6 
weeks into TBM therapy with adjunctive corticosteroids. The REALITY trial studied an enhanced 
prophylaxis package consisting of 12 weeks of fluconazole (100mg od) and isoniazid TB preventative 
therapy, 5 days of azithromycin, and a stat dose of albendazole in addition to the standard of care co-
trimoxazole in PLHIV with CD4+ T-cell count <100 cells/µl at the time of ART initiation, compared to 
co-trimoxazole alone.43 The group who received the enhanced prophylactic package had a 27% lower 
relative rate of death at 24 weeks compared to the control group. In the absence of baseline CrAg 
testing the enhanced prophylaxis reduced the incidence of cryptococcal disease (9 [1.0%] vs. 23 
[2.6%], P = 0.01) and candidiasis (10 [1.1%] vs. 23 [2.6%], P = 0.02) and was well tolerated.43 Whilst we 
are fortunate to have access to CrAg LFA tests in research settings, sadly this is not the case in all 
routine care settings, so I believe there may be a role for routine fluconazole, dosed of 200 mg daily, 
in the first 8 weeks of TBM treatment in PLHIV whilst steroids are being used and ART therapy is yet 
to be initiated/switched. 
Whilst most PLHIV routinely receive co-trimoxazole prophylactic therapy, additional antibiotics could 
also be considered to prevent concomitant bacterial hospital acquired infections, though given the 
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widespread antimicrobial resistance this may be counterproductive. In the REALITY trial no reduction 
in death due to bacterial infections was observed in the group who received azithromycin 500mg 
daily for 5 days.43 The most common blood stream infection in PLHIV is M. tuberculosis so this would 
already be treated by the TBM therapy.44 However, with prolonged hospital admissions, intravenous 
access for dexamethasone and urethral catheterisation patients are also susceptible to other MDR 
nosocomial infections, which would be interesting to quantify in future studies.  
10.3.3.5 Adjunctive steroids in HIV/TBM 
The worldwide use of high dose corticosteroids in PLHIV with TBM is questionable given that there is 
no data confirming a benefit in PLHIV. In the 2004 Thwaites dexamethasone trial there was a trend 
towards a 9-month survival benefit in the 98 PLHIV within the study but the follow-up period was too 
short to exclude an increased risk of HIV-related cancers and late fatalities. A prospective study of 
prednisolone in TB pericarditis with a 2-year follow-up found a 3.3-fold increased risk of HIV-related 
cancers, particularly Kaposi’s sarcoma, with use of corticosteroids in PLHIV.45 This is corroborated by a 
trial of prednisolone in pleural TB which found a significantly higher incidence of Kaposi’s sarcoma 
(4.2 cases/100 person-years compared to 0 cases with placebo).46 A prospective study is underway to 
examine the long-term safety of corticosteroids in PLHIV in Asia (NCT03092817) but it is unfortunate 
that this trial will not include PLHIV in Africa who may experience a quite different array of steroid-
related complications.  
In summary, I can infer that HIV-associated TBM is part of the disseminated TB disease spectrum, 
which is known to co-exist with generalised immune activation, organ dysfunction and susceptibility 
to co-infections. Corticosteroids may be beneficial in some patients yet harmful in others and a more 
targeted immunomodulatory therapy (for example aspirin) may be preferable as well as additional 
prophylactic antifungals until ART-related immune reconstitution has occurred.   
10.3.4 High dose rifampicin should be studied at a larger scale for TBM (and 
disseminated TB disease) with adequately powered studies 
Based on the observation that the vast majority of TBM patients have CSF levels below the rifampicin 
MIC in Uganda, it is hard to justify the ongoing use of standard TB therapy for the treatment of TBM. 
However, changing TB treatment regimens is a complex undertaking from a large-scale programmatic 
perspective so a very compelling body of evidence must exist for the WHO and national policy-
makers, to consider the cost-effectiveness and implementation considerations including the pill 
burden, tolerability and safety in the absence of blood test monitoring in most African settings. 
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Therefore, a phase III trial is warranted, and since oral rifampicin 35 mg/kg achieves therapeutic levels 
in CSF this is a good regimen to take forward, particularly given that 40 mg/kg has recently been 
shown to be the maximum tolerable dose.14 Such a study needs to factor into the sample size 
calculations and analysis plan a priori that a significant proportion of enrolees will not have the 
disease of interest and non-TB morbidity and mortality is high in PLHIV/AIDS. I would caution against 
enrolling PLHIV with ‘possible’ TBM unless a reasonable effort has been made to exclude other 
pathologies (e.g. CSF viral PCR and brain imaging) or allowing broad eligibility criteria whilst ensuring 
that the sub-groups of definite/probable TBM are adequately powered for the primary end-point. An 
adequately powered study will therefore be large and lengthy. Nested within such trials, detailed CSF 
and blood immune profiling will help better characterize the response to therapy and unique drivers 
of poor outcomes.  
We know that high-dose rifampicin accelerates the time to sputum culture conversion in pulmonary 
TB, so it may well result in more rapid clearance of disseminated TB disease, albeit a difficult thing to 
measure microbiologically. I would postulate that a trial of high-dose rifampicin in all forms of 
disseminated TB (including TBM) as evidenced by positive urine LAM (FujiLAM or Alere) may be 
valuable, and also quicker to recruit that a TBM-specific study.  
10.4 Future research and engagement 
10.4.1 Model burden of disease and cost-effectiveness of upstream interventions 
Hospitalized HIV-associated TB patients pose a significant challenge to healthcare services and care-
givers; in one report TBM cases account for up to 19% of hospitalised TB cases, often requiring 
prolonged hospital stays and rehabilitation periods.47 The incidence of TBM in Uganda cannot be 
ascertained from the data I have available currently, so modelling studies would be useful to 
understand the burden of TBM nationally, including its contribution to TB deaths, survival with 
disability, and disability/quality adjusted life years associated with the condition. A modeller at the 
University of Sheffield (Dr Pete Dodd), investigators from Cape Town, USA, Vietnam and myself are 
trying to model the global burden of TBM disease by triangulating information from available national 
level data, TB and TBM cohorts, post-mortem studies and laboratory data.  
The cost-effectiveness of upstream interventions could be also modelled. I hypothesize that 
comprehensive screening for TB in HIV outpatient clinics including consistent access to urine 
diagnostics (Alere LAM) would be cost-effective in Uganda (as it is in South Africa and Malawi48) and 
help to achieve the End TB targets. The availability of urine Alere LAM in hospital settings is also 
important, but might not be far enough upstream to avert death and disability given how late people 
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present to hospital. TPT in outpatient HIV settings has been shown to reduce incident TB and must be 
more widely implemented.26    
Policy-makers and other stakeholders in Uganda must prioritise TB screening, access to Alere LAM 
and TPT in HIV outpatient settings. I plan to ensure that IDI and the many Kampala City Council HIV 
clinics which it oversees have TB screening and TPT embedded in their standard operating 
procedures. I will present our findings at an IDI research forum and will invite the National 
Tuberculosis Control Programme, Center for Disease Control, UNITAID and other stakeholders to 
advocate for prioritization of TB screening and TPT, alongside community-based HIV testing. In 
addition, along with the Medical Officers, I will present to the Kiruddu Hospital management, medics 
and medical students at a grand round to share our findings and advocate for provision of lumbar 
puncture equipment. 
10.4.2 Continue to improve low and high technology diagnostics for TBM 
According to the WHO’s End TB strategy, improved diagnostic tests are required as a means to 
stop the global tuberculosis epidemic by 2035. Thanks to collaborative efforts from Foundation 
for Innovative New Diagnostics (FIND), funders and researchers worldwide there are promising 
non-sputum-based diagnostics in the pipeline, as shown in Figure 10.4, some of which will also 
have utility in TBM.  
Figure 10.4 Non-sputum-based TB diagnostic pipeline. 
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FujiFilm SILVAMP TB-LAM will detect more TB than Alere LAM and its diagnostic performance in TBM 
needs to be properly evaluated, both on urine and CSF. We have recently conducted a pilot study of 
FujiLAM on CSF in Uganda on 101 adults with suspected TBM and the results are quite promising: 
sensitivity of FujiLAM on CSF was 74% (25/34) for definite TBM and 51% for definite or probable TBM, 
compared to 94% (32/34) and 54% (32/59) for Xpert Ultra. FujiLAM specificity was surprisingly good 
98% (41/42) for probable/definite TBM (submitted to Clinical Infectious Diseases on 15th October 
2020). We are also beginning a collaborative study with FIND examining FujiLAM on urine in 
suspected TBM patients. FujiLAM has the advantage of being a near patient test with results available 
in under an hour, so it may have a role in supporting treatment decisions in probable/possible TBM 
cases, but unlike Xpert Ultra, it does not provide any information on rifampicin resistance so would 
ideally be used as an adjunctive test. FujiLAM may have a role in reducing the diagnostic lead time in 
smaller health facilities where the Xpert platform is not rapidly accessible, e.g. facilities where Xpert 
provided through a hub-and-spoke system, and the turnaround time for results can be several days.   
Lots of questions remain to be explored regarding the potential of mNGS as a diagnostics tool – 
particularly when considering the host immune signature. In some patients a very vigorous host 
immune response may be so effective at controlling the infection that it renders it impossible to 
detect the bacilli/DNA with conventional tests, yet the immune signature could provide evidence of 
M. tuberculosis infection. Using CSF samples collected by the meningitis research team in Uganda
beyond the Xpert Ultra study participants, and in collaboration with Dr Wilson and Dr Ramachandran
at UCSF, a combined host and pathogen classifier was developed in a training sample set and is now
being examined in a larger validation sample set. Preliminary results recently presented at American
Academy of Neurology conference (Appendix A6b) found that among ‘probable’ TBM cases (i.e.
negative by Xpert Ultra and >11 points) the host transcriptomic classifier predicted that 71% (5/7)
were TBM including one case where M. tuberculosis DNA was identified by mNGS. Within ‘possible’
TBM cases (i.e. negative by Xpert Ultra and >9 points), the host transcriptomic signature classified
9/53 (17%) as TBM, including one mNGS-positive TBM case. mNGS also identified 9 other pathogens
(4 viral, 2 bacterial, 2 toxoplasmosis and 1 TBM-viral co-infection) within the ‘possible’ TBM group.
The host and pathogen classifier findings will be submitted for publication by Dr Ramachandran in the
near future. The turnaround time, cost and the degree of technical expertise required for mNGS are
rate-limiting factors in LMIC settings currently. However, work is underway to create a low-tech host
signature assay for the Cepheid Xpert platform.
Researchers at Stanford University have embraced the heterogeneity in host responses between 
different TB populations and using machine learning techniques on global publicly available TB 
datasets have identified a combinatory score (TB-score) based on whole blood mRNA levels of only 
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three differentially expressed genes (GBP5, DUSP3 and KLF2) which can discriminate between active 
TB disease and other diseases.49 Cepheid have taken this 3-gene signature and developed a prototype 
host response cartridge (Xpert-MTB-HR-Prototype) that quantifies 3-gene mRNA-levels in whole 
blood (fingerprick sample). FIND have recently examined the performance of the Xpert-MTB-HR-
Prototype on bio-banked blood samples from PLHIV/TB: area under the receiver-operator-
characteristics (ROC) curve was 0.89 (95% CI, 0.83-0.94) for active TB against a comprehensive 
microbiological reference standard.50 A host response assay for TB would be a huge leap forwards for 
diagnosis of paucibacillary TB disease and extrapulmonary TB and I am keen to explore this assay in 
Ugandan TBM suspects. Whether the whole blood and CSF host transcriptional signature differ 
remains to be determined. Preliminary results of CSF host transcriptional profiling from UCSF suggest 
that a combination of 4 genes (GBP5, SOD2, FTL, NFKBIA) discriminate TBM from other forms of 
meningitis but this will continue to be refined on a larger sample set.  
A TBM host – pathogen – diagnostic framework remains to be defined; one proposed framework is 
depicted in Figure 10.5.  
Figure 10.5. Diagnostic framework for TBM. Along the 
horizontal axis is increasing immune response and along 
the vertical axis is organism burden. As immune response 
increases organism burden declines, and thus increasingly 
sensitive tests with lower limits of detection are needed to 
detect disease. At the far right end the immune response 
is so strong the bacilli/DNA are undetectable by PCR but an 
immune signature could be used to diagnose disease. Th1 
= T helper cell 1 (cell-mediated immunity against 
intracellular bacteria, mediated by IFN-g and IL-2, effector 
cells macrophages and CD8+ T-cells).51 
Whilst the technology is exciting and fast-moving we must not neglect the importance of grassroots 
good clinical decision making. Medical Officers in Uganda and other LMIC settings are often working 
without senior support having to make highly emotive treatment decisions. It is perhaps not 
surprising that in the chapter 4 retrospective cohort that there was such a heterogeneity in amount of 
empirical treatment given between the two Ugandan referral hospital sites.52 A clinical predication 
tool built with local data might be able to support clinicians in making these challenging decisions. A 
smartphone application that uses a data-driven model (that considers presenting clinical features, 
results of CSF and other diagnostics tests) could serve as a clinical prediction tool to support decision-
making. I am collaborating with investigators from Witwatersrand University and University of 
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Minnesota on an individual patient data meta-analysis and the development of a clinical predication 
tool, the protocol for which has been published.53 My specific role was systematically reviewing 
abstracts from a comprehensive literature search and identifying RCTs, cohort or cross-sectional 
studies which met the eligibility criteria. From the studies identified we have gathered data from over 
5000 individuals from 7 countries (including Uganda). The data is currently being cleaned and the 
modelling approach finalised by data scientists on the team.  
10.4.3 Better characterization of the TBM population 
We need to better characterise the patient population from both a microbiological and 
immunological perspective so the we can understand the different clinical phenotypes, burden of co-
infection, co-morbidities and the heterogeneity in the immune response. Extensive microbiological 
characterisation (including post-mortem examinations) allows for a better estimate of the true TB 
status and identification of other co-infections and morbidities. It would also be interesting to 
examine whether these is any relationship between genetic diversity in M. tuberculosis and clinical 
phenotype, as has recently been described in pulmonary TB.54 It is incredible to consider  
From an immunology perspective, host immunity clearly contributes to TBM pathogenesis, but 
exactly how still needs to be defined in our Ugandan HIV/TBM population. A fascinating recent report 
from a study nested in ongoing Vietnamese and Indonesian TBM clinical trials found that active 
Strongyloides stercoralis infection (by stool microscopy or PCR) modulated CSF inflammatory 
response (reduced pre-treatment CSF neutrophils, CSF IFN-g, and TNF-α) and was associated with 
reduced neurological complications by 3 months when compared to patients without active S. 
stercoralis infection (3.8% [1/26] vs. 30% [22/110] respectively, p=0.01). Additionally, there was 
reduced Xpert positivity in the active S. stercoralis group (3.8% [1/26]) vs. the S. stercoralis uninfected 
group (28.2% [31/110]) (p=0.03)55 It is incredible to think that a intestinal helminth infection could 
have an impact on inflammatory response to TB with a knock on effect on diagnostics and disease 
outcomes. Who knows what impact helminth infections are having on TB disease in Uganda, 
particularly Schistosoma mansoni infection which is endemic in country. Helminth infection may be an 
additional contributory factor to the degree of heterogeneity we see in TBM presentation and 
outcomes and should certainly be explored further.  
There may also be heterogeneity between ethnic populations, for example the LTA4H genetic 
polymorphism in Vietnamese adults which strongly determines steroid responsiveness and survival 
from TBM, did not have the same impact in Indonesians with TBM. Therefore, we must be cautious 
about extrapolating findings from one population into another, and multi-country studies are called 
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for. Nested within diagnostic or interventional studies in Uganda, we need to characterise cellular 
populations, cytokines and transcriptomic profiles, and identify responses that correlate with clinical 
outcomes. This may identify new biomarkers and potential targets for host-directed therapies (HDTs). 
Pathogen-related biomarkers are also important to 
further explore both in urine (Ultra, LAM, FujiLAM) 
and CSF (lactate, PCR cycle threshold, FujiLAM). In 
our Ugandan TBM cohort, recent exploratory 
analysis of Xpert Ultra bacillary load as measured by 
PCR cycle threshold (Ct, low Ct = high bacillary load) 
suggests that high bacillary load is a predictor of 
death, Figure 10.6. We need contemporary immune 
profiling to disentangle these relationships and 
elucidate a microbiologic and immunologic 
framework for TBM disease.   
Figure 10.6. Kaplan Meier survival estimate by CSF Ultra cycle threshold (Ct) from 101 patients with suspected or confirmed 
TBM. Where Ultra results were positive the IS1081/IS6110 Ct values were divided into tertiles. The survival of patients with 
negative Ultra results is shown by the green line. (In press Clinical Infectious Diseases) 
The Medical Research Council TBM severity grade is a simple and useful tool for assessing severity but 
it is not clear whether it informs prognosis in Africans with HIV/TBM. With larger datasets it may be 
possible to derive and externally validate a prognostic score in HIV/TBM which considers baseline 
characteristics such as GCS, focal neurology, blood results (CD4+ T cell count, haemoglobin, sodium), 
CSF results (Xpert Ultra result and Ct, lactate, WCC), urine TB results (LAM or Ultra or both), ART 
status.  
Illuminating the pathogenesis of HIV/TBM is clearly fundamental to improving outcomes. Although 
immunology studies were outside the scope of this PhD I hope stored samples will be useful in 
providing some future insights.  
10.4.4 Optimising antimicrobial therapy for TBM 
The momentum around high dose rifampicin is building and a number of clinical trials have recently 
been funded examining high-dose rifampicin, including three trials in Uganda as outlined below: 
1. ALTER – phase II, open-label factorial design RCT. High-dose rifampicin (35mg/kg) orally for 4
weeks +/- linezolid 1200mg orally for 4 weeks. standard dose H, Z, E. N=60 Site: Masaka
Hospital. PI: Dr F. Chow. Sponsor: UCSF, USA. NCT04021121.
https://clinicaltrials.gov/ct2/show/NCT04021121
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2. INTENSE TBM – phase III, open-label placebo-controlled RCT. High-dose rifampicin 35mg/kg
for 8 weeks, +/- linezolid 1200 mg orally for 4 weeks then 600 mg for 4 weeks, +/- aspirin
100mg/day. Standard dose H, Z, E. N=768. Site: Mbarara Regional Referral Hospital, Uganda
(along with sites in Cote D’Ivoire, Madagascar, South Africa). PI: Sponsor: French National
Agency for Research on AIDS and Viral Hepatitis. NCT03927313 https://intense-
tbm.org/clinical-trial.
3. HARVEST – phase III, two-arm parallel design double-blind placebo-controlled RCT. Standard
RHZE + rifampicin 1800mg orally 8 weeks versus placebo. N=500. Site: Mulago National
Referral Hospital (along with sites in South Africa and Indonesia). PI: Prof Ruslami and Dr
Meya. Sponsor: Infectious Diseases Institute, Uganda. ISRCTN15668391.
http://www.isrctn.com/ISRCTN15668391
Our group in Uganda are leading the HARVEST trial which is examining an intervention which would 
be relatively easy to implement if it proves to be efficacious – RHZE as standard combination therapy 
plus a flat dose of 3 x 600mg rifampicin tablets for 8 weeks. Modelling work by collaborators at 
Radboud University Medical Centre has shown that weight-based dosing of rifampicin yields a small 
non-clinically relevant decrease in variability in total rifampicin exposure,56 so using a flat-dose 
intervention is a reasonable and less complex approach. Rifampicin is cheap and generically made 
within Africa which might facilitate implementation.  
In the implementation of any novel TB regimen the safety of its use outside of a clinical trial setting 
(i.e. without routine blood test monitoring) must be considered alongside potential drug interactions 
with ART or other over-the-counter medicines. Liver toxicity is probably the biggest safety concern in 
TB cohorts worldwide, it occurred in 11% of Rift enrolees, and can be fatal if medications are not 
interrupted. Although, in TBM, interruption of treatment is associated with poor outcomes in itself, so 
pragmatic guidance needs to be developed about how to manage DILI in a LMIC setting. The 
approach that I adopted in Rift study (interruption of pyrazinamide in isolation if ALT >3xULN) allowed 
other TB drugs to be continued, but requires availability of individual formulations of antituberculous 
agents. This approach, along with tolerating a higher LFT threshold before any drugs are interrupted, 
will be further explored in a sub-study of the HARVEST trial. Given that high-dose rifampicin can cause 
a transient hyperbilirubinaemia in the first 1-2 weeks, jaundice may be a misleading early symptom 
but late onset jaundice may be a worrying feature. Blood biomarkers for DILI risk are being 
investigated so that high risk patients could be identified at the start of treatment and active liver 
monitoring planned.57 
The PanACEA consortium have recently suggested that the most promising programmatic strategy for 
high dose rifampicin in the treatment of pulmonary TB would be to start TB therapy with a standard 
rifampicin dose, allowing the body to get used to rifampicin in terms of facilitating clearance 
autoinduction and bilirubin clearance, before escalating the dose.14 After this initial period, a higher 
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dose of rifampicin could be introduced in all patients. However, in TBM where there is high early 
mortality, this approach is unlikely to be successful. Personalized medicine using a low-cost point of 
care device to estimate rifampicin concentrations in real-time with titration for individual maximum 
exposures is also an option that needs to be explored.14 Outside of the high-dose rifampicin arena, 
rifapentine, a fellow rifamycin, has recently been shown to be effective in the treatment of pulmonary 
TB as part of a 4-month treatment regimen with moxifloxacin, isoniazid and pyrazinamide. The CSF 
pharmacokinetics of rifapentine warrant examination in case it becomes a WHO-recommended 
regimen.58   
It is important that diagnostic and immunology studies are nested within RCTs for the reasons 
outlined in sections above and so that if the interventions don’t work we can understand why. 
Optimal methods and timing of sample collection have recently been outlined in a paper by the TBM 
consortium.59 It is possible that high-dose rifampicin will reduce CSF cell trafficking and immune 
activation as a result of faster TB killing, conversely more rapid killing might prompt a more florid 
immune response, we will only know if longitudinal samples are collected for immune profiling. 
10.4.5 Optimising the host status 
In parallel with optimal antimicrobial therapy we must endeavour to optimise the host status, both 
through supportive care and HDTs to allow high-dose rifampicin time to exert its killing effect. Local 
supportive care solutions need to be defined and tested as interventions from northern settings tend 
to generalise poorly to low resource settings; for example, ‘early-goal directed therapy for sepsis’ and 
‘goal-directed therapy for suspected acute bacterial meningitis’, both paradoxically led to increased 
mortality in sub-Saharan Africa.60,61 Clearly, basic supportive considerations such as nutrition, 
thromboprophylaxis, co-trimoxazole prophylaxis +/- antifungals are important in this highly 
immunocompromised group. Anemia has been associated with poor outcomes in HIV/TB so the role 
of blood transfusion could also be further explored. 
Cerebral infarction occurs in around 25%62 of TBM cases and was associated with a twofold increase 
in mortality in a recent meta-analysis.63 TBM is a hypercoagulable inflammatory state, which 
contributes to the pathogenesis of stroke, and I hypothesise that an adjunctive medication which can 
reduce the incidence and severity of strokes will be essential to reduce TBM death and disability, of 
which high-dose aspirin in the most promising. I believe one size does not fit all when it comes to 
TBM. We need to identify which sub-populations benefit or are harmed by adjunctive corticosteroids 
and how their ART status intersects with steroid requirements, and likewise who may benefit from 
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other HDTs such as aspirin or other immunomodulating drugs to augment or dampen specific 
immune responses.  
In HIV/TBM the timing and choice of ART regimen will also be key to improving outcomes. If the M. 
tuberculosis antigen burden is cleared more rapidly with high-dose rifampicin it may be possible to 
start ART earlier (rather than waiting til week 8 as is current practice in many settings), which may 
shorten the period that the individual remains susceptible to opportunistic illnesses. As DTG is rolled 
out as first-line HIV treatment across Africa, we must confirm that high-dose rifampicin can be used 
safely with DTG-based ART after dose-adjustment to 50 mg twice daily, both from a PK and safety 
perspective. Whilst expert opinion is that CYP450 enzyme induction is already maximal with standard 
dose rifampicin, the were some cautionary findings within the RIFAVIRENZ study (section 1.5.3), so 
this needs to be confirmed with adequately powered nested PK study (planned within HARVEST trial). 
10.5 Conclusion 
TBM is the second leading cause of adult meningitis in Uganda, is largely seen in people with 
advanced HIV-related immunosuppression and carries a mortality of approximately 40%. Introduction 
of the Cepheid Xpert platform in government hospitals has increased rates of microbiological 
confirmation of TBM to around 50%, and Xpert Ultra is the best first test for TBM with a sensitivity of 
77% for probable/definite TBM and negative predictive value of 93%. Disseminated TB, detectable by 
urine Alere LAM or urine Xpert Ultra, is present in over half of patients with HIV/TBM and urine Ultra 
positivity may serve as a prognostic biomarker. The disseminated nature of TB disease and associated 
multi-system dysfunction may be a driver of the excess mortality in HIV-associated TBM.  
With currently WHO-recommended TB treatment, CSF rifampicin concentration is subtherapeutic in 
the majority of TBM patients in Uganda. Compared to standard TB therapy, total serum and CSF 
exposures are increased by roughly 6-fold and roughly 8-fold with intravenous rifampicin 20 mg/kg 
and oral rifampicin 35 mg/kg respectively. Almost all the participants who received high-dose 
rifampicin had CSF levels above the local M. tuberculosis rifampicin MIC. There was no excess toxicity 
with high-dose rifampicin but no impact on survival or functional outcomes was observed in this 
phase II study. An upcoming multi-centre phase III study, including sites in Uganda, Indonesia and 
South Africa will examine the impact of high-dose rifampicin on survival from TBM. Nested within this 
trial, through old fashioned pathology studies combined with modern ‘omics’ approaches, we aim to 
better understand the different clinical phenotypes and unique drivers of poor outcomes in HIV/TBM 
including co-infections, immune activation/exhaustion, poly-pharmacy including ART and 
corticosteroids.  
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Whilst we continue to optimise antimicrobial and host-directed therapies for TBM we must also 
remember that prevention is better than cure. Upstream interventions such as HIV testing, earlier 
ART initiation and interventions to support ART adherence and retention in care are vital to prevent 
the apparent main driver of TBM in Uganda – advanced HIV disease. Improved TB screening including 
access to urine TB diagnostics in outpatient settings and tuberculosis preventative therapy are also 
important tools in reducing incident TBM and its associated morbidity and mortality in Uganda.  
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Background. There is substantial variation in the reported treatment outcomes for adult tuberculous meningitis (TBM). Data 
on survival and neurological disability by continent and HIV serostatus are scarce.
Methods. We performed a systematic review and meta-analysis to characterize treatment outcomes for adult TBM. Following a 
systematic literature search (MEDLINE and EMBASE), studies underwent duplicate screening by independent reviewers in 2 stages 
to assess eligibility for inclusion. Two independent reviewers extracted data from included studies. We employed a random effects 
model for all meta-analyses. We evaluated heterogeneity by the I2 statistic.
Results. We assessed 2197 records for eligibility; 39 primary research articles met our inclusion criteria, reporting on treatment 
outcomes for 5752 adults with TBM. The commonest reported outcome measure was 6-month mortality. Pooled 6-month mortality 
was 24% and showed significant heterogeneity (I2 > 95%; P < .01). Mortality ranged from 2% to 67% in Asian studies and from 23% 
to 80% in Sub-Saharan African studies. Mortality was significantly worse in HIV-positive adults at 57% (95% CI, 48%–67%), com-
pared with 16% (95% CI, 10%–24%) in HIV-negative adults (P < .01). Physical disability was reported in 32% (95% CI, 22%–43%) of 
adult TBM survivors. There was considerable heterogeneity between studies in all meta-analyses, with I2 statistics consistently >50%.
Conclusions. Mortality in adult TBM is high and varies considerably by continent and HIV status. The highest mortality is 
among HIV-positive adults in Sub-Saharan Africa. Standardized reporting of treatment outcomes will be essential to improve future 
data quality and increase potential for data sharing, meta-analyses, and facilitating multicenter tuberculosis research to improve 
outcomes.
Keywords.  tuberculous meningitis; mortality; neurological sequelae; systematic review; meta-analysis.
In 2018, 10 million cases of tuberculosis were reported globally 
[1]; tuberculous meningitis accounts for 1%–5% of these cases 
[2]. Tuberculous meningitis is the most severe form of tubercu-
losis and is responsible for a considerable burden of neurolog-
ical sequelae and mortality; a systematic review of treatment 
outcomes in 1636 children with tuberculous meningitis esti-
mated a mortality rate of 19.3% [3]. There is considerable varia-
tion in the reported outcomes for adult tuberculous meningitis 
across available studies; the reasons for this remain unclear. 
Two recent systematic reviews of adult tuberculous meningitis 
outcomes reported substantial heterogeneity in mortality and 
the proportion of deaths among those diagnosed with TBM, 
with pooled estimates of 22.8% and 24.7% [4, 5]. However, 
neither review attempted to explain the variation in treatment 
outcomes by stratifying studies by HIV status and geographical 
location. In addition, Wen and colleagues excluded all investiga-
tional treatment studies, effectively excluding major treatment 
randomized controlled trials (RCTs) investigating regimens 
that have now become the standard of care (eg, adjunctive ster-
oids and delayed antiretroviral therapy [ART] for those with 
HIV-associated tuberculous meningitis). Furthermore, there 
is a paucity of data in recent meta-analyses on drug resistance 
rates, treatment regimens, and steroid use. HIV co-infection 
has been shown to be a risk factor for death (hazard ratio, 2.5; 
95% CI, 1.9–3.4) in Vietnamese adults with tuberculous menin-
gitis [6], but this remains to be explored systematically in other 
regions [7–9]. Neurological disability in adult tuberculous men-
ingitis survivors has not been studied in detail in meta-analyses. 
In 2 recent systematic reviews, the prevalence of disability in 
adult tuberculous meningitis survivors varied between 29% and 
50% [4, 5]. However, neither review provided data on the nature 
and severity of neurological sequelae in tuberculous meningitis 
survivors.
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We performed a systematic review and meta-analysis to char-
acterize treatment outcomes, namely all-cause mortality and 
neurological sequelae, for adult tuberculous meningitis across a 
range of epidemiological settings. We endeavored to perform a 
definitive review by including the best quality data available and 
performing a robust quality assessment of the studies included.
METHODS
Literature Search Strategy
This review followed the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement 
for the reporting of systematic reviews and meta-analyses [10]. 
A systematic electronic search was conducted using MEDLINE 
and EMBASE with the aim of identifying all studies reporting 
treatment outcomes in adult tuberculous meningitis from 1988 
to the present. This time period corresponds to the WHO rec-
ommendation of standard quadruple therapy for the treatment 
of tuberculosis [1]. Controlled and natural language terms iden-
tified key search concepts such as “tuberculosis,” “meningitis,” 
“mortality,” “complications,” and “outcome.” The full search 
strategies are presented in Supplementary Appendix A. Searches 
were conducted on July 9, 2018.
Study Selection
A 2-stage sifting process was employed: (1) at title and abstract 
and (2) at full-text level according to eligibility criteria as de-
tailed below. Sifting was performed in duplicate independently 
by 2 reviewers, and any unresolved disagreements were re-
solved by a third independent reviewer. Reference and citation 
checking were conducted for included articles.
Studies were eligible for inclusion if they (i) included adults 
(aged ≥15 years) with confirmed or suspected TB meningitis; 
(ii) utilized diagnostic criteria to systematically evaluate pa-
tients for tuberculous meningitis; (iii) reported on at least 1
of the following outcome measures: neurological sequelae,
in-hospital mortality, mortality at the end of follow-up; (iv)
employed any of the following study designs: consecutive case
series, case–control study, cohort study, randomized controlled
study, systematic review, or meta-analysis.
The following exclusion criteria were applied: (i) studies with 
<10 participants; (ii) studies limited to specific complications or 
comorbidities (eg, hydrocephalus, tuberculoma, or surgical inter-
vention); (iii) studies not providing at least a backbone of standard 
fixed-dose combination antituberculous therapy; (iv) studies not 
specifying treatment given; (v) studies published before 1988; (vi) 
studies not written in English; (vii) any systematic review super-
seded by an updated systematic review; (viii) narrative reviews not 
adding new data or new analysis of data to existing knowledge.
Data Extraction and Data Synthesis
Two authors independently extracted data on study character-
istics, recruitment populations, and treatment outcomes from 
eligible studies using a standardized, piloted electronic data 
capture database (REDCap, Vanderbilt University, Nashville, 
TN, USA). We captured data on geographical region, number 
of HIV-positive participants, British Medical Research Council 
(MRC) tuberculous meningitis grade at presentation, treat-
ment regimens utilized, use of corticosteroids, and outcomes 
reported at specified time points for each study. Any unresolved 
disagreements in extraction were resolved by a third inde-
pendent reviewer.
We used each study’s definition of neurological sequelae as 
reported in the study. For articles that utilized the modified 
Rankin Scale or the Barthel index, “disability” was defined as 
“any disability that impeded the patient’s ability to carry out 
tasks they once performed.” This is was represented as a score of 
>2 on the Modified Rankin Scale or <80 on the Barthel Index.
For systematic reviews, individual study-level data were not
extracted or analyzed; only the summary estimates were re-
corded for comparison, and citation checking was performed 
to ensure all relevant source manuscripts had been identified.
Data Analysis
We used the proportion of all-cause deaths and neurological 
sequelae within each study to define outcomes of tuberculous 
meningitis for the meta-analyses. As such, all meta-analyses 
used random effects models and employed the DerSimonian 
and Laird method on Freeman-Tukey transformed propor-
tions, which is the established approach for this type of analysis 
[11–13]. We graphically displayed data in forest plots, which 
display point estimates of tuberculous meningitis outcomes in 
each study, with 95% confidence intervals. We generated pooled 
effect estimates by inverse variance–weighting each individual 
point estimate, such that the estimates with lower variances con-
tributed more to the pooled estimate [13]. The overall pooled 
estiamte for mortality was stratified by follow-up outcome re-
porting time. Interstudy and subgroup heterogeneity were as-
sessed with the I2 statistic. All analyses were conducted in Stata, 
version 15.1 (StataCorp, College Station, TX, USA), with the 
“metaprop” command [14].
Quality Assessment
The 39 articles included in the meta-analysis were assessed 
for study quality using the Downs and Black tool, a 27-item 
quality assessment checklist [15]. Each study was scored on 
a 32-point scale for items that examined quality of reporting, 
external validity, internal validity (bias and confounding), and 
study power. Study power was estimated according to sample 
size methodology. Studies were scored as follows; 0 if no sample 
size calculation was made or reported in the manuscript (given 
for observational studies); 3 if a power calculation was done 
but there were insufficient numbers of patients recruited; 5 
if the power calculation was done and sufficiently powered. 
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assessed for risk of bias. As treatment outcomes were of interest 
in these analyses and not treatment or intervention efficacy, we 
included all studies regardless of quality assessment score.
Role of Funding Source
The Fogarty International Center of the National Institutes of 
Health provided funding fellowship support to the lead au-
thor of the study. The funders had no role in the study design, 
data collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to 
submit for publication.
RESULTS
Search Results, Studies, and Participants Included
Our searches yielded 2562 reports. After removal of duplicates 
(n = 365), 2197 studies underwent title and abstract screening, 
and 264 full texts were reviewed (Figure 1). Thirty-nine studies 
met our eligibility criteria for inclusion and analysis (Table  1). 
These 39 studies were published between 1995 and 2018; 10 
(26%) were case series, 21 (54%) were cohort studies, and 8 
(21%) were randomized controlled trials. Studies arose from 18 
countries, including a range of epidemiological settings; 24 (62%) 
were from high–TB burden settings, and 15 (38%) were from 
low–TB burden settings. A total of 26 (67%) studies were con-
ducted in Asia, and 5 (13%), 5 (13%), and 2 (5%) were conducted 
in Europe, Africa, and the Americas, respectively (Figure  2). 
Study quality scores ranged from 8 to 32, with a score of 32 
indicating the highest quality. The median quality score for in-
cluded articles (interquartile range [IQR]) was 18 (15–20). Our 
meta-analysis includes reported treatment outcomes for 5752 
adults with tuberculous meningitis. Participant age ranged from 
15 to 88 years. Seven studies included 1078 HIV-positive patients: 
302 (28%) from Africa and 776 (72%) from Asia. MRC tubercu-
lous meningitis grade was reported in 29 studies, in which 28% 
(1354/4761) of participants presented with MRC grade I disease, 
48% (2302/4761) with grade II, and 20% (967/4761) with grade 
III. A total of 37 studies (n = 5623 participants) reported the clas-
sification or uniform case definition of enrolled participants. Of
Full-text articles excluded (n = 225)
Nontuberculous meningitis (n = 13)
No systematic diagnostic criteria for diagnosing tuberculous meningitis (n = 25)
Did not report at least 1 outcome of interest (n = 9)
Ineligible study type or study type not specified (n = 10)
Fewer than 10 study participants (n = 3)
Non-English articles (n = 27)
Study conducted before 1988 (n = 8)
Study sample limited to patients with specific complications or comorbidities (n = 5)
Full text unable to be located (n = 27)
No disaggregated tuberculous meningitis data (n = 6)
No disaggregated adult data (n = 58)
No specified treatment drugs, doses, and duration (n = 30)
Narrative reviews or new analysis of existing data (n = 2)
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those, 40% (2243/5623) were microbiologically confirmed tuber-
culous meningitis and 49% (2741/5623) were suspected tuber-
culous meningitis, the latter of which included 21% (1013/5623) 
with probable tuberculous meningitis and 12% (663/5623) with 
possible tuberculous meningitis according to the uniform case 
definition [16]. Only 12 studies reported on drug resistance rates; 
10 studies included patients with multidrug-resistant tubercu-
losis (n = 49), and 12 studies included patients with mono-drug-
resistant tuberculosis, of which 10 studies included isoniazid 
resistance (n = 112 participants), 6 studies included rifampin re-
sistance (n = 12 participants), and 1 study included streptomycin 
resistance (n = 1 participant).
The most common treatment regimen was standard 4-drug 
therapy of rifampicin, isoniazid, pyrazinamide, and etham-
butol (RHZE) with no additional antituberculous drugs 
(n  =  17 studies). Seven studies used streptomycin in ad-
dition to or in replacement for ethambutol (Table  1). The 
median treatment duration (IQR) was 9 (9–12) months. 
Corticosteroids were given to all patients in 19 studies and to 
some participants in 10 studies (Table 1). Treatment outcomes 
by corticosteroid use were examined in a meta-analysis with 
included studies, but this was not the aim or design of our 
meta-analysis, and a significant amount of heterogeneity in 
mortality between studies was unexplained (Supplementary 
Appendix B). A  Cochrane meta-analysis on corticosteroid 
use in TBM was published in 2016 [57].
Mortality Assessment and Outcomes
A wide range of mortality end points were reported: 15% (6/39) 
studies reported 1-month mortality, 5% (2/39) studies reported 
2-month mortality, 8% (3/39) studies reported 3-month mor-
tality, 18% (7/39) studies reported 6-month mortality, 13%
(5/39) studies reported 12-month mortality, and 2% (1/39) 
reported 5-year mortality. Other reported outcomes included 
in-hospital mortality (n = 6 studies) and median time to death 
(n = 4 studies). In the 6 studies that reported on “in-hospital 
mortality,” only 1 study reported on the length of hospitaliza-
tion, which ranged from 4 to 10 days until death or discharge. 
Five studies did not define “in-hospital mortality” in terms of 
time frame.
To investigate time-specific mortality, articles were 
grouped by follow-up outcome reporting time point. Articles 
that reported outcomes ≤3  months were included in the 
3-month reporting category to summarize “early” mortality.
Articles that reported outcomes >3 months to 6 months were
included in the 6-month reporting category. Articles that re-
ported outcomes >6 months were included in the 12-month
reporting category. Of articles reporting outcomes at 3, 6, and 
12 months, pooled mortality was 23% (95% CI, 14%–35%),
23% (95% CI, 14%–33%), and 25% (95% CI, 17%–33%), re-
spectively (Figure  3). There was significant heterogeneity
(I2  =  95%; P  <  .01) for all outcome reporting time points.
There was no marked heterogeneity in mortality between
outcome reporting time points (P = .60), but it was included
in the pooled analysis, resulting in a pooled mortality of 24%
(95% CI, 19%–29%).
Mortality End Points by HIV Status
Seven studies reported mortality for HIV-positive adults. For 
HIV-positive adults, pooled mortality was 57% (95% CI, 48%–
67%), compared with 16% (95% CI, 10%–24%) in HIV-negative 
adults (Figure 4). HIV status explained a significant amount of 
the observed heterogeneity in tuberculous meningitis mortality 
(P < .01).























Figure 2. Tuberculous meningitis mortality by country. Pooled mortality for tuberculous meningitis by country. Mortality for countries with only 1 study reflect the reported 
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Figure 3. Tuberculous meningitis mortality by outcome reporting time point. Forest plots depicting mortality due to tuberculous meningitis at 3, 6, and 12 months. One study 
was excluded because the outcome time point was not reported.
Mortality End Points by Geographical Region
Most studies reporting on tuberculous meningitis mortality 
were conducted in India and the Asian continent (n = 27; 70%), 
where pooled mortality ranged from 2% to 67% (Figure  2). 
The countries reporting the highest tuberculous meningitis 
mortality were located in Sub-Saharan Africa, where mortality 
ranged from 23% to 80%. Continent (Africa vs Asia) explained 
a significant amount of the observed heterogeneity in tubercu-
lous meningitis mortality (P = .02).
Temporal Variation in Mortality End Points
To investigate changes in tuberculous meningitis treatment out-
comes over time, we conducted a temporal analysis in which 
individual studies were allocated to 1 of 5 time periods and strat-
ified analyses were conducted. Time periods were subdivided 
into 5-year windows from 1995 onwards, and pooled mortality 
was analyzed within each time window. The highest pooled 
mortality was 31% (95% CI, 14%–51%) in articles published 
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by time window (Supplementary Appendix C). In earlier time 
periods, heterogeneity in survival was greatest, and heteroge-
neity appears to have declined in more recent time periods.
Neurological Disability
Functional outcomes among survivors was a prespecified end 
point in 24 studies; 10 studies reported on functional outcomes 
using the Modified Rankin Scale score (n = 6) or the Barthel 
Index (n = 5), 10 studies reported on neurocognitive disability 
without using a specified scale or measurement tool, and 5 
studies reported using “clinical assessments.”
The timing and method of neurological assessments varied 
between studies; the most commonly used outcome assess-
ment was physical disability conducted at the end of follow-up. 
In this analysis, participants were considered disabled if there 
was any indication of functional disability as reported by the 
Modified Rankin Scale or Barthel Index. Of the studies utilizing 
the Modified Rankin Scale, the pooled proportion of patients ex-
periencing some level of physical disability was 26% (95% CI, 
18%–35%), with considerable heterogeneity (Supplementary 
Appendix D). Of the studies using the Barthel Index, the pro-
portion of patients experiencing some level of physical disability 
was 32% (95% CI, 22%–43%), with only moderate heterogeneity.
DISCUSSION
In this rigorous systemic review and meta-analysis, we reviewed 
treatment outcomes for >6000 adults with tuberculous menin-
gitis, and our data clearly demonstrate that the mortality and 
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Figure 4. Tuberculous meningitis mortality by HIV status. Forest plot depicting mortality due to tuberculous meningitis stratified by HIV status. HIV status explains a signif-
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neurological sequelae associated with tuberculous meningitis 
remain unacceptably high. Although there was significant het-
erogeneity between studies (I2 > 95%), the overall risk of death 
was 23% at 3 months and 25% at 12 months. In patients who did 
survive, neurological sequelae were common, affecting nearly 
one-third of all patients. Furthermore, our temporal analysis 
of treatment outcomes indicates that prognosis has improved 
little over time. Our results are in concordance with 2 recently 
published systematic reviews, which reported overall morality 
associated with adult tuberculous meningitis to be 23% and 
25% and risk of neurological sequelae to be 29% and 50%, re-
spectively. Our study expands on the current literature through 
subgroup meta-analyses to evaluate differential treatment out-
comes by HIV status and geographical region.
We have demonstrated that patients with HIV-associated tu-
berculous meningitis have 3-fold higher mortality compared 
with HIV-negative cohorts; mortality in HIV-negative cohorts 
ranged between 10% and 24%, compared with 48%–67% in 
HIV-positive cohorts (P  <  .01). Pathogenesis research is ur-
gently needed to investigate the disproportionate mortality as-
sociated with HIV co-infection in tuberculous meningitis and 
to identify potential interventions or preventative measures.
Second, our data demonstrate that despite adoption of 
standardized treatment regimens for tuberculous meningitis, 
considerable global disparities in treatment outcomes exist. 
Pathogenesis work has shown that even within a Vietnamese 
population, a single genetic polymorphism significantly impacts 
corticosteroid responsiveness and survival from TBM [58]. The 
extent of the heterogeneity observed in this meta-analysis raises 
the possibility that genetic or other latent factors may con-
tribute to outcome, and the current one-size-fits all approach to 
treatment may be effective in some individuals/populations and 
less effective in others. Our subgroup meta-analyses indicate 
that patients in the African continent have a higher mortality 
compared with all other continents. This may in part be ex-
plained by the higher co-prevalence of HIV. However, given the 
considerable resource limitations including a lack of intensive 
care facilities typical of many settings in Sub-Saharan Africa, it 
is likely that the management of commonly encountered com-
plications of tuberculous meningitis including hyponatremia, 
raised intracranial pressure, hydrocephalus, stroke, and noso-
comial infections is suboptimal. Further research is needed to 
determine the attributable mortality due to a lack of supportive 
or critical care in Sub-Saharan Africa. Our systematic literature 
review highlights the historical paucity of clinical studies pub-
lished from this continent. In order to address the devastatingly 
poor outcomes from HIV-associated meningitis, particularly 
for those in Sub-Saharan Africa, we need to design, fund, and 
deliver more clinical research.
Our meta-analyses of follow-up time-specific mortality at 3, 
6, and 12 months highlight that >90% of tuberculous menin-
gitis deaths occur in the first 3  months. This may justify that 
3-month mortality is a reasonable RCT end point, potentially
making study trial follow-up shorter and cheaper, thereby ac-
celerating research outputs. However, the considerable heter-
ogeneity found in these analyses, as well as inconsistencies in
reporting outcomes, indicates that further evidence is needed
to justify a 3-month clinical trial end point. Clinical studies to
identify drivers of early mortality in tuberculous meningitis
may inform the design of treatment intensification strategies
and other adjunctive interventions.
Concerningly, our results demonstrate that minimal im-
provements in survival have been made over time. There are 
a number of temporal factors that may have affected outcomes 
in certain time periods including the height of the HIV epi-
demic in the 1990–2005 period: ART rollout in the 1995–2010 
window, the increasing availability of more rapid diagnostics in 
the form of the Xpert MTB/Rif assay in the 2010–2020 window 
facilitating the diagnosis of tuberculous meningitis where it was 
previously unconfirmed, and, lastly, gradually increasing rates 
of antituberculous drug resistance worldwide. Reporting bias, 
which may have varied over time, must also be considered.
Our analysis has several limitations. First, although we only 
included studies that employed a prespecified diagnostic crite-
rion for tuberculous meningitis, there was considerable varia-
tion in the quality of diagnostic criteria used, and diagnostics 
have changed over time. We chose not to restrict diagnostic 
criteria to microbiologically confirmed tuberculous menin-
gitis because doing so would have restricted our meta-analysis 
to 40% (n = 2243) of adults, and furthermore we wanted our 
results to be generalizable to real-world clinical settings where 
confirmation rates are often only moderate. We do, however, 
recognize that misclassification of undifferentiated meningitis 
cases as tuberculous meningitis is common, especially when 
left to physician discretion, as may have been the case in some 
of the patients included in our meta-analysis, which would un-
dermine the accuracy of our outcome estimates. Second, in the 
spirit of generalizability, we chose to include case series, which 
are primarily descriptive and not wholly representative of the 
populations they are drawn from. Although this may have 
posed some unmeasurable bias, we believe that this would not 
have substantially impacted our results, as mortality and neu-
rological sequelae, our outcomes of interest, would not have 
measured differently or changed based on study design. Third, 
the specific antituberculous regimen utilized and drug resist-
ance rates within the cohorts were inconsistently reported in 
studies; therefore, we were unable to conduct stratified meta-
analyses based on drug resistance patterns. The International 
Tuberculous Meningitis Research Consortium paper on stand-
ardized methods for enhanced quality and comparability of 
tuberculous meningitis studies specifies that it is essential to 
document the dose, route of administration, and duration of all 
antituberculosis drugs used in tuberculous meningitis studies 
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the optimal treatment of tuberculous meningitis, and therefore 
to facilitate cross-study comparisons and interrogate differences 
in study outcomes, basic information about the treatment pro-
vided is essential.
Finally, there was a considerable lack of standardization of 
reporting on treatment outcomes. This was particularly marked 
with respect to reporting of neurological sequelae; first, neu-
rological sequalae were rarely reported (only 10/39 [26%] 
studies including any data on neurological sequalae), the tools 
used were inconsistent (9 tools in total), and the time points 
for assessment were rarely reported. This inconsistent reporting 
hampered comparison of data across studies. Given the im-
portance of neurological disability in tuberculous meningitis 
and the importance of developing a standardized evidence 
base against which to assess new treatments, the International 
Tuberculous Meningitis Research Consortium recommends 
that the Modified Rankin Score be used as the first-line tool, 
which should be recorded at 12 months from antituberculosis 
treatment initiation in all adults [59]. We support this recom-
mendation, and in addition we would suggest that mortality be 
routinely reported on at 3, 6, and 12 months, if possible, to im-
prove study comparability.
The strengths of this work include its size, with 39 individual 
studies included from Asia, Africa, Europe, and the Americas, 
making our estimates broadly generalizable to a range of set-
tings. Our systematic review is larger than 2 previously pub-
lished systematic reviews of adult tuberculous meningitis [4, 
5]. In comparison to Wen et al. [4], we decided to include ran-
domized controlled trials in our systematic review, which en-
abled us to include the highest quality of trial evidence, and we 
also reported drug resistance rates within each included study. 
In comparison to Wang et al. [5], we ascertained variation in 
treatment outcomes geographically and reported on the nature 
and severity of reported neurological sequelae. Overall, we as-
sessed a wide range of covariates to investigate the heteroge-
neity in treatment outcomes observed. To our knowledge, this 
is the most extensive critical appraisal of tuberculous meningitis 
outcomes to date.
In conclusion, adult tuberculous meningitis is associated 
with considerable neurological morbidity and mortality and 
remains a major challenge in TB-endemic regions. The worst 
outcomes are observed by those with HIV co-infection in 
Sub-Saharan Africa, where risk of death is 3-fold higher. Our 
study was limited by suboptimal reporting on diagnostic cri-
teria utilized, drug resistance rates, and details of treatment 
regimens used, as well as highly variable outcome reporting. 
Adoption of standardized reporting systems across tubercu-
lous meningitis studies would not only facilitate cross-study 
comparisons, but would also improve the quality of research 
outputs overall and support collaborative research across cen-
ters with an aim of improving tuberculous meningitis out-
comes globally.
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>10/12 pts w/out imaging
>12 pts with imaging
POSSIBLE
6-9 points without imaging
6-11 points with imaging
NOT TBM
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Introduction
In many human immunodeficiency virus (HIV) endemic 
countries, tuberculous meningitis (TBM) is the second most 
common cause of adult meningitis after cryptococcal meningitis1, 
and accounts for 1–5% of all tuberculosis (TB) cases2. TBM is 
the most severe form of TB and causes substantial morbidity 
and mortality in children and immunocompromised adults3,4. 
HIV infection is known to increase the risk of death in 
patients with TBM, as does TBM stage at the time of treatment 
initiation2,5. As is the case in cryptococcosis, high-quality nursing 
care is a critical component in managing TBM patients6.
Similarly, diagnosis of TBM is very challenging, especially in 
resource-limited settings where diagnosis relies on a combina-
tion of clinical, radiological and laboratory findings. The World 
Health Organisation (WHO) recommends Xpert MTB/RIF 
Ultra for the diagnosis of TBM using cerebrospinal fluid (CSF). 
Culture has many limitations related to turnaround time and 
sensitivity, and also requires considerable infrastructure and 
costs7. Therefore, the development of early point of care 
diagnosis for TBM is a priority. Recent studies have 
demonstrated that the next generation Xpert MTB/RIF Ultra 
is the most sensitive diagnostic test in HIV-positive adults7. 
However, Xpert MTB/RIF Ultra is not a bedside test, and thus 
access to same day results remain a challenge in many settings7.
Assays based on the detection of mycobacterial lipoarabinoman-
nan (TB-LAM) antigen in urine have emerged as potential 
point-of-care tests for extra-pulmonary TB8. There is evidence 
that urine TB-LAM may help to reduce mortality and predict 
poor outcomes9,10. The WHO recently added the TB-LAM assay 
onto its essential diagnostic list and recommended TB-LAM 
in hospitalised HIV positive adults with signs and symptoms 
of TB11,12. However, there are conflicting results about TB-LAM 
assay sensitivity for TBM diagnosis13 in CSF. With reference 
to definite TBM, Cox et al. found a 75% sensitivity using CSF 
from the fourth ventricle in an autopsy cohort from 91 
HIV-infected adults14. However, Bahr et al. had no positive 
TB-LAM tests using lumbar CSF from 67 HIV patients with 
meningitis13. In light of these results, and now that Xpert 
MTB/RIF Ultra is used instead of Xpert MTB/RIF, we aimed to 
further explore the utility of CSF TB-LAM test for the diagnosis 
of TBM among HIV-positive adults presenting with suspected 
meningitis.
Methods
Study setting and participants
Between April 2018 and June 2019, we assessed and performed 
diagnostic lumbar punctures on HIV-positive patients admitted 
to Mulago National Referral Hospital with suspected meningitis 
in Kampala, Uganda. Screening for TBM was performed 
cross-sectionally as part of the High Dose Rifampicin for 
Tuberculous Meningitis (RIFT) trial (ISRCTN registration 
number ISRCTN42218549, last updated 24/04/2018)15. 
Therefore, we did not calculate a sample size for the 
current study but included all participants that fit the screening 
criteria for the RIFT trial15. All included participants were 
HIV-infected adults (≥18 years old) who provided written 
informed consent by participant or surrogate, with a suspected 
diagnosis of TBM (meningitis symptoms, clinical signs of 
meningism). Demographic information and baseline characteris-
tics for participants were collected through clinical reviews using 
customized meningitis screening case report forms approved 
by the relevant ethics committees (Mulago Hospital Research 
Ethics Committee, Uganda National Council of Science and 
Technology, and the University of Minnesota). Opening 
pressures for CSF were measured using a manometer, followed 
by standard microbiology analysis (CrAg, cell count, protein, 
glucose, lactate, culture).
Diagnostic tests
In addition to standard microbiology analysis, CSF was tested 
with TB-LAM (Alere, Massachusetts, USA), and the test strip 
interpreted as per manufacturer’s instructions. Briefly, the 
protective foil cover was removed from each test and the strip 
labelled with the participant’s number. Two drops (or 60μL) of 
CSF were added to the sample pad. The test was then read after 
25 minutes under standard indoor lighting conditions. The 
reference card was used in interpretation of the results by 
holding it alongside the patient window. For positive results, 
purple/gray bars appeared in both the control window and the 
patient window of the strip. For negative results, one purple/
gray bar appeared in the control window of the strip and no bar 
appeared in the patient window of the strip. If there was no bar 
            Amendments from Version 1
Based on the two reviewers’ comments to version 1, major 
changes were made to the conclusion and Table 1 while minor 
changes were made to the results section as seen in the tracked 
changes. We added the suggested reference in the discussion 
section. Table 1 was modified to present the characteristics 
of patients with diagnosis of definite, probable, possible and 
not-TBM. A sentence was added on cerebral imaging. We also 
added a sentence about the patients who were positive with urine 
LAM and those who were positive with urine Ultra. We added an 
explanation about the 17% of patients had unknown outcome. A 
limitation was added that TB culture was not used. However, we 
have found Ultra to be more sensitive than culture (70% versus 
43% against definite/probable) for the diagnosis of TBM in our 
population (Bahr, Lancet ID, 2018). In the conclusion section, 
we have mentioned the Fuji LAM that is a new LAM POC test 
that has higher sensitivity in urine than the determine LAM POC 
and should also be evaluated for diagnosis of TB meningitis 
both in urine and CSF. Lastly, based on the second reviewer’s 
comments, we would like to say that a cellular CSF is common 
in this population with advanced HIV disease even in the setting 
of a confirmed TB or CM infection (Cresswell, Int J Infect Dis 
2018). The not-TBM group scored <6 points on the uniform case 
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in the control window of the strip, the result was considered 
invalid and the test repeated. The strips were retained and 
cross checked by a second researcher to corroborate the 
finding.
CSF was also tested with Xpert MTB/Rif Ultra (Cepheid). 
Briefly, 2ml of sample reagent was added to 1ml of whole CSF 
and then left to stand at room temperature for 15 minutes. 
Then, 2ml of the sample mixture was transferred into the Xpert 
MTB/Rif Ultra cartridge and loaded into the Xpert machine. 
The test was run for 90 minutes and results from the assay 
indicate whether or not Mycobacteria TB (MTB) was detected 
in the sample. If MTB was detected, the results also stated 
whether resistance to rifampin was detected.
Test analysis
Data were analyzed using STATA version 14 (STATA, College 
Station, Texas). The disease prevalence, sensitivity, specificity, 
positive predictive values, negative predictive values and test 
accuracy were estimated at 95% confidence interval (CI). The 
diagnostic performance of CSF TB-LAM was compared to 
positive CSF Xpert MTB/Rif Ultra (definite TBM) and a 
composite reference of probable or definite TBM according 
to the uniform case definition16. Summaries were made in 
frequency & percentages for each baseline characteristic con-
sidered as a categorical, and medians (interquartile range) when 
each characteristic is considered as a continuous variable. For 
baseline variables with some missing data, we calculated the 
statistics using the available numbers.
Ethical statement
Institutional review board approvals for the study and the 
associated screening process were obtained locally in Uganda 
(Mulago Hospital Research Ethics Committee, approval number 
MREC 1260); and from the London School of Hygiene and 
Tropical Medicine, UK (14388), University of Minnesota 
(1304M31361) and by the Uganda National Council of Science 
and Technology (HS136ES). Written informed consent for 
participation in the study and data publication was obtained 
from all participants or from their surrogates (e.g. family 
member or guardian) where the patient had altered mental status 
and did not have the capacity to provide consent.
Results
Overall, 59 HIV-positive hospitalized participants with 
suspected meningitis underwent diagnostic lumbar punctures, of 
which 20% (12/59) had definite TBM, 9% (5/59) had probable 
TBM, 25% (15/59) had possible TBM, and 46% (27/59) 
had not-TBM17. Of those with not-TBM (n=27), 10 had 
cryptococcosis. Women comprised 50% of participants with an 
overall median age for all participants of 33 years (interquar-
tile range [IQR]: 28, 40). Only 29% of the participants were 
receiving antiretroviral therapy at diagnosis. Among partici-
pants reporting a headache (n=57), the median duration of 
headache was 14 days (IQR: 14, 24). The CSF opening 
pressures at baseline (n=45) had a median of 200 mmH
2
O 
(IQR: 120, 260). Overall, 55% (n=36) had an acellular CSF, 
whilst those with a CSF lymphocytic pleocytosis had a 
median CSF white blood cell of 160 cells/μL (IQR: 135, 268) 
(Table 1). Only about 10% of the participants had cerebral imag-
ing done as the CT scanner was dysfunctional for part of the 
study period. About twenty five percent of the patients had a 
positive TB-LAM while 20% had a positive urine MTB/Rif Ultra.
With respect to the reference standard of definite TBM 
(positive CSF Xpert TB/Rif Ultra), the CSF TB-LAM assay 
had a sensitivity of 33% (4/12), specificity of 96% (45/47), 
positive predictive value (PPV) of 67% (4/6), and negative 
predictive value (NPV) of 85% (45/53). When compared to a 
composite reference of definite/probable TBM, the TB-LAM 
assay had a sensitivity of 24% (4/17), specificity of 95% 
(40/42), PPV of 67% (4/6), NPV of 76% (40/53) (Table 2). 
There were two false positive tests with TB-LAM (3+ grade), 
without any CSF pleocytosis, normal protein, normal glucose, 
negative cryptococcal antigen, and normal CSF opening 
pressure. One patient was discharged alive without TB therapy. 
The second patient had a headache for 60 days at presentation, 
but they were lost to follow up (i.e. self-discharged) without 
an etiologic diagnosis. In-hospital mortality in CSF TB-LAM 
positive patients was 17% (1/6) compared to 0% (0/8) in those 
with definite TBM by Xpert MTB/Rif Ultra but negative 
LAM. About 17% of patients had unknown outcome. This 
was because the study population included patients screened 
for a clinical trial but only a minority were subsequently 
enrolled into the trial. We endeavoured to follow screen failures 
through to hospital discharge but this was not possible in all 
cases.
Conclusion
In conclusion, a rapid CSF point of care test for TBM is needed; 
however, this study demonstrated a poor diagnostic performance 
of the existing Alere TB-LAM on CSF among HIV-associated 
tuberculous meningitis. Our results corroborate the findings 
of a recent Zambian study which demonstrated 22% sensitiv-
ity for CSF LAM against a reference standard of TB culture18. 
While the relatively modest sample size is a limitation, a 
larger sample size is unlikely to fundamentally alter the find-
ings of sensitivity. One explanation could be that TB-LAM 
is likely not be found in sufficient quantities in lumbar CSF. 
TB culture was not used, which is also a limitation of the 
accuracy analysis. However, Xpert Ultra has a sensitivity 
that is greater than culture in our setting7. The novel Fujifilm 
SILVAMP TB-LAM (FujiLAM) assay has been shown to 
have higher sensitivity in urine than the Alere TB-LAM and 
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Sensitivity Specificity PPV NPV Test Accuracy
Definite/probable 
TBM
28.8% (17/59) 23.5% (4/17) 95.2% (40/42) 66.7% (4/6) 75.5% (40/53) 74.6% (44/59)
95% CI 17.8 to 42.1% 6.8 to 49.9% 83.8 to 99.4% 28.7 to 90.8% 70.1 to 80.2% 61.6 to 85%
Definite TBM 20.3% (12/59) 33.3% (4/12) 95.7% (45/47) 66.7% (4/6) 84.9% (45/53) 83.1% (49/59)
95% CI 10.9 to 32.8% 9.9 to 65.1% 85.5 to 99.5% 29.3 to 90.6% 78.9 to 89.4% 71 to 91.6%
Data presented are the percentage, numerator/denominator, and 95% confidence intervals (CI). Test Accuracy = overall probability 
that a patient will be correctly classified. PPV = Positive predictive value, NPV = negative predictive value, TBM = tuberculous 
meningitis.
Table 1. Characteristics of the study population.
Baseline characteristics Overall (N=59) Definite TBM (n=12) Probable TBM (n=5) Possible TBM (n=15) Not-TBM (n=27)
N* Statistic N* Statistic N* Statistic N* Statistic N* Statistic
Women, n (%) 58 29 (50) 12 6 (50) 5 3 (60) 15 4 (26.7) 26 16 (61.5)
Age in years, median (IQR) 58 33 (28-40) 12 29 (28-33) 5 26 (24-34) 15 35 (32-43) 26 34 (26-46)
On ART, n (%) 47 29 (62) 11 7 (63.6) 2 2 (100) 11 3 (27.3) 23 17 (73.9)
Headache, n (%) 57 46 (81) 12 10 (83.3) 5 4 (80) 14 12 (85.7) 26 20 (76.9)
Duration of headache, 
median (IQR) days
45 14 (14-24) 10 17.5 (14-30) 4 14 (10.5-17.5) 12 17.5 (14-31.5) 19 14 (7-30)
Glasgow Coma Scale score, 
mean (SD)
55 13 (2.6) 12 12.5 (2.9) 5 11.8 (2.4) 14 12.7 (2.9) 24 14.3 (2.1)
CSF CrAg positive, n (%) 58 10 (17) 12 0 (0) 5 0 (0) 15 0 (0) 26 10 (38.4)
CSF Opening Pressure, 
median (IQR) mmH2o
45 200 (120-260) 7 180 (70-240) 3 260 (95-400) 13 190 (120-270) 22 215 (120-260)




55 160 (135-268) 8 280 (162.5-575) 4 173 (130-237.5) 3 80 (35-160) 4 145 (87.5-210)
CSF protein, median (IQR) 
mg/dL
52 57 (28-141) 11 184 (107-316) 5 158 (147-215) 13 44 (35-72) 23 31 (22-61)
CSF glucose, median (IQR) 
mg/dL
32 65 (34-82) 7 44 (19.8-61) 3 90 (68-108) 8 86 (56.3-104) 14 61 (31-80)
CSF lactate, median (IQR) 
mmol/L
36 3.9 (2.2-9) 8 9.7 (8.2-11.2) 4 9.2 (6.3-11.1) 8 3.4 (2.3-8.1) 16 2.4 (1.9-3.8)
Duration of hospitalization, 
median (IQR) days

























Data presented are percentages (%), medians and interquartile ranges (IQR). N= number of participants with data for each parameter. * Participants with data 
available. ART = antiretroviral therapy, CSF = cerebrospinal fluid, WBC = white blood cells.
warrants evaluation for diagnosis of TB meningitis both in 
urine and CSF19.  
Data availability
Underlying data
Figshare: CSFLAM_data set revised.xlsx. https://doi.org/10.6084/
m9.figshare.9415853.v117
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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Evidence Search Service 
Results of your search request 
Intensified antibiotic treatment of tuberculous meningitis 
ID of request: 13495 
Date of request: 4th June, 2018 
Date of completion: 6th July, 2018 
If you would like to request any articles or any further help, please contact:  Tom Roper at 
tom.roper@bsuh.nhs.uk  
Please acknowledge this work in any resulting paper or presentation as: Evidence search: 
Intensified antibiotic treatment of tuberculous meningitis. Tom Roper. ( 6th July, 2018). 




Date range used (5 years, 10 years): No restrictions  
Limits used (gender, article/study type, etc.): None  
Search terms and notes (full search strategy for database searches below): 
MEDLINE and EMBASE were searched with text word and controlled vocabulary terms. Duplicates 
were removed, but no relevance screen undertaken. References supplied by the search requester 
were used to make a test set, against which iterations of the strategy could be tested.  
A search of Cochrane Central located four papers, all of which were also retrieved by the 
MEDLINE and EMBASE searches. 
Some commentary on the search strategy may be helpful. Taking MEDLINE as the examples, lines 
1-3 locate the concept of tuberculous meningitis, while lines 5-7 locate antibiotic treatment. I then
combined those concepts with AND and then the string intensif*, This is the most simple form of
the search and returns 11 results in MEDLINE, and exactly the same number in EMBASE.
I then added further lines to expand the concept of intensified treatment. Line 23 looks for 
increased doses, while lines 24 and 25 look for combinations of drugs. Lines 26 to 40 retrieve the 
specific drugs you mentioned, and lines 41 and 42 find other anti-tubercular treatments that might 
be used. The final lines bring all these together. 
For more information about the resources please go to: https://www.bsuh.nhs.uk/library/ . 
Contents  
B. Search History
Source Criteria Results 
1. Medline "TUBERCULOSIS, MENINGEAL"/ 6850 
2. Medline ((TB OR tubercul*) ADJ2 mening*).ti,ab 6694 
3. Medline ((TB OR tubercul*) ADJ2 (brain OR cerebral OR neurological)).ti,ab 929 
4. Medline (1 OR 2 OR 3) 9166 
5. Medline exp ANTI-BACTERIAL AGENTS / 658150 
Appendix 4
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Source Criteria Results 
6. Medline ((anti-bacterial OR anti-mycobacterial OR antibacterial OR antimycobacterial OR bacteriocidal) ADJ1 (agent* OR compound*)).ti,ab 9703 
7. Medline (antibiotic* OR anti-biotic* OR anti-microbial OR antimicrobial*).ti,ab 391914 
8. Medline (5 OR 6 OR 7) 849977 
9. Medline (4 AND 8) 2673 
10. Medline (intensif*).ti,ab 27057 
11. Medline (9 AND 10) 11 
12. EMBASE "TUBERCULOUS MENINGITIS"/ 6409 
13. EMBASE ((TB OR tubercul*) ADJ2 mening*).ti,ab 5995 
14. EMBASE ((TB OR tubercul*) ADJ2 (brain OR cerebral OR neurological)).ti,ab 831 
15. EMBASE (12 OR 13 OR 14) 8843 
16. EMBASE exp "ANTIBIOTIC AGENT"/ 1222782 
17. EMBASE ((anti-bacterial OR anti-mycobacterial OR antibacterial OR antimycobacterial OR bacteriocidal) ADJ1 (agent* OR compound*)).ti,ab 11832 
18. EMBASE (antibiotic* OR anti-biotic* OR anti-microbial OR antimicrobial*).ti,ab 516096 
19. EMBASE (16 OR 17 OR 18) 1422112 
20. EMBASE (15 AND 19) 1892 
21. EMBASE (intensif*).ti,ab 48787 
22. EMBASE (20 AND 21) 11 
23. Medline
((increas* OR higher OR greater OR larger OR non-standard OR 
nonstandard) ADJ2 (dose OR course OR treatment OR therapy OR 
regimen)).ti,ab 
198218 
24. Medline "DRUG THERAPY, COMBINATION"/ 156462 
25. Medline ((combination OR additional) ADJ2 (dose OR course OR treatment OR therapy OR regimen)).ti,ab 98861 
26. Medline ISONIAZID/ 17997 
27. Medline (isoniazid).ti,ab 14320 
28. Medline ETHAMBUTOL/ 3764 
29. Medline (ethambutol).ti,ab 4769 
30. Medline PYRAZINAMIDE/ 3075 
31. Medline (pyrazinamide).ti,ab 3471 
32. Medline LINEZOLID/ 2608 
33. Medline (linezolid).ti,ab 4950 
34. Medline (moxifloxacin).ti,ab 4006 
35. Medline LEVOFLOXACIN/ 2920 
36. Medline (levofloxacin).ti,ab 6618 
37. Medline STREPTOMYCIN/ 21618 
38. Medline (streptomycin).ti,ab 19951 
39. Medline ETHIONAMIDE/ 1273 
40. Medline (ethionamide).ti,ab 895 
41. Medline exp "ADMINISTRATION, INTRAVENOUS"/ 136688 
42. Medline (intravenous ADJ (adminstration OR infusion OR dose OR course OR treatment OR therapy OR regimen)).ti,ab 33103 
43. Medline (23 OR 24 OR 25) 423600 
44. Medline (41 OR 42) 158915 
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45. Medline (26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40) 66653 
46. Medline exp "ANTIBIOTICS, ANTITUBERCULAR"/ 41976 
47. Medline ((antitubercular OR tuberculostatic) ADJ (treatment OR therapy OR regimen)).ti,ab 1152 
48. Medline (46 OR 47) 43043 
49. Medline (45 OR 48) 102036 
50. Medline (43 OR 44) AND 49 10355 
51. Medline (9 AND 50) 158 
52. EMBASE 
((increas* OR higher OR greater OR larger OR non-standard OR 
nonstandard) ADJ2 (dose OR course OR treatment OR therapy OR 
regimen)).ti,ab 
183035 
53. EMBASE *"DRUG COMBINATION"/ 2250 
54. EMBASE ((combination OR additional) ADJ2 (dose OR course OR treatment OR therapy OR regimen)).ti,ab 121867 
55. EMBASE ISONIAZID/ 54009 
56. EMBASE (isoniazid).ti,ab 17629 
57. EMBASE ETHAMBUTOL/ 27872 
58. EMBASE (ethambutol).ti,ab 6840 
59. EMBASE PYRAZINAMIDE/ 22124 
60. EMBASE (pyrazinamide).ti,ab 4700 
61. EMBASE LINEZOLID/ 17476 
62. EMBASE (linezolid).ti,ab 7197 
63. EMBASE (moxifloxacin).ti,ab 5733 
64. EMBASE LEVOFLOXACIN/ 31026 
65. EMBASE (levofloxacin).ti,ab 10460 
66. EMBASE STREPTOMYCIN/ 51063 
67. EMBASE (streptomycin).ti,ab 18204 
68. EMBASE ETHIONAMIDE/ 5294 
69. EMBASE (ethionamide).ti,ab 1009 
70. EMBASE "INTRAVENOUS DRUG ADMINISTRATION"/ 370088 
71. EMBASE (intravenous ADJ (adminstration OR infusion OR dose OR course OR treatment OR therapy OR regimen)).ti,ab 35033 
72. EMBASE (52 OR 53 OR 54) 301692 
73. EMBASE (70 OR 71) 389820 
74. EMBASE (55 OR 56 OR 57 OR 58 OR 59 OR 60 OR 61 OR 62 OR 63 OR 64 OR 65 OR 66 OR 67 OR 68 OR 69) 150357 
75. EMBASE exp "TUBERCULOSTATIC AGENT"/ 150733 
76. EMBASE ((antitubercular OR tuberculostatic) ADJ (treatment OR therapy OR regimen)).ti,ab 1504 
77. EMBASE (75 OR 76) 151192 
78. EMBASE (74 OR 77) 225605 
79. EMBASE (72 OR 73) AND 77 7168 
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Worldwide, 10.4 million people are estimated to have fallen 
ill with Tuberculosis (TB) in 2016, resulting in 1.3 million 
deaths, and an additional 374,000 TB deaths in people living 
with HIV1. The African region carries the greatest burden 
relative to its population; 281 cases for every 100,000 people, 
more than double the global average of 133 per 100,000. Addi-
tionally, of the 1.2 million HIV-infected people who developed 
TB worldwide, 74% were in the African World Health Organisation 
(WHO) region2.
The true incidence of TB meningitis is not known due to lack 
of accurate diagnostics and scarce epidemiological data in 
many TB endemic regions. Central nervous system (CNS) TB 
accounts for ~1% of notified TB cases in Germany and the 
USA, but this proportion is likely to be significantly higher 
in HIV endemic regions where TB frequently manifests as 
disseminated disease3,4. As such, in the wake of the HIV epidemic; 
TB meningitis (TBM) is one of the leading causes of menin-
gitis in both adults and children in Africa5,6. It is estimated there 
is likely to be well over 100,000 cases annually worldwide.
Prognosis of TBM
TBM, the most devastating form of TB, is associated with a 
mortality of 7–28% of HIV-uninfected7, and 29–63% of HIV-
infected patients8,9. The driver of this 2 to 3-fold increased 
risk of death in HIV co-infection has not yet been elucidated. 
Neuro-disability is seen in up to 50% of survivors, regardless 
of their HIV serostatus. TBM cases account for up to 19% of 
all hospitalized HIV-associated TB cases and pose a significant 
challenge to healthcare services and care-givers, often requiring 
prolonged hospital stays and long rehabilitation periods10. 
Delays in seeking medical care, diagnosis, and initiation of 
treatment are contributing factors to the high morbidity and 
mortality, particularly in resource-limited settings.
Clinical TBM management
Early treatment with anti-tuberculous therapy and adjunctive 
corticosteroids is the most effective way of reducing death 
and disability from TBM. However, currently morbidity and 
mortality remains unacceptably high5. Whilst the 4th edition of 
the WHO treatment guidelines suggest substituting ethambutol 
with streptomycin during the intensive phase of treatment this 
has not been widely adopted for a number of reasons, and 
treatment for TBM does not differ from that of pulmonary 
TB, with rifampicin (R), isoniazid (H), pyrazinamide (Z) and 
ethambutol (E) given for two months (intensive phase) followed 
by rifampicin and isoniazid (continuation phase), except that 
continuation phase is prolonged to complete 9–12 months2,11. 
Due to variable TB drug penetration across the blood-brain 
barrier and blood-cerebrospinal fluid (CSF) barrier, optimal 
treatment regimens for pulmonary TB may not be the most 
effective options for TBM. Inadequate CNS drug penetration may 
be an important contributory factor to the high early mortality 
in TBM12. Improved early treatment outcomes may be achieved by 
altering drug selection, drug doses, and routes of administration 
to ensure adequate drug delivery to the site of disease and 
maximal early mycobactericidal activity in the CNS.
Rifampicin in TBM
Rifampicin is the cornerstone drug in the treatment of TBM, 
as evidenced by the fact that those infected with rifampicin- 
resistant Mycobacterium tuberculosis (M.tb) strains have a 
near-universal fatal outcome, even with treatment with second-
line drugs in resource-rich settings5,13,14. Mortality is not nearly 
so high in patients with isoniazid mono-resistant TBM6. 
In addition to male sex and low body weight, which are asso-
ciated with more rapid drug clearance15, malabsorption may 
contribute to reduced systemic drug bioavailability in HIV-infected 
persons16–21. A recent comprehensive meta-analysis of rifampicin 
pharmacokinetics confirmed that during the initial days of 
TB treatment rifampicin total plasma exposure to rifampicin 
is reduced in HIV co-infected adults (AUC 37.2mg.h/L in 
HIV-positive versus 56.7mg.h/L in HIV-negative, p=0.003). 
Interestingly, this association did not persist in steady-state 
(>7 days on therapy, once saturation of first-pass metabo-
lism and the establishment of metabolic autoinduction is well 
established)22. Lower plasma levels of antituberculous agents 
are predictive of poorer outcomes in pulmonary TB23, thus the 
lower plasma levels of rifampicin seen in HIV-positive indi-
viduals in the initial days of TBM therapy may be particularly 
relevant in TB meningitis, which carries a high early mortality. 
Specific factors that potentially play a role in reduced bioavail-
ability include HIV-related enteric infections17,18, HIV-associated 
enteropathy and chronic intestinal immune activation affecting 
regulation of drug transporters. Patients with TBM often 
present while critically ill, are vomiting and frequently receive 
drugs through a nasogastric tube. Such factors may further 
associate with reduced TB drug concentrations, which could 
explain the lower plasma rifampicin concentrations observed 
in patients with TBM compared to those with pulmonary TB 
taking the same dose from the same setting24,25. 
Rifampicin is largely protein bound and thus has limited CSF 
penetration, with reported CSF concentrations often reaching 
10–20% of those in plasma25,26. Suggested target concentra-
tions of rifampicin are >8mcg/ml at the site of disease, but 
CSF rifampicin concentrations seldom exceeded the minimum 
inhibitory concentration (MIC; 0.25mcg/ml) against M. tuber-
culosis at the standard oral adult dose (8–12mg/kg)12. Currently, 
little is known about rifampicin concentrations in brain matter, 
spinal cord or meninges and how plasma levels or inflammation 
affect tissue concentrations.
The evidence for the currently recommended dose of rifampicin 
(10mg/kg/day) in TBM treatment is scant, and this dose falls on 
the steep part of the dose-response curve for sterilising effect27. 
Recent studies by the Pan-African Consortium for the Evalu-
ation of Antituberculous Antibiotics in pulmonary TB have 
shown that rifampicin dosed at 35mg/kg is associated with 
improved early bactericidal activity and 2-fold faster rate of 
sputum conversion (Hazard Ratio 1.99, 95% CI:1.21-3.29) as 
compared to standard therapy. Furthermore, this dose was safe 
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and well tolerated, with a 14% grade 3-5 adverse event incidence 
as compared with 10% with standard 4-drug TB therapy with 
rifampicin dosed at 10mg/kg28.
Ruslami et al. investigated the safety and pharmacokinetic 
(PK) profiles of higher than normal dose intravenous (IV) 
rifampicin as well as oral moxifloxacin in adults with TBM. 
Although not powered to detect a mortality benefit, improved 
survival was observed in patients receiving 600mg IV 
rifampicin (~13mg/kg/day) compared to the oral standard dose 
(~10mg/kg/day). Patients who received IV rifampicin had a 
more rapid resolution of coma (4 versus 5 days), reduced mor-
tality at 8-weeks (24% versus 55%) and 6-months (34% versus 
65%); (adjusted Hazard Ratio=0.42; 95% CI 0.20-0.91, p=0.03) 
compared with those who received oral standard dose rifampicin. 
The change in rifampicin dose and mode of delivery was asso-
ciated with a 3-fold increase in plasma area under the time- 
concentration curve (AUC) and maximum concentration (C
max
) 
and a 3-fold increase in CSF C
max
 from 0.21 to 0.60 mcg/mL.
A second phase II study in Indonesia evaluating increased oral 
doses of 30mg/kg or 20mg/kg versus standard of care (10mg/kg) 
also reported no increase in toxicity in the high dose arms and 
CSF C
max
 was significantly increased (25.5 mg/L [11.9 to 55.5], 
18.1 mg/L [2 to 43.6], 7.2 mg/L [2.2 to 14.1] respectively, 
<0.001). In those with microbiologically confirmed TBM there 
was a trend towards lower 6-month mortality in the 30mg/kg 
arm compared to standard of care (7% versus 36% (HR 0.16 
[0.02 to 1.34], p=0.09)29.
In contrast, a large Vietnamese trial of an intensified TBM treat-
ment containing oral rifampicin 15mg/kg/day versus standard 
of care showed no differential effect on mortality (27.7% versus 
27.9%, hazard ratio 0.94; 95%CI 0.73 to 1.22; p=0.66)30
The conflicting evidence from prior trials evaluating the ben-
efits of higher than standard doses of rifampicin for TBM 
creates a situation of equipoise that can only be answered with 
an adequately powered phase III trial examining a rifampicin 
dose with proven pharmacokinetic-pharmacodynamic superiority 
to the standard of care. This phase II study aims to demonstrate 
pharmacokinetic superiority of one or both of the investiga-
tional arms so that the most favourable dose may ultimately be 
taken forward into a phase III study. Additionally, it is important 
to generate PK and safety data from HIV-positive African 
adults, as HIV co-infection can have a significant impact on 
TBM outcomes, pharmacokinetics and drug toxicity.
Protocol
This is version 1.2.1, 19th February 2018.
Hypotheses
Our primary hypothesis is that intravenous rifampicin (20mg/kg) 
and high dose oral rifampicin (35mg/kg) will result in signifi-
cantly increased plasma and CSF exposure during the critical 
early days of TBM treatment as compared to standard control 
(10mg/kg oral rifampicin).
Our secondary hypotheses are that high dose rifampicin will 
lead to improved early mycobacterial clearance from the CNS, 
reduced inflammatory response, and thereby will result in more 
rapid resolution of coma, improved long-term functional status, 
reduced TBM immune reconstitution inflammatory syndrome 
(IRIS) incidence and lower mortality.
Main study objectives
Primary objective. Our primary objective is to determine whether 
higher-dose rifampicin, delivered either orally at 35mg/kg/day 
or intravenously at 20 mg/kg/day for 2-weeks (followed by 
orally at 35 mg/kg/day for 6-weeks) is safe and provides expo-
sure profiles that are favourable compared to the 10 mg/kg 
standard dose oral rifampicin.
Secondary objectives. Our secondary objectives are to observe 
whether greater rifampicin exposure in CSF is associated with 
any clinical benefit including more rapid resolution of coma, 
improved long-term functional status, reduced TBM-IRIS 
incidence and lower mortality.
Ancillary studies
Two ancillary studies will be conducted within the RifT trial, the 
second of which will only take place at Mulago Hospital.
Evaluation of the diagnostic accuracy of Xpert MTB/Rif 
Ultra (Ultra) in TBM. Our hypothesis is that CSF Ultra is 
significantly more sensitive than CSF Xpert MTB/Rif or culture 
in the diagnosis of TBM.
Descriptive study of brain tissue rifampicin concentrations on 
autopsy specimens. Our hypothesis is that brain tissue con-
centrations will correlate with plasma and CSF concentration 
and will be significantly higher in the investigational arms.
Design and setting
RifT is a three arm, parallel group, phase II open label randomised 
controlled trial (see Figure 1), evaluating three rifampicin regi-
mens over an 8-week intervention period, as follows:
A.  Intravenous 20mg/kg/day rifampicin for 2-weeks
(followed by oral rifampicin 35mg/kg/day for 6-weeks)
B.  Oral 35mg/kg/day rifampicin for 8-weeks
C.  Standard of care oral rifampicin (~10mg/kg/day) for
8-weeks
All participants will receive a standard backbone of oral TB 
treatment (consisting of isoniazid ~5mg/kg/day, pyrazinamide 
~25mg/kg/day, ethambutol ~20mg/kg/day) and daily IV dex-
amethasone (0.4mg/kg/day) for 1 week then weaned over a 
6–8 week period, as per WHO guidelines.
The trial will be set in two hospitals in Uganda: Mulago National 
Referral Hospital and Mbarara Regional Referral Hospital. 
The study population will be adults (≥18 years of age) with 
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We will use a composite safety endpoint for the 8-week inter-
vention period that includes clinical grade 3-5 adverse events
(AEs) (as classified by Division of AIDS (DAIDS) Toxicity
Scale) or all serious adverse events (SAEs), drug-induced
liver injury (DILI), grade 3-5 defined by alanine transaminase
(ALT) >5x upper limit of normal (ULN), or discontinuation of




Mortality at 8- and 24-weeks post randomisation will be
compared between study arms.
2. Time to normalization of conscious level
We will determine days from randomisation until observation
of a GCS of 15 which is achieved for ≥2 consecutive days.
3. Functional status
The modified Rankin scale at 8 and 24 weeks will be used in
determining functional outcomes.
4. TB immune reconstitution inflammatory syndrome
TB-IRIS will be diagnosed according to published case
definitions31. TB-IRIS will be determined independently by 2 trial
clinicians blinded to treatment allocation.
Inclusion and exclusion criteria
Inclusion criteria. Participants to be included in the study are 
consecutive patients ≥18 years with clinically suspected TBM 
based on meningitis symptoms, clinical signs of meningism and 
anti-tuberculous chemotherapy planned by the attending physi-
cian. In addition, they must have either a bedside CSF glucose to 
plasma ratio <50%, or absolute CSF glucose <40mg/dl or 
2.2mmol/l or a positive CSF acid fast bacilli (AFB) smear or 
positive Xpert MTB/Rif or Ultra. Written informed consent 
must be given by either by the participant or by surrogate if the 
participant has altered mental state.
Figure 1. Study flow chart.
Meningitis symptoms n=800
Diagnostic sub-study on Ultra Diagnostic lumbar puncture for TBM panel n=240
Suspected or confirmed TBM enrolled to RIFT study n=60
Likely cryptococcal meningitis n=560





standard of care HZE
n=20
Oral Rifampicin 35mg/kg/day
standard of care HZE
n=20
Standard of care RHZE
n=20
Day 2 (+/-1): Plasma PK: 0,2,4,8 hours post dose. CSF PK sample
Day 12 (+/-2): single plasma and CSF PK sample
Day 14 switch IV Rifto PO 35mg/kg/day
Daily clinical review. Timing of hospital discharge as clinically indicated.
Week 4 (+/-1) outpatient visit: medication and clinical review
Week 24 (+/-2): detailed neurocognitive assessment, med review, clinical review
Study termination
Week 8 (+/-1): detailed neurocognitive assessment, clinical review
Medication review: begin standard dose continuation phase of TB treatment
HIV: adherence counseling session, initiate/switch ART
4 weekly follow-up in HIV clinic after initiating ART
In event of IRIS for study physician review, LP, labs, and treatment
Cryptococcal antigen (blood)
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Exclusion criteria. Patients with jaundice or known liver cir-
rhosis will not be eligible to enrol. Additionally, those who have 
received more than 3 doses of TB treatment within the previous 
3 days, or have discontinued TB treatment in the prior 14 days, or 
those with known allergy to rifamycins, isoniazid, pyrazinamide, 
ethambutol or study drug excipients are not eligible. Those with 
known current/previous rifampicin drug-resistant M. tuberculosis 
infection or those with concurrent cryptococcal meningi-
tis or those known to be currently taking any drug that has a 
clinically relevant interaction with rifampicin or other first-line 
TB drugs, including ritonavir, atazanavir or darunavir will not be 
eligible. Individuals who cannot or are unlikely to attend regular 
clinic visits or are pregnant or breastfeeding or where we lack 
consent from participant or family members are not eligible. 
Those with known porphyria or known chronic renal failure with 
eGFR <10ml/min are not eligible.
Randomisation and treatment allocation
Adults who have given consent for, and undergone, a diagnostic 
screening lumbar puncture and are eligible for enrolment will 
then be approached for enrolment consent after which they 
will be randomised. Randomisation will occur at study entry 
and must occur prior to the 4th dose of TB treatment. Partici-
pants will be randomised by a computer generated permutated 
block randomization algorithm of different sized blocks with a 
1:1:1 randomization ratio into the three arms described above.
Randomisation will be stratified by:
1. Clinical site
2.  British Medical Research Council (BMRC) TBM disease
grade I or II/III at time of consent
All randomised participants will initiate their allocated study 
TB treatment within 24 hours of randomisation, and preferably 
the same day. As TBM is a medical emergency, initiation 
of standard of care TB treatment will not be delayed whilst 
waiting for randomisation.
Treatment discontinuation. Due to the urgent need to begin 
TBM therapy to reduce mortality, enrolment will not be delayed 
whilst waiting for enrolment blood test results and partici-
pants will be replaced a posteriori if baseline ALT>3x ULN. 
As infection with a rifampicin resistant TB strain is an exclu-
sion criterion, all patients in whom rifampicin resistant TB is 
identified after randomisation may have their treatment altered 
as per physician judgement. Once randomised, analysis is 
by modified intent-to-treat (ITT).
Interventions
Diagnostic lumbar puncture. At the time of screening, after 
informed consent has been received, a diagnostic lumbar 
puncture will be performed with a ~10ml CSF sample collected. 
The sample with then be tested with an enhanced TB diagnostic 
panel including Xpert MTB/Rif, Ultra, MGIT culture, Biofire 
meningoencephalitis multiplex polymerase chain reaction and 
next generation sequencing.
Antituberculous therapy
Intravenous rifampicin arm (R20IV)
For the first 14 days study drug will be administered as intrave-
nous rifampicin 20mg/kg once daily. Study medications will be 
dispensed during hospitalization to ward staff who will adminis-
ter the drugs to the participants under directly observed therapy. 
Rifampicin 600mg will be reconstituted with 10 ml of sterile 
water for a dilution of 60 mg per ml of reconstituted solution. The 
weight-specific volume of rifampicin solution will be drawn up 
(Table 1) then further diluted in 500 ml 5% Dextrose solution. 
The solution will be administered as a continuous infusion 
via a peripheral venous catheter over 2 hours. Thereafter the 
line will be flushed with 5 ml 0.9% normal saline after which 
the cannula will be capped. Other antituberculous drugs 
(isoniazid, pyrazinamide and ethambutol) will be given orally by 
weight (Table 2) as intact tablets unless they are unable to 
swallow voluntarily, e.g. in participants with a depressed level 
of consciousness, in which case tablets will be crushed and 
given via nasogastric tube.
After 14 days of intravenous rifampicin the participant will 
be switched to high dose oral rifampicin (35mg/kg) for the 
remaining 6 weeks of the intervention period administered as 
per the participants in the high dose oral rifampicin arm.
High dose oral rifampicin arm (R35PO) Oral rifampicin 
at 25mg/kg for 8 weeks, in addition to standard fixed dose 
combination quadruple antituberculous tablets containing 
~10mg/kg of rifampicin, will be administered for the first 
8 weeks. Fixed-dose combination tablets according to weight 
bands as presented (Table 3) will be dispensed with addi-
tional 300mg oral rifampicin tablets to make the rifampicin 
dose up to ~35mg/kg/day. All study drugs will be taken orally 
during this period (either as intact tablets or via nasogastric 
tube). Study drugs will be administered under directly observed 
therapy by nursing staff whilst the participant remains in 
hospital. After discharge study drugs will be dispensed to 
participants at the week 4 visit. Fixed dose combination antitu-
berculous therapy will be prescribed through routine care 
pathways initially via the hospital and subsequently via linked 
TB clinics according to National Guidelines. Participants will 
be weighed at each visit and TB drug dose will be adjusted 
as necessary. At the end of the intervention period (week 8) 
the participant begins standard of care continuation phase TB 
treatment (Table 4).
Control arm, standard of care arm (R10PO) The control 
arm will receive standard of care TB treatment: Oral rifampicin 
~10 mg/kg, isoniazid ~5 mg/kg, pyrazinamide ~25 mg/kg, 
ethambutol ~20 mg/kg in fixed-dose combination tablets 
according to weight bands for 8 weeks (Table 4). Participants 
will receive intact tablets or via nasogastric tube. Fixed dose 
combination antituberculous therapy will be prescribed through 
routine care pathways initially via the hospital and subsequently 
via at TB clinics according to National Guidelines.
Pharmacokinetic sampling. Intensive plasma PK sampling 
will take place on day 2(+/-1) at hours 0, 2, 4 and 8 post dose 
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Table 1. Intravenous administration of rifampicin by weight for day 
0–14 in the intravenous rifampicin arm (arm R20IV).





















































































28.5 – 31.49 600 10 1.0
31.5 – 34.49 660 11 1.1
34.5 – 37.49 720 12 1.2
37.5 – 40.49 780 13 1.3
40.5 – 43.49 840 14 1.4
43.5 – 46.49 900 15 1.5
46.5 – 49.49 960 16 1.6
49.5 – 52.49 1020 17 1.7
52.5 – 55.49 1080 18 1.8
55.5 – 58.49 1140 19 1.9
58.5 – 61.49 1200 20 2.0
61.5 – 64.49 1260 21 2.1
64.5 – 67.49 1320 22 2.2
67.5 – 70.49 1380 23 2.3
70.5 – 73.49 1440 24 2.4
73.5 – 76.49 1500 25 2.5
76.5 – 79.49 1560 26 2.6
79.5 – 82.49 1620 27 2.7
82.5 – 85.49 1680 28 2.8
85.5 – 88.49 1740 29 2.9
88.5 – 91.49 1800 30 3.0
Table 2. Daily number of tablets of isoniazin, pyrazinamide 
and ethambutol by weight during the first 14 days for the 









≤30–33 1.5 1.5 1
34 1.5 1.5 2
35–44 2 2 2
45–54 2.5 2.5 2
55 3 3 2
56–64 3 3 3
65 3 3.5 3
≥66 3.5 3.5 3
as well as a single CSF sample. Where possible a single plasma 
and CSF sample will be collected on day 14 (+/- 2 days).
Blood test monitoring. Routine blood monitoring will take 
place on days 1, 3, 7 and 14, week 4 and week 8 to monitor for 
any rifampicin-related toxicity (Table 5 and Table 6).
Neurocognitive assessment. Where possible a detailed neurocogni-
tive assessment will take place on week 8 and week 24.
Antiretroviral therapy. HIV-positive participants who are ART 
naïve or who have defaulted ART will initiate ART after com-
pletion of the intensive phase of TB treatment (at week 8) 
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Table 3. Daily administration of oral rifampicin during the first 8 weeks in 
the high dose oral rifampicin arm (R35PO) and week 2–8 in arm R20IV.






30–37 kg 2 tabs 3 tabs 1200
38–54 kg 3 tabs 4 tabs 1650
55–70 kg 4 tabs 5 tabs 2100
≥ 71 kg 5 tabs 6 tabs 2550
Table 4. Daily number of fixed dose tablet in the control arm (arm R10PO) 
during week 0–8 and for all arms during the continuation phase of treatment.
Weight Intensive Phase (week 0–8) Continuation Phase 
(month 3–12)
RHZE fixed dose combination daily 
(150/75/400/275 mg)3
RH (150/75)3 RH (300/150)3
30–37 kg 2 tabs 2 tabs
38–54 kg 3 tabs 3 tabs
55–70 kg 4 tabs 2 tabs
≥ 71 kg 5 tabs 2 tabs
in accordance with WHO and Ugandan guidelines. An efavirenz 
-based regimen or dose-adjusted (twice daily) dolutegravir- 
based regimen would be used in accordance with Ugandan
HIV treatment guidelines (currently under revision)32. Partici-
pants who were enrolled on a failing efavirenz-based regimen
will be switched at week 8 to a dose-adjusted dolutegravir-based
regimen. Current protease inhibitor or nevirapine-based ART
is an exclusion criteria so we do not anticipate having partici-
pants on these agents. All participants will be registered at the
Infectious Diseases Institute HIV clinic or the Mbarara Hospital
HIV clinic such that their HIV care lies within the national HIV
service framework.
Adverse events and safety reporting
The principles of ICH GCP require that both investigators and 
sponsors follow specific procedures when notifying adverse 
events or reactions in clinical trials. The definitions of the EU 
Directive 2001/20/EC Article 2 based on the principles of ICH 
GCP apply to this trial protocol. All adverse events will be 
assessed for seriousness, causality and expectedness. Causality 
in relation to study drug (rifampicin) is assessed as unrelated, 
unlikely, possible, probable or definite based on temporal 
relationship and clinical judgement. If the event is serious and 
unrelated or unlikely to be related it is classified as an SAE. If 
the event is possibly, probably or definitely related it is clas-
sified as a Serious Adverse Reaction (SAR). Expectedness 
of the adverse reaction is assessed using the summary of 
product characteristics (SPC) at the time of the event. An 
unexpected adverse reaction is one not previously reported in the 
SPC, or one that is more frequent or more severe than previously 
reported. If a SAR is assessed as being unexpected it becomes 
a suspected unexpected serious adverse reaction (SUSAR). 
Intensity will be graded using the DAIDS toxicity scale.
The Trial Management Group at the Infectious Diseases Insti-
tute (IDI) must be notified of all grade 3-5 AEs, SAEs and 
SARs within 24 hours, thereafter they are responsible for 
reporting SAEs, SUSARs to the Sponsor, regulatory authorities 
and ethics committees in accordance with local regulatory and 
institutional guidelines.
Interim analyses. Interim analysis of safety will occur after 
24 participants (8 per arm) have completed the week 8 visit. 
The committee can modify the frequency of interim analysis 
and early termination could occur if the data safety committee 
decides there is an unacceptable level of toxicity in any of the 
investigational arms.
Data collection
Baseline and subsequent assessment. Participants will be fol-
lowed as in-patients for the first 14 days and then approxi-
mately 4 weekly as outpatients until week 24, see Table 5 and 
Table 6. If a trial participant dies during the in-patient period 
additional consent will be sought from family members for a 
post-mortem examination to explore cause of death and levels 
of rifampicin in brain tissue. Recruitment will continue for 
12–18 months with an additional 6 months follow-up period. 
The trial will be considered closed when the last participant 
has completed 24 weeks in the study, all SAEs resolved and all 
follow-up and laboratory reports have been received.
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Table 5. In-patient schedule of events.
Study visit Screening Enrolment D1 Day 2 Day 3 Day 7 Day 10 Day 14 Further 
Hospitalization
Visit window (days) ±1 ±1 ±1 ±1 ±2
Screening Consent X
Assess eligibility criteria X
Informed enrolment consent X
Clinical history and examination
Past medical history (X)
Medication review (X) X X X X X X X
Document HIV status (X)
Current symptoms (X) X X X X X X X
Examination (X) X X X X X X X
GCS score (X) X X X X X X X
BMRC disease grade X X X X X X X
Adverse events assessmentb X X X X X X X
Investigations
HIV-test (if not known positive) (X)
Cryptococcal antigen (X)
Sodium/Potassium Xi Xi X X X
Glucose (bedside) (X)
Creatinineh Xi Xi X X X
Hepatic panela Xi Xi X X X X
Blood Count (including differential) Xi Xi X X
CD4 count if HIV-positive Xi Xi
Pregnancy test Women
CSF sample (aim >10ml, as per SOPc) (X) Xd as clinically indicated 








Plasma PK sampling 0, 2, 4, 8 hrs X
Sparse plasma PK (one sample) X
Chest radiograph (+/-)
CT headf +/- +/-
Abdominal Ultrasound Scan X
Urine sampleg (X)
Blood/DNA/RNA storage with consent with consent
Approx. volume blood (mL) 0 20 20 3 7 0 7 7
()= part of routine medical care
a Hepatic panel = alanine aminotransferase (ALT), alkaline phosphatase (ALP) and bilirubin. Hepatitis BsAg, Hepatitis C Ab and INR will be 
added if baseline ALT is elevated. In the event of DILI hepatic panel will be performed more regularly.
b Adverse events will be recorded according to DAIDS toxicity scale
c SOP = standard operating procedure detailing exact processing and testing algorithm of CSF
d CSF PK will be timing randomised to early (2–4hrs) or medium (4–6hrs) or late interval (6–8hrs) post dose.
f Contrast enhanced CT head is indicated if there is focal neurology at baseline or during enrolment period
g Urine sample may be collected for testing with LAM (lipoarobinmannan) or urine Xpert MTB/Rif Ultra as part of TB work-up
h Additional renal monitoring will be undertaken in those with abnormal baseline creatinine
i Baseline bloods must occur at either screening or enrolment visit. It is likely these visits will be on the same day. If baseline bloods were 
done at screening and enrolment occurs >48 hours later baseline blood tests will be repeated.
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Data handling and data management. Source documents are 
made up of detailed case report forms (CRFs), laboratory results, 
radiology results and other relevant documents. Data entry 
will occur via the DataFax system, whereby the paper-based 
case record forms are scanned, emailed to a server, and data 
entered by intelligent character recognition. After an initial auto-
mated error-checking, secondary review for accuracy is then 
performed by the DataFax team at the Infectious Diseases 
Institute, Uganda. The DataFax system allows for automated 
data queries to alert for any missing data on an ongoing basis. 
Second, this also allows for permanent archiving and potential 
remote review by oversight bodies. Study forms will be har-
monized between all study sites enabling multi-site data 
management. The investigator will retain study essential source 
documents for 20-years after the completion of the study, as 
per Ugandan guidelines. Digital images of the source documents 
will be retained for an indefinite period.
Quality control and assurance. Site monitoring is conducted 
to ensure that the human subject protection, study procedures, 
laboratory, study intervention administration, and data collection 
processes are of high quality and meet the sponsor, ICH E6 
and regulatory guidelines. The study may be subject to audit 
by the London School of Hygiene & Tropical Medicine under 
their remit as Sponsor, as well as other regulatory bodies to 
ensure adherence to Good Clinical Practice.
Statistical considerations
Sample size. Approximately 800 adults presenting with symp-
toms of meningitis will be assessed, of which it is anticipated 
two-thirds will have cryptococcal meningitis. The circa 240 
patients with negative CSF cryptococcal antigen (crAg) will 
undergo a comprehensive TBM diagnostic panel (Xpert MTB/Rif, 
Xpert Ultra, mycobacterial growth indicator tube (MGIT) culture, 
and/or next generation sequencing) from which we anticipate 
Table 6. Out-patient schedule of events.
Study visit Week 4 Week 8 Week 12 Week 18 Week 24 Sick Visit
Visit window (weeks) ±1 ±1 ±1 ±2 ±2 As needed
Dispensing of study drug X standard fixed dose therapy til 12 months as 
per local guidelines























Adverse events assessment X X X X X
Medication review X X X X X
Examination X X X X X
Modified Rankin score X X
Detailed neurocognitive follow-up X X
Center for Epidemiological Studies 
of Depression Scale (CES-D)
X X
Sodium, potassium X (if clinically 
indicated)
Creatinine X (if clinically 
indicated)
Hepatic Panela X X X (if clinically 
indicated)
FBC, differentialb X (if clinically 
indicated)
Storage bloodsc X X (IRIS event 
only)
CSF with storage X (if clinically 
indicated)
ART counsellingd X X
Commence/switch ARTd X
Total volume of blood (ml) 20 20
aHepatic panel = ALT, ALP, bilirubin +/- INR
bFBC; full/complete blood count
cBlood will be collected and stored for research if storage consent has been received, refer to site SOP.
dHIV-infected patients not receiving effective ART, ART counselling to be performed by qualified counsellors 
as per standard clinic procedures. Physician discretion allowed for timing of ART initiation.
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60 people with suspected or confirmed TBM will be recruited 
into the randomised trial.
The sample size is determined following the assumption that PK 
parameters are normally distributed on the log scale. Estimated 
rifampicin log-transformed C
max
 standard deviation is taken 
from Ruslami et al.1 The global study significance level (alpha) 
will be 10%, which is appropriate for phase II studies. Using 
the Bonferonni correction for multiple testing, each individual 
comparison will be made with alpha of 5%. Group sample sizes 
of n=15 achieve 90% power to reject the null hypothesis of equal 
means when the log-transformed population mean difference 
is 0.54mg/L with standard deviation of ±0.36mg/L in the 
control group and ±0.48mg/L (33% higher) in the experimen-
tal group, with a significance level of 0.05 using a two-sided, 
two sample unequal variance t-test. If the standard deviation 
differs from our estimate, the overall detectable effect size at 90% 
power will be 1.5 times the standard deviation, and 1.27 times the 
standard deviation at 80% power. We will not formally compare 
equivalence of the two investigational arms as this would require 
a larger sample size. Comparison of the two investigational 
arms will be primarily descriptive.
This phase II study would be underpowered to detect a survival 
benefit unless the effect size is large. A one-sided log rank test 
with 20 subjects per arm provides 80% power at 0.05 signifi-
cance to detect a hazard ratio of 0.285 when 40% of controls 
survive 8-weeks. This assumes no more than 1 person drops 
out or is lost to follow-up per arm. The prior lost to follow up 
rate has been <1% in recent Ugandan meningitis trials.
Statistical methods. After data cleaning, analysis will proceed 
according to the pre-specified analysis plan using Stata version 
13. The trial will be reported in accordance with CONSORT
guidelines and primary analyses will be conducted by the
participant’s originally assigned group (ITT). Analyses will be
conducted on individuals from both study sites together and all
analyses will be adjusted for site, BMRC grade and any baseline
variables associated with missingness of the analysis outcome.
Primary analysis
Pharmacokinetic analysis
The following pharmacokinetic parameters will be calculated 
using standard two-stage approach involving calculation of phar-












 - area under the time concentration curve from
hour 0 to hour 24
4.  Time > MIC is the duration of time where the drug
concentration level is greater than the minimal inhibi-
tory concentration for the M. tuberculosis isolate (either
the individual or the median MIC of the study population)
Safety analysis
The number and proportion of individuals who reported any 
kind of clinical grade 3-5 AE during the study period will be 
presented by intervention arm. Data for safety will be analysed 
in accordance with the ITT principle. The main analysis will 
be a composite safety endpoint over the 8-week intervention 
period:
•  AEs, clinical Grade 3-5 as classified by DAIDS Toxicity
Scale
•  All SAEs
•  DILI, grade 3-5 (ALT >3x ULN with symptoms or
5x ULN without symptoms)
•  Discontinuation of rifampicin for >5 days in the first
8 weeks for any cause
Time to experiencing an adverse event will be compared 
between treatment arms using cumulative incidence functions 
and a Cox proportional hazards regression model adjusted 
for site and BMRC TBM grade. Death will be considered a 
competing risk. The individual subgroups of AEs that make up 
the composite endpoint will be summarised. A secondary analysis 
of rifampicin-related toxicity (probable or definitely related, 
as assigned on the adverse events case record form) will be 
presented by intervention arm.
Clinical outcomes
Survival at 8 and 24 weeks will be calculated using the risk 
difference, from a generalised linear regression model adjusted 
for site and BMRC TBM grade. Kaplan-Meier curves will also 
be used to compare time to death between treatment arms, with 
censoring and loss to follow-up handled as previously described. 
Cox proportion hazards regression will be used to assess the 
effects of rifampicin dose, plasma/CSF rifampicin concentration, 
HIV, MRC severity grade and baseline GCS on survival.
When calculating time to normalization of GCS continuous- 
valued secondary endpoints will be compared with general linear 
models or Wilcoxon rank-sum tests as appropriate. Death can be 
considered a competing risk. χ2 test will be used for comparison 
of proportions of patients with TBM-IRIS by intervention arm.
Secondary analysis. We will explore the relationship between 
rifampicin exposures and clinical outcomes using a population 





 as the exposure variables. Survival, pro-
portion with normalisation of conscious level and functional 
status (as determined by modified Rankin score) are the response 
variables.
Planned subgroup analyses. Specified high-risk subgroups are 
of interest because of potential different responses to intrave-
nous rifampicin from both an efficacy and safety perspective, 
and the clinical utility in future physician decision-making. 
With standard therapy, worse clinical outcome is associated 
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with altered mental status, high organism burden. Subgroups of 
interest include:
1. TBM Diagnostic category (Definite, Probable, Possible)33
2.  British Medical Research Council (BMRC) TBM disease
severity7
3. CSF inflammation (CSF white blood cells) by tertiles
4. CD4 at study entry
5. ART status at study entry
Analysis of ancillary studies. The results of ancillary studies 
will be reported separately from the main trial.
Findings of the diagnostic sub-study will be reported in line 
with the Standards for the Reporting of Diagnostic Accuracy 
studies (STARD) guidelines. Sensitivity and specificity will be 
calculated against a composite reference standard (any positive 
CSF test for M. tuberculosis) and against the published uni-
form case definition of ‘probable’ or ‘definite’ TBM33. A latent 
class analysis will also be performed.
The studies on brain tissue concentration at autopsy will be 
primarily descriptive.
Ethical considerations
Confidentiality. Participants will be identified only by means 
of a coded identification number specific to each participant. 
All participant-related information (including CRFs, laboratory 
results, radiology reports etc.) will be kept strictly confi-
dential. All records will be kept in a secure, locked location 
and only research staff will have access to the records. With 
consent, information relevant for the future HIV care will be 
shared with relevant HIV clinic for continuity of care and patient 
safety.
All computerized databases will identify participants by numeric 
codes only, and will be password-protected. Upon request, 
participant records will be made available to the study sponsor, 
monitors, applicable regulatory entities, including the Uganda 
National Council of Science and Technology, Uganda National 
Drug Authority, Mulago Institutional Review Board, or London 
School of Hygiene and Tropical Medicine.
Consent. An estimated >80% of the study population will have 
altered mental status at initial hospital presentation. Those 
presenting with meningitis and altered mental status are at the 
greatest risk of death, and enhanced TBM therapy may have 
the greatest benefit for them. This hypothesis deserves testing 
via inclusion into the clinical trial. Secondly, as most persons 
with TBM present with altered mental status, in order to make 
results generalizable to all TBM patients, we wish to offer enrol-
ment to all persons. Subjects unable to give informed consent 
due to altered mental status may have surrogate consent provided 
by proxy from their caregiver/next of kin.
For subjects enrolled by surrogate consent, if and when the 
participant regains the physical and mental capacity to give 
consent, information will be provided to them and written 
informed consent will be sought for continuation in the trial. If a 
patient or representative declines to give consent for continuation 
at this stage, his/her wishes will be respected.
A person who speaks and understands the language of the 
informed consent document, but does not read and write, can be 
enrolled in a study by “making their mark” or via a thumbprint 
on the informed consent document. In this event, an impartial, 
literate third party must witness the entire consent process 
and sign the informed consent document. The witness’s name, 
signature, and relationship must be recorded on the informed 
consent document. A member of the study team is not an 
impartial third party.
Supplementary File 1 contains the participant information sheet 
and consent form.
Sample use and storage. Additional consent will be sought 
for the long-term storage of samples (including blood, spinal 
fluid, DNA/RNA) for use in future research. In this case, sam-
ples will be stored for the purposes of future research, unless 
the subject asks for them to be destroyed. Alternatively, subjects 
may give limited consent to the collection and testing of 
samples for the purposes of this research only, after which the 
samples will be destroyed.
Withdrawals. Subjects may withdraw from the study at any 
time by withdrawing subject consent, and will be eligible to 
continue to receive TB treatment from a primary TB clinic of 
their choice. Subjects enrolled in the study but choosing to 
leave the hospital early against medical advice will continue to 
participate in the study if they wish. Additional phone calls by 
study personnel will encourage the subject to seek follow up 
TB care and to re-join the trial per the on-going schedule of 
events. Assessment of vital status will continue via telephone 
calls at a minimum, unless consent is completely withdrawn. 
Participants will be asked if they would like their accrued data 
to be destroyed.
Ethical approval. The investigators have obtained approval 
from the Research Ethics Committees of the London School 
of Hygiene and Tropical Medicine (14388), as well as the 
Mulago Hospital Institutional Review Board (MHREC1260), 
the Uganda National Council of Science and Technology, the 
Ugandan National Drug Authority and Mbarara Hospital.
Any further amendments will be submitted and approved by 
each ethics committee.
Trial committees
The trial sponsor is London School of Hygiene and Tropical 
Medicine (LSHTM; Keppel Street, London, WC1E 7HT, UK; 
Tel: 0207 6368636). The trial management group (TMG) will 
oversee day to day management of the trial and is formed of the 
principal investigators (PI), site PI in Mbarara, a neurologist and 
a statistical advisor. The TMG will meet weekly. The trial steer-
ing committee (TSC) has members of the TMG and independent 
members (Professor Guy Thwaites (Chair), Professor Alison 
Elliott, Professor Reinout van Crevel, Dr Joe Jarvis, Dr Frank 
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Mugabe (Head of National TB and Leprosy Programme), 
a patient representative). The TSC provides supervision for 
the trial and advice through the independent Chair. The data 
safety committee (DSC) (Professor Robert Wilkinson (Chair), 
Dr William Worodria, Dr Mindy Clarke, Dr Agnes Kiragga 
(independent statistician), Dr Christine Sekaggya-Wiltshire) will 
advise the TSC regarding continuation, modification or premature 
closure of the trial. The DMC is independent from the Sponsor.
Publication policy
We will share results though presentations at scientific confer-
ences and in peer-reviewed open-access journals. De-identified 
individual patient data will be stored on LSHTM secure data 
repository (LSHTM Data Compass) for patients who have given 
consent to data sharing at the time of enrolment.
Discussion
Tuberculous meningitis is highly fatal despite current WHO 
recommended therapy, particularly in HIV-positive people, who 
are 2–3 times more likely to die than their HIV-negative coun-
terparts. Recent evidence from Indonesian phase II studies 
suggests that significantly higher dose IV or oral rifampicin 
enhances CNS penetration and may reduce mortality. However, 
there is currently no available pharmacokinetic data on high-
dose rifampicin for TBM in an HIV-positive African population. 
Furthermore, intravenous rifampicin is not widely available so 
finding a bioequivalent oral dose, that reaches target levels in the 
CNS, is a priority.
In this phase II study we anticipate the sample size will not be 
sufficient to detect small differences in mortality between the 
treatment arms. However, the pharmacokinetic and pharmaco-
dynamic data will be used to define optimal rifampicin dose, 
and route of administration in an HIV-positive population, and 
this will be taken forward into a larger phase III randomised 
controlled trial, if safe and tolerable.
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Viral Causes of Meningitis Detected by Metagenomic Next-generation Sequencing in a Ugandan 
Tuberculous Meningitis Cohort 
Presented at American Academy of Neurology 2020 
Neurology. 2020;94(15) 
Authors: Carson Quinn, Prashanth Ramachandran, Morris Rutakingirwa, Ananta Bangdiwala, Enock 
Kagimu, Kiiza Tadeo Kandole, Fiona Cresswell, David Meya, David Boulware, Michael Wilson 
Objective: To identify viral infections by metagenomic next-generation sequencing (mNGS) in 
Ugandan HIV-infected patients with presumed tuberculous meningitis (TBM). 
Background: Most Ugandan patients with HIV infection and meningitis whose CSF tests negative for 
cryptococcal antigen are treated as presumed TBM. Viral meningitis masquerading as TBM needs to 
be considered. 
Design/Methods: CSF was obtained from 71 patients at Kiruddu National Referral Hospital in Kampala, 
Uganda, who were classified according to the Uniform Case Definition as definite (n=16), probable 
(n=7), or possible TBM (n=48). After total RNA and DNA were extracted, and unbiased cDNA and DNA 
libraries were sequenced, viruses were identified using a custom bioinformatics pipeline. 
Results: Viruses other than HIV-1 were identified in 37 patients, of which 6 were likely pathogenic 
(measles virus (n=2), Wesselsbron virus (n=1), rubella virus (n=1), herpes simplex virus (HSV)-1 (n=1), 
and HSV-2 (n=1)). All (n=6) were in patients classified as possible TBM (definite and probable TBM, 
n=0). Only the HSV-2 infected patient received contemporaneous multiplex PCR testing given lack of 
clinical improvement on anti-tubercular therapy. The patient with HSV-1 presented with headache, 
fever, and focal neurologic deficits, followed by pneumonia and death. One patient with measles virus 
was co-infected with Cryptococcus neoformans and did not improve with antifungal treatment. The 
other measles virus-infected patient had seizures progressing to coma and death. The patient 
infected with rubella virus had cutaneous Kaposi Sarcoma and a milder presentation of meningism 
after initiating antiretrovirals. Wesselsbron virus, an endemic flavivirus, was found in a patient with 
meningism, confusion, and hepatomegaly, who died from respiratory failure despite anti-tubercular 
therapy. 
Conclusions: The Uniform Case Definition of possible TBM, while sensitive, is not specific. mNGS of 
CSF identified alternate candidate viral etiologies in 12.5% (n=6) of possible TBM cases. Two infections 




Improving Tuberculous Meningitis Diagnosis – A Combined Host and Pathogen Classifier 
Presented at American Academy of Neurology 2020. 
Neurology. 2020;94(15). 
Authors: Prashanth Ramachandran, Akshaya Ramesh, Fiona Cresswell, Carson Quinn, Morris 
Rutakingirwa, Ananta Bangdiwala, Enock Kagimu, David Meya, Emily Crawford, David Boulware, 
Michael Wilson.  
Objective: To assess the diagnostic performance of metagenomic next-generation sequencing (mNGS) 
combined with host differential gene expression for tuberculous meningitis (TBM) versus other 
causes of meningitis. 
Background: GeneXpert RIF/MTB Ultra is ~70% sensitive for definite/probable TBM. Definite TBM is 
microbiologically proven. Probable TBM has negative microbiology but scores ≥10 points on the case 
definition scale. 90–98% of mNGS sequencing data reflect host gene expression. Host transcriptomic 
signatures may differ by pathogen and thus, enhance diagnostic utility. We assessed CSF mNGS and 
transcriptomics for identifying TBM and other pathogens misclassified as TBM. 
Cohort: 157 HIV-infected Ugandan adults with sub-acute meningitis: Definite (n=15), probable (n=7), 
and possible (n=53) TBM; non-TB meningitis (n=82). 
Method: Unbiased RNA and DNA libraries were sequenced. We performed metagenomic analysis 
through a custom bioinformatics pipeline. Transcriptomic diagnostic classifier was developed using 22 
samples (11 TB + 11 other), which, along with cases with co-infections, were not included in the final 
analysis. 
Results: mNGS was 80% concordant (12/15) against definite TBM with 3 additional cases of TBM 
detected (1 probable and 2 possible). Host transcriptomics displayed 83% (5/6) sensitivity (inclusive of 
mNGS-positive TBM), 78% (62/79) specificity, and 98% negative predictive value. Among probable 
TBM cases the host transcriptomic classifier predicted 71% (5/7) were TBM including the 1 mNGS-
positive TBM case. Within possible TBM, mNGS identified 9 other pathogens (4 viral, 2 bacterial, 2 
toxoplasmosis and 1 TBM-viral co-infection). The host transcriptomic signature classified 9/53 
possible TBM cases as TBM, including the 1 mNGS-positive TBM case. 
Conclusions: mNGS and host transcriptomics combined for 77% (17/22) sensitivity against 
definite/probable TBM. mNGS alone detected TB or alternate pathogens in 19% (10/53) of possible 
TBM cases. Further optimization of the classifier is required to increase accuracy. The combined assay 
will be assessed on a validation cohort with results presented at the meeting. 
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Illuminating Tuberculous Meningitis with Metagenomics and FLASH Enrichment 
Presented at American Academy of Neurology  
Authors: Prashanth Ramachandran, Fiona Cresswell, Charles Langelier, Saharai Caldera, Amy Lyden, 
Aaron McGeever, Josh Batson, Rene Sit, Norma Neff, Katherine Travisano, Lillian Khan, Joe DeRisi, 
David Boulware, Emily Crawford, Michael Wilson 
Objective: To enhance detection of Mycobacterium tuberculosis meningitis (TBM) and anti-microbial 
resistance (AMR) mutations in HIV-infected Ugandan adults with meningitis, using metagenomic next 
generation sequencing (mNGS) of CSF coupled with CRISPR-Cas9 enrichment technology. 
Background: TBM diagnosis is difficult. mNGS permits broad detection of CNS pathogens in a single 
assay. Further, targeted enrichment of low abundance genes by up to 105-fold is possible with Finding 
Low Abundance Sequences by Hybridization (FLASH), which is a novel CRISPR-Cas9 technology. 
Combining these technologies could improve detection of TB and associated AMR mutations. 
Design/Methods: Cohort: 15 patients with subacute meningitis: 6 definite TBM, 4 Cryptococcus (1 
meningitis, 3 symptomatic antigenemia), 1 potential Cryptococcus-immune reconstitution 
inflammatory syndrome (IRIS), and 4 unknown 
Method: DNA was extracted from CSF, and unbiased cDNA libraries were sequenced on an Illumina 
NextSeq. In parallel, FLASH enrichment was performed by incubating phosphatase blocked-DNA 
fragments with recombinant Cas9 and 314 computationally designed guide RNAs targeting 46 TB-
AMR genes, allowing adapter ligation of the exposed ends and preferential amplification. 
Results: Unbiased mNGS: Low abundance (0.03–6.41 rpm) TB reads were identified in 100% of the 
definite TB samples (n=6), and Cryptococcus neoformans was detected in 100% of cryptococcal cases 
(n=4). Among the 4 unknowns, Cryptococcus (n=1) and Toxoplasma gondii (n=1) were detected. The 
first FLASH experiment demonstrated up to a 100-fold increase in TB read abundance in definite TBM 
cases and detection of an additional case of TBM that had initially been mis-classified as Cryptococcus 
paradoxical IRIS. 
Conclusions: We report the development of a novel TBM and AMR CSF diagnostic protocol combining 
the agnostic ability of mNGS with FLASH, a CRISPR-Cas9 tool that enriches pathogen sequences of 
interest. These promising preliminary data suggest the possibility of developing an “all-in-one” assay 
to detect TB, any associated AMR genes and any additional or alternate infections. 
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